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Chapter 1 
1 Introduction 
  
2 Chapter 1 
1.1 G-Protein-coupled receptors 
1.1.1 GPCRs as drug targets and their classification  
G-Protein-coupled receptors (GPCRs) constitute the largest group of integral membrane proteins that 
transmit a wide variety of signals across the cell membrane.1 GPCRs respond to a broad range of 
extracellular stimuli such as biogenic amines, purines, lipids, amino acids, peptides and proteins, 
odorants, pheromones, ions and even photons.2 More than 800 GPCRs are encoded in the human 
genome (approximately 2-3% of the human genome) including about 400 functional non-olfactory 
receptors.3 For roughly 120 of the latter, referred to as orphan receptors, endogenous ligands are not 
known to date.4 More than 50 GPCRs are targeted by approved drugs,5 which represent 30 - 40 % of 
all marketed drugs,6 emphasizing the current value in the treatment of human diseases, as well as 
the prospects for the development of GPCR ligands as future drugs. Based on structural differences, 
mammalian GPCRs were classified in five groups: rhodopsin, secretin, adhesion, glutamate and 
frizzled/taste2.7 The common structural features of the GPCR superfamily are seven membrane-
spanning helices, connected by three alternating intracellular and extracellular loops and flanked by 
an extracellular N-terminus and an intracellular C-terminus, respectively. The rhodopsin-like family, 
also referred to as class A of GPCRs, is by far the largest and best studied subgroup containing 
receptors for odorants, small molecules such as biogenic amines, peptides and glycoprotein 
hormones (~700 GPCRs). The binding sites of small endogenous ligands are located within the seven 
transmembrane (TM) domains, whereas binding of more space filling ligands, for example peptides 
and glycoproteins, occurs at the amino terminus (N-terminus), extracellular loops and amino acids 
located at the top of the TM helices.8  
1.1.2 G-Protein activation, ligand classification and signal transduction 
Several models have been proposed for the molecular mechanism involved in the activation of 
GPCRs upon interaction with appropriate ligands. Among them, the cubic ternary model9-11 is 
considered most suitable for explaining the pharmacodynamic activities of the majority of interacting 
ligands (cf. Figure 1.1). This model distinguishes between an active (R*) and an inactive (R) receptor 
state. These two states are in equilibrium and are allowed to isomerize independently from agonist 
binding. This kind of a spontaneous activation of the receptor in the absence of agonists is referred 
to as constitutive activity.12 Both receptor states are able to bind G‐proteins, but only the active 
receptor – G‐protein complex (R*G) induces GDP/GTP exchange, resulting in signal transduction. 
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Figure 1.1 A. Two-state cubic ternary complex model of GPCR activation (R: inactive state of the receptor, R*: 
active state of the receptor, G: G-Protein, A: agonist). Signaling complexes mediating GDP/GTP exchange are 
highlighted in red. B. Ligand classification according to their capability of shifting the equilibrium to either side 
of both states. According to Seifert et al.
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Ligands are classified according to their capability of shifting the equilibrium to either side of both 
states. Full agonists preferentially bind to the R* state, stabilizing the active conformation and 
thereby enhancing the functional response. On the opposite, inverse agonists particularly interact 
with and stabilize the inactive conformation R of the receptor and reduce the percentage of 
spontaneously active receptors. Neutral antagonists bind to both conformations with the same 
affinity without altering the equilibrium, but impairing the binding of other ligands. Partial agonists 
and partial inverse agonists are less effective in stabilizing the active or the inactive receptor 
conformation, respectively.13 However, the two-state model of GPCR activation cannot sufficiently 
explain all observed experimental findings. The function of GPCRs is considered much more complex 
in terms of ligand binding (orthosteric, allosteric), different conformational states, accessory protein 
interaction, phosphorylation, G-Protein coupling, oligomerization and internalization.14-17 
Furthermore, there is growing evidence of several inactive and active receptor conformations,18 
suggesting that structurally different ligands stabilize distinct receptor conformations, resulting in 
different biological responses.19 In summary, the two-state model provides a molecular basis for 
classical concepts of pharmacology and helps to explain the properties of drugs acting as agonist, 
antagonist and inverse agonist, but the real situation is not completely reflected. After activation, the 
majority of GPCRs is able to transduce signals into cells through G-Protein coupling.20 Agonist binding 
to extracellular or transmembrane domains of a GPCR (or agonist-free constitutive activity) promotes 
conformational changes that initiate coupling of intracellular receptor domains to a heterotrimeric G-
Protein. This agonist-receptor-G-Protein complex, termed as ternary complex, triggers a G-Protein 
conformational change and results in the release of GDP from the Gα-subunit. Subsequently, the 
activated heterotrimeric G-Protein dissociates into Gα-GTP and Gβγ subunits, both of which then 
interact with effector proteins like enzymes or ion channels resulting in cellular biological 
responses.21 The intrinsic GTPase activity of the GTP-bound Gα subunit terminates the signal by the 
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hydrolysis of GTP to GDP, i. e. the cycle is completed by reversion of the G-Protein to the inactive 
heterotrimeric state (see Figure 1.2). Subsequently, the GDP-bound G -subunit re-associates with 
G  enabling the next G-Protein cycle.22 According to the structure and signaling pathway of the G -
subunits, G-Proteins are divided into four main families, termed Gs, Gi/o, Gq/11 and G12/13.
23 The G s 
family activates adenylyl cyclases (AC 1–9), resulting in increased cellular levels of the second 
messenger cAMP (3´-5´-cyclic adenosine monophosphate). By contrast, the G i family shows inverse 
effects, inhibiting the AC activity (AC 5 and AC 6). cAMP regulates various cellular effects such as 
activation of the protein kinase A (PKA) or the mitogen‐activated protein kinase (MAPK) pathway, 
both modulating gene expression.24 Members of the Gαq/11 family activate the phospholipases Cβ1-3 
(PLCβ), which catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to 1,2-
diacylglycerol (DAG) and inositol-1,4,5- trisphosphate (IP3). The latter second messenger controls 
calcium efflux from the endoplasmic reticulum. DAG and the released calcium control the activity of 
several protein kinase C (PKC) isoforms, which in turn activate a number of other proteins by 
phosphorylation.25,26 Finally, the Gα12 proteins interact with Ras homology GEFs (guanine-nucleotide 
exchange factor) (RhoGEFs) that regulate cytoskeletal assembly.27 Not only the G ‐subunit, but also 
the G ‐heterodimers are involved in signal transduction and regulate certain effectors such as PLC  
and ion channels.28 
 
Figure 1.2 Activation of a heterotrimeric G-Protein by interaction with an agonist-occupied GPCR. The activated 
receptor is represented by R*, whereas the inactive form is termed R. The dissociated subunits regulate their 
respective effector proteins such as adenylyl cyclase (AC) and calcium channels. Further details are described in 
the text (modified from
29
). 
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1.1.3 G-Protein independent signaling, -arrestin and functional selectivity 
Although the vast majority of GPCRs is able to transduce signals into cells via G-Protein coupling, 
recent work has indicated that GPCRs participate in numerous other protein-protein interactions, 
which generate intracellular signals independent of G-Protein activation.24 For instance, GPCR 
dimerization, the interaction with receptor activity‐modifying proteins (RAMPs) and the binding of 
various scaffolding proteins to GPCRs modulate GPCR signaling.20 Most compelling, the discovery that 
-arrestins (arrestin 2 and 3) function as alternative transducers of GPCR signals, has challenged the 
basic concept of GPCR signaling.20,30,31 Originally regarded as mediators of GPCR desensitization 
(through internalization into clathrin-coated pits),32,33 -arrestins are ubiquitously expressed cellular 
regulatory proteins that are meanwhile recognized as true adapter proteins that transduce signals to 
multiple effector pathways such as MAPKs (mitogen-activated protein kinase), SRC (v-src avian 
sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog), nuclear factor B (Nf- B) and 
phosphatidylinositol 3-kinase (PIK3).34 An updated model of signal transduction should comprise 
signaling by G‐proteins and/or ‐arrestins, as well as desensitization and internalization by 
-arrestins.34 The selective stimulation of some, but not all, possible signaling pathways has been 
postulated as ‘functional selectivity’,35 also known as ‘biased agonism’36 or differential receptor-
linked effector actions.37,38 Apparently, depending on the ligand, the conformational changes of 
GPCRs are biased, giving rise to different behavior and interactions.16 Such biased ligands are not 
only useful tools to investigate GPCR signaling, but might also harbor a potential as fine-tuned 
therapeutics.39 Besides, allosteric ligands, which could modulate the signaling cascades and 
biochemical responses triggered by endogenous ligands, can also impose biased agonism, showing 
promise in clinical pharmacology.40 
1.2 Histamine and the histamine receptor family 
1.2.1 Histamine as endogenous ligand 
The biogenic amine histamine (2-(1H-imidazol-4-yl)ethanamine) is a local mediator, 
immunomodulator and neurotransmitter targeting the histaminergic system. First biological effects 
of histamine like vasodilatation and smooth muscle contraction have been reported more than one 
hundred years ago.41 Histamine contains two basic functionalities, a primary aliphatic amine and 
imidazole. At physiological pH, the amine group is protonated, and two different tautomers of this 
monocation are the predominating forms (Figure 1.3).42 
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In the body, histamine is synthesized from the amino acid L-histidine 
through decarboxylation.43,44 Nowadays, histamine is considered , an 
ubiquitous and multifunctional biogenic amine which is involved in 
various physiological and pathophysiological processes. High tissue 
concentrations of histamine are found in particular in the lungs, the 
skin, connective tissues and the gastrointestinal tract.44 It is stored in 
mast cells,45 basophils,46 platelets,46 enterochromaffin‐like cells (ECL) 
of the stomach,47 endothelial cells,48 and it is also found in neurons.49 
In the brain, histaminergic neurons are involved in the sleep-wake 
cycle, energy and endocrine homeostasis, synaptic plasticity and 
learning.50 In mast cells and basophils, histamine is stored in 
secretory granules and released during allergic conditions, resulting 
in smooth muscle contraction, vasodilatation and an increase in vascular permeability.51 After 
release, in response to immunological and non-immunological stimuli, histamine is degraded by two 
catabolic pathways. The first pathway involves methylation of histamine by histamine 
N-methyltransferase and the second pathway involves oxidative deamination by diamine oxidase.52 
The biological effects are mediated by the interaction with currently four histamine receptor (HR) 
subtypes, termed H1R, H2R, H3R and H4R, all belonging to the rhodopsin-like family A of GPCRs.
44,53-55 
1.2.2 Histamine receptors and their ligands 
In this chapter, various molecular pharmacological aspects of the four histamine receptor subtypes, 
including the availability of selective agonists and antagonists, will be discussed. In 1966 the term 
histamine H1 receptor (H1R) was introduced by Ash and Schild, who suggested the existence of a 
second HR subtype (non‐H1 receptor, H2R) as not all effects provoked by histamine could be 
antagonized by classical antihistamines.56 Activation of the H1R has long been known to be associated 
with allergic conditions.44,57 As a consequence, antagonists of this receptor subtype (popularly 
referred to as antihistamines) have been used as anti-allergic drugs since the 1940s.44 The H2R plays a 
pivotal role in gastric acid secretion,58 and H2R antagonists have been used as antiulcer drugs (‘H2R 
blockers’).57 The histamine H3R is located predominantly in the central nervous system (CNS) and acts 
both as a presynaptic autoreceptor,59 modulating histamine release from histaminergic neurons, and 
as an inhibitory heteroreceptor.60,61 H3R antagonists are being investigated as potential drugs for 
therapeutic applications against a variety of CNS disorders such as Alzheimer’s disease, attention-
deficit/hyperactivity disorder (ADHD), epilepsy, migraine, narcolepsy, obesity, schizophrenia and 
depression.62 In the years 2000 and 2001, the H4R was identified and cloned independently by 
 
Figure 1.3 Tautomeric forms of 
the histamine monocation. 
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several research groups.63-69 It is considered as a new therapeutic target for the modulation of 
various inflammatory and immunological processes and disorders.70-73 
1.2.2.1 The histamine H1 receptor 
The histamine H1 receptor (H1R) was first cloned in 1993.
74 The corresponding receptor protein 
consists of 487 amino acids.74 It is mainly expressed on smooth muscle cells, endothelial cells and in 
the CNS and is involved in the pathophysiology of allergy and inflammatory reactions.75 Via the H1R, 
histamine induces, for instance, vasodilatation, bronchoconstriction, increased vascular permeability, 
pain and itching upon insect stings.76 Upon agonist stimulation, the H1R predominantly couples to the 
pertussis-toxin insensitive Gαq/11 proteins. Its stimulation triggers the inositol phospholipid signaling 
system, resulting in the formation of IP3 and DAG (cf Chapter 1.1.2), which results in 
Ca2+-mobilization from intracellular stores and activation of protein kinase C.75,77 H1R antagonists 
(antihistamines) have been used for decades for the treatment of allergic disorders (e.g. allergic 
rhinitis, chronic urticarial and atopic dermatitis), nausea and vomiting, and for sedation.78,79 First 
generation antihistamines, such as mepyramine or diphenhydramine, are highly lipophilic 
compounds which cross the blood brain barrier, block central H1 receptors and cause sedation.44 
More polar H1R antagonists such as cetirizine and fexofenadine were developed to reduce this 
undesired effect in the treatment of allergic diseases (‘non-sedative’ second generation of H1R 
blockers).57,80 Mepyramine is still the most commonly used reference H1R antagonist and radioligand 
([3H]mepyramine) for pharmacological studies.81 Besides, H1R agonists such as 2-methylhistamine 
and supra(histaprodifen), have been used as pharmacological tools to study H1R functions in cellular 
systems.82 So far, betahistine is the only marketed H1R agonist; the drug is therapeutically used in the 
treatment of Menière`s disease (cf. Figure 1.4).83,84 
1.2.2.2 The histamine H2 receptor 
The histamine H2R was pharmacologically characterized by Black et al. in 1972,
58 using the first H2R 
antagonist burimamide, which was able to block the histamine-mediated gastric acid secretion and 
the positive chronotropic effect on the heart. In 1991, Gantz and coworkers were able to clone the 
canine and human H2Rs.
85,86 The human H2R consists of 359 amino acids and is expressed in a variety 
of tissues including brain, uterus, airways, gastric parietal cells and the heart.57,87 The H2R primarily 
couples to the Gαs family of G-Proteins, leading to an increase in intracellular cAMP levels and the 
activation of PKA (cf. Section 1.1.2).85,88,89 Depending on the used cell system, the H2R may 
additionally trigger calcium signaling by coupling to the Gαq/11 G-Protein.
90-92 
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Figure 1.4 Structures of selected H1R agonists and antagonists. 
An essential physiological function of the H2R is the control of gastric acid secretion from parietal 
cells.58 Activation of cardiac H2Rs mediates positive chronotropic and inotropic effects,
93 and 
histamine-mediated smooth muscle relaxation has been documented in airways, uterus and blood 
vessels.94 The first marketed H2R antagonist cimetidine revolutionized the treatment of peptic ulcer 
and gastro-oesophageal reflux disease.44 Following cimetidine, several other H2R antagonists 
ranitidine, famotidine, nizatidine and roxatidine have been successfully used in the treatment of 
gastric and duodenal symptoms (ulcers),95 but are nowadays mostly replaced by more effective 
proton pump inhibitors, such as omeprazole, and by eradication of Helicobacter pylori.44,96-98 Apart 
from marketed drugs, numerous structurally related compounds,87 e.g. iodoaminopotentidine,99 
BMY25368,100 and tiotidine,101 are known as H2R antagonists (structures are given in Figure 1.6). For 
radioligand binding studies [3H]tiotidine102 and [125I]iodaminopotentidine103-105 were used. More 
information about available radioligands and the characterization of a new H2R radioligand is given in 
Chapter 5. Recently, a series of H2R antagonists was developed in our working group, replacing the 
cyanoguanidine group of potentidine-related piperidinomethylphenoxyalkylamines by squaramides. 
Additional coupling with -aminoalkyl spacers allows for labeling reactions or bivalent ligand 
construction.106 Whereas H2R antagonists became standard drugs for the treatment of gastric and 
duodenal ulcers,107,108 H2R agonists have been mainly used as pharmacological tools to study the 
physiological and pathophysiological role of this histamine receptor. A first step towards a selective 
H2R agonist was the discovery of dimaprit and amthamine, which were found to be almost as active 
as histamine at the H2R, but hardly display any H1R agonism.
109,110 Highly potent and selective 
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guanidine-type H2R agonists like impromidine
111,112 and arpromidine113 had been developed,114 
which, however, showed poor oral bioavailability.87 Drug-like properties were improved according to 
a bioisosteric approach, by an exchange of the guanidine by an acylguanidine moiety, resulting in 
NG-acylated imidazolylpropylguanidines (e.g. UR‐AK24, Figure 4.1, Chapter 4).115 Further 
improvement, concerning selectivity was achieved by the introduction of a 2‐amino‐4‐methylthiazol‐
5‐yl moiety as a bioisostere of the imidazole ring.116 Thus, NG-acylated 
aminothiazolylpropylguanidines (e.g. UR‐BIT24) combine the high selectivity for the H2R with 
improved pharmacokinetic properties, resulting in valuable pharmacological tools to evaluate the 
physiological role of H2Rs. Recently, the application of the bivalent ligand approach to acylguanidines 
yielded agonists, which are highly selective and up to 4000 times more potent than histamine at the 
guinea pig right atrium.117 Furthermore, another indication for the clinical use of histamine as H2R 
agonist evolved, based on the finding that histamine ameliorates the course of acute myeloid 
leukemia.118-120  
 
Figure 1.5 Structures of selected H2R agonists. 
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Figure 1.6 Structures of selected H2R antagonists. 
1.2.2.3 The histamine H3 receptor 
The histamine H3R was discovered by Arrang et al. in 1983
59 and cloned in 1999.121 The hH3R consists 
of 445 amino acids122 and is mainly expressed in the CNS, where it acts as a presynaptic auto- and 
heteroreceptor, controlling the release of histamine and various other neurotransmitters, including 
dopamine,123 serotonin,124 noradrenalin46 and acetylcholine.125 The H3R is suggested to be involved in 
various CNS functions, for instance, the regulation of locomotor activity, wakefulness and food 
intake, thermoregulation and memory.126 In the periphery, H3R activation was shown to occur in the 
cardiovascular system, the gastrointestinal tract and the airways.127-130 The activation of H3Rs leads to 
a decrease in intracellular cAMP levels via coupling to Gi/o proteins and inhibition of the adenylyl 
cyclase. Besides, activation of phospholipase A2 (PLA2), MAPKs and phosphatidyl inositol 3-kinase, 
inhibition of the Na+/H+ exchanger and modulation of intracellular calcium was demonstrated.131,132 
Antagonists for the H3R are promising agents
131,133,134 in several therapeutic areas including dementia, 
Alzheimer`s disease, narcolepsy, deficit hyperactivity disorder, schizophrenia as well as for the 
treatment of myocardial ischemic arrhythmias, migraine and inflammatory and gastric acid-related 
diseases.62,122,135-140 
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Figure 1.7 Structures of selected H3R agonists and antagonists. 
The first potent H3R antagonists, thioperamide
141 and clobenpropit142 were derived from the 
structure of histamine and have an imidazole ring in common. To improve the drug‐like properties 
and to prevent potential drug‐drug interactions, several pharmaceutical companies developed non‐
imidazole H3R antagonists, for instance JNJ10181457 and JNJ5207852.
133,143 Recently, the H3R 
antagonist pitolisant (tiprolisant) has been introduced as an orphan drug for the treatment of 
narcolepsy.144,145 Typical H3R agonists are N -methylhistamine and (R)- -methylhistamine
141 as well 
as imetit146 and the H3R selective ligands immepip and methimepip,
137 which are structurally less 
related to histamine (structures are shown in Figure 1.7). Almost exclusively, the application of the 
H3R agonists [
3H]histamine, [3H]Nα-methylhistamine and [3H](R)-α-methylhistamine, as well as of the 
inverse agonist [125I]iodophenpropit or of the antagonist [3H]thioperamide have been described in 
radioligand binding experiments.107,147,148 
1.2.2.4 The histamine H4 receptor 
In 1975, Clark and co-workers reported on histamine induced chemotaxis of human eosinophils that 
was not inhibited by H1 or H2 receptor antagonists.
149 Two decades later, Raible and colleagues 
suggested a novel HR subtype on human eosinophils. The authors observed that the histamine 
triggered calcium mobilization in human eosinophils could be blocked by the H3R antagonist 
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thioperamide. However, the potent H3R agonist (R)‐α‐methylhistamine was less potent than 
histamine in inducing calcium mobilization; this was not compatible with a H3R mediated effect.
150,151 
Finally, the human H4R was identified and cloned ‒ at that time as an orphan receptor ‒ in 2000 and 
2001, independently by several research groups.63-69 Cloning of the H3R gene provided the basis for a 
fourth histamine receptor subtype due to their high sequence homology (about 40% overall 
sequence identity and about 58% sequence identity within the transmembrane domains).121 The 
human receptor subtype consists of 390 amino acids and, as in case of the H3R, couples to 
Gi/o-proteins, resulting in adenylyl cyclase inhibition,
64,152 activation of MAPKs67 and calcium 
mobilization.153 Besides the coupling to G-Proteins, the activation of β-arrestin by several H4R ligands 
was recently reported.154-156 The H4R was suggested to be expressed in bone marrow and 
immunocytes such as mast cells, basophils, eosinophils, monocytes, T-lymphocytes and dendritic 
cells.157,158 Furthermore, detection of the H4R was purported on nerves from the nasal mucosa, in the 
enteric and, together with the other histamine receptor subtypes, in the central nervous system.152 
Based on studies with H4R knockout mice, it has been suggested that the H4R plays a 
proinflammatory role in bronchial asthma, atopic dermatitis, allergic rhinitis, and pruritus.44,53,152,159 If 
so, H4R antagonists could be useful drugs for the treatment of these conditions.
51,53,152,160 The H4R 
was also suggested as a new therapeutic target for the treatment of colitis, pain, cancer, rheumatoid 
arthritis and multiple sclerosis.70-72,161,162 The supposed role of the H4R in immunological responses 
overlaps with the function of the H1R, suggesting that combined H1- and H4-receptor ligands might be 
beneficial for the treatment of inflammatory diseases.51,163-166 In search for novel H4R antagonists or 
inverse agonists, the imidazole-containing H3R inverse agonist thioperamide has been identified as 
H4R inverse agonist with similar potency and has been frequently used as a reference compound 
(structure is given in Figure 1.7).167 A high-throughput screening campaign led to the identification of 
the indole carboxamide JNJ7777120 as a selective H4R antagonist.
168 JNJ7777120 has been widely 
used as the prototypical H4R antagonist in animal models to assess the (patho)physiological role of 
the H4R.
51. However, in vivo results of JNJ7777120 must be interpreted with caution in view of partial 
agonistic activity at murine H4R orthologs in vitro,
169 -arrestin recruitment to the hH4R
154-156 and off-
target effects at higher concentrations.170 For a more detailed view at JNJ7777120 cf. Chapter 6. 
Meanwhile, other highly selective and potent H4R antagonists, e.g. with quinazoline
171 and 
pyrimidine160,172 scaffold, have been developed (cf. Figure 1.8; an overview is given by Schreeb et 
al.173). Some H4R ligands had entered clinical studies, e.g. UR-63325, the first H4R antagonist from 
which clinical data were reported,174,175 ZPL-38937887 (formerly PF-03893787)172 and 
JNJ39758979.160 To further investigate the pathophysiological role of the H4R, selective agonists are 
of particular interest as pharmacological tools.  
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Figure 1.8 Structures of selected H4R agonists and antagonists. 
Due to the high sequence homology of the H4R with the H3R, especially in the transmembrane 
domains, it is not surprising that the H4R is activated by numerous compounds which were originally 
designed as H3R agonists, and, consequently, contain an imidazole ring, for instance 
(R)-α-methylhistamine, Nα-methylhistamine and imetit (Figure 1.7).167,176 Histamine and its homologs 
homohistamine (spacer length of three methylene groups) and imbutamine (four methylene groups) 
are agonists with similar hH3R and hH4R affinity, whereas the higher homolog impentamine (five 
methylene groups) is an almost full hH3R agonist but shows no agonistic activity at the hH4R.
167,177,178 
The hH3R inverse agonist clobenpropit
142 turned out to be a potent partial agonist at the hH4R and 
one of the few compounds that activate the hH4R, but not the hH3R, rendering clobenpropit an 
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interesting pharmacological tool (structure is shown in Figure 1.7).167 The first ligands with improved 
selective H4R activation were the cyanoguanidine OUP-16, a chiral tetrahydrofurane related to 
imifuramine,179 and 5-methylhistamine (also referred to as 4-methylhistamine),167 which was initially 
reported as a selective H2R agonist.
58 The dimaprit analog VUF 8430180 turned out to be an H4R 
agonist with about 100- and 30-fold selectivity over the other H2R and the H3R, respectively (cf. 
Chapter 4).180 Similarly, NG-acylated imidazolylpropylguanidine-type H2R agonists such as UR-AK24 
were shown to be more potent at the hH3R and hH4R. Truncation of the N
G-acyl groups resulted in 
potent, nearly full, H4R agonists such as UR-PI294, which possesses improved selectivity over the 
hH1R and hH2R, but shows residual activity at the hH3R (cf. Chapter 4).
181 Aiming at improved 
selectivity for the H4R, the acylguanidine moiety was replaced by a non-basic cyanoguanidine group. 
Further structural optimization led to highly potent and selective cyanoguanidine-type H4R agonists 
such as UR-PI376 and trans-(+)-(1S,3S)-UR-RG98.182,183 Another recently reported structural class of 
ligands comprising selective H4R agonists are 2-arylbenzimidazoles (Lee-Dutra et al., 2006), 
previously developed as H4R antagonists by Johnson & Johnson.
184
 One of these compounds, which is 
characterized by a histamine substructure, has sub-nanomolar hH4R affinity and is among the most 
potent hH4R agonists described so far.
185 For a more detailed view at this class of compounds cf. 
Chapter 3. Very recently, Z-configured oxime analogs of the selective H4R antagonists JNJ7777120
186 
and JNJ10191584 (VUF 6002)187 were reported as a new class of H4R agonists.
188 All of them are 
selective for the hH4R and show only low (if any) affinities for the other histamine receptor subtypes. 
The oxime-type compounds are of particular value as pharmacological tools for the study of the H4R 
in rodents. In contrast to these oxime-type ligands, numerous other H4R agonists (and antagonists) 
show pronounced species-dependent discrepancies regarding potencies, receptor selectivities and 
even opposite qualities of action.54,90,169,176,189 Thus, the predictive value of translational animals may 
be severely compromised due to ortholog dependent discrepancies. Except for the monkey H4R, 
which shows an overall amino acid homology with the human H4R of 93%,
189 homologies range from 
65 to 71%. Accordingly, the sequence differences between human, rat, and mouse H4R have been 
reported to cause significant differences in affinity for the endogenous agonist histamine.190 Hence, 
future prospects of H4R agonists (and antagonists) as molecular tools to study the H4R in vivo will 
strongly depend on balanced activities on the receptor orthologs of humans and laboratory animals. 
A general overview of published radioligands for the H4R is given in Chapter 6. 
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1.3 NPY and the NPY receptor family 
1.3.1 Neuropeptide Y 
The 36 amino acid peptides 
pancreatic polypeptide (PP), 
neuropeptide Y (NPY, cf. Figure 1.9) 
and peptide YY (PYY) are structurally 
related peptides, which bind to G-
Protein coupled receptors of the NPY 
receptor family. NPY, one of the most 
abundant neuropeptides in the 
central and peripheral nervous 
system,192 was first isolated by 
Tatemoto and coworkers from porcine brain in 1982,193 and was proven to be highly conserved in 
various species. For all these peptides, C-terminal amidation is essential for biological activity.194 NPY 
receptors are widely distributed in the central and peripheral nervous system. They are involved in 
the regulation of numerous physiological processes such as blood pressure, food intake, pain 
sensitivity, anxiety/anxiolysis, depression, obesity and hormone release.195,196  
1.3.2 NPY receptors and their ligands 
The diverse biological effects of NPY are mediated by the activation of different receptor subtypes 
which are all members of the GPCR superfamily. To date, five mammalian NPY receptor subtypes, 
termed Y1, Y2, Y4, Y5 and y6 receptor, have been cloned.
197-204 The y6 receptor was found to be 
functional in mice, but non‐functional in most mammalian species.205 All NPY receptor subtypes were 
shown to activate pertussis toxin sensitive Gi/o proteins, mediating the inhibition of forskolin‐
stimulated cAMP accumulation.206,207  
1.3.2.1 The NPY Y2 receptor and its ligands 
In 1986, the Y2 receptor was identified by pharmacological studies with N‐terminally truncated 
analogs of NPY and PYY using vascular preparations (e.g. NPY(3‐36) and NPY(13‐36)).194 The cloned 
hY2R consists of 381 amino acids and has only ~30% identity to the Y1R and the Y4R, respectively. This 
receptor subtype turned out to be highly conserved across species with a sequence homology of 
90-96%.204,208-210 The argininamide BIIE 0246,211 the first reported potent and selective Y2R antagonist, 
proved to be a valuable tool for the study of Y2R. Meanwhile, there is growing interest in the Y2R as a 
therapeutic target, not least stimulated by recently published brainpenetrant, orally available Y2R 
 
Figure 1.9 Tertiary structure of porcine NPY according to Allen et 
al.
191
 basic residues (green); acid residues (blue); tyrosine residues 
(cyan). 
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antagonists such as JNJ31020028,212 JNJ5207787213 and SF-11214, as well as structural analogs of the 
latter, such as CYM 9552 or CYM 9484,215 and imidazolidine-2,4-diones, such as NVP-833216 (for a 
recent review cf. Mittapalli et al.,217 structures are presented in Figure 1.10). Aiming at potent and 
subtype-selective tracers for the Y2R, a series of derivatives of argininamide-type Y2R antagonist 
BIIE 0246 was synthesized in our working group.218,223  
 
Figure 1.10 Structures of selected Y2R antagonists. 
Most of the resulting NG-substituted (S)-argininamides related to BIIE0246 showed Y2R antagonistic 
activities and binding affinities similar to those of the parent compound, corroborating the 
hypothesis that the guanidine–acylguanidine exchange is a promising and broadly applicable 
bioisosteric approach.218 Radioligands used for the study of Y2R are, for instance, [
3H]NPY,219,220 
[125I]PYY,221 and [125I]PYY(3–36),222,223 which are devoid of subtype selectivity. Attachment of a 
[2,3-3H2]propionyl group through an appropriate linker to the guanidine group of above mentioned 
(S)-argininamide-type NPY Y2R antagonist resulted in the first selective nonpeptide radioligand for 
the Y2R ([
3H]UR-PLN196).224 
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1.3.2.2 Ligands for the NPY Y1, Y4 and Y5 receptors 
In the last two decades, a multitude of highly potent and selective non-peptidic Y1R antagonists with 
affinities in the nanomolar and subnanomolar range have been developed, including BIBP 3226225 
and J-104870 (Figure 1.11).226 For a review see Brennauer et al.227 The investigation of a series of 
NG-substituted BIBP 3226 derivatives revealed that especially electron-withdrawing substituents such 
as acyl, alkoxycarbonyl and carbamoyl are tolerated. Therefore, a bioisosterism of guanidines and 
acylguanidines was suggested for this class of compounds.228-230 High-affinity radioligands for the 
characterization of the Y1R are, apart from [
125I]NPY and [3H]BIBP 3226, two NG-acylated 
argininamides from our laboratory, [3H]UR-MK114231 and [3H]UR-MK136.232 Both compounds are 
highly potent and selective radiotracers for the Y1R. 
The peptide VD-11, an analog of the C-terminus of NPY, was reported to act as a competitive 
antagonist at the Y4R.
233 However, high-affinity non-peptide Y4R ligands are not known so far. 
Acylguanidines such as UR-AK49 (Figure 1.11), which were designed as histamine H2 receptor ligands, 
proved to be weak Y4R antagonists.
234,235 These compounds may serve as lead structures towards 
potent small molecule antagonists for the Y4R. Recently, UR-MK188, a dimeric argininamide-type 
neuropeptide Y receptor antagonist was reported to be the most potent  Y4R antagonist known so 
far.236 Up to date, nonpeptidic selective radioligands for the Y4R are not described in literature. 
In case of the Y5R, the situation is comparable to the Y1R. The search for new drugs for the treatment 
of obesity led to numerous highly potent and selective non-peptidic antagonists with broad 
structural diversity. Some of these compounds have entered clinical trials. Along these lines, 
MK-0557 (Merck & Co., Inc.) was tested in phase II trials, but was withdrawn due to lack of significant 
effect on body weight.237 A selection of Y5R antagonists with Ki values in the low nanomolar range is 
given in Figure 1.11 (for a review see Brennauer et al.227). Recently, a Y5R selective radioligand was 
reported as an insurmountable pseudo-irreversible non-peptide antagonist.238 
18 Chapter 1 
 
Figure 1.11 Examples of nonpeptidic selective Y1R, Y4R and Y5R antagonists. [a] Rudolf et al.;
225
 [b] Kanatani et 
al.;
239
 [c] Ziemek et al.;
235
 [d] Keller et al.;
236
 [e] Criscione et al.;
240
 [f] Kanatani et al.;
241
 [g] Walker et al.;
242
 [h] 
Erondu et al.
243
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1.4 Receptor–ligand binding assays 
Receptor screening methodologies make use of either the determination of a functional response 
(e.g. cell proliferation or changes in the concentration of second messengers such as Ca2+ or the 
interaction of a ligand with its receptor.244 Binding of a ligand to its receptor is the initial and 
indispensable step in the cascade of reactions that finally cause a pharmacological effect.245 
Various assay technologies measuring receptor–ligand interactions are available and can be used in 
multiple ways. Firstly, they can be applied as a tool for basic research on the receptor itself by 
determining receptor distribution and identifying receptor subtypes. Secondly, screening of new 
chemical entities and the discovery of endogenous ligands is facilitated by receptor–ligand binding 
assays, despite the fact that receptor–ligand binding assays do not predict pharmacological activity 
(agonism or antagonism) of compounds.246 Finally, binding assays can be used to quantify an analyte 
that is present in a biological matrix with high sensitivity and reproducibility by comparing the 
displaced amount of labeled ligand with standard curves constructed with known concentrations of 
the analyte.244  
Assays requiring a labeled ligand or receptor are divided in radioactive and non-radioactive assay 
technologies. While radioreceptor assays are fast, sensitive, easy to use and reproducible, their major 
disadvantages are that they are potentially hazardous to human health, produce radioactive waste, 
require special laboratory conditions and licenses, and there is a need for separation of bound from 
free ligand.247 This has led to the development of non-radioactive assays based on technologies using 
either colorimetry, fluorescence or (chemo-/bio-) luminescence.244 Such optical methods comprise 
fluorescence polarization (FP),248 fluorescence/bioluminescence resonance energy transfer 
(FRET/BRET),249 flow cytometry250 or total internal reflection fluorescence (TIRF).251 Furthermore, 
surface plasmon resonance (SPR),252 affinity selection mass spectrometry (AS-MS)253 and nuclear 
magnetic resonance spectroscopy (NMR)254 allow for label-free assays. In summary, a shift from 
radioactive to fluorescence-based or label-free detection of receptor–ligand interactions has been 
observed over the past years.  
However, most of the new approaches are not well established and validated. Therefore radioligand 
binding is still an indispensable procedure in drug research, especially in the screening of compound 
libraries. The major advantage of radioligand binding is the robustness of the readout.244 In the 
following, radiochemistry-based techniques commonly applied for the investigation of ligand-
receptor interactions with focus on radioligand binding experiment will be presented.255 
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1.4.1 Radioligand Binding Methods 
A number of different receptor sources can be employed, such as whole animals, slices of tissue, 
whole cells, membrane fractions, cytosolic extracts, and purified solubilized receptor proteins.247 
There are three basic types of radioligand binding experiments: Firstly, saturation experiments by 
which the affinity of the radioligand for the receptor of interest and the number of specific binding 
sites can be determined;256 secondly, kinetic experiments whereby the rate constants of association 
and dissociation of a radioligand are accessible.257 Thirdly, radioligand binding assays are widely used 
to identify unlabeled compounds which specifically bind to certain receptors. An unlabeled 
compound that is able to bind to the receptor of interest will compete with the radiolabeled ligand. 
Thus, competition curves using increasing concentrations of the unlabeled ligand can be constructed 
and the affinity of the unlabeled ligand for the receptor can be calculated.258 
1.4.1.1 Selection of radioligands 
In choosing the appropriate radioligand for a radioreceptor assay, several criteria have to be met. 
Firstly, the radioligand should be selective and possess a high affinity for the respective receptor (the 
radioligand should bind selectively to the receptor type or subtypes of interest under assay 
conditions. Secondly, the radioligand should be radiochemically pure and have a high specific activity. 
Furthermore, the radioligand should be chemically stable and resistant to enzymatic degradation. 
Finally, in case of optically active ligands, the eutomer of the radioligand is preferred, to avoid 
interference and to prevent complicate analysis as a consequence of the presence of the less active 
enantiomer.244,259 Further important issues to consider, include the choice of the radioisotope 
(preferably 3H or 125I, occasionally 32/33P and 35S), the extent of nonspecific binding, and whether the 
radioligand is an agonist or an antagonist. Tritium as a radioisotope, compared to 125-iodine, has a 
longer half-life (12.3 years vs. 60 days), which is of advantage with respect to performing both 
synthesis and pharmacological studies, and the compound is more convenient to handle with respect 
to safety precautions.260 Because of their short half-lives, iodinated radioligands are usually 
purchased or prepared every 4-6 weeks, whereas tritiated ligands can often be used for several 
months or even years. An advantage of iodinated radioligands is their higher specific activity (up to 
2200 vs. 30-100 Ci/mmol), which makes them particularly useful when the density of receptors is low 
or the amount of tissue is small. It is more convenient and less expensive to use iodinated ligands, 
since scintillation fluid is not needed, thus eliminating purchasing and disposal costs.261 Agonist 
radioligands may label only a portion of the total receptor population (the high affinity state in case 
of GPCRs), whereas antagonist ligands label all receptors. On the other hand, a radiolabeled agonist 
may more accurately reflect receptor alterations of biological significance. Nonspecific binding is 
binding to sites other than the receptors of interest. This can include other receptors, non-receptor 
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binding sites in the tissue (e.g., the lipid bilayer), and also binding to filter material. Usually, the 
radioligand with the lowest nonspecific binding is best. An assay is considered barely adequate if 50% 
of the total binding is specific, 70% is good, and 90% is excellent.257 Membrane preparations are most 
widely used and probably provide the most reproducible and reliable data. Nevertheless, radioligand 
binding techniques can be applied to other preparations, such as purified receptors, solubilized 
receptors, whole cells, and tissue slices. The choice of preparation depends on the question to be 
addressed.247 Further aspects of interest are an appropriate choice of the assay conditions and an 
efficient technique for the separation of free and bound radioligands (cf.247,261,262). In conclusion, the 
basic principle of radioligand binding is quite simple, but careful application of these assays requires 
careful consideration of the above mentioned details. When properly conducted and appropriately 
interpreted, these assays can be an extremely powerful tool for the study of receptors.261 
1.4.2 Radioligands for the histamine H2, H4 and NPY Y2 receptor 
Information about available radioligands for the histamine H2, H4 and NPY Y2 receptor and the 
characterization of new radioligands is given in Chapter 5-7. 
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The discovery of the histamine H4 receptor almost 15 years ago, has stimulated the evaluation of this 
GPCR as a new therapeutic target for the modulation of various inflammatory and immunological 
disorders.1 Nevertheless, its biological role is far from being understood. The analysis of the 
(patho)physiological mechanisms of the H4R and the validation as a drug target using antagonists and 
agonists in translational animal models are seriously hampered by substantial species-dependent 
differences regarding potencies, receptor selectivity and even by opposite activities of available 
ligands.2,3 Hence, potent and selective ligands including agonists are required as pharmacological 
tools to further explore the (patho)physiological function of the H4R. Therefore, this work aimed at 
the design and synthesis of potent and selective H4R agonists. Recently, Savall et al. identified 
2-arylbenzimidazoles as highly potent and selective H4R ligands.
4 Highest agonistic activity and 
selectivity over the other HR subtypes was reported to reside in a compound with a specific 
substitution pattern, including methyl and fluorine residues, at the benzimidazole and a histamine 
moiety. Starting from this compound as a lead, in one subproject of this work a library of structurally 
related analogs was designed and synthesized to elucidate the structure-activity and structure-
selectivity relationships of this class of compounds. 
The early pharmacological and physiological characterization of the H4R was based on investigations 
using compounds identified as H4R agonists or antagonists among known ligands of the other 
histamine receptor subtypes.5 As the hH4R shares the highest sequence homology with the hH3R, it is 
not astonishing that numerous hH3R ligands, especially ligands incorporating an imidazole moiety as 
the endogenous ligand histamine, bind to the hH4R as well. N
G-alkylated and acylated imidazolyl-
propylguanidines were originally developed as H2R agonists.
6-8 However, several of them were found 
to be potent at the H3R and H4R, too.
9 VUF 8430, (S-(2-guanidinylethyl)isothiourea), also initially 
designed as an H2R agonist, proved to be a potent hH4R agonist with ~30-fold selectivity over the 
hH3R (full agonism) and negligible affinity for hH1R and hH2R.
10,11 Aiming at H4R agonists with 
increased selectivity for the H4R over the other HR subtypes, the second part of this work was 
focused on the combination of an imidazole-free molecule like VUF 8430 with the acylguanidine 
moiety of the NG-acylated imidazolylpropylguanidines. 
The theory of radioligands binding is simple, the experiments can be conveniently performed and 
applied to a wide range of preparations, including purified and solubilized receptors, membrane 
preparations, whole cells, tissue slices, and even whole animals.12 However, radioligands are not 
commercially available for every target. Furthermore, the applicability of available radioligands is 
often compromised by moderate affinity, lack of selectivity towards related receptor subtypes, high 
nonspecific binding and radiochemical instability.13 Therefore, another aim of this work was the 
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synthesis and pharmacological characterization of tritium-labeled radioligands for G-Protein coupled 
receptors (GPCRs).  
There has been a shortage of high affinity radioligands for the investigation of the histamine H2 
receptor. For example, [3H]tiotidine,14 which shows a high degree of unspecific binding, and 
[125I]iodoaminopotentidine,15 which has a short half-life and is more difficult to handle with respect 
to safety precautions, are no longer commercially available. Within a series of H2R antagonists with 
piperidinomethylphenoxyalkyl moieties connected to a squaric amide residue, UR-DE257 showed the 
highest affinity and selectivity for the H2R.
16 As a subproject of this thesis, the radiosynthesis and the 
pharmacological characterization of [3H]UR-DE257 are described. 
JNJ7777120 ((5-chloro-1H-indol-2-yl)(4-methylpiperazine-1-yl)methanone) has been described as the 
first potent and selective H4R antagonist in 2003.
17 Its radiolabeled analog was published, but is not 
commercially available.18 Hence, a further aim was to synthesize [3H]JNJ7777120 in house and to 
evaluate the suitability of this radioligand to study various H4R orthologs. 
To better understand the biological role of the different NPY receptor subtypes, especially of the NPY 
Y2R, pharmacological tools such as radio- and fluorescent ligands are required.
19 Aiming at potent 
and subtype selective tracers for the Y2R, a series of derivatives of BIIE 0246 was synthesized in our 
laboratory.20 Application of the guanidine-acylguanidine bioisosteric approach resulted in the first 
tritiated Y2R selective non-peptide radioligand, [
3H]UR-PLN196.21 More detailed binding and 
functional studies revealed insurmountable antagonism versus pNPY and pseudo-irreversible binding 
at the Y2R. In the final part, the synthesis and characterization of [
3H]UR-PLN208, a structurally 
related radiotracer is reported and binding as well as functional data are compared with 
[3H]UR-PLN196 and their unlabeled analogs. 
In summary, the first aim of this doctoral thesis was to design, synthesize and pharmacologically 
characterize new H4R agonists to gain more information about structure-activity and structure-
selectivity relationships and to develop H4R subtype and selective compounds, which could serve as 
molecular determinants. The second part of this work focused on the synthesis of tritium-labeled 
radioligands for different GPCRs and their applicability as pharmacological tools. 
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Characterization of 2-Arylbenzimidazoles 
as Potent and Selective Histamine H4 
Receptor Ligands 
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3.1 Introduction 
Although the number of ligands addressing the H4R is continuously increasing, their potential value in 
the treatment of immunological and inflammatory diseases such as asthma and rheumatoid arthritis 
has still to be proven. Potent and selective ligands including agonists are required as pharmacological 
tools to further explore the (patho)physiological function of the H4R. However, the investigation of 
numerous H4R agonists in animal models is hampered by species-dependent discrepancies regarding 
potencies and histamine receptor subtype selectivities.1,2 Recently, Savall et al. identified 
2-arylbenzimidazoles as highly potent and selective hH4R ligands.
3 Highest potency and selectivity 
over the other HxR subtypes were reported to reside in a compound with a specific substitution 
pattern including methyl and fluorine residues at the benzimidazole and a histamine moiety (3.16 cf. 
Figure 3.1 and Scheme 3.2). As part of a project on histamine H4R ligands, the aim of the present 
work was to synthesize a small library of compounds related to 3.16 and to elucidate the structure-
activity- and structure-selectivity relationships on human histamine receptors (hH1,2,3,4R) and the 
murine H4R, recombinantly expressed in Sf9 insect cells, using GTP S binding- and steady-state 
GTPase-assays, as well as radioligand binding experiments.  
 
Figure 3.1 Structural variation in a series of 2-arylbenzimidazoles derived from 3.16.
3
 
 Chemistry 45 
 
Emphasis will be put on the substitution pattern at the benzimidazole moiety of 3.16. Moreover, the 
number of basic centers will be varied to elucidate their influence on hH4R binding and selectivity. 
The imidazole-bearing moiety will be modified with respect to a series of histamine analogs 
previously published1,4 and replaced by non-imidazole moieties, aiming at improved H4R selectivity 
compared to the other HxR subtypes. In our laboratory the introduction of a tritium-labeled propionyl 
group is well-established as a strategy for the development of new radioligands.5-8 Therefore, a series 
of 2-arylbenzimidazoles bearing a propionic amide or a NG-propionylated acylguanidine group was 
synthesized in ‘cold form’ and investigated for binding to the HxR subtypes.  
3.2 Chemistry 
As shown in Scheme 3.1 and Scheme 3.2, the 2-arylbenzimidazoles 3.16-3.20 were synthesized 
following the procedure of Savall et al.9 starting with an oxidation of the respective benzene-1,2-
diamine and 4-hydroxybenzaldehyde derivative with Na2S2O5 to form the benzimidazoles 3.7-3.10. 
O-Alkylation with the respective bromo-chloro-alkane and coupling with trityl-protected histamine 
3.2, followed by acidic deprotection, led to the 2-arylbenzimidazoles 3.16-3.20. The protection of the 
histamine was carried out with triphenylmethyl chloride (Trl-Cl) according to Ghorai et al.10 (cf. 
Scheme 3.2). The synthesis of 3.22 and 3.23 followed the same principle. Alkylation with 
Boc-protected 3-bromopropanamine 3.21 and acidic deprotection yielded 3.22 and 3.23, which were 
both pharmacologically investigated and used as building blocks for further synthesis. 
 
Scheme 3.1 Synthesis of 3.2. Reagents and conditions: (a) Trl-Cl, NEt3, CHCl3, 0 °C-rt, 27 h, 46%; (b) 5% TFA in 
CH2Cl2, 0 °C - rt, 4 h, 61%. 
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Scheme 3.2 Synthesis of the benzimidazole derivatives 3.16-3.20, 3.22 and 3.23. Reagents and conditions: 
(a) 3.5 or 3.6, Na2S2O5, DMF, 90 °C, 2 h, 61-95%; (b) Cs2CO3, MeCN, 1-bromo-3-chloropropane or 1-bromo-4-
chlorobutane, 70 °C, 17 h, 16-62%; (c) K2CO3, NaI, 2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.2), n-butanol, 
90 °C, 15-94 h, 14-24%; (d) 3-bromopropylamine hydrobromide, Boc2O, DIPEA, CH2Cl2, rt, 18 h, 74%; (e) 1) 3.7 
or 3.8, Cs2CO3, MeCN, 70 °C, 17 h; 2). TFA, CH2Cl2, rt, 5-8 h, 27-30%. 
The guanidine 3.26 was prepared, according to Feichtinger et al.11, from guanidine hydrochloride by 
di-Boc protection (3.24), followed by the reaction of 3.24 with trifluoromethane sulfonic anhydride 
to give 3.25. Subsequently, 3.23 was treated with the guanidinylating reagent 3.25 under mild basic 
conditions releasing triflic amide, which could be easily removed by aqueous work-up. Finally, 
cleavage of the Boc‐protecting groups gave 3.26 (cf. Scheme 3.3). 
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Scheme 3.3 Synthesis of the guanidine derivative 3.26. Reagents and conditions: (a) Guanidine hydrochloride, 
Boc2O, NaOH, water/dioxane, 0 °C-rt, 26 h, 35%; (b) triflic anhydride, NEt3, CH2Cl2, -78 °C-rt, 4h, 81%; (c) 3.22, 
NEt3, CH2Cl2, rt, 3 h, 33%. 
The NG‐acylated guanidine 3.30 was prepared according to the synthetic pathway outlined in Scheme 
3.4 from amine 3.22 and N-Boc-protected N’-(propionyl)-S-methylisothiourea (3.29), which was 
obtained via a three-step synthesis. N-Boc protected S-methylisothiourea (3.28) was synthesized as 
described previously.12-14 Subsequently, 3.28 was treated with propionic acid under standard 
conditions for amide coupling, using TBTU and NEt3.
15 Treatment of the amine 3.22 with the 
guanidinylating reagent 3.29 in the presence of HgCl2 - the metal ion reacts as a desulfurizing agent 
via complex formation16,17 - followed by Boc‐deprotection with trifluoroacetic acid yielded the 
acylguanidine 3.30. 
 
Scheme 3.4 Synthesis of the acylated guanidine 3.30. Reagents and conditions: (a) Thiourea, MeI, MeOH, rt, 
1 h, 98%; (b) Boc2O, NEt3, rt, 20 h, 74%; (c) propionic acid, TBTU, DIPEA, rt, O/N, 89%; (d) 1) 3.22 (as free base), 
HgCl2, NEt3, CH2Cl2, rt, 20 h; 2) TFA, CH2Cl2, rt, 5 h, 71%. 
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Scheme 3.5 Synthesis of the amides 3.31-3.37. Reagents and conditions: (a) For 3.31, 3.32: 3.22 or 3.23, 
propionic acid, EDC × HCl, HOBt × H2O, DIPEA, THF, rt, 22 h, 41-48%; for 3.33-3.36: 3.22, respective acid, TBTU, 
DIPEA, DMF, rt, 20 h, 13-55%; for 3.37: 3.22, 3-phenylpropanoyl chloride, DIPEA, CH2Cl2, 0 °C-rt, 9 h, 59%. 
The amides 3.31-3.37 were prepared as highlighted in Scheme 3.5. The guanidine building blocks 
3.22 and 3.23 were coupled to propionic acid using EDC and HOBt as coupling reagents to give the 
amides 3.31 and 3.32. The compounds 3.33-3.36 were synthesized by acylation with UR-PG13910 (for 
3.33), 5-chloroindole-2-carboxylic acid (for 3.34), UR-PG1718 (for 3.35) and UR-AK31812 (for 3.36) 
using TBTU as coupling reagent. 5-Chloroindole-2-carboxylic acid (TCI, Tokyo, Japan) is commercially 
available, UR-AK318,19 UR-PG17 and UR-PG13918 were available in our laboratory. The amine 3.22 
was allowed to react with the commercially available 3-phenylpropanoyl chloride under basic 
conditions to afford compound 3.37. 
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Scheme 3.6 Synthesis of the imidazole derivatives 3.41, 3.45, 3.48-3.50 and 3.58-3.60 . Reagents and 
conditions: (a) Formamide, 170 °C, 4 h, 48%; (b) Trl-Cl, NEt3, MeCN, rt, 27 h, 95%; (c) hydrazine x H2O, EtOH, rt, 
24 h, 96%; (d) histamine x 2 HCl, dimethoxymethane, 0.01 M HCl, reflux, 19 h, 72%; (e) benzyl succinimidyl 
carbonate, NEt3, CH2Cl2, 0 °C-rt, 1 h, 58%; (f) Trl-Cl, NEt3, MeCN, rt, 24 h, 66%; (g) Pd/C, H2, MeOH, rt, 4 h, 90%; 
(h) benzyl chloroformate, NEt3, DMF, rt, 24 h, 81%; (i) TFA, CH2Cl2, rt, 4 h , 96%; (j) TFA, CH2Cl2, rt, 4 h , 98%; 
(k) Pd/C, H2, MeOH, rt, 20 h, 88%; (l) phthalic anhydride, NEt3, toluene, reflux, 24 h, 48-53%; (m) Trl-Cl, NEt3, 
MeCN, rt, 24 h, 40-91%; (n) hydrazine x H2O, EtOH or n-BuOH, rt, 24 h, 96-100%. 
 
The amines required for the preparation of imidazole-containing ligands 3.62-3.64, 3.67, 3.70 and 
3.71 had to be protected as depicted in Scheme 3.6. The trityl-protected 5-methylhistamine 
derivative 3.41 was prepared starting from 2-(3-bromo-4-oxopentyl)isoindoline-1,3-dione (3.38),20 
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which was allowed to react with formamide according to a Bredereck synthesis21 to give the 
imidazole 3.39. After trityl protection of the imidazole (3.40) and hydrazinolysis of the phthalimide 
group, 3.41 was obtained in good yield. The intermediate 3.42 (spinaceamine) was achieved by a 
modified Pictet-Spengler reaction22,23 with histamine and dimethoxymethane in 0.01 M HCl. 
Cbz-protection of the amine with benzyl succinimidyl carbonate, followed by trityl-protection of the 
imidazole and cleavage of the Cbz group by hydrogenolysis gave 3.45. The imidazole derivatives 3.49 
and 3.50, which were also tested for hH4R affinity, were obtained from UR-MK251 (3.46), which was 
synthesized by Dr. Max Keller, after acidic Boc-deprotection (3.49) and hydrogenation over Pd/C 
catalyst (3.50). For the coupling with the benzimidazole 3.22, the imidazole in UR-MK251 (3.46) was 
protected with Cbz. Subsequently, the Boc group was removed under acidic conditions to produce 
the primary amine 3.48. To incorporate homohistamine (n = 3) in 3.22, compound 3.5524 was 
converted to 3.58 by hydrazinolysis of the phthalimide group. Imbutamine (3.51,20 n = 4) and 
impentamine (3.52,24 n = 5), were available in our laboratory. Compounds 3.53 and 3.54 were 
obtained from the reaction of the corresponding amine (3.51 or 3.52) with phthalic anhydride. Trityl 
protection of the imidazole, followed by hydrazinolysis of the phthalimide group afforded the trityl 
protected primary amines 3.59 and 3.60.  
Preparation of the compounds 3.62-3.73 (cf. Scheme 3.7) started from 3.11 (cf. Scheme 3.2), which 
was converted to the corresponding iodinated analog (3.61) under Finkelstein25 conditions. 
Conversion of the respective primary amines (3.41 for 3.62; 3.58 for 3.63, 3.59 for 3.64, 
5-methylimbutamine20 for 3.65, thia-5-methylimbutamine26 for 3.66, 3.60 for 3.67, mono-Boc 
protected ethandiamine UR-MK74,27 for 3.68, 6.1 for 3.69, 3.48 for 3.70, 3.45 for 3.71, 6.3 for 3.72) 
to the secondary amines 3.62‐3.73 was performed by heating in a microwave oven with 3.61 in 
acetonitrile (Scheme 3.7). Subsequently, acidic deprotection was performed if required. Preparation 
of 3.75 started from the N-Boc-protected derivative of 3.68 (3.73), followed by Cbz-protection of the 
secondary amine. Subsequently, acidic Boc-deprotection, propionylation with succinimidyl 
propionate under basic conditions and cleavage of the Cbz group by hydrogenolysis yielded 3.75. 
Hydrogenolysis was performed in methanol in the presence of TFA to prevent methylation of the 
secondary amine.28 The propionylated compound 3.76 was obtained by conversion of 3.69 with the 
help of succinimidyl propionate. 
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Scheme 3.7 Synthesis of the compounds 3.61-3.76. Reagents and conditions: (a) NaI, acetone, reflux, 72 h, 
90%; (b) 1) respective amine, K2CO3, MeCN, microwave 130 °C, 20 min, for 3.62-3.64 and 3.67-3.73: 2) TFA, 
CH2Cl2, rt, 5-8 h, 28-65%; (c) 1) benzyl chloroformate, NEt3, CH2Cl2, 0 °C-rt, 24 h; 2) TFA, CH2Cl2, rt, 4 h, 55%; 
(d) 1) succinimidyl propionate, NEt3, MeCN/DMF, 24 h, rt; 2) Pd/C, H2, TFA, MeOH, rt, 16 h, 65%; 
(e) succinimidyl propionate, NEt3, MeCN, 24 h, rt, 76%. 
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3.3  Pharmacological Results and Discussion 
The synthesized 2-arylbenzimidazoles 3.16-3.20, 3.22, 
3.23, 3.26, 3.30-3.37, 3.62-3.72, 3.75 and 3.76, as well as 
the building blocks 3.42 (spinaceamine), 3.49 and 3.50 
were investigated at the hH1R, hH2R, hH3R and hH4R in 
radioligand binding assays using membrane preparations 
of Sf9 insect cells expressing the hH1R + RGS4, hH2R−Gsαs 
fusion protein, hH3R + Gαi2 + Gβ1γ2 or hH4R + Gαi2 + Gβ1γ2, 
respectively.29 Moreover, the reference H4R ligands 
histamine, homohistamine, imbutamine, impentamine, 5-
methylhistamine, 5-methylimbutamine and thia-5-
methylimbutamine30 were included (Figure 3.2). The most 
promising compounds 3.16-3.19, 3.22, 3.23, 3.30-3.32, 
3.62-3.65, 3.67, 3.70 and 3.71 were tested for agonism and antagonism at the hH1R in [
33P]GTPase 
binding assays using membrane preparations of Sf9 insect cells expressing the hH1R + RGS4,31-34 at 
the hH2R, hH3R and hH4R in [
35S]GTP S binding assays using membrane preparations of Sf9 insect 
cells expressing the hH2R−Gsαs fusion protein,35,36 expressing the hH3R + G i2 + G 1 2
37,38 or expressing 
the hH4R plus G i2 plus G 1 2 (cf. Figure 3.3).
33 To verify whether the response was H4R mediated, the 
Kb values of standard neutral antagonists were determined from the concentration-dependent 
inhibition of 2-arylbenzimidazole 3.16induced increase in [35S]GTPγS binding. Moreover, with respect 
to the potential use of the synthesized H4R ligands in translational animal models, selected 
compounds were analysed in radioligand binding studies using HEK293 cells stably expressing the 
murine H4R and in [
35S]GTP S binding assays using membrane preparations of Sf9 insect cells 
expressing the mH4R + G i2 + G 1 2. In the following, agonistic potencies are expressed as EC50 
values. Intrinsic activities ( ) refer to the maximal response induced by the standard agonist 
histamine, unless otherwise stated. Compounds identified to be inactive as agonists ( < 0.1 or 
negative values, respectively), were also investigated in the antagonist mode. The corresponding Kb 
values of neutral antagonists and inverse agonists were determined from the concentration-
dependent inhibition of the histamine-induced increase in [35S]GTP S binding or [33P]GTPase 
cleavage. Binding data represent Ki values determined by displacement of [
3H]pyrilamine (hH1R), 
[3H]UR-DE257 (hH2R), [
3H]N -methylhistamine (hH3R), [
3H]histamine (hH4R) or [
3H]UR-PI2945 (mH4R). 
 
 
Figure 3.2 Structure of histamine and its 
analogs. 
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3.3.1 Histamine receptor subtype affinities of the synthesized compounds 
3.3.1.1 Variation of the substitution pattern 
The investigation of compound 3.16 in radioligand binding assays revealed discrepancies compared 
to published data (Figure 3.4, Table 3.1).3 The affinity was 50-fold lower at the hH4R (Ki = 11.2 ± 
1.8 nM) than reported by Savall et al. (0.21 nM).3 The pharmacological evaluation of the 
2-arylbenzimidazoles 3.17-3.19 with a modified substitution pattern at the hH4R revealed nearly 
identical Ki values (8.5 to 14.4 nM). As shown for compound 3.20, the elongation of the linker had no 
effect on hH4R affinity. The hH3R affinities of 3.16-3.20 were comparable (486-1270 nM), however 
the hH2R affinities for 3.17 and 3.18 were 10-fold lower than those of 3.16 and 3.19, indicating that 
the omission of the O-methyl group at the phenyl ring increases the hH4R selectivity compared to the 
hH2R. Nevertheless, this group is important for functional activity at hH4R and affinity at the mH4R 
(see below). The hH1R affinities were low and comparable to the reported data (Ki = 5380-
16500 nM).3  
3.3.1.2 Structural variations of arylbenzimidazole-type hH4R ligands  
As an imidazole moiety is known to reduce hH4R selectivity compared to the other histamine 
receptor subtypes, the compounds 3.26, 3.34-3.37, 3.68, 3.69 and 3.72 were investigated for their 
affinity at the hH4R and selectivity towards the other HxR subtypes. Unfortunately, most of the tested 
compounds had only very weak affinity at the hH4R. The guanidine 3.26 revealed a lower affinity at 
the hH4R compared to 3.16, no affinity at the hH3R, but retained affinity at the hH2R. The 
carboxamide 3.34-3.37 showed almost no binding to the hHxR subtypes. It may be speculated that 
bulky aromatic residues are not tolerated in this position. It is more likely that, apart from the 
benzimidazole moiety, an additional basic center should be present to enable H3R and H4R binding. 
However, a guanidine group alone appears to be inappropriate. The introduction of a diamine led to 
a decrease in hH4R binding in case of 3.68 (20‐fold) and 3.69 (4-fold), whereas the selectivities over 
the other HxR subtypes remained unchanged for both compounds. The incorporation of a moiety 
that corresponds to the structure of the H4R antagonist JNJ7777120 (3.72, cf. Chapter 6) resulted in a 
drastic loss in affinity at the hH4R as well as for the hH2R and hH3R. Summed up, only compounds 
bearing two basic amino functions showed sufficient affinity at the hH4R. The most promising 
bioisosteres of the imidazole ring are nitrogen-containing aliphatic residues or heterocycles bearing 
two basic moieties. 
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Figure 3.3 Structures of the investigated 2-arylbenzimidazoles. 
The data for higher homologs of histamine and their ring-substituted or conformationally 
constrained analogs coupled with a 2-arylbenzimidazole building-block (3.62-3.67, 3.71), compared 
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to the histamine analog 3.16 and previously published data,4 are summarized in Table 3.1. In general, 
these compounds, except for 3.66 (Ki = 13.1 nM), revealed similar hH4R affinities (Ki = 0.58-8.7 nM) 
and were higher as for 3.16. Highest affinity for the hH4R within this series resided in compound 3.64; 
the Ki value was in the sub-nanomolar range (0.58 nM) and 20-fold lower than that determined for 
3.16 in our laboratory. Lowest hH3R affinity was found for 3.71 (for hH4R: Ki = 5.1 nM, ref: 3.3 nM;
3 
for hH3R: Ki = 18400 nM, cf. Figure 3.4) corresponding to an over 3600-fold selectivity for the hH4R 
and also an over 270-fold selectivity over the hH2R. Contrary to this, spinaceamine (3.42) alone 
afforded almost no hH4R affinity. By analogy with histamine and imbutamine, methyl substitution at 
the 5-imidazolyl ring resulted in a preference for the hH4R (for 3.62: 480-fold, for 3.65: 145-fold over 
the hH3R). The selectivities for the demethylated homologs were lower (60-fold for 3.16 and 85-fold 
for 3.64, respectively). In addition, the derivative 3.67, providing a five membered linker, showed a 
slight preference for the hH3R (Ki = 4.8 nM) than for the hH4R (Ki = 8.7 nM) and remarkably high 
affinity for the hH2R (Ki = 41.2 nM). Highest binding affinity at the hH2R was determined for imidazole 
3.70. With a Ki value of 14.5 nM at the hH2R this compound revealed almost 50-fold selectivity for 
the hH2R over the hH3R and almost 150-fold selectivity over the hH4R, respectively. In contrast, the 
structurally related building block 3.49, as well as its reduced derivative 3.50, showed no affinity at 
the hH2R. This makes 3.70 an excellent starting point to explore the structural requirements for hH2R 
selectivity in this class of compounds. Hence, imidazole derivatives with further elongated spacers 
would most probably not result in improved hH4R affinity. Instead, future prospects herein should 
focus on the synthesis of conformationally constrained spacers to further explore the structure‐
activity relationships of hH4R preferring 2-arylbenzimidazoles. The Ki values of 3.62-3.67 and 3.71 at 
the hH2R were comparable and in the range of 200 to 1400 nM. 
 
Figure 3.4 Competition binding curves of 3.16 and 3.71 at hHxR subtypes. 
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Regardless of being known as a building block for the preparation of cimetidine, compound 3.66, the 
thia-analog of 5-methylimbutamine, did not prefer the H2R, but revealed an over 240-fold selectivity 
for the hH4R compared to the hH2R and an over 360-fold selectivity over the hH3R, although the hH4R 
affinity (Ki = 13.1 nM) was lower than for other homologs in this series. In contrast, compound 3.30, 
in which the secondary amine of 3.66 is exchanged by an amide, showed an over 350-fold higher 
hH4R affinity, indicating that this basic functionality is crucial for hH4R binding.  
3.3.1.3 Introduction of a propionyl group  
The introduction of a tritium-labeled propionyl group has been established as a strategy for the 
synthesis of new radioligands for GPCRs.5-8 Therefore, a series of 2-arylbenzimidazoles with a 
propionic amide or a NG-propionyl guanidine moiety was synthesized and investigated for affinity 
towards the HxR subtypes. These investigationsligands revealed quite promising results, stimulating 
the search for hH4R radioligands. The results for the propionyl group bearing molecules 3.30-3.32, 
3.75 and 3.76 are presented in Table 3.1. Propionylation of the amino group in 3.22 and 3.23 
abolished the hH4R binding, obviously due to the missing basic center in this changed part of the 
molecule as mentioned above. The propionylation of the primary amine in 3.68 led to a 17-fold loss 
of affinity at the hH4R (3.75, Ki = 3850 nM). Highest affinity for the hH4R within this set of 
propionylated compounds was determined for 3.76 with a Ki of 132 nM. The exchange of the 
ethylene linker in 3.75 with a piperazine afforded an almost 30-fold increase in affinity. Unlike most 
of the other investigated compounds, 3.76 showed almost no binding to the hH2R and hH3R. Even 
though the affinity of 3.76 is too low for being considered a potential radioligand, the lack of affinity 
at the other hHxR subtypes is a promising starting point for the development of new 
2-arylbenzimidazole-type ligands, including compounds bearing different nitrogen-containing 
heterocycles as well as an appropriate group for radiolabeling in the center of the molecule. 
Surprisingly, ligand 3.30 bound to the hH2R with a Ki value in a low three-digit nanomolar range 
(Ki = 101 nM), with an over 360-fold selectivity over the hH3R receptor and a 30-fold selectivity over 
the hH4R. This compound could be a starting point in the search for novel hH2R ligands (cf. 3.70), 
especially regarding radioligands, because the available radioligands (cf. Chapter 5) are far from 
being ideal. 
 
 Table 3.1 Ki values of the synthesized 2-arylbenzimidazoles and histamine analogs at the hHxR subtypes determined in radioligand binding studies.
[a]
 
Compound 
hH1R hH2R hH3R hH4R Selectivity 
H2:H3:H4 Ki / nM n Ki / nM n Ki / nM n Ki / nM n 
Histamine 200
[b]
 534 ± 52 3 20.1 ± 3.1 4 13.1 ± 1.1 4 41 : 1.5 : 1 
Homohistamine n.d. n.d. 94.4 ± 0.4 2 31.8 ± 11.3 3 - : 3 : 1 
Imbutamine n.d. n.d. 4.3 ± 0.8 2 12.7 ± 0.8 2 - : 1 : 3 
Impentamine n.d. n.d. 36.9 ± 7.0 2 627 ± 63 3 - : 1 : 17 
5-Methylhistamine n.d. n.d. 9940 ± 1400 2 28.5 ± 4.4 3 - : 349 : 1 
5-Methylimbutamine n.d. n.d. 639 ± 227 2 68.8 ± 14.5 3 - : 9.3 : 1 
Thia-5-Methylimbutamine n.d. n.d. 1670 1 1460 1 - : 1.2 : 1 
3.16 10800 ± 840 2 548 ± 208 3 673 ± 190 2 11.2 ± 1.8 3 49 : 60 : 1 
3.17 10400 ± 400 2 6490 ± 270 2 1020 ± 30 2 8.5 ± 0.4 2 764 : 120 : 1 
3.18 5380 ± 360 2 3660 ± 704 2 486 ± 15 2 14.4 ± 0.5 2 254 : 34 : 1 
3.19 16500 ± 1500 2 516 ± 168 2 1270 ± 130 2 10.5 ± 0.5 2 49 : 121 : 1 
3.20 n.d. 734 ± 170 2 810 ± 110 3 7.0 ± 2.0 3 105 : 116 : 1 
3.26 n.d. 2000 ± 565 2 > 50000 2 3100 ± 120 2 1 : - : 1.6 
3.30 n.d. 101 ± 16 3 36800 ± 13200 3 3350 ± 1040 2 1 : 364 : 33 
3.31 n.d. n.a.
[c]
 2 n.a.
[c]
 2 > 30000 2 - 
3.32 n.d. n.a.
[c]
 2 n.a.
[c]
 2 > 50000 2 - 
3.33 n.d. > 10000 2 > 50000 2 4610 ± 1360 3 - 
3.34 n.d. n.a.
[c]
 2 5550 ± 2260 2 n.a.
[c]
 2 - 
3.35 n.d. > 30000 2 > 30000 2 > 50000 2 - 
3.36 n.d. n.a.
[c]
 2 n.a. 2 > 50000 2 - 
3.37 n.d. n.d. - n.a.
[c]
 2 n.a.
[c]
 2 - 
 Table 3.1 (continued) 
Compound 
hH1R hH2R hH3R hH4R Selectivity 
H2:H3:H4 Ki / nM n Ki / nM n Ki / nM n Ki / nM n 
3.42 n.d. > 30000 2 7880 ± 290 2 5050 ± 54 2 - : 1.6 : 1 
3.49 n.d. n.a.
[c]
 2 n.a.
[c]
 2 2350 ± 360 2 - 
3.50 n.d. n.a.
[c]
 2 9450 ± 1280 3 n.a.
[c]
 2 - 
3.62 n.d. 377 ± 111 3 1190 ± 10 2 2.5 ± 0.6 5 151 : 476 : 1 
3.63 n.d. 308 ± 57 2 68.4 ± 9.8 3 3.6 ± 1.6 3 86 : 19 : 1 
3.64 n.d. 223 ± 84 2 49.0 ± 14.1 3 0.58 ± 0.20 4 385 : 85 : 1 
3.65 n.d. 391 ± 194 2 421 ± 19 4 2.9 ± 0.2 3 135 : 145 : 1 
3.66 n.d. 3140 ± 580 2 4750 ± 470 2 13.1 ± 1.5 4 240 : 363 : 1 
3.67 n.d. 41.2 ± 5.8 2 4.8 ± 0.5 2 8.7 ± 2.3 4 8.6 : 1 : 1.8 
3.68 n.d. > 20000 2 9830 ± 1550 2 231 ± 28 2 - : 43 : 1 
3.69 n.d. > 10000 2 4150 ± 1040 3 40.0 ± 19.8 2 - : 104 : 1 
3.70 n.d. 14.5 ± 3.8 3 686 ± 21 2 2150 ± 970 3 1 : 47 : 148 
3.71 n.d. 1390 ± 190 2 18400 ± 990 2 5.1 ± 0.9 3 273 : 3610 : 1 
3.72 n.d. > 20000 2 > 40000 2 6940 ± 410 2 - 
3.75 n.d. > 20000 2 >40000 2 3850 ± 840 2 - 
3.76 n.d. > 50000 2 > 80000 2 132 ± 51 3 - 
[a] Determination of hH1R binding by displacement of [
3
H]pyrilamine (5 nM) from Sf9 cell membranes expressing the hH1R + RGS4, hH2R binding by displacement of 
[
3
H]UR-DE257 (30 nM) from Sf9 cell membranes expressing the hH2R−Gsαs, hH3R binding by displacement of [
3
H]N
α
-methylhistamine (3 nM) from Sf9 cell membranes 
expressing the hH3R + Gαi2 + Gβ1γ2 or hH4R binding by displacement of [
3
H]histamine (15 nM) from Sf9 cell membranes expressing the hH4R + Gαi2 + Gβ1γ2 was 
determined as described in the Pharmacology section. [b] Data taken from Igel et al. 2010.
5
 [c] Means no affinity; measured at a ligand concentration of 100 μM. n.d. 
means not determined. n gives the number of independent experiments performed in triplicate each. 
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3.3.1.4 Functional activities at recombinant human histamine receptor subtypes 
Selected compounds were investigated for agonism or antagonism at hH1R in functional GTPase 
assay and at hH2R, hH3R and hH4R subtypes in functional [
35S]GTPγS assays using the above 
mentioned membrane preparations. In general, the determined EC50 or Kb values of the tested 
compounds were in good accordance to the Ki values determined in radioligand binding assays (cf. 
Table 3.1 and Table 3.2). The hH4R agonistic potency for 3.16 in the GTP S assays was 5-times lower 
compared to the data determined by Savall et al. in a reporter gene assay.3 The EC50 values of 
3.16-3.19 at the hH4R are in the one-digit nM range (2 to 4 nM). These four compounds acted as full 
or almost full agonists ( : 0.8-1.0). The lack of 5-F and/or 6-Me caused a change in H4R selectivity. In 
particular, the antagonistic activity at the hH1R and hH2R (3.16) turned into agonism. The hH2R 
affinity increased, whereas the activities at the hH1R remained negligibly low. EC50 values at the hH2R 
and hH3R ranged from 300 to 10000 nM. Therefore, the specific substitution pattern is important for 
the functional activity, even when the affinity at the hH4R is not influenced. The primary amines 3.22 
and 3.23 did not show notable affinity for hH2, hH3 and hH4 receptors and acted as weak antagonists 
at all hHxR subtypes. The propionamides 3.31 and 3.32 had negligible activity at the hH2R and were 
inactive at the hH3R. Compound 3.32 (EC50 = 1500 nM, : 0.35) was a moderate partial agonist at the 
hH4R, superior to 3.31 (EC50 = 4430 nM, : 0.66) in potency but not in intrinsic activity. The 
2-arylbenzimidazoles 3.62-3.65 and 3.67 bearing histamine-like moieties had higher potencies at the 
hH4R than the parent compound 3.16 (Ki: ~0.3 to 2 nM). Moreover these compounds acted as full 
agonists ( : ~1), which also holds for the histamine analogs 5-methylhistamine, homohistamine, 
imbutamine and 5-methylimbutamine.4 These results are in agreement with data from previous 
studies on imidazole-type hH4R agonists, suggesting that ethylamine and butylamine side chains are 
eqalent substructures. Selectivities over the hH2R were high and ranged from 1100 to 15000-fold. 
Selectivities over the hH3R were similar to 3.16 and decreased with the length of the alkyl linker. The 
introduction of the 5-methyl group led to a strong increase in selectivity towards the hH2R (over 
15000-fold). In addition, compound 3.67, comprising the longest spacer within this series (n = 5), was 
an almost full hH3R agonist, but, in accordance with the data for impentamine,
4 showed no agonistic 
activity at the hH4R. The spacer length of five methylene groups obviously prevents optimal 
orientation of the ligand in the binding pocket of the hH4R. Highest selectivity over the hH3R was 
obtained for 3.71 (EC50 = 2.64 nM; : 0.35, over 34000-fold selectivity over the hH3R) and 1300-fold 
selectivity over the hH2R. For 3.30, the Ki values at the hH2R (Ki = 101 nM) could not be confirmed in 
the GTP S assay (Kb = 2350 nM, : -0.23). Compound 3.70 revealed a Kb value of 18.6 nM ( : -0.20), 
which makes 3.70 a promising candidate for structural optimization toward new H2R antagonists. 
 Table 3.2 Potencies and efficacies of selected synthesized compounds at the hHxR subtypes in functional [
35
S]GTP S assays
[a]
 and [
33
P]GTPase assays.
[b]
  
Compound 
hH1R hH2R hH3R hH4R 
EC50 or 
(Kb) / nM 
 n 
 EC50 or  
(Kb) / nM 
 n 
 EC50 or  
(Kb) / nM 
 n 
 EC50 or  
(Kb) / nM 
 n 
Histamine 190 ± 8
[c]
    1200 ± 300
[c]
 1.00   23.2 ± 7.2
[d,e]
 1.00 2  10.2 ± 1.8
[f,g]
 1.00 4 
Homohistamine n.d.  n.d.  103 ± 63
[h]
 0.81 ± 0.06 3  19.3 ± 2.2
[i]
 0.77 ± 0.06 3 
Imbutamine n.d.  n.d.  3.13 ± 1.1
[j]
 0.82 ± 0.13 3  66.1 ± 24.6
[k]
 0.69 ± 0.07 4 
Impentamine n.d.  n.d.  (57.6 ± 28.8)
[l]
 0.13 ± 0.02 2  (n.d.) -0.01 ± 0.02 3 
5-Methylhistamine n.d.  n.d.  12000 ± 3130 0.70 ± 0.11 3  70.3 ± 44.1
[m]
 0.98 ± 0.03 3 
5-Methylimbutamine n.d.  n.d.  980 0.36 ± 0.11 2  59.4 ± 20.2 0.80 ± 0.08 5 
Thia-5-Methylimbutamine n.d.  n.d.  751 ± 303 0.49 ± 0.05 3  1590 ± 1300 0.70 ± 0.01 3 
3.16 (> 10000) -0.07 ± 0.12 2  (686 ± 175) -0.05 ± 0.02 2  (1520 ± 220) -0.09 ± 0.07 2  2.71 ± 0.55 0.92 ± 0.04 4 
3.17 > 10000 0.52 ± 0.19 2  413 ± 85 0.30 ± 0.07 2  (641 ± 34) -0.04 ± 0.12 2  2.62 ± 0.25 1.00 ± 0.03 2 
3.18 (> 10000) 0.06 ± 0.09 2  (865 ± 163) -0.03 ± 0.09 2  (242 ± 30) -0.52 ± 0.22 2  3.54 ± 0.00 0.96 ± 0.13 2 
3.19 > 10000 0.44 ± 0.17 2  278 ± 4 0.31 ± 0.03 2  (660 ± 1) 0.06 ± 0.01 2  2.36 ± 0.08 0.81 ± 0.02 2 
3.22 (> 10000) n.d. 2  (> 10000) -0.24 ± 0.08 2  (> 10000) -1.24 ± 0.23 2  (> 10000) -0.48 ± 0.07 2 
3.23 (> 10000) n.d. 2  (> 10000) -0.09 ± 0.00 2  (> 10000) -0.72 ± 0.11 2  (> 10000) -0.06 ± 0.09 2 
3.30 n.d.  (2350 ± 1100) -0.47 ± 0.00 2  n.d.  n.d. 
3.31 (> 10000) n.d. 2  (> 10000) -0.10 ± 0.02 2  Inactive
[n]
  4430 ± 1570 0.66 ± 0.02 2 
3.32 (> 10000) n.d. 2  (> 10000) -0.09 ± 0.09 2  Inactive
[n]
  1500 ± 182 0.35 ± 0.20 2 
 Table 3.2 (continued) 
Compound 
hH1R hH2R hH3R hH4R 
EC50 or 
(Kb) / nM 
 n 
 EC50 or (Kb) / 
nM 
 n 
 EC50 or (Kb) / 
nM 
 n 
 EC50 or (Kb) / 
nM 
 n 
3.62 n.d.  (4340 ± 910) -0.09 ± 0.01 3  (107 ± 23) -0.66 ± 0.13 2  0.283 ± 0.17 1.02 ± 0.07 4 
3.63 n.d.  (3040 ± 660) -0.26 ± 0.06 3  (210 ± 4) 0.10 2  1.98 ± 0.57 1.13 ± 0.04 2 
3.64 n.d.  (1340 ± 230) -0.21 ± 0.02 3  (27.0 ± 9.9) -0.06 ± 0.16 2  1.15 ± 0.78 1.03 ± 0.06 5 
3.65 n.d.  n.d.  n.d.  0.488 ± 0.20 1.02 ± 0.10 5 
3.67 n.d.  (719 ± 294) -0.25 ± 0.05 3  30.0 ± 4.0 0.79 ± 0.04 3  (18.1 ± 2.7)
[o]
 -0.27 ± 0.12 3 
3.70 n.d.  (18.6 ± 6.3) -0.20 ± 0.01 2  n.d.  n.d. 
3.71 n.d.  (3420 ± 750) -0.23 ± 0.01 3  (> 90000) -0.70 ± 0.08 2  2.64 ± 0.96 0.97 ± 0.06 4 
[a] [
35
S]GTPγS functional binding assays with membrane preparations of Sf9 cells expressing the hH3R + Gαi2 + Gβ1γ2 or the hH4R + Gαi2 + Gβ1γ2 or the hH2R‐Gsαs fusion 
protein were performed as described in section Pharmacological methods. [b] Steady‐state GTPase activity in Sf9 cell membranes expressing the hH1R + RGS4 was 
determined as described in section Pharmacological methods. [a,b] Reaction mixtures contained ligands at a concentration from 1 nM to 1 mM as appropriate to generate 
saturated concentration-response curves. The intrinsic activity (α) of histamine was set to 1.00 and α values of other compounds were referred to this value. The α values 
of neutral antagonists and inverse agonists were determined at a concentration of 10 μM. The Kb values of neutral antagonists and inverse agonists were determined in 
the antagonist mode versus histamine (1 µM for the hH1R and the hH2R, 100nM for the hH3R and the hH4R, respectively) as the agonist. Kb values were calculated 
according to the Cheng-Prusoff equation.
39
 [c] Data taken from Xie et al. 2006.
40
 [d] ref
5
: EC50 25 nM. [e] ref
41
: EC50 13 nM. [f] ref
5
: EC50 12 nM. [g] ref
41
: EC50 11 nM. 
[h] ref
41
: EC50 40 nM. [i] ref
41
: EC50 200 nM. [j] ref
41
: EC50 0.6 nM. [k] ref
5
: EC50 32 nM. [l] ref
41
: EC50 4 nM. [m] ref
5
: EC50 71 nM. Data from the literature: [d,f,m] EC50 values 
determined in the steady-state GTPase assay on membranes of Sf9 cells expressing the human hH3R or hH4R.
5
 [g–j,l] EC50 values determined from the inhibition of 1mM 
forskolin-induced CRE- -galactosidase activity in SK-N-MC/ hH3 or SK-N-MC/hH4 cells.
41
 [n] Measured at a ligand concentration of 100 μM. [o] The Kb values of 3.67 were 
determined in the antagonist mode versus 3.16 (100 nM); cf. 3.3.2. n.d. means not determined. n gives the number of independent experiments performed in triplicate 
each. 
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3.3.2 Inhibition of the hH4R agonistic effect of 3.16 by standard H4R antagonists 
The pharmacological characterization (competition binding experiments, GTP S- and GTPase assays) 
of all compounds was determined using membranes of Sf9 insect cells expressing the respective HxR 
subtype. When using membranes instead of intact cells, G-proteins are directly accessible to the 
evaluated compounds. Thus, the possibility of direct, receptor independent G-protein activation has 
to be taken into account. In addition, most of the investigated ligands, including the previously 
published potent H4R agonist 3.16, contain the imidazole ring as a polar basic moiety combined with 
a more lipophilic residue. Therefore, and because of the cationic-amphiphilic properties of the 
molecule, a direct interaction of 3.16 with G-proteins cannot be ruled out. Such implications have 
been deetected for many compounds, mainly peptides, but also for cationic-amphiphilic HR 
ligands.42-45 Hence, [35S]GTPγS binding was induced with 3.16 (100 nM) and the effect of increasing 
concentrations of the standard H4R antagonists JNJ7777120 and iodophenpropit and the inverse 
agonist thioperamide, was evaluated. As shown in Figure 3.5, [35S]GTPγS binding was successfully 
inhibited by all three ligands in a concentration-dependent manner. As anticipated, thioperamide 
was more effective than the other standard H4R antagonists due to its inverse agonistic activity at the 
hH4R.  
 
   
Compound Kb / nM Kb(ref) / nM
[a]
 
Thioperamide 103 ± 48 148 ± 16
[a]
 
JNJ7777120 34.6 ± 4.7 25.1 ± 2.7
[a]
 
Iodophenpropit 26.8 ± 9.1 20.9 ± 2.3
[b]
 
3.67 18.1 ± 2.7 8.7 ± 2.3
[c]
 
   
Figure 3.5 Inhibition of the 2-arylbenzimidazole 3.16 stimulated [
35
S]GTPγS binding at the hH4R by the H4R 
antagonists iodophenpropit and JNJ7777120 and the inverse agonist thioperamide. Functional [
35
S]GTPγS 
binding assays with membrane preparations of Sf9 cells expressing the hH4R + Gαi2 + Gβ1γ2 was performed as 
described in section Pharmacological methods. Reaction mixtures contained 100 nM of 3.16. Data were 
analyzed by nonlinear regression and were best fit to sigmoidal concentration-response curves. Data points 
shown are the means of two independent experiments performed in triplicate each. [a] Kb values of the 
reference H4R antagonists were taken from Wifling et al.
46
; [b] Wifling, D. Personal communication, University 
of Regensburg. 2014; [c] Ki value, cf. Table 3.1. 
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The Kb values determined for thioperamide, iodophenpropit and JNJ7777120 for inhibition of the 
response to 3.16 in the functional assay were in good agreement with Kb values from binding studies 
reported by Wifling et al. (Figure 3.5).41,46 These results suggest that 3.16 competes with the H4R 
antagonists for the same binding site. Furthermore, 3.76 was found to be an antagonist at the hH4R, 
with a Kb value of 18.1 nM, which was in good agreement to the Ki value from [
3H]histamine binding 
studies. Summed up, these data confirm that the 2-arylbenzimidazole 3.16 acts as a hH4R agonist in 
the [35S]GTPγS binding assay without direct G-protein stimulation. 
3.3.2.1 Potencies, efficacies and affinities at the mH4R 
Nowadays GPCR ligands are routinely optimized for activity at the human receptor of interest. The 
analysis of the (patho)physiological role of the H4R and its validation as a possible drug target using 
antagonists and agonists in translational animal models are seriously hampered by tremendous 
species‐dependent differences regarding potencies (up to several orders of magnitude, depending on 
the assay system) of the pharmacological tools.46-49 The reason behind is the low homology of the 
human H4R and most of the H4R species variants (hH4R and mH4R: 68%, hH4R and rH4R: 69%).
1,50 
Therefore, with respect to future in vivo studies and better understanding the differences between 
the murine and human H4R’s, the activities of H4R ligands on species orthologues, in particular on the 
murine H4R, should be taken into consideration. To elucidate the potential use of the synthesized 
2-arylbenzimidazoles in murine models, selected compounds (3.16-3.19) were investigated in 
radioligand binding studies determined on HEK-293 cells expressing the mH4R (HEK293-FLAG-mH4R-
His6)
51 using [3H]UR-PI2945 as radioligand. In addition, compounds 3.16, 3.62-3.65, 3.67 and 3.71 
were tested in functional [35S]GTPγS assays using membrane preparations of Sf9 insect cells 
coexpressing the mH4R + Gαi2 + Gβ1γ2.
49 The results are summarized in Table 3.3. The investigated 
compounds 3.16-3.20 showed preference for the human H4R compared to the murine ortholog in 
radioligand binding affinity. The affinity of 3.16 was 10-fold lower at the mH4R (Ki = 113 ± 21 nM) 
than reported.3 The lack of the typical substitution pattern (F and/or Me) led to a 4-6 fold decrease in 
mH4R affinity relative to compound 3.16. In the functional [
35S]GTPγS assays, 3.16 acted as full 
agonist (  = 1.04) with a EC50 value of 139 nM, which was in good accordance to binding data and 
corresponded to  50-fold lower potency compared to the hH4R (cf. Table 3.2).The histamine 
homologs 3.62-3.65 also revealed increased functional activities on the mH4R compared to the data 
for the hH4R (14- to 170-fold), but were still almost full agonists ( : 0.68-0.99).  
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Table 3.3 Affinities, potencies and efficacies of selected synthesized compounds at the mH4R in radioligand 
binding studies
[a]
 and functional [
35
S]GTPγS assays
[b]
 
Compound 
mH4R 
Ki / nM
[a]
 n  EC50 or (Kb) / nM
[b]
  n 
Histamine 129 ± 36 2  3220 ± 424 1.00 3 
3.16 113 ± 21 3  139 ± 22 1.04 ± 0.08 3 
3.17 595 ± 151 3  n.d. 
3.18 520 ± 3 3  n.d. 
3.19 365 ± 142 3  n.d. 
3.62 n.d.  47.4 ± 14.1 0.99 ± 0.06 3 
3.63 n.d.  55.2 ± 15.2 0.74 ± 0.14 3 
3.64 n.d.  21.3 ± 3.6 0.68 ± 0.09 3 
3.65 n.d.  7.0 ± 0.15 0.80 ± 0.19 3 
3.67 n.d.  (1340 ± 0) 0.02 ± 0.06 2 
3.71 n.d.  (6230 ± 220) -0.06 ± 0.07 3 
[a] Determination of mH4R binding by displacement of [
3
H]UR-PI294
5
 (5 nM) from HEK293-FLAG-mH4R-His6 
cells; [b] [
35
S]GTPγS functional binding assays with membrane preparations of Sf9 cells expressing the 
mH4R + Gαi2 + Gβ1γ2 were performed as described in section Pharmacological methods. Reaction mixtures 
contained ligands at a concentration from 1 nM to 1 mM as appropriate to generate saturated concentration-
response curves. The intrinsic activity (α) of histamine was set to 1.00 and α values of other compounds were 
referred to this value. The α values of neutral antagonists and inverse agonists were determined at a 
concentration of 10 μM. The Kb values of neutral antagonists and inverse agonists were determined in the 
antagonist mode versus histamine (10 µM) as the agonist. Kb values were calculated according to the Cheng-
Prusoff equation.
39
 n.d. means not determined. n gives the number of independent experiments performed in 
triplicate each. 
Highest potency was found for the 5-methylimbutamine derivative 3.65 with an excellent EC50 value 
of 7 nM (  = 0.80), regardless of a 14-fold decrease in activity compared to the hH4R. It bears 
mentioning that the introduction of the 5-methyl residue in 3.62 and 3.65 increased activity of the 
corresponding parent compounds 3.16 and 3.64 in the same way at both the mH4R and  the hH4R. By 
analogy with the hH4R, the impentamine derivative 3.67 behaved as a neutral antagonist at the 
mH4R, too, with a Kb value of 1340 nM and an intrinsic activity of 0.02, accompanied by a 74-fold loss 
of activity compared to the hH4R. The reported weak antagonism for 3.71 at the mH4R in a reporter 
gene assay was confirmed (Kb = 6230 nM,  = -0.06; pA2ref = 15800 nM
3). This means that the hH4R 
agonism had switched to antagonism at the murine ortholog, making  3.71 an interesting ligand to 
explore the molecular determinant of differential H4R ortholog activation, e. g., by molecular 
modeling studies. In summary, similar to the results of previous studies with agonists such as UR‐
PI37652 and trans‐(+)‐(1S,3S)‐UR‐RG98,20 the investigation of this class of 2-arylbenzimidazoles 
uncovered differences between activities on the human and murine H4R ortholog. Compound 3.65, 
bearing a 5-methylimbutamine residue was the most potent agonist at the murine H4R and may be 
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considered a potential pharmacological tool in mouse models. Compounds such as 3.71 may be of 
special interest in future studies due to biased signaling for human and murine orthologs within one 
type of functional assay. 
3.3.3 Muscarinic receptor subtype affinities of 3.16 on CHO-M1 and CHO-M2 cells 
Numerous compounds bearing a benzimidazole moiety with different pharmacological activities are 
known from the literature, e.g., as angiotensin AT1 receptor antagonists or proton-pump 
inhibitors.53,54 In order to further explore the selectivity of the synthesized 2-arylbenzimidazoles, 3.16 
was tested exemplarily in radioligand binding assays at human muscarinic M1 and M2 receptors stably 
expressed in CHO cells, which were available in our laboratories. For both muscarinic receptor 
subtypes the determined Ki values were in the micromolar range, amounting 6350 nM for the hM1R 
and 2510 nM for the hM2R, respectively, corresponding to 570-fold or 220-fold lower affinity 
compared to the hH4R. Hence, the inclusion of other targets, GPCRs as well as non-GPCR receptors, is 
important for additional pharmacological investigation of these benzimidazole-type ligands. 
 
    
 Ki / nM n 
 
hM1R
[a]
 6350 ± 490 2 
 
hM2R
[a]
 2510 ± 152 2  
    
  
Figure 3.6 Competition binding curves of 3.16 at the hM1/2R subtypes. [a] Determination of hM1R or hM2R binding 
data by displacement of [
3
H]N-methylscopolamine (0.2 nM) from CHO-K9 cells expressing the hM1R or the hM2R (cf. 
Pharmacology section). n gives the number of independent experiments performed in triplicate each. 
3.4 Summary and Outlook 
In search for new selective and potent hH4R and mH4R agonists we tested a series of 
2-arylbenzimidazoles starting from the structure of the recently published H4R agonist 3.16.
3 
Radioligand binding studies and GTP S assays using membranes of Sf9 insect cells expressing the 
respective human histamine receptor subtype revealed 20-fold lower affinity and potency of 3.16 at 
the hH4R compared to the data gained from different assays and reported in the literature. Further 
investigations showed that the substitution pattern at the 2-arylbenzimidazole is not essential for the 
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activity at the hH4R, but is important for functional selectivity over the other hHxR subtypes as well as 
for mH4R affinity. Aiming at improved selectivity for the H4R, the histamine motif in 3.16 was methyl-
substituted or varied regarding the chain. Extension of the carbon chain between imidazole and 
amino group from two (as in the histamine derivative 3.16) up to four methylene groups 
(imbutamine derivative 3.64) was tolerated, revealing higher affinities and potencies, in part in the 
sub-nanomolar range. By incorporation of impentamine (3.67) agonism switched to antagonism at 
the hH4R, and antagonism to agonism at the hH3R. In addition, compound 3.67 showed higher 
affinity at the hH3R than at the hH4R (cf. Figure 3.6).  
 
Figure 3.7 Structure-activity relationships of 2-arylbenzimidazole-type H4R ligands. 
Besides the introduction of a 5-methyl substituent at the imidazole ring, rigidization to a 
spinaceamine derivative (3.71) was most effective regarding H4R selectivity. Structural changes with 
the aim to replace the imidazole moiety, for example by introduction of guanidines, amides and 
aromatic residues, resulted in a decrease in affinity at the hH4R. Thus, only compounds bearing two 
basic amino functions showed moderate to very high affinity at the hH4R. With respect to future 
studies in this field, the most nitrogen-containing aliphatic residues or heterocycles bearing two basic 
moieties should be considered as promising bioisosteres for replacement of the imidazole ring. The 
imidazole 3.70, in which the linker connecting the secondary amine and the imidazole has a length of 
six atoms, has high affinity at the hH2R, with almost 50-fold selectivity over the hH3R and almost 
150 fold selectivity over the hH4R, respectively. These data suggest that the 2-arylbenzimidazole 
scaffold alone is not the key to hH4R affinity. As displayed, high affinity and selectivity is possible for 
the hH2R, hH3R and hH4R as well, depending on appropriate ‘decoration’ of the scaffold. Affinities 
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and activities for this class of 2-arylbenzimidazoles at the mH4R were lower compared to the data for 
the hH4R. Such differences were to be expected due to the low homology of hH4R and mH4R (68%) 
and in view of published data for various H4R ligands. Nevertheless, the 5-methylimbutamine 
derivative 3.65, suprisingly, revealed a one-digit nanomolar EC50 value with almost full mH4R agonist 
activity; this compound might be useful as a pharmacological tool for studies on murine receptors. 
Moreover, the conformationally constrained analog 3.71 proved to be an agonist at the hH4R and an 
antagonist at the mH4R, respectively. This makes 3.71 an interesting tool for investigations on the 
differences in the activation mechanisms of H4R orthologs at the molecular level and an auspicious 
scaffold for molecular modeling studies as well as ligand-based rational design. 
The construction of propionic amides as potential 
radioligands for the human and murine H4R based 
on the arylbenzimidazole scaffold yielded 
compounds with strongly decreased affinity, 
obviously due to the loss of basicity by conversion 
of an amino group to a non-basic carboxylic amide. 
Therefore, to further pursue the [3H]propionylation 
strategy, future projects should focus on attaching the propionic residues in a different part of the 
molecule, e. g. at the functionalized heterocyle, to retain at least two basic moieties in the core 
structure of the molecule. As an alternative approach enabling tritium labeling, the introduction of a 
methyl group residue at a basic center could be explored, e.g. the methylation of the secondary 
amine in 3.62 or 3.65 with the help of methyl iodide or methyl tosylate (Figure 3.8). Both alkylating 
agents are commercially available for radiolabeling in high specific activity and the labeling strategy 
with [3H]MeI has been established in our laboratory (cf. Chapter 6 and Appendix). By analogy, 
according to this concept, the methylation of 3.70 could be explored to generate a new radioligand 
for the hH2R. 
In conclusion, the search for potent and selective H4R agonists bearing a 2-arylbenzimidazole scaffold 
derived from 3.16 resulted in a series of ligands with high affinity and functional activity. The results 
may contribute to a better understanding of the structure-activity- and structure-selectivity 
relationships of H4R ligands on human and murine receptor orthologs. Moreover, selected 
compounds harbor the potential of being used as pharmacological tools to further investigate the 
(patho)physiological function of the H4R. In addition, high affinity at the hH2R, the hH3R, the hH4R and 
the mH4R depending on the substitution pattern make the 2-arylbenzimidazole building block an 
extremely versatile scaffold to play around with subtype, functional and ortholog selectivity in the 
field of histamine receptors. 
 
Figure 3.8 Methylated 2-arylbenzimidazoles. 
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3.5 Experimental Section 
3.5.1 Chemistry 
3.5.1.1 General conditions 
Chemicals and solvents were purchased from the following suppliers: Merck KGaA (Darmstadt, 
Germany), Acros Organics (Geel, Belgium), Sigma Aldrich GmbH (Munich, Germany) and TCI (Tokyo, 
Japan). All solvents were of analytical grade or distilled prior to use and stored over molecular sieves 
(4 Å) under protective gas. Deuterated solvents for NMR spectroscopy were from Deutero GmbH 
(Kastellaun, Germany). DMF was purchased from Sigma-Aldrich Chemie GmbH and stored over 3 Å 
molecular sieves. Millipore water was used throughout for the preparation of buffers and HPLC 
eluents. If moisture-free conditions were required, reactions were performed in dried glassware 
under inert atmosphere (argon or nitrogen). Column chromatography was carried out using Merck 
silica gel Geduran 60 (0.063-0.200 mm) and Merck silica gel 60 (0.040-0.063 mm) for flash-column 
chromatography. In certain cases, flash-chromatography was performed on an Intelli Flash-310 Flash-
Chromatography Workstation from Varian Deutschland GmbH (Darmstadt, Germany). Reactions 
were monitored by thin layer chromatography (TLC) on Merck silica gel 60 F254 aluminium sheets 
and spots were visualized with UV light at 254 nm and/or iodine vapor, ninhydrine spray, vanillin 
solution, or ammonium molybdate/cerium(IV) sulfate solution. IR spectra were measured on a FTS 
3000 MX spectrometer (Excalibur Series) from Bio-Rad (USA) equipped with an attenuated total 
reflectance (ATR) unit (Specac Golden Gate Diamond Single Reflection ATR System). UV‐ and VIS 
spectra were recorded on a Cary 100 UV/VIS photometer (Varian Inc., Mulgrave, Victoria, Australia). 
Nuclear Magnetic Resonance (1H NMR and 13C NMR) spectra were recorded on an Avance-300 
(1H: 300 MHz, 13C: 75 MHz), Avance-400 (1H: 400 MHz, 13C: 101 MHz), or Avance-600 (1H: 600 MHz, 
13C: 151 MHz) NMR spectrometer from Bruker BioSpin (Karlsruhe, Germany). Tetramethylsilane was 
added as internal standard (chemical shift δ = 0 ppm) to all samples. Multiplicities are specified with 
the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), p (quintet), m (multiplet), 
bs (for broad singulett), as well as combinations thereof. The multiplicity of carbon atoms (13C-NMR) 
was determined by DEPT 135 and DEPT 90 (distortionless enhancement by polarization transfer): 
“+” primary and tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon atom 
(negative DEPT 135 signal), “quat” quaternary carbon atom. In certain cases 2D-NMR techniques 
(HSQC, HMQC, HMBC, and COSY) were used to assign 1H and 13C chemical shifts. Low-resolution mass 
spectrometry (LRMS) was performed on a Finnigan ThermoQuest TSQ 7000 instrument using an 
electrospray ionization (ESI) source or on a Finnigan SSQ 710A instrument (EI, 70 eV). The compounds 
were analyzed by LC-MS using the following LC method (Agilent 1100 Series HPLC): Column: 
Phenomex Luna C18, 2.5 μm, 50 x 2.1 mm HST (Phenomenex, Aschaffenburg, Germany); column 
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temperature: 40 °C; flow: 0.40 mL/min; solvent A: MeCN, solvent B: 0.1% aq. formic acid; gradient 
program: 0–1 min: A/B 5:95, 1–8 min: 5:95–98:2, 8–11 min: 98:2, 11–12 min: 98:2–5:95, 
12-15 min: 5:95. High-resolution mass spectrometry (HRMS) was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an ESI source. 
Melting points (mp) were measured on a Büchi 530 (Büchi GmbH, Essen, Germany) and are 
uncorrected. Lyophilisation of the products was done with a Christ alpha 2‐4 LD, equipped with a 
Vacuubrand RZ 6 rotary vane vacuum pump. Preparative HPLC was performed with a pump model 
K-1800 (Knauer, Berlin, Germany), the column was a Eurospher-100 (250 x 32 mm) (Knauer, Berlin, 
Germany) or a Nucleodur 100‐5 C18 ec (250 × 21 mm, 5 μm (Macherey‐Nagel, Düren, Germany), 
which was attached to the UV-detector model K-2000 (Knauer, Berlin, Germany). UV-detection was 
done at 220 or 254 nm. The temperature was between RT and 30 °C and the flow rate between 18 
and 37 mL/min. The mobile phase was 0.1% TFA in millipore water and MeCN. All compounds were 
filtered through PTFE‐filters (25 mm, 0.2 μm, Phenomenex Ltd., Aschaffenburg, Germany) prior to 
preparative HPLC. Analytical HPLC analysis was performed on a system from Merck, composed of an 
L‐5000 controller, a 655A‐12 pump, a 655A‐40 auto sampler and an L‐4250 UV‐VIS detector. Except 
for 3.30, 3.37, 3.42, 3.62, 3.63 and 3.68 the column was a Eurospher-100 (250 x 4 mm, 5 µm) 
(Knauer, Berlin, Germany, t0 = 3.32 min) at a flow rate of 0.8 mL/min. For 3.30, 3.37, 3.42, 3.62, 3.63 
and 3.68 the column was a Luna C18(2) (150 × 4.6 mm, 3 μm) (Phenomenex, Aschaffenburg, 
Germany, t0 = 2.88 min). UV detection was done at 220 nm. Mixtures of 0.05% TFA in MeCN and 
0.05% aq. TFA were used as mobile phase. Helium degassing prior to HPLC analysis was necessary. 
Compound purities were calculated as percentage peak area of the analyzed compound by UV 
detection at 220 nm. The capacity (retention) factors were calculated according to k = (tR-t0)/t0. 
3.5.2 Chemistry 
3.5.2.1 Preparation of the imidazole 3.2 
N-Trityl-2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.1)55,56 
To a solution of histamine dihydrochloride (3.7 g, 20 mmol, 1 eq) and NEt3 (8.1 g, 80 mmol, 4 eq) in 
CHCl3 (50 mL) was added dropwise a solution of trityl chloride (22.3 g, 80 mmol, 4 eq) in CHCl3 
(50 mL) under external cooling with ice within 1.5 h. The mixture was allowed to warm up at rt and 
stirred for 27 h. The solvent was evaporated under reduced pressure, and the solid residue was 
suspended in 100 mL of water. After stirring for 1 h, the product was extracted with CHCl3 (2 x 
150 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by 
flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 30 min: A/B 100/0 – 90/1 (v/v), SF 
15-120 g) and afforded a yellow foam-like solid (5.3 g, 46%), mp 210 °C (lit.55 202-203 °C). Rf = 0.6 
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(CH2Cl2/MeOH 25:1. 
1H-NMR (300 MHz, CDCl3): δ (ppm) 2.40 (t, J = 6.2, 2H), 2.73 (t, J = 6.2, 2H), 6.51 
(s, 1H), 7.08-7.31 (m, 24H), 7.34 (d, J = 1.0, 1H), 7.35-7.45 (m, 6H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 
29.59, 42.89, 70.87, 75.18, 118.62, 126.19, 127.82, 128.06, 128.11, 128.80, 129.87, 138.47, 140.19, 
142.71, 146.48. MS (LC-MS, ESI): m/z 596.3 [M+H+]. C43H37N3 (595.77). 
 
2-(1-Trityl-1H-imidazol-4-yl)ethanamine (3.2)55,56 
To a solution of 3.1 (4.7 g, 7.92 mmol) in CH2Cl2 (25 mL) at 0 °C, 1.3 mL of TFA (1.94 g, 17.0 mmol, 
2.15 eq) were added dropwise. After stirring for 10 min at the same temperature, the mixture was 
allowed to warm up to rt and was stirred for additional 4 h. After removing the solvent, the residue 
was neutralized with saturated NaHCO3(aq) (100 mL) and extracted with CHCl3 (3 x 100 mL), washed 
with water (400 mL), brine (400 mL) and dried over anhydrous Na2SO4. After removing the solvent, 
the residue was chromatographed with CHCl3/MeOH/NEt3 (94/5/1) on silica to obtain a yellow foam-
like solid (2.0 g, 61%), mp 111 °C (lit.55 126-128 °C). Rf = 0.25 (CHCl3/MeOH/NEt3 94/5/1). 
1H-NMR 
(300 MHz, CDCl3): δ (ppm) 2.84 (t, J = 6.5, 2H), 3.20 (t, J = 6.8, 2H), 6.58 (s, 1H), 7.16-7.01 (m, 6H). 
7.37-7.22 (m, 10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 27.27, 40.70, 75.39, 118.72, 128.18, 129.80, 
138.04, 138.52, 142.31. MS (LC-MS, ESI): m/z 354.0 [M+H+]. C24H23N3 (353.46). 
 
3.5.2.2 Preparation of the benzimidazoles 3.7-3.10 
General procedure for the synthesis of the benzimidazoles 3.7-3.109 
A solution of the pertinent phenylenediamine (3.3 or 3.4, 1.00-1.04 eq) and the respective 
benzaldehyde (3.5 or 3.6, 1 eq) in DMF was treated with Na2S2O5 (1 eq). After heating for 2 h at 90 °C, 
the reaction mixture was cooled to rt and then diluted with ice/water. The resulting suspension was 
stirred for 4 h, then cooled to 0 °C and filtered through a glass fritted funnel, the solid washed with 
cold water and dried in vacuo. 
 
4-(5-Fluoro-4-methyl-1H-benzo[d]imidazole-2-yl)-3-methylphenol (3.7) 
The title compound was prepared from 3.3 (8.6 g, 0.061 mol, 1 eq), 3.5 (8.4 g, 0.061 mol, 1 eq) and 
Na2S2O5 (11.7 g, 0.061 mol, 1 eq) in DMF (120 mL) according to the general procedure yielding a 
brown solid (15.6 g, 99%), mp >261 °C (decomposed). Rf = 0.14 (CH2Cl2/MeOH 90/10). 
1H-NMR 
(300 MHz,  DMSO-d6): δ (ppm) 2.45 (s, 3H), 2.52 (d, J = 0.9, 3H), 6.83-6.94 (m, 2H), 7.33-7.44 (m, 1H), 
7.62 (d, J = 8.3, 1H), 7.67 (dd, J = 8.9, 4.3, 1H), 10.76 (bs, TFA). 13C-NMR (75 MHz,  DMSO-d6 + 10 µL 
TFA): δ (ppm) 9.37 (d, J = 3.3), 19.84, 110.77 (d, J = 23.4), 112.45 (d, J = 10.2), 113.63, 113.74 (d, J = 
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26.5), 114.15, 118.09, 128.49, 132.57 (d, J = 10.1), 133.01, 139.95, 151.42 (d, J = 1.1), 157.86 (d, J = 
238.7), 158.47 (q, J = 32.8, TFA), 161.23. MS (LC-MS, ESI): m/z 256.9 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C15H14FN2O
+: 257.1085, found: 257.1085. 
 
4-(1H-Benzo[d]imidazol-2-yl)phenol (3.8)57 
The title compound was prepared from 3.4 (5.1 g, 0.047 mol, 1.04 eq), 3.6 (5.5 g, 0.045mol, 1 eq) and 
Na2S2O5 (8.6 g, 0.045 mol, 1 eq) in DMF (90 mL) according to the general procedure yielding a tan 
solid (6.8 g, 72%), mp >272 °C (decomposed, lit.57 279 °C) . Rf = 0.31 (CH2Cl2/MeOH 96/4). 
1H-NMR 
(300 MHz,  DMSO-d6): δ (ppm) 7.06 (d, J = 8.8, 2H), 7.44 (dd, J = 3.2, 6.1, 2H), 7.74 (dd, J = 3.1, 6.1, 
2H), 8.11 (d, J = 8.8, 2H), 10.76 (bs, TFA). 13C-NMR (75 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 113.85 
(2C), 114.08, 116.63 (2C), 125.21 (2C), 130.05 (2C), 132.56 (2C), 149.79, 158.47 (q, J = 32.8, TFA), 
162.34. MS (GC-MS, EI): m/z 210.1 [M+•]. C13H10N2O (210.23). 
 
4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)phenol (3.9)9 
The title compound was prepared from 3.3 (200 mg, 1.43 mmol, 1.04 eq), 3.6 (167 mg, 1.37 mmol, 
1 eq) and Na2S2O5 (260 mg, 1.37 mmol, 1 eq) in DMF (3 mL) according to the general procedure 
yielding a yellow powder (216 mg, 65%), mp >249 °C (decomposed). Rf = 0.17 (CH2Cl2/MeOH 96/4). 
1H-NMR (300 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.52 (d, J = 1.1, 1H), 7.08 (d, J = 8.8, 2H), 7.30-
7.40 (m, 1H), 7.61 (dd, J = 4.3, 8.9, 1H), 8.09 (d, J = 8.8, 2H), 10.86 (bs, TFA). 13C-NMR (75 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 9.48 (d, J = 3.2), 110.82 (d, J = 23.7), 112.07 (d, J = 10.0), 113.28, 
113.93 (d, J = 26.8), 115.41 (q, J = 289.1, TFA), 116.63 (2C), 128.08, 130.63 (2C), 132.24 (d, J = 10.1), 
150.90, 158.16 (d, J = 238.9), 158.66 (q, J = 37.9, TFA), 162.65. MS (GC-MS, EI): m/z 242.2 [M+•]. 
C14H11FN2O (242.25). 
 
4-(1H-Benzo[d]imidazol-2-yl)-3-methylphenol (3.10) 
The title compound was prepared from 3.4 (1.0 g, 9.25 mmol, 1.04 eq), 3.5 (1.2 g, 8.89 mmol, 1 eq) 
and Na2S2O5 (1.7 g, 8.89 mmol, 1 eq) in DMF (18 mL) according to the general procedure yielding a 
brown powder (0.63 g, 61%), mp >218 °C (decomposed). Rf = 0.16 (CH2Cl2/MeOH 96/4). 
1H-NMR 
(300 MHz,  DMSO-d6): δ (ppm) 2.55 (s, 3H), 6.70-6.78 (m, 2H), 7.16 (dd, J = 6.0, 3.2, 2H), 7.49-7.56 (m, 
1H), 7.58 (d, J = 8.2, 2H), 9.76 (s, 1H), 12.43 (bs, 1H). 13C-NMR (75 MHz,  DMSO-d6 + 10 µL TFA): δ 
(ppm) 19.95, 113.77, 114.07, 115.87 (q, J = 291.7, TFA), 117.80, 118.35, 125.83 (2C), 131.65 (2C), 
133.10, 140.07, 150.06, 158.85 (q, J = 36.4, TFA), 161.52. MS (GC-MS, EI): m/z 224.1 [M+•]. C14H12N2O 
(224.26). 
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3.5.2.3 Preparation of the benzimidazolylphenyl chloroalkyl ether 3.11-3.159 
General procedure for the O-alkylation of (hydroxyphenyl)benzimidazoles9 
A suspension of the pertinent (hydroxyphenyl)benzimidazole (1.0 eq), and Cs2CO3 (1.0-1.5 eq) in 
MeCN was treated with the respective alkyl halides (1.0-1.1 eq) and the reaction mixture heated to 
70 °C for 17 h. The reaction mixture was cooled to rt, diluted with CH3Cl and filtered through a glass 
fritted funnel to remove inorganic solids. The filtrate was concentrated under reduced pressure and 
purified by flash-chromatography. 
 
2-[4-(3-Chloropropoxy)-2-methylphenyl]-5-fluoro-4-methyl-1H-benzo[d]imidazole (3.11)9 
The title compound was prepared from 3.7 (1.0 g, 3.90 mmol, 1 eq), 1-bromo-3-chloropropane 
(0.61 g, 3.90 mmol, 1 eq) and Cs2CO3 (1.9 g, 5.85 mmol, 1.5 eq) in MeCN (12 mL) according to the 
general procedure. The crude product was purified by flash‐chromatography (eluent hexanes (A), 
EtOAc (B); gradient: 0 to 30 min: A/B 100/0 – 50/50 (v/v), SF 15-24 g) yielding a yellow foam-like solid 
(0.53 g, 44%), mp >261 °C (decomposed). Rf = 0.46 (CH2Cl2/MeOH 96/4). A sample of 50 mg was 
purified by preparative HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. 
TFA 30/70−60/40, tR = 12.5 min). MeCN was removed under reduced pressure. After lyophilisation 
3.11 (hydrotrifluoroacetate) was obtained as white fluffy solid (33.8 mg, 50%) nm. RP-HPLC (220 nm): 
99.4% (gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, 31-40 min: 90/10, tR = 22.5 min, k = 
10.1). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.21 (p, J = 6.3, 2H), 2.50 (s, 3H), 2.52 (d, J = 
1.2, 3H), 3.81 (t, J = 6.4, 2H), 4.22 (t, J = 6.1, 2H), 7.06-7.13 (m, 2H), 7.36-7.42 (m, 1H), 7.69 (dd, J = 
4.3, 8.9, 1H), 7.73 (d, J = 8.5, 1H), 13.14 (bs, TFA). 13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 
9.37 (d, J = 3.2), 19.82, 31.61, 41.86, 64.81, 110.84 (d, J = 23.6), 112. 51 (d, J = 7.2), 112.55, 113.94 (d, 
J = 27.0), 115.74 (q, J = 291.2, TFA), 115.93, 117.22, 128.40, 132.48 (d, J = 10.2), 132.97, 140.16, 
150.89 (d, J = 1.5), 158.04 (d, J = 239.1), 158.66 (q, J = 36.5, TFA), 161.50. MS (LC-MS, ESI): m/z 333.0 
[M+H+]. HRMS (EI-MS): m/z M+• calcd. for C18H18ClFN2O: 332.1092, found: 332.1092. 
 
2-[4-(3-Chloropropoxy)phenyl]-1H-benzo[d]imidazole (3.12)9 
The title compound was prepared from 3.8 (5.7 g, 0.027 mol, 1 eq), 1-bromo-3-chloropropane (4.3 g, 
0.027 mol, 1 eq) and Cs2CO3 (9.2 g, 0.028 mol, 1.04 eq) in MeCN (87 mL) according to the general 
procedure. The crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); 
gradient: 0 to 60 min: A/B 100/0 – 96/4 (v/v), SF 65-400 g) yielding a white powder (3.6 g, 46%), mp 
204 °C. Rf = 0.31 (CH2Cl2/MeOH 96/4). 
1H-NMR (300 MHz,  DMSO-d6): δ (ppm) 2.20 (p, J = 5.9, 2H), 
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3.79 (t, J = 6.1, 2H), 4.20 (t, J = 5.5, 2H), 7.24 (d, J = 8.5, 2H), 7.44-7.56 (m, 2H), 7.73-7.84 (m, 2H), 8.18 
(d, J = 8.5, 2H). 13C-NMR (75 MHz,  DMSO-d6): δ (ppm) 31.57, 41.83, 65.03, 113.87 (2C), 115.29, 
115.68 (2C), 125.65 (2C), 129.98 (2C), 131.91 (2C), 149.03, 159.20 (d, J = 34.9, TFA), 162.39.MS (LC-
MS, ESI): m/z 287.1 [M+H+]. C16H15ClN2O (286.76). 
 
2-[4-(3-Chloropropoxy)phenyl]-5-fluoro-4-methyl-1H-benzo[d]imidazole (3.13) 
The title compound was prepared from 3.9 (158 mg, 0.652 mmol, 1 eq), 1-bromo-3-chloropropane 
(113 mg, 0.717 mmol, 1.1 eq) and Cs2CO3 (319 g, 0.978 mmol, 1.5 eq) in MeCN (2 mL) according to 
the general procedure. The crude product was purified by flash-chromatography (eluent hexanes (A), 
EtOAc (B); gradient: 0 to 40 min: A/B 100/0 – 50/50 (v/v), SF 10-4 g) yielding a yellow foam-like solid 
(129 mg, 62%), mp 146 °C. Rf = 0.35 (CH2Cl2/MeOH 96/4). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): 
δ (ppm) 2.23 (p, J = 6.2, 2H), 2.55 (d, J = 1.3, 3H), 3.82 (t, J = 6.4, 2H), 4.26 (t, J = 6.1, 2H), 7.33 (d, J = 
9.0, 2H), 7.35-7.41 (m, 1H), 7.65 (dd, J = 4.2, 8.8, 1H), 8.20 (d, J = 9.0, 2H), 9.93 (bs, TFA). 13C-NMR 
(101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.46 (d, J = 3.4), 31.59, 41.85, 65.14, 110.88 (d, J = 23.8), 
112.18 (d, J = 10.4), 114.08 (d, J = 27.0), 115.19, 115.26 (q, J = 288.7, TFA), 115.71 (2C), 128.15, 
130.44 (2C), 132.33 (d, J = 10.2), 150.45 (d, J = 1.4), 158.18 (d, J = 239.1), 158.55 (q, J = 38.2, TFA), 
162.60. MS (LC-MS, ESI): m/z 318.9 [M+H+]. HRMS (ESI-MS): [M+H+] calcd. for C17H17ClFN2O
+: 
319.1008, found: 319.1015. 
 
2-[4-(3-Chloropropoxy]-2-methylphenyl)-1H-benzo[d]imidazole (3.14) 
The title compound was prepared from 3.10 (377 mg, 1.68 mmol, 1 eq), 1-bromo-3-chloropropane 
(291 mg, 1.85 mmol, 1.1 eq) and Cs2CO3 (822 mg, 2.52 mmol, 1.5 eq) in MeCN (5 mL) according to the 
general procedure. The crude product was purified by flash-chromatography (eluent hexanes (A), 
EtOAc (B); gradient: 0 to 45 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g) yielding a white powder (82 mg, 
16%), mp 192 °C. Rf = 0.40 (CH2Cl2/MeOH 96/4). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 
2.22 (p, J = 6.2, 2H), 2.53 (s, 3H), 3.82 (t, J = 6.4, 2H), 4.23 (t, J = 6.0, 2H), 7.08-7.15 (m, 2H), 7.59 (dd, J 
= 3.1,6.1, 2H), 7.74 (d, J = 8.4, 1H), 7.85 (dd, J = 3.1, 6.1, 2H), 8.88 (bs, TFA). 13C-NMR (101 MHz, 
DMSO-d6 + 10 µL TFA): δ (ppm) 19.87, 31.59, 41.88, 64.85, 112.81, 114.08, 115.27 (q, J = 288.8, TFA), 
115.54, 117.41, 125.98, 131.53, 132.98, 140.16, 149.57, 158.52 (q, J = 38.1, TFA), 161.66. MS (LC-MS, 
ESI): m/z 301.0 [M+H+]. HRMS (ESI-MS): [M+H+] calcd. for C17H18ClN2O
+: 301.1109, found: 301.1102. 
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2-[4-(4-Chlorobutoxy)-2-methylphenyl]-5-fluoro-4-methyl-1H-benzo[d]imidazole (3.15) 
The title compound was prepared from 3.7 (500 mg, 1.95 mmol, 1 eq), 1-bromo-4-chlorobutane 
(335 mg, 1.95 mmol, 1 eq) and Cs2CO3 (953 mg, 2.93 mmol, 1.5 eq) in MeCN (6 mL) according to the 
general procedure. The crude product was purified by flash-chromatography (eluent hexanes (A), 
EtOAc (B); gradient: 0 to 45 min: A/B 100/0 – 75/25 (v/v), SF 15-24 g) yielding a yellow sticky oil 
(360 mg, 53%). Rf = 0.44 (CH2Cl2/MeOH 96/4). 
1H-NMR (300 MHz,  DMSO-d6): δ (ppm) 1.93-2.03 (m, 
4H), 2.53 (s, 3H), 2.57 (s, 3H), 3.64 (t, J = 6.2, 2H), 4.04 (t, J = 5.7, 2H), 6.75-6.85 (m, 2H), 6.99 (dd, J = 
10.2, 8.8, 1H), 7.33 (s, 1H), 7.56 (d, J = 8.5, 1H). MS (LC-MS, ESI): m/z 346.9 [M+H+]. C19H20ClFN2O 
(346.83). 
 
3.5.2.4 Preparation of the imidazole derivatives 3.16-3.20 
General procedure for the synthesis of the imidazole derivatives 3.16-3.209 
The alkyl halides (1 eq) K2CO3 (2 eq), NaI (1 eq) and 2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.2, 3 eq) 
in n-butanol were heated to 90 °C for 15-94 h. The reaction mixture was cooled to rt, diluted with 
CHCl3 and filtered through a glass fritted funnel to remove inorganic solids. The filtrate was 
concentrated under reduced pressure and purified by flash-chromatography. The residue was 
dissolved in CH2Cl2, TFA was added and the reaction mixture was stirred until removal of the 
protecting group was complete (5-8 h, TLC control). After evaporation of the solvent in vacuo, the 
crude product was purified by preparative RP-HPLC. 
 
N-[2-(1H-Imidazol-4-yl)ethyl]-3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]-
propan-1-amine tris(hydrotrifluoroacetate) (3.16) 
The title compound was prepared from 3.11 (97 mg, 0.291 mmol, 1 eq), K2CO3 (81 mg, 0.583 mmol, 
2 eq), NaI (44 mg, 0.291 mmol, 1 eq) and 2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.2, 309 mg, 
0.874 mmol, 3 eq) in n-butanol (1.2 mL) by heating for 23 h according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH + 1% NEt3 (B); 
gradient: 0 to 60 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g). Deprotection in CH2Cl2 (5 mL) and TFA 
(1 mL) followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: 
MeCN/0.1% aq. TFA 20/80−50/50, tR = 7.6 min) afforded 3.16 (tris(hydrotrifluoroacetate)) as white 
fluffy solid (34.5 mg, 19%). Rf = 0.11 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 287, 254, 
207, 190 nm. RP-HPLC (220 nm): 99.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 
min: 90/10, tR = 11.2 min, k = 3.0). 
1H-NMR (600 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.12 (p, J = 6.9, 
2H), 2.50 (s, 3H), 2.53 (s, 3H), 3.07 (t, J = 7.5, 2H), 3.13-3.19 (m, 2H), 3.29-3.35 (m, 2H), 4.19 (t, J = 6.0, 
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2H), 7.06-7.10 (m, 2H), 7.42 (d, J = 9.2, 1H), 7.54 (s, 1H), 7.70 (dd, J = 4.1, 8.9, 1H), 7.74 (d, J = 8.4, 
1H), 8.87 (t, J = 5.1, 2H), 9.05 (d, J = 1.2, 1H), 13.82 (bs, TFA), 14.33 (s, 1H), 14.65 (s, 1H). 13C NMR 
(151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.36 (d, J = 3.1), 19.78, 21.19, 25.45, 44.27, 45.07, 65.14, 
110.85 (d, J = 23.6), 112.51, 112.52 (d, J = 9.4), 114.10 (d, J = 26.7), 115.33 (q, J = 289.4, TFA), 115.84, 
116.99, 117.13, 128.23, 128.78, 132.32 (d, J = 10.1), 133.01, 134.43, 140.11, 150.79, 157.98 (d, J = 
239.6), 158.41 (q, J = 37.7, TFA), 161.40. MS (LC-MS, ESI): m/z 408.0 [M+H+]. HRMS (EI-MS): m/z M+• 
calcd. for C23H26FN5O: 407.2121, found: 407.2121. 
 
3-[4-(1H-Benzo[d]imidazol-2-yl)phenoxy]-N-[2-(1H-imidazol-4-yl)ethyl]propan-1-amine 
tris(hydrotrifluoroacetate) (3.17) 
The title compound was prepared from 3.12 (70 mg, 0.244 mmol, 1 eq), K2CO3 (68 mg, 0.488 mmol, 
2 eq), NaI (37 mg, 0.244 mmol, 1 eq) and 2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.2, 259 mg, 
0.732 mmol, 3 eq) in n-butanol (1.5 mL) by heating for 22 h according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH + 1% NEt3 (B); 
gradient: 0 to 60 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g). Deprotection in CH2Cl2 (5 mL) and TFA 
(1 mL) followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: 
MeCN/0.1% aq. TFA 20/80−50/50, tR = 11.1 min) afforded 3.17 (tris(hydrotrifluoroacetate)) as white 
fluffy solid (20.3 mg, 14%). Rf = 0.10 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 308, 253, 
202, 191 nm. RP-HPLC (220 nm): 99.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 
min: 90/10, tR = 6.9 min, k = 1.5). 
1H-NMR (600 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.10-2.17 (p, J = 
6.3, 2H), 3.07 (t, J = 7.5, 2H), 3.13-3.20 (m, 2H), 3.28-3.35 (m, 2H), 4.24 (t, J = 6.0, 2H), 7.31 (d, J = 8.9, 
2H), 7.54 (s, 1H), 7.56 (dd, J = 3.1, 6.1, 2H), 7.83 (dd, J = 3.1, 6.1, 2H), 8.21 (d, J = 8.9, 2H), 8.86 (s, 2H), 
9.05 (d, J = 1.1, 1H), 13.82 (bs, TFA). 13C NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 21.18, 25.37, 
44.22, 45.05, 65.38, 113.85 (2C), 115.29, 115.33 (q, J = 289.4, TFA), 115.77 (2C), 116.98, 125.90 (2C), 
128.77, 130.07 (2C), 131.71 (2C), 134.42, 149.07, 158.51 (q, J = 37.7, TFA), 162.34. MS (LC-MS, ESI): 
m/z 362.1 [M+H+]. HRMS (EI-MS): m/z M+• calcd. for C21H23FN5O: 361.1903, found: 361.1901. 
 
N-[2-(1H-Imidazol-4-yl)ethyl]-3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)phenoxy]propan-1-
amine tris(hydrotrifluoroacetate) (3.18) 
The title compound was prepared from 3.13 (103 mg, 0.323 mmol, 1 eq), K2CO3 (89 mg, 0.646 mmol, 
2 eq), NaI (48 mg, 0.323 mmol, 1 eq) and 2-(1-Trityl-1H-imidazol-4-yl)ethanamine (3.2, 343 mg, 0.969 
mmol 3 eq) in n-butanol (5 mL) by heating for 94 h according to the general procedure. The crude 
product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH + 1% NEt3 (B); gradient: 0 to 
60 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g). Deprotection in CH2Cl2 (5 mL) and TFA (1 mL) followed by 
76 Chapter 3 
preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 
20/80−50/50, tR = 11.9 min) afforded 3.18 (tris(hydrotrifluoroacetate)) as white fluffy solid (32.0 mg, 
16%). Rf = 0.15 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 306, 256, 201, 190 nm. 
RP-HPLC (220 nm): 99.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 min: 90/10, 
tR = 10.9 min, k = 2.9). 
1H-NMR (600 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.06-2.20 (m, 2H), 2.55 (d, 
J = 0.5, 3H), 3.07 (t, J = 7.5, 2H), 3.13-3.25 (m, 2H), 3.27-3.37 (m, 2H), 4.24 (t, J = 6.0, 2H), 7.30 (d, J = 
9.0, 2H), 7.34-7.44 (m, 1H), 7.54 (s, 1H), 7.66 (dd, J = 4.1, 8.8, 1H), 8.23 (d, J = 8.9, 2H), 8.87 (s, 2H), 
9.05 (d, J = 1.2, 1H), 13.82 (bs, TFA). 13C NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.41 (d, J = 
3.2), 21.18, 25.39, 44.23, 45.05, 65.36, 110.83 (d, J = 23.6), 112.19 (d, J = 10.2), 113.91 (d, J = 27.2), 
115.33 (q, J = 289.4, TFA), 115.58, 115.65, 116.98, 128.77, 128.41, 130.30, 132.62 (d, J = 9.0), 134.42, 
150.45, 158.04 (d, J = 239.42), 158.51 (q, J = 37.7, TFA), 162.26. MS (LC-MS, ESI): m/z 394.1 [M+H+]. 
HRMS (EI-MS): m/z M+• calcd. for C21H23FN5O: 393.1965, found: 393.1969. 
 
3-[4-(1H-Benzo[d]imidazol-2-yl)-3-methylphenoxy]-N-[2-(1H-imidazol-4-yl)ethyl]propan-1-amine 
tris(hydrotrifluoroacetate) (3.19) 
The title compound was prepared from 3.13 (69 mg, 0.229 mmol, 1 eq), K2CO3 (63 mg, 0.459 mmol, 
2 eq), NaI (34 mg, 0.229 mmol, 1 eq) and 2-(1-Trityl-1H-imidazol-4-yl)ethanamine (3.2, 243 mg, 
0.688 mmol 3 eq) in n-butanol (4 mL) by heating for 94 h according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH + 1% NEt3 (B); 
gradient: 0 to 60 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g). Deprotection in CH2Cl2 (5 mL) and TFA 
(1 mL) followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: 
MeCN/0.1% aq. TFA 20/80−50/50, tR = 10.5 min) afforded 3.19 (tris(hydrotrifluoroacetate)) as white 
fluffy solid (25.3 mg, 18%). Rf = 0.09 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 294, 250, 
206, 191 nm. RP-HPLC (220 nm): 99.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 
min: 90/10, tR = 6.5 min, k = 1.3). 
1H-NMR (600 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.10 (p, J = 6.3, 
1H), 2.54 (s, 2H), 3.07 (t, J = 7.5, 1H), 3.16 (p, J = 6.3, 1H), 3.28-3.35 (m, 1H), 4.20 (t, J = 6.0, 1H), 7.06-
7.11 (m, 1H), 7.54 (d, J = 0.5, 1H), 7.60 (dd, J = 3.1, 6.1, 1H), 7.76 (d, J = 8.4, 1H), 7.86 (dd, J = 3.1, 6.1, 
1H), 8.82-8.90 (m, 1H), 9.05 (d, J = 1.3, 1H), 13.91 (bs, TFA). 13C NMR (151 MHz,  DMSO-d6 + 10 µL 
TFA): δ (ppm) 19.88, 21.19, 25.43, 44.26, 45.06, 65.13, 112.72, 114.07 (2C), 115.31 (q, J = 289.3, TFA), 
115.67, 116.99, 117.30, 125.92 (2C), 128.77, 131.59 (2C), 132.93, 134.43, 140.08, 149.46, 158.50 (q, J 
= 37.8, TFA), 161.44. MS (LC-MS, ESI): m/z 376.0 [M+H+]. HRMS (EI-MS): m/z M+• calcd. for C22H25N5O: 
375.2059, found: 375.2056. 
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N-[2-(1H-Imidazol-4-yl)ethyl]-4-(4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy)-
butan-1-amine tris(hydrotrifluoroacetate) (3.20) 
The title compound was prepared from 3.15 (84 mg, 0.263 mmol, 1 eq), K2CO3 (73 mg, 0.526 mmol, 
2 eq), NaI (39 mg, 0.263 mmol, 1 eq) and 2-(1-trityl-1H-imidazol-4-yl)ethanamine (3.2, 279 mg, 
0.789 mmol 3 eq) by heating in n-butanol (2 mL) for 15 h according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH + 1% NEt3 (B); 
gradient: 0 to 60 min: A/B 100/0 – 50/50 (v/v), SF 10-8 g). Deprotection in CH2Cl2 (5 mL) and TFA 
(2 mL) followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: 
MeCN/0.1% aq. TFA 20/80−50/50, tR = 10.6 min) afforded 3.20 (tris(hydrotrifluoroacetate)) as white 
fluffy solid (37.1 mg, 24%). Rf = 0.09 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 292, 250, 
207, 192 nm. RP-HPLC (220 nm): 99.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 
min: 90/10, tR = 6.5 min, k = 1.3). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.72-1.88 (m, 
4H), 2.49 (s, 3H), 2.53 (d, J = 1.2, 3H), 3.01-3-09 (m, J = 7.3, 4H), 3.22-3.32 (m, 2H), 4.13 (t, J = 5.7, 2H), 
7.04-7.10 (m, 2H), 7.39-7.47 (m, 1H), 7.53 (s, 1H), 7.67-7.75 (m, 2H), 8.72 (s, 2H), 9.05 (d, J = 1.3, 1H), 
14.10 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.43 (d, J = 3.3) 19.85, 21.26, 
22.51, 25.79, 45.12, 46.74, 67.44, 110.96 (d, J = 23.9), 112.60 (d, J = 10.4), 112.65, 114.22 (d, J = 27.9), 
115.52 (d, J = 289.1, TFA), 115.63, 117.10, 117.21, 128.25, 128.90, 132.34 (d, J = 10.2), 133.11, 
134.50, 140.23, 150.94, 158.20 (d, J = 239.1), 158.69 (q, J = 37.5, TFA), 161.81. MS (LC-MS, ESI): m/z 
422.2 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C24H29FN5O
+: 422.2351, found: 422.2354. 
3.5.2.5 Preparation of the benzimidazolylphenoxyalkylamines 3.22-3.23 
tert-Butyl 3-bromopropylcarbamate (3.21)58,59 
To a solution of 3-bromopropylamine hydrobromide (6.6 g, 30 mmol, 1 eq) and DIPEA (89.3 g, 
72 mmol, 2.4 eq) in CH2Cl2 (40 mL) was added dropwise a solution of Boc2O (7.9 g, 36 mmol, 1.2 eq) 
in CH2Cl2 (20 mL) within 10 min. The mixture was stirred at rt for 18 h. The mixture was washed with 
0.1 M HCl, brine and water, dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 30 min: A/B 100/0 – 
60/40 (v/v), SF 25-80 g) and afforded a colorless oil (5.2 g, 74%). Rf = 0.78 (CH2Cl2/MeOH 25:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.41 (s, 9H), 1.93-2.07 (m, 2H), 3.16-3.27 (m, 2H), 3.41 (t, J = 6.5, 
2H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.46, 30.91, 32.78, 39.06, 79.47, 156.08. MS (GC-MS, CI): 
m/z 238.1 [M+H+]. C8H16BrNO2 (238.12). 
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General procedure for the synthesis of the benzimidazolylphenoxyalkylamines 3.22-3.239 
A suspension of the pertinent (hydroxyphenyl)benzimidazole (1 eq), and Cs2CO3 (1.5 eq) in MeCN was 
treated with the alkyl halide (1 eq) and heated to 70 °C for 17 h. The reaction mixture was cooled to 
rt, diluted with CHCl3 and filtered through a glass fritted funnel to remove inorganic solids. The 
filtrate was concentrated under reduced pressure and purified by flash-chromatography. The 
combined fractions were dissolved in CH2Cl2, TFA was added and the reaction mixture was stirred 
until the protection group was removed (5-8 h, TLC control). After evaporation of the solvent in 
vacuo, the crude product was purified by preparative RP-HPLC. 
 
3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propan-1-amine 
bis(hydrotrifluoroacetate) (3.22) 
The title compound was prepared from 3.7 (1.30 g, 5.00 mmol, 1 eq), 3.21 (1.21 g, 5.00 mmol, 1 eq) 
and Cs2CO3 (2.48 g, 7.61 mmol, 1.5 eq) in MeCN (16 mL) according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 
30 min: A/B 100/0 – 96/4 (v/v), SF 25-40 g) yielding a yellow foam-like solid. Deprotection in CH2Cl2 
(60 mL) and TFA (10 mL) gave a brown solid as di-TFA-salt (1.05 g, 27%). A sample of 45 mg was 
purified by preparative HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. 
TFA 20/80−50/50, tR = 10.6 min). MeCN was removed under reduced pressure. After lyophilisation 
3.22 (bis(hydrotrifluoroacetate)) was obtained as white fluffy solid (27.5 mg, 61%). Rf = 0.17 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 217, 201 nm. RP-HPLC (220 nm): 99.2% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 min: 90/10, tR = 12.3 min, k = 3.4). 
1H-
NMR (300 MHz, MeOH-d4): δ (ppm) 2.15-2.26 (m, 2H), 2.53 (s, 2H), 2.58 (d, J = 1.7, 2H), 3.19 (t, J = 
7.4, 2H), 4.24 (t, J = 5.8, 2H), 7.05-7.15 (m, 2H), 7.34-7.43 (m, 1H), 7.64 (dd, J = 4.2, 8.9, 1H), 7.71 (d, J 
= 8.5, 1H). 13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.36 (d, J = 3.2), 19.76, 26.87, 36.28, 
65.13, 110.86 (d, J = 23.7), 112.45 (d, J = 9.8), 112.55, 114.15 (d, J = 26.9), 115.29 (q, J = 289.1, TFA), 
115.64, 117.21, 128.15, 132.24 (d, J = 10.0), 133.03, 140.10, 150.83, 158.11 (d, J = 239.1), 158.53 (q, J 
= 38.0, TFA), 161.53. MS (LC-MS, ESI): m/z 314.0 [M+H+]. HRMS (EI-MS): m/z M+• calcd. for 
C18H20FN3O: 313.1590, found: 313.1585. 
 
3-[4-(1H-Benzo[d]imidazol-2-yl)phenoxy]propan-1-amine bis(hydrotrifluoroacetate) (3.23) 
The title compound was prepared from 3.8 (2.00 g, 9.51 mmol, 1 eq), 3.21 (2.27 g, 9.51 mmol, 1 eq) 
and Cs2CO3 (4.64 g, 14.3 mmol, 1.5 eq) in MeCN (30 mL) according to the general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 
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30 min: A/B 100/0 – 96/4 (v/v), SF 25-60 g) yielding a white solid. Deprotection in CH2Cl2 (60 mL) and 
TFA (10 mL) gave a brown solid as di-TFA-salt (1.40 g, 30%). A sample of 50 mg was purified by 
preparative HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 
15/75−40/60, tR = 12.2 min). MeCN was removed under reduced pressure. After lyophilisation 3.23 
(bis(hydrotrifluoroacetate)) was obtained as white fluffy solid (32.4 mg, 65%). Rf = 0.21 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 310, 218, 201 nm. RP-HPLC (220 nm): 100% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, 31-40 min: 90/10, tR = 7.6 min, k = 1.6). 
1H-NMR (300 MHz,  DMSO-d6): δ (ppm) 1.99-2.15 (m, 2H), 2.92-3.09 (m, 2H), 4.23 (t, J = 6.1, 2H), 7.29 
(d, J = 9.0, 2H), 7.52 (dd, J = 3.2, 6.1, 2H), 7.82 (dd, J = 3.1, 6.1, 2H), 7.94 (s, 3H), 8.22 (d, J = 8.9, 
2H),14.10 (bs, TFA). 13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 22.76, 36.35, 65.36, 113.84 
(2C), 114.35, 115.33 (q, J = 289.4, TFA), 115.81 (2C), 125.91 (2C), 130.08 (2C), 131.68 (2C), 149.11, 
158.51 (q, J = 37.7, TFA), 162.47.MS (LC-MS, ESI): m/z 268.1 [M+H+]. HRMS (EI-MS): m/z M+• calcd. for 
C16H17N3O: 267.1372, found: 267.1376. 
 
3.5.2.6 Preparation of the guanidine 3.26 
N,N'-Bis(tert-butoxycarbonyl)guanidine (3.24)11,60 
1,4-Dioxane (250 mL) was added to a solution of guanidine hydrochloride (12.0 g, 0.126 mol) and 
NaOH (20.1 g, 0.502 mol) in water (125mL) and the resulting mixture was cooled to 0 °C. Boc2O 
(60.3 g, 0.276 mol) was added in one portion and the reaction mixture was allowed to warm to rt 
within 2 h. After stirring for 26 h the mixture was concentrated under reduced pressure to one third 
of its original volume. The resulting suspension was diluted with water (250 mL) and extracted with 
EtOAc (3 x 250 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 10 min: A/B 100/0 – 90/10 (v/v), 
10 to 30 min: A/B 90/10, SF 65-400 g) and afforded a white solid (11.5 g, 35%), mp 145 °C (lit.11 
144 °C). Rf = 0.4 (CH2Cl2/MeOH 50:1). 
1H-NMR (300 MHz,  DMSO-d6): δ (ppm) 1.41 (s, 18H), 8.58 (bs, 
2H), 10.53 (bs, 1H). 13C NMR (75 MHz,  DMSO-d6): δ (ppm) 27.83, 79.81, 158.19. MS (LC-MS, ESI): m/z 
260.0 [M+H+]. C11H21N3O4 (259.30). 
 
N,N'-Di-Boc-N"-(trifluoromethanesulfonyl)guanidine (3.25)11 
A solution of N,N'-di-Boc-guanidine (3.24) (8.57 g, 34.0 mmol) and NEt3 (3.59 g, 35.0 mmol, 1.05 eq) 
in CH2Cl2 (170 mL) was cooled to -78 °C. Triflic anhydride (10.0 g, 35.0 mmol) was added dropwise 
within 20 min. After the addition was completed, the mixture was allowed to warm to rt within 4 h. 
The solution was transferred to a separation funnel, washed with saturated KHSO4(aq.) and water and 
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dried over anhydrous Na2SO4. Concentration in vacuo afforded a white solid (10.7 g, 81%). mp 96 °C 
(lit.11 115 °C). Rf = 0.9 (CH2Cl2/MeOH 50:1). 
1H-NMR (300 MHz,  DMSO-d6): δ (ppm) 1.46 (s, 18H), 
11.07 (bs, 2H). 13C NMR (75 MHz,  DMSO-d6): δ (ppm) 27.52, 83.40, 150.09, 152.33. MS (LC-MS, ESI): 
m/z 391.1 [M+H+]. C12H20F3N3O6S (391.36). 
1-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}guanidine 
bis(hydrotrifluoroacetate) (3.26) 
Compound 3.22 (bis(hydrotrifluoroacetate, 200 mg, 0.369 mmol, 1 eq) was added to a solution of 
N,N'-Di-Boc-N"-(trifluoromethanesulfonyl)guanidine (3.25, 146 mg, 0.369 mmol, 1 eq) and 
triethylamine (123 mg, 1.22 mmol, 3.3 eq) in dichloromethane (3mL), and the mixture was stirred at 
rt for 3 h. After completion of the reaction, the mixture was diluted with dichloromethane (7 mL) and 
washed with saturated NaHCO3(aq) (10 mL) and brine (10 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash-chromatography (eluent CH2Cl2 (A), 
MeOH (B); gradient: 0 to 15 min: A/B 100/0 – 50/1 (v/v), 15 to 20 min: A/B A/B 50/1 – 5/1 (v/v), SF 
10-8 g) and afforded a yellow oil (146 mg, 71%). Deprotection in CH2Cl2 (30 mL) and TFA (6 mL) gave a 
brown solid as di-TFA-salt (153 mg, 100%). A sample of 50 mg was purified by preparative HPLC 
(column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, tR = 
11.4 min). MeCN was removed under reduced pressure. After lyophilisation 3.26 
(bis(hydrotrifluoroacetate)) was obtained as white fluffy solid (23.4 mg, 47%). Rf = 0.15 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 291, 250, 198, 193 nm. RP-HPLC (220 nm): 
98.7% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 min: 90/10, tR = 16.9 min, k = 
6.3). 1H-NMR (300 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.98 (p, J = 6.2, 2H), 2.49 (s, 3H), 2.53 (s, 3H), 
3.30 (q, J = 6.5, 2H), 4.14 (t, J = 6.0, 2H), 7.05-7.12 (m, 2H), 7.38-7.48 (m, 1H), 7.66-7.75 (m, 2H), 7.78 
(t, J = 5.4, 1H), 14.10 (bs, TFA). 13C NMR (75 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.50 (d, J = 3.2), 
19.88, 28.20, 45.81, 65.38, 108.12 (d, J = 13.2), 110.96 (d, J = 23.9), 112.64 (d, J = 18.1), 112.65, 
114.09, 115.34 (q, J = 288.9, TFA), 115.63, 128.16, 132.19, 133.16, 140.23, 150.86, 158.54 (d, J = 
227.2), 158.63 (q, J = 38.1, TFA), 161.72. MS (LC-MS, ESI): m/z 355.9 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C19H23FN5O
+: 356.1881, found: 356.1885. 
3.5.2.7 Preparation of NG-propionyl guanidine 3.30 
S-Methylthiouronium iodide (3.27)12 
Synthesis of 3.27 is described in Chapter 4 (Compound 4.1). 
 
N-tert-Butoxycarbonyl-S-methylisothiourea (3.28)12 
Synthesis of 3.28 is described in Chapter 4 (Compound 4.2). 
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N-tert-Butoxycarbonyl-N’-(propionyl)-S-methylisothiourea (3.29)61 
Synthesis of 3.29 is described in Chapter 4 (Compound 4.4). 
N-(N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}carbamimidoyl)-
propionamide bis(hydrotrifluoroacetate) (3.30) 
Building block 3.22 (bis(hydrotrifluoroacetate), 152 mg, 0.281 mmol, 1 eq) was dissolved in water 
(10 mL), the solution was alkalized with 0.5 NaOH (pH 11), extracted three times with CH2Cl2 (10 mL), 
the organic phase dried over anhydrous MgSO4 and concentrated in vacuo (70 mg, 0.22 mmol, 1 eq). 
The released base, the guanidinylating reagent 3.29 (55 mg, 0.22 mmol, 1 eq) and HgCl2 (122 mg, 
0.45 mmol, 2 eq) were dissolved in 2 mL CH2Cl2. NEt3 (67.8 mg, 0.67 mmol, 3 eq) was added and the 
mixture was stirred for 20 h at rt. Subsequently, the precipitate was filtered over Celite. Purification 
by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 30 min: A/B 100/0 – 96/4 (v/v), 
SF 10-4 g)) afforded the intermediate as white solid. Deprotection in CH2Cl2 (5 mL) and TFA (1 mL) 
gave a yellow solid as di-TFA-salt (101 mg, 71%). A sample of 45 mg was purified by preparative HPLC 
(column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 
tR = 14.3 min). MeCN was removed under reduced pressure. After lyophilisation 3.30 
(bis(hydrotrifluoroacetate)) was obtained as white fluffy solid (27 mg, 27%). Rf = 0.24 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 294, 249, 215, 197 nm. RP-HPLC (220 nm): 
97.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95-80/20, 31-40 min: 90/10, tR = 15.7 min, k = 8.3). 
1H-NMR (300 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.04 (t, J = 7.4, 3H), 2.05 (p, J = 7.4, 2H), 2.45 (q, J 
= 7.4, 2H), 2.48 (s, 3H), 2.52 (s, 3H), 3.48 (q, J = 6.2, 2H), 4.17 (t, J = 5.8, 2H), 7.05-7.12 (m, 2H), 7.38-
7.48 (m, 1H), 7.66-7.76 (m, 2H), 8.79 (s, 1H), 9.42 (s, 1H), 14.10 (bs, TFA). 13C-NMR (75 MHz,  DMSO-
d6 + 10 µL TFA): δ (ppm) 8.31, 9.48 (d, J = 3.4), 19.87, 27.43, 29.73, 40.35, 65.85, 110.98 (d, J = 24.1), 
112.61 (d, J = 9.5), 112.63, 114.30 (d, J = 27.1), 115.41 (q, J = 289.0, TFA), 115.69, 119.10, 128.19, 
132.28 (d, J = 10.3), 133.15, 140.20, 154.97 (d, J = 252.0), 158.75 (q, J = 37.8, TFA), 161.70, 176.27.MS 
(LC-MS, ESI): m/z 412.22 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C22H27FN5O2
+: 412.2143, 
found: 412.2147. 
 
3.5.2.8 Preparation of the carboxylic amides 3.31-3.37 
General procedure for the preparation of 3.31-3.329 by amide coupling 
The respective carboxylic acid (1 eq) was dissolved in anhydrous THF. EDC × HCl (1 eq), HOBt × H2O 
(1 eq) and DIPEA (1.5 eq) were added, and the reaction mixture was stirred at rt under argon 
atmosphere for 2 h. Subsequently, the building block 3.22 or 3.23 (1 eq) and DIPEA (2.5 eq), 
dissolved in anhydrous THF were added in one portion. The solution was stirred at rt for 20 h. The 
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solvent was evaporated under reduced pressure and the residue was dissolved in CH2Cl2 (25 mL). The 
solution was washed with saturated NaHCO3(aq.) and brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash-chromatography (eluent CH2Cl2 (A), 
MeOH (B); gradient: 0 to 40 min: A/B 100/0 – 90/10 (v/v), SF 15-8 g) and afforded a white solid. 
 
N-(3-(4-(1H-Benzo[d]imidazol-2-yl)phenoxy)propyl)propionamide (3.31) 
The title compound was prepared from propionic acid (14 mg, 0.182 mmol), EDC × HCl (35 mg, 
0.182 mmol), HOBt × H2O (28 mg, 0.182 mmol) and DIPEA (35 mg, 0.270 mmol) in THF (2 mL), 
followed by the addition of 3.23 (90 mg, 0.182 mmol) and DIPEA (59 mg, 0.600 mmol) in THF (0.5 mL) 
(38 mg, 48%). Rf = 0.35 (CH2Cl2/MeOH 90/10). UV/VIS (20 mM HCl): λmax 311, 217, 197 nm. RP-HPLC 
(220 nm): 99.4% (gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, 31-40 min: 90/10, 
tR = 9.0 min, k = 2.2). 
1H-NMR (300 MHz, MeOH-d4): δ (ppm) 1.13 (t, J = 7.6, 3H), 2.01 (p, J = 6.5, 2H), 
2.21 (q, J = 7.6, 2H), 3.39 (t, J = 6.9, 2H), 4.11 (t, J = 6.2, 2H), 7.05-7.13 (m, 2H), 7.20-7.26 (m, 2H), 
7.54-7.61 (m, 2H), 7.98-8.06 (m, 2H). 13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.96, 28.53, 
28.78, 35.37, 66.05, 112.52 (2C), 114.86, 115.40 (q, J = 289.8, TFA), 115.73 (2C), 125.81 (2C), 130.01 
(2C), 131.64 (2C), 149.10, 158.47 (q, J = 37.4, TFA), 162.73, 172.98. MS (LC-MS, ESI): m/z 323.9 
[M+H+]. HRMS (EI-MS): m/z M+• calcd. for C19H21N3O2: 323.1634, found: 323.1635. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}propionamide 
(hydrotrifluoroacetate) (3.32) 
The title compound was prepared from propionic acid (11 mg, 0.148 mmol), EDC × HCl (28 mg, 
0.148 mmol), HOBt × H2O (23 mg, 0.148 mmol) and DIPEA (29 mg, 0.222 mmol) in THF (2 mL), 
followed by the addition of 3.22 (80 mg, 0.148 mmol ) and DIPEA (48 mg, 0.369 mmol) in THF 
(0.5 mL) (Yield: 29 mg, 41%.) Rf = 0.41 (CH2Cl2/MeOH 90/10). UV/VIS (20 mM HCl): λmax 292, 218, 
197 nm. RP-HPLC (220 nm): 100% (gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, 31-40 min: 
90/10, tR = 12.7 min, k = 3.5). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.11 (t, J = 7.6, 3H), 1.92 (p, J = 6.3, 
2H), 2.18 (q, J = 7.6, 2H), 2.45 (s, 3H), 2.52 (d, J = 1.1, 3H), 3.38 (q, J = 6.5, 2H), 3.94 (t, J = 5.9, 2H), 
6.13 (bs, 1H), 6.58 (dd, J=2.4, 8.5, 1H), 6.69 (d, J=2.3, 1H), 6.90-7.02 (m, 1H), 7.27-7.38 (m, 2H). 
13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.34 (d, J = 3.2), 9.97, 19.73, 28.69, 35.42, 65.80, 
79.19, 110.81 (d, J = 23.7), 112.44 (d, J = 10.1), 112.52, 114.07 (d, J = 27.0), 115.25 (q, J = 289.2, TFA), 
115.38, 117.18, 128.08, 132.20 (d, J = 9.8), 132.94, 140.02, 150.88, 158.03 (d, J = 236.8), 158.43 (q, J = 
38.0, TFA), 161.76, 179.98. MS (LC-MS, ESI): m/z 370.0 [M+H+]. HRMS (EI-MS): m/z M+• calcd. for 
C21H24FN3O2: 369.1853, found: 369.1848.  
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General procedure for the preparation of 3.33-3.36 by amide coupling 
The acid (1.1 eq) was dissolved in DMF (3 mL). DIPEA (3 eq) and TBTU (1.1 eq) were added and the 
reaction mixture was stirred at rt under argon atmosphere for 10 min. The building block 3.22 (1 eq) 
and DIPEA (3 eq), dissolved in DMF (1 mL) were added slowly and stirring was continued for 20 h. The 
crude product was purified by preparative RP-HPLC (column: Gemini-NX C18, 250 × 21 mm). MeCN 
was removed under reduced pressure. After lyophilisation 3.33-3.36 was obtained as white fluffy 
solid (TFA-salts). 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-3-[(5-methyl-1H-
imidazol-4-yl)methylsulfanyl] propionamide (bis(hydrotrifluoroacetate)) (3.33) 
The title compound was prepared from 2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]acetic acid 
(UR-PG139)55 (30 mg, 0.163 mmol),TBTU (52 mg, 0.163 mmol) and DIPEA (57 mg, 0.443 mmol) in 
DMF (3 mL), followed by the addition of 3.22 (80 mg, 0.148 mmol ) and DIPEA (57 mg, 0.443 mmol) in 
THF (1 mL) according to general procedure (gradient for HPLC purification: 0−30 min: MeCN/0.1% aq. 
TFA 15/85−40/60, tR = 13.2 min; Yield: 43 mg, 41%). Rf = 0.13 (CH2Cl2/MeOH 90/10, as free base). 
UV/VIS (20 mM HCl): λmax 292, 248, 227, 217 nm. RP-HPLC (220 nm): 100% (gradient: 0−30 min: 
MeCN/0.1% aq. TFA 20/80−80/20, 31-40 min: 90/10, tR = 13.3 min, k = 4.7). 
1H-NMR (400 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 1.90 (p, J = 6.4, 2H), 2.26 (s, 3H), 2.49 (s, 3H), 2.53 (d, J = 0.9, 3H), 
3.09 (s, 2H), 3.25 (d, J = 6.7, 2H), 3.90 (s, 2H), 4.12 (t, J = 6.2, 2H), 7.04-7.12 (m, 2H), 7.39-7.46 (m, 
1H), 7.67-7.74 (m, 2H), 8.17 (t, J = 5.5, 1H), 8.92 (s, 1H), 9.15 (bs, TFA), 14.25 (bs, 2H) .13C-NMR 
(101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 8.41, 9.16 (d, J = 3.1), 19.57, 23.61, 28.49, 33.58, 35.69, 
65.54, 110.66 (d, J = 23.8), 112.31 (d, J = 10.5), 112.36, 113.92 (d, J = 27.0), 115.15 (q, J = 289.3, TFA), 
115.31, 117.00, 125.11, 126.26, 127.96, 132.06 (d, J = 10.3), 132.80, 132.94, 139.89, 150.70, 157.90 
(d, J = 239.5), 158.33 (q, J = 37.8, TFA), 161.56, 168.68. MS (LC-MS, ESI): m/z 482.20 [M+H+]. HRMS 
(ESI-MS): m/z [M+H+] calcd. for C25H29FN5O2S
+: 482.2021, found: 482.2022. 
 
5-Chloro-N-{3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-1H-
indole-2-carboxamide (hydrotrifluoroacetate) (3.34) 
The title compound was prepared from 5-chloro-1H-indole-2-carboxylic acid (32 mg, 0.163 mmol), 
TBTU (52 mg, 0.163 mmol) and DIPEA (57 mg, 0.443 mmol) in 3 mL of DMF, followed by the addition 
of 3.22 (80 mg, 0.148 mmol ) and DIPEA (57 mg, 0.443 mmol) in THF (1 mL) according to general 
procedure (gradient for HPLC purification: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, tR = 16.8 min; 
Yield: 12 mg, 13%). Rf = 0.16 (CH2Cl2/MeOH 90/10, as free base). UV/VIS (20 mM HCl): λmax 290, 223, 
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198 nm. RP-HPLC (220 nm): 100% (gradient: 0−30 min: MeCN/0.1% aq. TFA 40/60−90/10, 31-40 min: 
90/10, tR = 16.6 min, k = 6.1). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.98-2.10 (m, 2H), 
3.49 (dd, J = 12.2, 6.3 Hz, 2H), 4.18 (t, J = 6.0 Hz, 2H), 7.01-7.27 (m, 5H), 7.37-7.47 (m, 2H), 7.61-7.77 
(m, 3H), 8.69 (t, J = 5.4, 1H), 11.79 (s, 1H), 11.97 (bs, TFA). 13C-NMR (151 MHz,  DMSO-d6 + 10 µL TFA): 
δ (ppm) 9.42 (d, J = 3.0), 19.78, 28.93, 35.98, 65.95, 106.91, 110.93 (d, J = 23.9), 112.52 (d, J = 9.6), 
112.67, 114.09 (d, J = 28.3), 115.35, 115.20 (q, J = 288.3, TFA), 117.30, 120.63, 123.47, 124.51, 
128.00, 128.04, 128.29, 130.10, 132.16 (d, J = 10.0), 133.09, 134.93, 140.16, 150.93, 158.11 (d, J = 
239.1), 158.55 (q, J = 38.4, TFA), 161.02, 161.97. MS (LC-MS, ESI): m/z 491.16 [M+H+]. HRMS (ESI-MS): 
m/z [M+H+] calcd. for C27H25ClFN4O2
+: 491.1645, found: 491.1654. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-3-(4-fluorophenyl)-
3-phenylacrylamide (hydrotrifluoroacetate) (3.35) 
The title compound was prepared from 3-(4-fluorophenyl)-3-phenylacrylic acid (PG17) (39 mg, 
0.163 mmol), TBTU (52 mg, 0.163 mmol) and DIPEA (57 mg, 0.443 mmol) in DMF (3 mL), followed by 
the addition of 3.22 (80 mg, 0.148 mmol ) and DIPEA (57 mg, 0.443 mmol) in THF (1 mL) according to 
general procedure (gradient for HPLC purification: 0−30 min: MeCN/0.1% aq. TFA 40/70−70/30, tR = 
10.4 min; Yield: 53 mg, 55%). Rf = 0.15 (CH2Cl2/MeOH 90/10, as free base). UV/VIS (20 mM HCl): λmax 
294, 253, 228, 218 nm. RP-HPLC (220 nm): 99.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 
40/60−90/10, 31-40 min: 90/10, tR = 17.5 min, k = 6.5). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ 
(ppm) 1.70-1.90 (m, 2H), 2.49 (s, 3H), 2.53 (s, 3H), 3.11-3.28 (m, 2H), 3.98 (dt, J = 20.1, 6.2 Hz, 2H), 
6.44 (d, J = 9.8 Hz, 1H), 6.99-7.09 (m, 2H), 7.10-7.38 (m, 8H), 7.38-7.47 (m, 1H), 7.66-7.75 (m, 2H), 
8.07 (dt, J = 5.6, 32.3, 1H), 11.35 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.38 
(d, J = 3.2), 19.78, 28.74, 35.36 (d, J = 6.1), 65.76, 110.89 (d, J = 23.7) 112.51 (d, J = 10.6), 112.61, 
114.19 (d, J = 26.4), 114.65 (d, J = 21.4), 115.26 (d, J = 288.8), 115.36, 115.42 (d, J = 21.6), 117.20, 
122.89 (d, J = 7.0), 127.70, 127.89, 127.92 (d, J = 33.1), 128.58, 129.33, 129.77 (d, J = 8.4), 131.47 (d, 
J = 8.3), 132.19 (d, J = 10.2), 133.01, 135.40, 138.99, 140.09 (d, J = 2.8), 141.26, 147.46 (d, J = 46.7), 
150.92, 158.13 (d, J = 236.5), 158.53 (q, J = 38.2, TFA), 161.78 (d, J = 244.3), 161.85, 165.45 (d, J = 
12.3). MS (LC-MS, ESI): m/z 538.23 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C33H30F2N3O2
+: 
538.2301, found: 538.2305. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-4-(4-fluorophenyl)-
3-methylbutanamide (hydrotrifluoroacetate) (3.36) 
The title compound was prepared from 4-(4-fluorophenyl)-3-methylbutanoic acid (AK318) (32 mg, 
0.163 mmol), TBTU (52 mg, 0.163 mmol) and DIPEA (57 mg, 0.443 mmol) in DMF (3 mL), followed by 
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the addition of 3.22 (80 mg, 0.148 mmol ) and DIPEA (57 mg, 0.443 mmol) in THF (1 mL) according to 
the  general procedure (gradient for HPLC purification: 0−30 min: MeCN/0.1% aq. TFA 37/63−67/33, 
tR = 10.2 min; Yield: 38 mg, 43%). Rf = 0.13 (CH2Cl2/MeOH 90/10, as free base). UV/VIS (20 mM HCl): 
λmax 299, 250, 229, 218 nm. RP-HPLC (220 nm): 99.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 
40/60−90/10, 31-40 min: 90/10, tR = 15.7 min, k = 5.7). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): 
δ (ppm) 0.80 (d, J = 6.5, 3H), 1.81-1.98 (m, 3H), 2.04-2.22 (m, 2H), 2.42 (dd, J = 7.8, 13.2, 1H), 2.47 (s, 
3H), 2.53 (d, J = 1.0, 3H), 2.61 (dd, J = 6.1, 13.2, 1H), 3.23 (q, J = 6.5, 2H), 4.11 (t, J = 6.2, 2H), 6.94-
7.02 (m, 3H), 7.04-7.10 (m, 2H), 7.26-7.35 (m, 1H), 7.38-7.46 (m, 1H), 7.66-7.73 (m, 2H), 7.95 (t, J = 
5.4, 1H), 11.96 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.38 (d, J = 3.3), 19.06, 
19.76, 28.95, 32.04, 35.44, 42.02, 42.41, 65.85, 110.90 (d, J = 23.7), 112.52 (d, J = 12.5), 112.59, 
112.79, 114.20 (d, J = 26.9), 115.25 (q, J = 288.6), 115.36, 115.76 (d, J = 20.6), 117.23, 125.26 (d, J = 
2.4), 128.07, 130.01 (d, J = 8.5), 132.18 (d, J = 10.2), 133.03, 140.11, 143.60 (d, J = 7.2), 150.92, 
158.16 (d, J = 239.2), 158.54 (q, J = 38.2), 161.89 (s), 162.27 (d, J = 243.0), 171.51. MS (LC-MS, ESI): 
m/z 492.25 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C29H32F2N3O2
+: 492.2457, found: 492.2468. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-3-
phenylpropanamide (hydrotrifluoroacetate) (3.37) 
A solution of 3.23 (bis(hydrotrifluoroacetate)) (8.57 g, 34.0 mmol) and DIPEA (3.59 g, 35.0 mmol, 
1.05 eq) in CH2Cl2 (1.8 mL) was cooled to 0 °C, and 3-phenylpropanoyl chloride (10.0 g, 35.0mmol) 
was added. The mixture was allowed to warm to rt within 1 h and stirred for further 8 h. 
Subsequently, CH2Cl2 (23 mL) was added, the solution was transferred to a separation funnel and 
washed with saturated NaHSO3(aq.) and brine. The organic phase was dried over anhydrous Na2SO4 
and concentrated in vacuo. The crude product was purified by preparative RP-HPLC (column: 
Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, tR = 16.5 min). MeCN 
was removed under reduced pressure. After lyophilisation 3.37 (hydrotrifluoroacetate) was obtained 
as white fluffy solid (24.4 mg, 59%.). Rf = 0.13 (CH2Cl2/MeOH 90/10, as free base). UV/VIS (20 mM 
HCl): λmax 277, 205, 190 nm. RP-HPLC (220 nm): 98.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95-
80/20, 31-40 min: 90/10, tR = 20.2 min, k = 11.0). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 
1.85 (p, J = 6.5, 3H), 2.38 (t, J = 7.7, 3H), 2.49 (s, 3H), 2.53 (d, J = 1.0, 3H), 2.82 (t, J = 7.7, 2H), 3.21 (q, J 
= 6.5, 2H), 4.03 (t, J = 6.3, 2H), 7.01-7.09 (m, 2H), 7.12-7.27 (m, 5H), 7.39-7.47 (m, 1H), 7.66-7.74 (m, 
2H), 7.93 (t, J = 5.4, 1H), 11.96 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.40 (d, 
J = 3.0), 19.78, 28.82, 31.19, 35.41, 37.09, 65.72, 110.87 (d, J = 23.7), 112.48 (d, J = 10.4), 112.58, 
114.15 (d, J = 25.1), 115.23 (d, J = 288.9, TFA), 115.35, 117.21, 125.93, 128.07, 128.28 (2C), 128.30 
(2C), 132.19 (d, J = 10.0), 132.99, 140.06, 141.36, 150.90, 157.96 (d, J = 288.7), 158.47 (q, J = 38.1, 
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TFA), 161.81, 171.47. MS (LC-MS, ESI): m/z 446.23 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C27H29FN3O2
+: 446.2238, found: 446.2246. 
 
3.5.2.9 Preparation of the histamine homolog 3.41 
2-[2-(5-Methyl-1H-imidazol-4-yl)ethyl]isoindoline-1,3-dione (3.39)62  
Compound 3.3862,63 (600 mg, 1.94 mmol) was dissolved in formamide (20 mL) and the mixture was 
stirred at 170 °C for 4 h. The solution was taken up in 250 mL of saturated NaHCO3(aq.) and extracted 
with CHCl3 (2 x 250 mL). The organic layer was dried over MgSO4 and evaporated in vacuo. Flash-
chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 25 min: A/B 100/0 – 90/10 (v/v), SF 15-
12 g) yielded a yellow solid (238 mg, 48%). mp 228 °C. Rf = 0.15 (CH2Cl2/MeOH 96/4). 
1H-NMR 
(300 MHz, CDCl3): δ (ppm) 2.10 (s, 3H), 2.92 (t, J = 7.1, 2H), 3.89 (t, J = 7.1, 2H), 7.52 (s, 1H), 7.60-7.86 
(m, 4H), 10.36 (s, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 10.21, 24.77, 37.75, 123.17 (2C), 128.26, 
132.00 (2C), 133.29, 133.93 (2C), 168.20 (2C). MS (LC-MS, ESI): m/z 255.9 [M+H+]. C14H13N3O2 
(255.27). 
 
2-[2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethyl]isoindoline-1,3-dione (3.40) 
To a solution of 3.39 (130 mg, 0.509 mmol, 1 eq) and NEt3 (92 mg, 0.917 mmol, 1.8 eq) in 2.5 mL of 
MeCN was added dropwise a solution of trityl chloride (170 mg, 0.611 mmol, 1.2 eq) in MeCN 
(0.5 mL). After stirring the mixture for 27 h, of CHCl3 (150 mL) was added and washed with water 
(100 mL). The organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 40 min: 
A/B 100/0 – 90/10 (v/v), SF 15-12 g) and afforded a yellow foam-like solid (241 mg, 95%), mp 190 °C. 
Rf = 0.35 (CH2Cl2/MeOH 96/4). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.28 (s, 3H), 2.89 (t, J = 6.9, 2H), 
3.97 (t, J = 6.9, 2H), 7.03-7.11 (m, 6H), 7.19 (m, 1H), 7.21-7.28 (m, 9H), 7.65-7.85 (m, 4H). 13C-NMR 
(75 MHz, CDCl3): δ (ppm) 11.54, 26.37, 38.07, 74.78, 123.21 (2C), 126.14, 127.79 (3C), 127.98 (6C), 
130.10 (6C), 132.26 (2C), 133.81 (2C), 136.72, 137.64, 141.99 (3C), 168.25 (2C). MS (LC-MS, ESI): m/z 
498.0 [M+H+]. C33H27N3O2 (497.59). 
 
2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethanamine (3.41)24 
A mixture of 3.40 (235 mg, 0.472 mmol, 1 eq) and hydrazine monohydrate (66 mg, 2.36 mmol, 5 eq) 
in EtOH (2.4 mL) was stirred at rt for 24 h. After removal of insoluble material, the filtrate was 
evaporated giving a pale brownish solid (167 g, 96%). mp 82 °C. Rf = 0.07 (CH2Cl2/MeOH 90/10). 
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1H-NMR (300 MHz, CDCl3): δ (ppm) 1.38 (s, 3H), 2.61 (t, J = 6.6, 2H), 2.97 (t, J = 6.6, 2H), 7.10-7.15 (m, 
6H), 7.21 (s, 1H), 7.26-7.34 (m, 9H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 
13C NMR (75 MHz, CDCl3) δ 
11.68, 25.62, 41.95, 74.78, 125.82, 127.84 (3C), 127.99 (3C), 130.05 (3C), 137.50, 138.00, 141.95 (3C). 
MS (LC-MS, ESI): m/z 368.21 [M+H+]. C25H25N3 (367.49). 
 
3.5.2.10 Preparation of the secondary amine 3.45 
4,5,6,7-Tetrahydro-3H-imidazo[4,5-c]pyridine dihydrochloride (3.42)22,23 
Histamine dihydrochloride (2.04 g, 11.1 mmol, 1 eq) was dissolved in hydrochloric acid (0.01 M, 
87 mL). After the addition of dimethoxymethane (0.837 g, 11.1 mmol, 1 eq), the mixture was heated 
at reflux for 19 h. Subsequently, the mixture was evaporated to dryness. The solid obtained was 
stirred in EtOH (30 mL) for 2 h, filtered off and dried in vacuo to give 3.42 (dihydrochloride) as white 
crystals (1.57 g, 72%). mp 270 °C (lit.22 270 °C). Rf = 0.07 (CH2Cl2/MeOH 90/10). UV/VIS (20 mM HCl): 
λmax 209, 192. IR (KBr): 3104, 2927, 2281, 1653, 1578, 1500, 1466, 1410 cm
-1. RP-HPLC (200 nm): 
99.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95-50/50, 31-40 min: 90/10, tR = 2.5 min, k = 0.5). 
1H-NMR (300 MHz, MeOH-d4): δ (ppm) 3.13 (t, J = 6.1, 2H), 3.66 (t, J = 6.1, 2H), 4.47 (s, 2H), 8.95 (s, 
1H). 13C-NMR (75 MHz, MeOH-d4): δ (ppm) 19.31, 40.28, 42.45, 122.13, 126.47, 135.95. MS (LC-MS, 
ESI): m/z 124.09 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C6H9N3: 124.0869, found: 124.0871. 
 
Benzyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate (3.43)64 
To a solution of 3.42 (495 mg, 2.53 mmol, 1 eq) and NEt3 (728 mg, 7.20 mmol, 3 eq) in CH2Cl2 (40 mL) 
at 0 °C, benzyl succinimidyl carbonate (597 mg, 2.40 mmol, 0.95 eq) in DMF (10 mL) was added 
dropwise within 10 min. After stirring for 10 min at the same temperature, the mixture was allowed 
to come to rt and stirring was continued for 1 h. Subsequently, the reaction mixture was transferred 
to a separation funnel, 400 mL of saturated K2CO3(aq) and 400 mL of EtOAc were added and the pH of 
the aqueous phase was adjusted to pH 10 by addition of 1 M NaOH(aq). The organic phase was 
washed with 150 mL of brine, dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 40 min: A/B 100/0 – 
90/10 (v/v), SF 25-40 g) and afforded a yellow oil (377 mg, 58%). Rf = 0.35 (CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 2.66 (t, J = 4.8, 2H), 3.76 (t, J = 4.8, 2H), 4.54 (s, 2H), 5.15 (s, 2H), 
7.26-7.41 (m, 5H), 7.47 (s, 1H), 8.31 (bs, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 22.10, 41.78, 42.78, 
67.39, 125.29, 127.83 (3C), 128.12, 128.53 (2C), 134.18, 136.46, 155.85. MS (LC-MS, ESI): m/z 258.12 
[M+H+]. C14H15N3O2 (257.29). 
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Benzyl 3-trityl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate (3.44) 
To a solution of 3.43 (282 mg, 1.10 mmol, 1 eq) and NEt3 (333 mg, 3.29 mmol, 3 eq) in MeCN (40 mL) 
was added dropwise a solution of trityl chloride (458 mg, 1.64 mmol, 1.5 eq) in MeCN (10 mL). After 
stirring the mixture for 24 h, the solvent was removed under reduced pressure and the residue was 
purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 40 min: A/B 100/0 – 
90/10 (v/v), SF 25-40 g) and afforded a yellow foam-like solid (360 mg, 66%), mp 86 °C. Rf = 0.45 
(CH2Cl2/MeOH 96/4). 
1H-NMR (400 MHz, CDCl3): δ (ppm) 1.67 (bs, 2H), 3.47 (bs, 2H), 4.60 (s, 2H), 
5.12 (s, 2H), 7.08-7.18 (m, 7H), 7.23-7.38 (m, 13H), 7.35 (s, 1H). 13C NMR (101 MHz, CDCl3): δ (ppm) 
24.32, 41.34, 43.75, 53.55, 67.19, 74.84, 127.83 (2C), 128.00, 128.10 (3H), 128.16 (6C), 128.22, 
128.49 (2C), 129.96 (6C), 138.17, 141.30, 141.62 (3C), 155.69. MS (LC-MS, ESI): m/z 500.23 [M+H+]. 
C33H29N3O2 (499.60). 
 
3-Trityl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine (3.45) 
To a solution of 3.44 (300 mg, 0.601 mmol, 1 eq) in MeOH (10 mL), 10% palladium-on-charcoal 
catalyst (30 mg) was added and a slow stream of hydrogen was led through a glass tube into the 
vigorously stirred suspension. After depletion of the starting material (4 h; control by TLC) the 
catalyst was removed by filtration through Celite. The filtrate was concentrated in vacuo to give the 
product as a clear sticky oil which was used in the next step without further purification (198 mg, 
90%). Rf = 0.15 (CH2Cl2/MeOH 96/4). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.87 (bs, 2H), 3.02 (bs, 2H), 
4.15 (s, 2H), 7.00-7.10 (m, 6H), 7.20-7.31 (m, 10H). MS (LC-MS, ESI): m/z 366.20 [M+H+]. C25H23N3 
(365.47). 
 
3.5.2.11 Preparation of the primary amines 3.48-3.50 
Benzyl 4-{3-[2-(tert-butoxycarbonylamino)ethylamino]-3-oxoprop-1-enyl}-1H-imidazole-1-carboxy-
late (3.47) 
To a solution of 3.46 (UR-MK251, 558 mg, 1.99 mmol, 1 eq) and NEt3 (806 mg, 7.96 mmol, 4 eq) in 
DMF (40 mL), benzyl chloroformate (679 mg, 3.98 mmol, 2 eq) in DMF (10 mL) were added dropwise 
within 10 min and the mixture was stirred at rt for 24 h. Subsequently, the reaction mixture was 
transferred to a separation funnel, 400 mL of 1 M NaOH(aq), 200 mL of EtOAc and 450 mL of water 
was added. The organic phase was washed with 200 mL of brine, dried over MgSO4 concentrated in 
vacuo. The crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); 
gradient: 0 to 50 min: A/B 100/0 – 90/10 (v/v), SF 25-40 g) and afforded a yellow foam-like solid 
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(668 mg, 81%), mp 153 °C. Rf = 0.35 (CH2Cl2/MeOH 90/10). 
1H-NMR (400 MHz, CDCl3): δ (ppm) 1.38 
(s, 9H), 3.16-3.44 (m, 4H), 4.64 (s, 2H), 6.64 (d, J = 15.2, 1H), 7.03 (s, 1H), 7.18-7.45 (m, 6H), 8.00 (s, 
1H). MS (LC-MS, ESI): m/z 415.20 [M+H+]. C21H26N4O5 (414.45). 
 
Benzyl 4-[3-(2-aminoethylamino)-3-oxoprop-1-enyl]-1H-imidazole-1-carboxylate bis(hydrotrifluoro-
acetate) (3.48) 
To a solution of 3.47 (334 mg, 0.807 mmol) in CH2Cl2 (2 mL), TFA (1 mL) was added dropwise. After 
stirring for 4 h, the solvent was removed under reduced pressure, resuspended twice in CH2Cl2 
(10 mL) to remove remains of TFA. Subsequently, the residue was dissolved in water (10 mL) and 
dried by lyophilisation to afford 3.49 (bis(hydrotrifluoroacetate)) as a white powder (360 mg, 96%). 
Rf = 0.05 (CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.79-3.02 (m, 
2H), 3.41 (q, J = 6.2, 2H), 5.15 (s, 2H), 6.64 (d, J = 16.0, 1H), 7.24-7.49 (m, 6H), 7.99 (s, 3H), 8.51 (t, J = 
5.7, 2H), 9.09 (bs, TFA), 9.16 (s, 1H). MS (LC-MS, ESI): m/z 315.15 [M+H+]. C16H18N4O3 (314.34). 
 
N-(2-Aminoethyl)-3-(1H-imidazol-4-yl)acrylamide bis(hydrotrifluoroacetate) (3.49) 
To a solution of 3.46 (0.50 g, 1.78 mmol) in CH2Cl2 (2 mL), TFA (1 mL) was added dropwise. After 
stirring for 4 h, the solvent was removed under reduced pressure, resuspended twice in CH2Cl2 
(10 mL) to remove remains of TFA. Subsequently, the residue was dissolved in water (10 mL) and 
dried by lyophilisation to afford 3.49 as a white powder (714 mg, 98%). A sample of 50 mg was 
purified by preparative HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. 
TFA 3/97, 31−40 min: 90/10 min, tR = 5.5 min). MeCN was removed under reduced pressure. After 
lyophilisation 3.49 (bis(hydrotrifluoroacetate)) was obtained as white fluffy solid (38 mg, 76%). 
Rf = 0.16 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 266, 192 nm. RP-HPLC (220 nm): 
99.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 3/97, 31-40 min: 90/10, tR = 8.7 min, k = 2.1). 
1H-NMR (300 MHz, MeOH-d4): δ (ppm) 3.13 (t, J = 5.9, 2H), 3.60 (t, J = 5.9, 2H), 6.75 (d, J = 15.9, 1H), 
7.49 (d, J = 15.9, 1H), 7.84 (s, 1H), 8.96 (s, 1H). 13C NMR (75 MHz, MeOH-d4): δ (ppm) 38.51, 40.75, 
121.18, 125.00, 126.31, 131.34, 137.13, 168.09.MS (LC-MS, ESI): m/z 181.04 [M+H+]. HRMS (ESI-MS): 
m/z [M+H+] calcd. for C8H13N4O
+: 181.1084, found: 181.1088. 
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N-(2-Aminoethyl)-3-(1H-imidazol-4-yl)propanamide bis(hydrotrifluoroacetate) (3.50) 
To a solution of 3.46 (194 mg, 0.475 mmol, 1 eq) in MeCN (10 mL), 10% palladium-on-charcoal 
catalyst (19 mg) was added and a slow stream of hydrogen was led through a glass tube into the 
vigorously stirred suspension for 4 h. Subsequently, stirring was continued at 1 atm H2 for 16 h. After 
depletion of the starting material (control by TLC) the catalyst was removed by filtration through 
Celite. The filtrate was concentrated in vacuo to give the product as a white solid (170 mg, 88%). A 
sample of 50 mg was purified by preparative HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 
min: MeCN/0.1% aq. TFA 3/97, 31−40 min: 90/10 min, tR = 5.8 min). MeCN was removed under 
reduced pressure. After lyophilisation 3.50 (bis(hydrotrifluoroacetate)) was obtained as white fluffy 
solid (28 mg, 56%). Rf = 0.15 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 222, 212 nm. 
RP-HPLC (220 nm): 98.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 3/97, 31-40 min: 90/10, tR = 
5.0 min, k = 0.8). 1H-NMR (300 MHz, MeOH-d4): δ (ppm) 2.65 (t, J = 7.3, 1H). 2.99-3.09 (m, 2H), 3.46 
(t, J = 5.9, 1H), 7.31 (d, J = 0.8, 1H), 8.77 (d, J = 1.3, 1H). 13C NMR (75 MHz, MeOH-d4): δ (ppm) 21.07, 
34.90, 38.23, 40.75, 117.01, 134.59, 134.67, 174.94. MS (LC-MS, ESI): m/z 183.12 [M+H+]. HRMS (ESI-
MS): m/z [M+H+] calcd. for C8H15N4O
+: 183.1240, found: 183.1240. 
 
3.5.2.12 Preparation of the primary amines 3.58-3.60 
General procedure for the preparation of the imidazoles 3.53 and 3.54 
The respective amine (1 eq), phthalic anhydride (7 eq) and NEt3 (3 eq) were put together in toluene 
connected with a water separator and refluxed for 24 h. The mixture was cooled to rt and the solvent 
was removed under reduced pressure. Subsequently, the residue was transferred to a separation 
funnel, 100 mL of EtOAc and 100 mL of brine were added and the pH of the aqueous phase was 
adjusted to pH 11 by addition of 1 M NaOH(aq). The aqueous phase was washed with 100 mL of EtOAc 
for three times and the combined organic phases were dried over MgSO4 and concentrated in vacuo 
to afford 3.53 or 3.54 as pale yellow solid which was used in the next step without further 
purification. 
 
2-[4-(1H-Imidazol-4-yl)butyl]isoindoline-1,3-dione (3.53)52 
The title compound was prepared from 3.51 (imbutamine dihydrobromide, 5.75 g, 19.1 mmol), 
phthalic anhydride (19.8 g, 133 mmol) and NEt3 (5.80 mg, 57.1 mmol) in toluene (150 mL) according 
to general procedure. (Yield: 2.47 g, 48%.). Rf = 0.45 (CH2Cl2/MeOH 90/10). mp 151 °C (lit.
52 
158-160 °C). 1H-NMR (300 MHz, MeOH-d4): δ (ppm). 1.57-1.73 (m, 4H), 2.63 (t, J = 6.9, 2H), 3.67 (t, J = 
6.6, 2H), 6.81 (s, 1H), 7.66 (s, 1H), 7.73-7.84 (m, 4H). 13C NMR (75 MHz, MeOH-d4): δ (ppm) 26.72, 
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27.77, 29.05, 38.53, 118.03, 124.09 (2C), 133.38 (2C), 135.35 (2C), 135.65, 137.46, 169.85 (2C). MS 
(LC-MS, ESI): m/z 270.13 [M+H+].  C15H15N3O2 (269.30). 
 
2-[5-(1H-Imidazol-4-yl)pentyl]isoindoline-1,3-dione (3.54) 
The title compound was prepared from 3.52 (impentamine, 0.670 g, 4.78 mmol), phthalic anhydride 
(4.54 g, 30.6 mmol) and NEt3 (1.33 mg, 13.1 mmol) in toluene (25 mL) according to general 
procedure. (Yield: 0.657 g, 53%). Rf = 0.45 (CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz, MeOH-d4): 
δ (ppm) 1.22-1.40 (m, 2H), 1.57-1.72 (m, 4H), 2.55 (t, J = 7.5, 2H), 3.61 (t, J = 7.2, 2H), 6.74 (s, 1H), 
7.57 (s, 1H), 7.70-7.82 (m, 4H), 7.88 (s, 1H). 13C NMR (75 MHz, MeOH-d4): δ (ppm) 27.08, 27.34, 
29.20, 29.90, 38.66, 118.18, 123.99 (2C), 133.22 (2C), 135.23 (2C), 135.50, 137.53, 169.69 (2C). MS 
(LC-MS, ESI): m/z 284.14 [M+H+]. C16H17N3O2 (283.33). 
 
General procedure for the preparation of the trityl-protECted imidazoles 3.56 and 3.57 
To a solution of 3.56 or 3.57 (1 eq) and NEt3 (1.5-3.0 eq) in MeCN was added dropwise a solution of 
trityl chloride (1.3 eq) in MeCN. After stirring the mixture for 24 h, the solvent was removed under 
reduced pressure. The crude product was purified by flash-chromatography. 
 
2-[4-(1-Trityl-1H-imidazol-4-yl)butyl]isoindoline-1,3-dione (3.56)65 
The title compound was prepared from 3.53 (500 mg, 1.86 mmol), trityl chloride (673 mg, 
2.41 mmol) and NEt3 (282 mg, 2.79 mmol) in MeCN (75 mL) according to general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 
50 min: A/B 100/0 – 90/10 (v/v), SF 25-40 g) and afforded a yellow foam-like solid (860 mg, 91%), 
mp 56 °C. Rf = 0.61 (CH2Cl2/MeOH 90/10). 
1H-NMR (400 MHz, CDCl3): δ (ppm) 1.64 (bs, 4H), 2.54 (bs, 
2H), 3.61 (bs, 2H), 6.50 (s, 1H), 7.04-7.12 (m, 6H), 7.20-7.27 (m, 9H), 7.32 (s, 1H), 7.54-7.78 (m, 4H). 
13C NMR (101 MHz, CDCl3): δ (ppm) 26.44, 27.66, 27.95, 37.62, 74.93, 117.86, 122.89 (2C), 127.77 
(3C), 127.83 (6C), 129.58 (6C), 132.00 (2C), 133.62 (2C), 138.08, 140.92, 142.34 (3C), 168.08 (2C). MS 
(LC-MS, ESI): m/z 512.23 [M+H+]. C34H29N3O2 (511.61). 
 
2-[5-(1-Trityl-1H-imidazol-4-yl)pentyl]isoindoline-1,3-dione (3.57)66 
The title compound was prepared from 3.54 (272 mg, 0.960 mmol), trityl chloride (348 mg, 
1.25 mmol) and NEt3 (291 mg, 2.79 mmol) in MeCN (50 mL) according to general procedure. The 
crude product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 
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50 min: A/B 100/0 – 90/10 (v/v), SF 25-40 g) and afforded a yellow foam-like solid (200 mg, 40%), 
mp 73 °C. Rf = 0.45 (CH2Cl2/MeOH 90/10). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.28-
1.39 (m, 2H), 1.58-1.71 (m, 4H), 2.50 (t, J = 7.5, 2H), 3.62 (t, J = 7.3, 2H), 6.48 (s, 1H), 7.08-7.14 (m, 
6H), 7.25-7.30 (m, 9H), 7.31 (s, 1H), 7.60-7.81 (m, 4H). 13C NMR (101 MHz, CDCl3): δ (ppm) 26.50, 
28.20, 28.40, 28.87, 38.02, 75.06, 117.79, 123.11 (2C), 127.94 (3C), 127.98 (6C), 129.77 (6C), 132.17 
(2C), 133.81 (2C), 138.21, 141.58, 142.57 (3C), 168.37 (2C). MS (LC-MS, ESI): m/z 526.25 [M+H+]. 
C35H31N3O2 (525.64). 
 
General procedure for the preparation of the imidazoles 3.58 - 3.60 
A mixture of 3.55-3.57 (1 eq) and hydrazine monohydrate (5-6.3 eq) in EtOH or n-butanol was stirred 
at rt for 24 h. After removal of insoluble material, the filtrate was evaporated giving a pale brownish 
solid which was used in the next step without further purification. 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (3.58)67 
The title compound was prepared from 3.55 (1.58 g, 3.18 mmol) and hydrazine monohydrate (1.00 g, 
20.0 mmol, 6.3 eq) in n-butanol (25 mL) according to general procedure, affording a yellow foam-like 
solid which was used in the next step without further purification (1.17 g, 100%), mp 107 °C (lit.52 
106-108 °C). Rf = 0.10 (CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.59-1.75 (m, 2H), 
2.47 (t, J = 7.5, 2H), 2.60 (t, J = 7.0, 2H), 6.43 (s, 1H), 6.97-7.08 (m, 6H), 7.15-7.21 (m, 9H), 7.25 (s, 1H). 
13C-NMR (75 MHz, CDCl3): δ (ppm) 25.67, 32.91, 41.49, 75.02, 117.80, 127.95 (3C), 127.97 (6C), 
129.72 (3C), 138.27, 141.23, 142.50 (3C). MS (LC-MS, ESI): m/z 368.0 [M+H+]. C25H25N3 (367.49). 
 
4-(1-Trityl-1H-imidazol-4-yl)butan-1-amine (3.59)65 
The title compound was prepared from 3.56 (430 mg, 0.841 mmol) and hydrazine monohydrate 
(210 mg, 4.20 mmol, 5 eq) in EtOH (6 mL) according to general procedure, affording a yellow sticky 
solid which was used in the next step without further purification (308 mg, 96%). mp 63 °C. Rf = 0.10 
(CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.36-1.68 (m, 4H), 2.45 (t, J = 7.5, 2H), 2.65 
(t, J = 6.9, 2H), 6.46 (s, 1H), 7.01-7.11 (m, 6H), 7.20-7.28– (m, 9H), 7.29 (s, 1H). 13C-NMR (75 MHz, 
CDCl3): δ (ppm) 26.43, 27.92, 32.06, 41.21, 74.98, 117.70, 127.92 (9C), 129.66 (6C), 138.10, 141.40, 
142.39 (3C). MS (LC-MS, ESI): m/z 382.23 [M+H+]. C26H27N3 (381.51). 
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5-(1-Trityl-1H-imidazol-4-yl)pentan-1-amine (3.60)65 
The title compound was prepared from 3.57 (200 mg, 0.381 mmol) and hydrazine monohydrate 
(95 mg, 1.90 mmol, 5 eq) in EtOH (3 mL) according to general procedure, affording a yellow foam-like 
solid which was used in the next step without further purification (148 mg, 98%), mp 73 °C. Rf = 0.10 
(CH2Cl2/MeOH 90/10). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.23-1.68 (m, 6H), 2.39-2.79 (m, 4H), 6.46 
(s, 1H), 7.04-7.15 (m, 6H), 7.25-7.34 (m, 10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 26.37, 28.18, 29.00, 
31.96, 41.41, 75.04, 117.75, 127.99 (9C), 129.77 (6C), 138.14, 141.69, 142.51 (3C). MS (LC-MS, ESI): 
m/z 396.24 [M+H+]. C27H29N3 (395.54). 
 
3.5.2.13 Preparation of the amines 3.62-3.73 
5-Fluoro-2-[4-(3-iodopropoxy)-2-methylphenyl]-4-methyl-1H-benzo[d]imidazole (3.61) 
A mixture of 3.11 (1.36 g, 4.09 mmol, 1 eq) and NaI (1.39 g, 27.8 mmol, 6.8 eq) in acetone (7 mL) was 
refluxed for 72 h. Subsequently, the solvent was removed und reduced pressure, the residue was 
dissolved in CH2Cl2 (20 mL), sonificated, filtered and dried in vacuo to afford a yellow foam-like solid 
(1.56 g, 90%). mp 76-78 °C. Rf = 0.41 (hexanes/EtOAc 2/1) nm. RP-HPLC (220 nm): 97% (gradient: 
0−30 min: MeCN/0.1% aq. TFA 5/95−80/20, 31-40 min: 90/10, tR = 26.0 min, k = 10.1). 
1H-NMR 
(400 MHz, CDCl3): δ (ppm) 2.27 (p, J = 6.3, 1H), 2.44 (s, 3H), 2.49 (d, J = 1.4, 3H), 3.37 (t, J = 6.7, 2H), 
4.03 (t, J = 5.8, 2H), 6.64 (dd, J = 2.5, 8.5, 1H), 6.75 (d, J = 2.5, 1H), 6.95 (dd, J = 8.8, 10.1, 1H), 7.24 
(dd, J = 4.4, 8.7, 1H), 7.37 (d, J = 8.5, 1H). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA) 3.76, 9.42 (d, J = 
3.2), 19.81, 32.36, 67.85, 110.97 (d, J = 23.7), 112.58 (d, J = 10.1), 112.72, 114.29 (d, J = 26.8), 115.35 
(d, J = 288.8, TFA), 115.68, 117.34, 128.13, 132.24 (d, J = 10.3), 133.15, 140.29, 150.94, 158.24 (d, J = 
239.6), 158.65 (q, J = 38.1, TFA), 161.75. MS (LC-MS, ESI): m/z 425.05 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C18H19FIN2O
+: 425.0521, found: 425.0522. 
 
General procedure for the preparation of the sECondary amines 3.62 and 3.73 
The iodinated compound 3.61 (1 eq), the pertinent amine (2-3.5 eq) and K2CO3 (4-7 eq) in MeCN 
were heated under microwave irradiation at 130 °C for 20 min. Subsequently, the solvent was 
removed in vacuo. For 3.65 and 3.66, the crude product was purified by preparative RP-HPLC. For all 
other compounds, the residue was dissolved in CH2Cl2, TFA was added and the reaction mixture was 
stirred until the protection group was removed (5-8 h, TLC control). After evaporation of the solvent 
in vacuo, the crude product was purified by preparative RP-HPLC. 
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3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]-N-[2-(5-methyl-1H-imidazol-
4-yl)ethyl]propan-1-amine tris(hydrotrifluoroacetate) (3.62) 
The title compound was prepared from 3.61 (50 mg, 0.118 mmol, 1 eq), 3.41 (152 mg, 0.413 mmol, 
3.5 eq) and K2CO3 (114 mg, 0.825 mmol, 7 eq) in MeCN (2.5 mL) according to general procedure. 
Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: Nucleodur 
250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−45/55, tR = 12.8 min) afforded 3.62 
(tris(hydrotrifluoroacetate)) as white fluffy solid (38 mg, 42%). Rf = 0.11 (CH2Cl2/MeOH/NH3 80/19/1). 
UV/VIS (20 mM HCl): λmax 295, 252, 209, 192 nm. RP-HPLC (220 nm): 98.8% (gradient: 0−30 min: 
MeCN/0.1% aq. TFA 5/95-80/20, 31-40 min: 90/10, tR = 13.3 min, k = 6.9). 
1H-NMR (400 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 2.07-2.17 (m, 2H), 2.25 (s, 3H), 2.50 (s, 3H, superimposed by solvent), 
2.53 (d, J = 1.0, 3H), 3.01 (t, J = 7.4, 2H), 3.11-3.28 (m, 4H), 4.19 (t, J = 6.0, 2H), 7.05-7.10 (m, 2H), 
7.38-7.47 (m, 1H), 7.70 (dd, J = 4.4, 9.1, 1H), 7.74 (d, J = 8.7, 1H), 8.87 (bs, 1H), 8.95 (s, 1H), 13.17 (bs, 
TFA), 14.22 (bs, 2H). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 8.61, 9.38 (d, J = 3.1), 19.79, 
20.23, 25.51, 44.32, 45.56, 65.21, 110.89 (d, J = 23.4), 112.55 (d, J = 9.9), 112.57, 114.17 (d, J = 26.3), 
115.31 (q, J = 288.9, TFA), 115.80, 117.16, 123.85, 126.28, 128.19, 132.28 (d, J = 10.4), 132.97, 
133.07, 140.17, 150.80, 158.14 (d, J = 239.3), 158.56 (q, J = 38.0, TFA), 161.47. MS (LC-MS, ESI): m/z 
422.24 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C24H29FN5O
+: 422.2351, found: 422,2354. 
 
N-[3-(1H-Imidazol-4-yl)propyl]-3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-
methylphenoxy]propan-1-amine tris(hydrotrifluoroacetate) (3.63) 
The title compound was prepared from 3.61 (116 mg, 0.272 mmol, 1 eq), 3.58 (305 mg, 0.817 mmol, 
3 eq) and K2CO3 (263 mg, 1.91 mmol, 7 eq) in MeCN (5.5 mL) according to the general procedure. 
Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: Nucleodur 
250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, tR = 9.0 min) afforded 3.63 
(tris(hydrotrifluoroacetate)) as white fluffy solid (58.2 mg, 28%). Rf = 0.13 (CH2Cl2/MeOH/NH3 
80/19/1). UV/VIS (20 mM HCl): λmax 294, 252, 205 nm. RP-HPLC (220 nm): 99.3% (gradient: 0−30 min: 
MeCN/0.1% aq. TFA 5/95-80/20, 31-40 min: 90/10, tR = 13.1 min, k = 6.8). 
1H-NMR (400 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 1.91-2.02 (m, 2H), 2.06-2.16 (m, 2H), 2.49 (s, 3H), 2.53 (d, J = 1.2, 3H), 
2.76 (t, J = 7.4, 2H), 2.94-3.05 (m, 2H), 3.06-3.18 (m, 2H), 4.18 (t, J = 6.0, 2H), 7.03-7.10 (m, 2H), 7.39-
7.45 (m, 1H), 7.46 (s, 1H), 7.65-7.77 (m, 2H), 8.70 (bs, 2H), 9.01 (s, 1H), 13.17 (bs, TFA), 14.24 (bs, 2H). 
13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.14 (d, J = 3.3), 19.56, 20.92, 24.25, 25.35, 
44.07, 45.83, 64.98, 110.67 (d, J = 23.7), 112.32 (d, J = 10.1), 112.33, 113.96 (d, J = 28.2), 115.09 (q, J 
= 288.8, TFA), 115.55, 115.67, 116.94, 127.95, 131.89, 132.04 (d, J = 10.5), 132.84, 133.93, 139.94, 
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150.57, 157.92 (d, J = 239.5), 158.33 (q, J = 38.0), 161.27. MS (LC-MS, ESI): m/z 422.24 [M+H+]. HRMS 
(ESI-MS): m/z [M+H+] calcd. for C24H29FN5O
+: 422.2351, found: 422.2346. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-4-(1H-imidazol-4-
yl)butan-1-amine tris(hydrotrifluoroacetate) (3.64) 
The title compound was prepared from 3.61 (60 mg, 0.141 mmol, 1 eq), 3.59 (184 mg, 0.481 mmol, 
3.4 eq) and K2CO3 (133 mg, 0.962 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general 
procedure. Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: 
Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−45/55, tR = 9.5 min) 
afforded 3.64 (tris(hydrotrifluoroacetate)) as white fluffy solid (42.9 mg, 39%). Rf = 0.12 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 291, 249, 208, 192 nm. RP-HPLC (220 nm): 
99.4% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR = 14.9 min, 
k = 5.4). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.54-1.75 (m, 4H), 2.04-2.18 (m, 2H), 
2.50 (s, 3H, superimposed by solvent), 2.53 (d, J = 1.0, 3H), 2.69 (t, J = 6.9, 2H), 2.91-3.04 (m, 2H), 
3.05-3.17 (m, 2H), 4.19 (t, J = 6.0, 2H), 7.04-7.10 (m, 2H), 7.38-7.48 (m, 2H), 7.71 (dd, J = 4.8, 9.6, 1H), 
7.74 (d, J = 8.5, 1H), 8.63 (bs, 2H), 8.99 (s, 1H), 13.54 (bs, TFA), 14.48 (bs, 2H). 13C-NMR (101 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 9.35 (d, J = 3.4), 19.79, 23.31, 24.84, 24.93, 25.58, 44.27, 46.58, 
65.21, 110.89 (d, J = 23.6), 112.56 (d, J = 10.1), 112.57, 114.13 (d, J = 29.5), 115.42 (q, J = 289.5, TFA), 
115.72, 115.82, 117.17, 128.24, 132.32 (d, J = 10.0), 132.97, 133.06, 133.93, 140.16, 150.84, 158.14 
(d, J = 239.3), 158.60 (q, J = 37.7, TFA), 161.49. MS (LC-MS, ESI): m/z 436.25 [M+H+]. HRMS (ESI-MS): 
m/z [M+H+] calcd. for C25H31FN5O
+: 436.2507, found: 436.2506. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-4-(5-methyl-1H-
imidazol-4-yl)butan-1-amine tris(hydrotrifluoroacetate) (3.65) 
The title compound was prepared from 3.61 (50 mg, 0.118 mmol, 1 eq), 4-(5-methyl-1H-imidazol-4-
yl)butan-1-amine (5-methylimbutamine, 63 mg, 0.413 mmol, 3.5 eq) and K2CO3 (114 mg, 
0.825 mmol, 7 eq) in MeCN (2.5 mL) according to the general procedure. Preparative RP-HPLC 
(column: Interchim, Puriflash C18HQ, 15 µm, 120 g; gradient: 0−30 min: MeCN/0.1% aq. TFA 
10/90−48/52, tR = 11.2 min) afforded 3.65 (tris(hydrotrifluoroacetate)) as white fluffy solid (57.8 mg, 
62%). Rf = 0.13 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 298, 256, 211, 192 nm. 
RP-HPLC (220 nm): 100% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR 
= 11.3 min, k = 3.8). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.52-1.68 (m, 4H), 2.02-2.17 
(m, 2H), 2.22 (s, 3H), 2.49 (s, 3H), 2.53 (d, J = 1.1, 3H), 2.64 (t, J = 6.5, 2H), 2.96 (bs, 2H), 3.10 (bs, 2H), 
4.18 (t, J = 6.0, 2H), 7.02-7.10 (m, 2H), 7.38-7.47 (m, 1H), 7.67-7.77 (m, 2H), 8.59 (bs, 2H), 8.89 (s, 1H), 
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13.09 (bs, TFA), 14.14 (bs, 2H). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 8.57, 9.38 (d, J = 
3.3), 19.79, 22.33, 24.90, 25.57, 44.29, 46.65, 65.21, 110.91 (d, J = 23.6), 112.55 (d, J = 9.8), 112.58, 
114.20 (d, J = 27.1), 115.30 (q, J = 288.9, TFA), 115.77, 117.18, 124.62, 127.96, 132.19 (d, J = 10.1), 
132.32, 133.08, 134.30, 140.18, 150.81, 158.16 (d, J = 239.7), 158.56 (q, J = 38.1, TFA), 161.52. 
MS (LC-MS, ESI): m/z 450.27 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C26H33FN5O
+: 450.2664, 
found: 450.2657. 
 
3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]-N-{2-[(5-methyl-1H-imidazol-
4-yl)methylsulfanyl]ethyl}propan-1-amine tris(hydrotrifluoroacetate) (3.66) 
The title compound was prepared from 3.61 (50 mg, 0.118 mmol, 1 eq), 2-[(5-methyl-1H-imidazol-4-
yl)methylsulfanyl)ethanamine dihydrochloride (101 mg, 0.413 mmol, 3.5 eq) and K2CO3 (114 mg, 
0.825 mmol, 7 eq) in MeCN (2.5 mL) according to general procedure. Preparative RP-HPLC (column: 
Interchim, Puriflash C18HQ, 15 µm, 120 g; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−48/52, tR = 
11.0 min) afforded 3.66 (tris(hydrotrifluoroacetate)) as white fluffy solid (54.4 mg, 57%). Rf = 0.07 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 293, 251, 209, 192 nm. RP-HPLC (220 nm): 
100% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR = 15.2 min, k = 
5.5). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.08-2.18 (m, 2H), 2.29 (s, 3H), 2.50 (s, 3H, 
superimposed by solvent), 2.53 (d, J = 1.0, 3H), 2.74 (t, J = 7.7, 2H), 3.09-3.27 (m, 4H), 3.92 (s, 2H), 
4.19 (t, J = 5.9, 2H), 7.04-7.10 (m, 2H), 7.39-7.46 (m, 1H), 7.70 (dd, J = 4.2, 9.0, 1H), 7.74 (d, J = 8.4, 
1H), 8.80 (bs, 2H), 8.95 (s, 1H), 12.24 (bs, TFA), 14.32 (bs, 2H). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL 
TFA): δ (ppm) 8.65, 9.37 (d, J = 3.0), 19.79, 22.92, 25.52, 26.52, 44.35, 46.02, 65.25, 110.89 (d, J = 
23.7), 112.55 (d, J = 10.1), 112.57, 114.16 (d, J= 26.6), 115.36 (q, J = 289.2, TFA), 115.82, 117.17, 
125.27,126.48, 128.22, 132.31 (d, J = 10.0), 133.06, 133.32, 140.16, 150.83, 158.14 (d, J = 239.3 Hz), 
158.58 (q, J = 37.8 Hz, TFA), 161.48. MS (LC-MS, ESI): m/z 468.22 [M+H+]. HRMS (EI-MS): m/z M+• 
calcd. for C25H31FN5OS
+: 468.2228, found: 468.2232. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-5-(1H-imidazol-4-
yl)pentan-1-amine tris(hydrotrifluoroacetate) (3.67) 
The title compound was prepared from 3.61 (60 mg, 0.141 mmol, 1 eq), 3.60 (178 mg, 0.450 mmol, 
3.2 eq) and K2CO3 (133 mg, 0.962 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general 
procedure. Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: 
Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−45/55, tR = 13.5 min) 
afforded 3.67 (tris(hydrotrifluoroacetate)) as white fluffy solid (35.8 mg, 32%). Rf = 0.12 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 294, 252, 206, 193 nm. RP-HPLC (220 nm): 
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98.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR = 14.4 min, k = 
5.2). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.30-1.40 (m, 2H), 1.56-1.70 (m, 4H), 2.04-
2.17 (m, 2H), 2.50 (s, 3H), 2.53 (d, J = 0.7, 3H), 2.65 (t, J = 7.6, 2H), 2.90-3.02 (m, 2H), 3.05-3.16 (m, 
2H), 4.18 (t, J = 5.9, 2H), 7.04-7.10 (m, 2H), 7.39-7.46 (m, 2H), 7.70 (dd, J = 4.3, 9.0, 1H), 7.74 (d, J = 
8.3, 1H), 8.61 (bs, 2H), 8.98 (s, 1H), 9.98 (bs, TFA), 14.43 (bs, 2H). 13C-NMR (101 MHz,  DMSO-d6 + 10 
µL TFA): δ (ppm) 9.36 (d, J = 3.2), 19.78, 23.63, 25.22, 25.30, 25.51, 27.37, 44.19, 46.79, 65.16, 110.84 
(d, J = 22.9), 112.50, 112.51 (d, J = 9.4), 114.05 (d, J = 28.2), 115.35 (q, J = 289.4), 115.51, 115.88, 
117.12, 128.28, 132.38 (d, J = 10.3), 132.98, 133.25, 133.78, 140.09, 150.82, 158.05 (d, J = 240.2), 
158.49 (q, J = 37.7, TFA), 161.38. MS (LC-MS, ESI): m/z 450.27 [M+H+]. HRMS (ESI-MS): m/z [M+H+] 
calcd. for C26H31FN5O
+: 450.2664, found: 450.2667. 
 
N-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}ethane-1,2-diamine 
tris(hydrotrifluoroacetate) (3.68) 
The title compound was prepared from 3.61 (50 mg, 0.118 mmol, 1 eq), tert-butyl 
2-aminoethylcarbamate (60 mg, 0.375 mmol, 3 eq) and K2CO3 (98 mg, 0.710 mmol, 6 eq) in MeCN 
(2.5 mL) according to the general procedure. Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed 
by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 
10/90−45/55, tR = 9.1 min) afforded 3.68 (tris(hydrotrifluoroacetate)) as white fluffy solid (39.8 mg, 
48%). Rf = 0.07 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 291, 254, 208, 192 nm. 
RP-HPLC (220 nm): 96.4% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95-80/20, 31-40 min: 90/10, tR 
= 13.0 min, k = 6.7). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.05-2.18 (m, 2H), 2.50 (s, 
3H, superimposed by solvent), 2.53 (d, J = 1.0, 3H), 3.07-3.29 (m, 6H), 4.19 (t, J = 6.0, 2H), 7.05-7.11 
(m, 1H), 7.39-7.46 (m, 1H), 7.70 (dd, J = 4.4, 9.1, 1H), 7.74 (d, J = 8.6, 1H), 8.05 (bs, 3H), 8.92 (bs, 2H), 
13.27 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.38 (d, J = 3.1), 19.79, 25.65, 
35.40, 44.23, 44.61, 65.16, 110.89 (d, J = 22.6), 112.55 (d, J = 9.7), 112.58, 114.19 (d, J = 27.0), 115.31 
(q, J = 288.9, TFA), 115.81, 117.19, 128.18, 132.27 (d, J = 10.2), 133.07, 140.17, 150.81, 158.15 (d, J = 
239.6), 158.57 (q, J = 38.0, TFA), 161.47. MS (LC-MS, ESI): m/z 357.21 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C20H26FN4O
+: 357.2085, found: 357.2086. 
 
5-Fluoro-4-methyl-2-{2-methyl-4-[3-(piperazin-1-yl)propoxy]phenyl}-1H-benzo[d]imidazole 
tris(hydrotrifluoroacetate) (3.69) 
The title compound was prepared from 3.61 (120 mg, 0.283 mmol, 1 eq), 6.1 (179 mg, 0.962 mmol, 
3.4 eq) and K2CO3 (98 mg, 1.92 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general procedure. 
Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: Interchim, 
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Puriflash C18HQ, 15 µm, 120 g; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−60/40, tR = 9.5 min) 
afforded 3.69 (tris(hydrotrifluoroacetate)) as white fluffy solid (134 mg, 65%). Rf = 0.10 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 293, 251, 206, 190 nm. RP-HPLC (220 nm): 
99.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−70/30, 31-40 min: 90/10, tR = 14.4 min, k = 
5.2). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.14-2.25 (m, 2H), 2.50 (s, 3H, superimposed 
by solvent), 2.53(d, J = 1.0, 3H), 3.32-3.72 (m, 10H), 4.19 (t, J = 6.0, 2H), 7.05-7.11 (m, 2H), 7.38-7.46 
(m, 1H), 7.71 (dd, J = 4.2, 9.0, 1H), 7.74 (d, J = 8.4, 1H), 9.42 (bs, 2H), 13.27 (bs, TFA). 13C-NMR (101 
MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.37 (d, J = 3.3), 19.81, 23.42, 40.38 (2C), 48.30 (2C), 53.30, 
65.22, 110.89 (d, J = 23.6), 112.57 (d, J = 10.1), 112.58, 114.09 (d, J = 27.8), 115.67 (q, J = 290.6), 
116.01, 117.20, 128.35, 132.44 (d, J = 10.2), 133.03, 140.16, 150.85, 158.11 (d, J = 239.5), 158.75 (q, J 
= 36.8, TFA), 161.37. MS (LC-MS, ESI): m/z 383.22 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C22H28FN4O
+: 383.2242, found: 383.2243. 
 
N-(2-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propylamino}ethyl)-3-
(1H-imidazol-4-yl)acrylamide tris(hydrotrifluoroacetate) (3.70) 
The title compound was prepared from 3.61 (60 mg, 0.141 mmol, 1 eq), 3.48 (151 mg, 0.450 mmol, 
3.4 eq) and K2CO3 (133 mg, 0.962 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general 
procedure. Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: 
Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−45/55, tR = 9.6 min) 
afforded 3.70 (tris(hydrotrifluoroacetate)) as white fluffy solid (35.9 mg, 43%). Rf = 0.09 
(CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 276, 257, 210, 190 nm. RP-HPLC (220 nm): 
99.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−70/30, 31-40 min: 90/10, tR = 14.0 min, k = 
5.0). 1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.05-2.18 (m, 2H). 2.50 (s, 3H, superimposed 
by solvent), 2.53 (d, J = 0.9, 3H), 3.06-3.23 (m, 4H), 3.47-3.56 (m, 2H), 4.19 (t, J = 5.9, 2H), 6.67 (d, J = 
16.0, 1H), 7.05-7.11 (m, 2H), 7.41 (d, J = 15.8, 1H), 7.40-7.46 (m, 1H), 7.70 (dd, J = 4.3, 9.0, 1H), 7.74 
(d, J = 8.3, 1H), 8.58 (t, J = 5.7, 1H), 8.70 (bs, 2H), 9.17 (s, 1H), 10.05 (bs, TFA). 13C-NMR (101 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 9.36 (d, J = 3.5), 19.79, 25.49, 35.71, 44.51, 46.58, 65.23, 110.83 (d, 
J = 22.9), 112.51 (d, J = 9.0), 112.52, 115.39 (q, J = 289.7, TFA), 115.90, 117.00 (d, J = 33.5), 119.71, 
120.29, 123.86, 124.74, 128.30, 129.09, 132.40 (d, J = 10.2), 132.96, 136.29, 140.07, 150.83, 158.50 
(q, J = 37.5, TFA), 158.60 (d, J = 243.7), 161.37, 164.98. MS (LC-MS, ESI): m/z 477.25 [M+H+]. HRMS 
(ESI-MS): m/z [M+H+] calcd. for C26H30FN6O2
+: 477.2409, found: 477.2404. 
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5-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-4,5,6,7-tetrahydro-
3H-imidazo[4,5-c]pyridine tris(hydrotrifluoroacetate) (3.71) 
The title compound was prepared from 3.61 (60 mg, 0.141 mmol, 1 eq), 3.45 (176 mg, 0.450mmol, 
3.4 eq) and K2CO3 (133 mg, 0.962 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general 
procedure. Deprotection in CH2Cl2 (5 mL) and TFA (2 mL) followed by preparative RP-HPLC (column: 
Interchim, Puriflash C18HQ, 15 µm, 120 g; gradient: 0−10 min: MeCN/0.1% aq. TFA 10/90, 
10−40 min: 10/90−30/40, tR = 7.2 min) afforded 3.71 (tris(hydrotrifluoroacetate))) as white fluffy 
solid (39.9 mg, 37%). Rf = 0.10 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 291, 249, 207, 
192 nm. RP-HPLC (220 nm): 99.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 
90/10, tR = 14.4 min, k = 5.2). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.23-2.34 (m, 2H), 
2.50 (s, 3H, superimposed by solvent), 2.53 (d, J = 0.9, 3H), 3.07 (t, J = 5.1, 2H), 3.46-3.55 (m, 2H), 
3.70 (bs, 2H), 4.22 (t, J = 5.9 Hz, 2H), 4.59 (bs, 2H), 7.04-7.12 (m, 2H), 7.37-7.45 (m, 1H), 7.71 (dd, J = 
4.3, 9.0, 1H), 7.74 (d, J = 8.3, 1H), 9.04 (s, 1H), 13.16 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL 
TFA): δ (ppm) 9.13 (d, J = 3.3), 17.88, 19.57, 23.68, 46.28, 48.59, 52.14, 65.05, 110.66 (d, J = 23.6), 
112.33, 112.34 (d, J = 9.9), 113.89 (d, J = 27.0), 115.27 (q, J = 289.9, TFA), 115.71, 116.97, 120.43, 
124.30, 128.04, 132.13 (d, J = 10.1), 132.83, 134.96, 139.94, 150.59, 157.90 (d, J = 239.4), 158.44 (q, J 
= 37.3, TFA), 161.19. MS (LC-MS, ESI): m/z 420.22 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C24H27FN5O
+: 420.2194, found: 420.2195. 
 
(5-Chloro-1H-indol-2-yl)(4-{3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-
methylphenoxy]propyl}piperazin-1-yl)methanone bis(hydrotrifluoroacetate) (3.72) 
The title compound was prepared from 3.61 (34 mg, 0.080 mmol, 1 eq), 6.3 (60 mg, 0.159 mmol, 
2 eq) and K2CO3 (44 mg, 0.318 mmol, 6.8 eq) in MeCN (2.5 mL) according to the general procedure. 
Preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 
20/80−50/50, tR = 18.5 min) afforded 3.72 (bis(hydrotrifluoroacetate)) as white fluffy solid (35.4 mg, 
56%). Rf = 0.24 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 297, 227, 217, 193 nm. 
RP-HPLC (220 nm): 99.0% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, 
tR = 17.1 min, k = 6.3). 
1H-NMR (400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 2.15-2.29 (m, 2H), 2.50 (s, 
3H, superimposed by solvent), 2.54 (d, J = 0.9, 3H), 3.13-3.79 (m, 8H), 4.21 (t, J = 5.8, 2H), 4.53-4.74 
(m, 2H), 6.91 (d, J = 1.5, 1H), 7.06-7.14 (m, 2H), 7.22 (dd, J = 2.1, 8.7, 1H), 7.39-7.50 (m, 2H), 7.68 (d, J 
= 2.0, 1H), 7.71 (dd, J = 4.3, 9.0, 1H), 7.75 (d, J = 8.5, 1H), 10.26 (bs, 1H), 11.88 (s, 1H), 13.02 (bs, TFA). 
13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.38 (d, J = 3.2), 19.80, 23.48, 51.07 (2C), 51.11, 
53.30 (2C), 65.34, 104.50, 110.91 (d, J = 23.5), 112.56 (d, J = 9.6), 112.61, 113.93, 114.20 (d, J = 28.2), 
115.32 (q, J = 288.9), 115.86, 117.23, 120.56, 123.84, 124.55, 127.90, 128.19, 130.52, 132.29 (d, J= 
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8.6), 133.10, 134.73, 140.20, 150.82, 158.16 (d, J = 239.4), 158.57 (q, J = 38.0, TFA), 161.46, 161.84. 
MS (LC-MS, ESI): m/z 560.22 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C31H32ClFN5O2
+: 560.2223, 
found: 560.2229. 
 
3.5.2.14 Preparation of the amide 3.75 
Benzyl 2-aminoethyl{3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}-
carbamate bis(hydrotrifluoroacetate) (3.74) 
3.61 (194 mg, 0.457 mmol, 1 eq), tert-butyl 2-aminoethylcarbamate (249 mg, 1.56 mmol, 3.4 eq) and 
K2CO3 (430 mg, 3.11 mmol, 6.8 eq) in MeCN (2.5 mL) were heated under microwave irradiation at 
130 °C for 20 min. The solvent was removed under reduced pressure and the residue was dried in 
vacuo. Subsequently, NEt3 (162 mg, 1.60 mmol, 3.5 eq) in CH2Cl2 (2 mL) and benzyl chloroformate 
(273 mg, 1.60 mmol, 3.5 eq) in CH2Cl2 (1 mL) were added dropwise at 0 °C within 10 min and the 
mixture was stirred at rt for 24 h. The reaction mixture was concentrated in vacuo. The crude 
product was purified by flash-chromatography (eluent CH2Cl2 (A), MeOH (B); gradient: 0 to 40 min: 
A/B 100/0 – 90/10 (v/v), SF 25-40 g) affording a white solid. mp 115 °C. Rf = 0.35 (CH2Cl2/MeOH 
90/10). Subsequently, 4 mL of CH2Cl2 and 1 mL of TFA was added dropwise. After stirring for 4 h, the 
solvent was removed under reduced pressure, resuspended twice in 10 mL of CH2Cl2 to remove 
remains of TFA. The residue was dissolved in 10 mL of water and dried by lyophilisation to afford 
3.74 (bis(hydrotrifluoroacetate)) as a white powder (182 mg, 55%). Rf = 0.05 (CH2Cl2/MeOH 90/10). 
1H-NMR (400 MHz, MeOH-d4): δ (ppm) 2.09 (bs, 2H), 2.50 (s, 3H), 2.58 (d, J = 1.4, 3H), 3.18 (bs, 2H), 
3.59 (bs, 2H), 3.64 (t, J = 6.1, 2H), 4.10 (bs, 2H), 5.10 (s, 2H), 6.91-7.09 (m, 2H), 7.28-7.43 (m, 6H), 
7.61-7.70 (m, 2H). 13C-NMR (101 MHz, MeOH-d4): δ (ppm) 9.39 (d, J = 3.8), 20.16, 29.07, 39.79, 46.13, 
49.34, 49.55, 67.12, 68.86, 112.45 (d, J = 23.8), 113.33 (d, J = 10.1), 113.97, 115.95 (d, J = 27.6), 
116.50, 118.56, 129.14, 129.28 (2C), 129.34, 129.67 (2C), 133.55 (d, J = 9.9), 133.68, 137.78, 141.53, 
152.70, 160.34 (d, J = 241.6), 163.90. MS (LC-MS, ESI): m/z 491.25 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C28H32FN4O3
+: 491.2453, found: 491.2449. 
 
N-(2-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propylamino}ethyl)-
propionamide bis(hydrotrifluoroacetate) (3.75) 
To a solution of 3.75 (135 mg, 0.188 mmol, 1 eq) and NEt3 (95 mg, 0.939 mmol, 5 eq) in MeCN/DMF 
(1/1, 2 mL), succinimidyl propionate (39 mg, 0.225 mmol, 1.2 eq) was added. After stirring at rt for 
24 h, the solvent was removed under reduced pressure. For deprotection, TFA (1.5 mg, 0.013 mmol, 
0.07 eq) in MeCN (3 mL) and 10% palladium-on-charcoal catalyst (11 mg) were added and a slow 
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stream of hydrogen was led through a glass tube into the vigorously stirred suspension for 4 h. 
Subsequently, stirring was continued at 1 atm H2 for further 16 h. After depletion of the starting 
material (control by TLC) the catalyst by filtration through Celite. The filtrate was concentrated in 
vacuo, followed by preparative RP-HPLC (column: Interchim, Puriflash C18HQ, 15 µm, 120 g; 
gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−45/55, tR = 12.2 min) affording 3.75 
(bis(hydrotrifluoroacetate)) as a white fluffy solid (120 mg, 65%). Rf = 0.20 (CH2Cl2/MeOH/NH3 
80/19/1). UV/VIS (20 mM HCl): λmax 292, 252, 198, 192 nm. RP-HPLC (220 nm): 99.9% (gradient: 
0−30 min: MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR = 15.4 min, k = 5.6). 
1H-NMR 
(400 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 1.01 (t, J = 7.6, 3H), 2.06-2.18 (m, 4H), 2.50 (s, 3H, 
superimposed by solvent), 2.53 (d, J = 1.2, 3H), 2.97-3.21 (m, 4H), 3.36 (q, J = 6.1, 2H), 4.18 (t, J = 5.9, 
2H), 7.03-7.13 (m, 2H), 7.37-7.46 (m, 1H), 7.70 (dd, J = 4.2, 8.9, 1H), 7.74 (d, J = 8.4, 1H), 8.06 (t, J = 
5.5, 1H), 8.67 (bs, 2H), 10.39 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.34 (d, J 
= 3.1), 9.58, 19.80, 25.47, 28.42, 35.30, 44.43, 46.79, 65.26, 111.10 (d, J = 31.7), 112.52, 112.52 (d, J = 
9.9), 113.97 (d, J = 27.5), 115.59 (q, J = 290.4, TFA), 115.97, 117.18, 128.39, 132.48 (d, J = 9.9), 
132.93, 140.05, 150.87, 158.02 (d, J = 239.1), 158.56 (q, J = 36.7, TFA), 161.35, 174.00. MS (LC-MS, 
ESI): m/z 413.24 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C23H30FN4O2
+: 413.2347, found: 
413.2349. 
 
3.5.2.15 Preparation of the amide 3.76 
1-(4-{3-[4-(5-Fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propyl}piperazin-1-
yl)propan-1-one bis(hydrotrifluoroacetate) (3.76) 
To a solution of 3.69 (50 mg, 0.082 mmol, 1 eq) and NEt3 (27 mg, 0.270 mmol, 3.3 eq) in MeCN 
(2.5 mL), succinimidyl propionate (17 mg, 0.098 mmol, 1.2 eq) was added. After stirring at rt for 24 h, 
the solvent was removed under reduced pressure. Preparative RP-HPLC (column: Interchim, Puriflash 
C18HQ, 15 µm, 120 g; gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−50/50, tR = 10.7 min) afforded 
3.78 (bis(hydrotrifluoroacetate)) as a white solid (35.0 mg, 76%). Rf = 0.22 (CH2Cl2/MeOH/NH3 
80/19/1). UV/VIS (20 mM HCl): λmax 293, 249, 192 nm. RP-HPLC (220 nm): 99.9% (gradient: 0−30 min: 
MeCN/0.1% aq. TFA 10/90−80/20, 31-40 min: 90/10, tR = 16.1 min, k = 5.9). 
1H-NMR (400 MHz,  
DMSO-d6 + 10 µL TFA): δ (ppm) 1.00 (t, J = 7.4, 3H), 2.13-2.27 (m, 2H), 2.30-2.45 (m, 2H), 2.50 (s, 3H, 
superimposed by solvent), 2.53 (d, J = 1.2, 3H), 2.86-3.68 (m, 8H), 4.19 (t, J = 5.9, 2H), 4.00-4.58 (m, 
2H), 7.05-7.11 (m, 2H), 7.37-7.48 (m, 1H), 7.71 (dd, J = 9.0, 4.3, 1H), 7.74 (d, J = 8.4, 1H), 10.11 (bs, 
1H), 12.32 (bs, TFA). 13C-NMR (101 MHz,  DMSO-d6 + 10 µL TFA): δ (ppm) 9.12, 9.37 (d, J = 3.2), 19.79, 
23.43, 25.30, 38.19, 41.85, 50.98, 51.22, 53.23, 65.32, 110.89 (d, J = 23.7), 112.54 (d, J = 8.0), 112.59, 
114.16 (d, J = 26.9), 115.38 (q, J = 289.3, TFA), 115.88, 117.21, 128.22, 132.31 (d, J = 10.4), 133.07, 
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140.18, 150.82, 158.14 (d, J = 239.5), 158.58 (q, J = 37.8, TFA), 161.42, 171.75. MS (LC-MS, ESI): m/z 
439.25 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C25H32FN4O2
+: 439.2504, found: 439.2408. 
 
3.5.3 Pharmacological Methods 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany). 
Guanosine diphosphate (GDP) was from Sigma-Aldrich Chemie GmbH (Munich, Germany), unlabeled 
GTPγS was from Roche (Mannheim, Germany) and thioperamide was from R&D Systems 
(Wiesbaden, Germany) [3H]pyrilamine and [3H]N -methylhistamine and [3H]histamine was purchased 
from Hartmann Analytic (Braunschweig, Germany). [35S]GTPγS was from PerkinElmer Life Sciences 
(Boston, MA) or Hartmann Analytic GmbH (Braunschweig, Germany). [3H]UR-DE257 (N-[6-(3,4-dioxo-
2-{3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino}-cyclobut-1-enylamino)hexyl]-[2,3-3H2]-propion-
amide) was synthesized as described in Chapter 5. 
 
3.5.3.1 Competition binding experiments on membrane preparations of Sf9 insect cells 
Competition binding experiments were performed on membrane preparations of Sf9 insect cells 
expressing the hH1R + RGS4, hH2R-GsαS, hH3R + Gαi2 + β1γ2 or the hH4R + Gαi2 + β1γ2. General 
procedures for the generation of recombinant baculoviruses, culture of Sf9 cells and membrane 
preparation have been described elsewhere.48,68 The respective membranes were thawed and 
sedimented by centrifugation at 4 °C and 13000 g for 10 min. Membranes were resuspended in 
binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). Each tube (total volume 
100 μL) contained 30 μg (hH1R), 40 μg (hH2R), 60 μg (hH3R) or 100 μg (hH4R) of membrane protein 
and increasing concentrations of unlabeled ligands. Radioligands: H1R: [
3H]pyrilamine, specific 
activity 20.0 Ci/mmol, Kd = 4.5 nM, c = 5 nM, nonspecific binding determined in the presence of 10 
µM of diphenhydramine; H2R: [
3H]UR-DE257 (radioligand was diluted with unlabeled ligand due to 
economic reasons), specific activity 63.0 Ci/mmol, Kd = 31 nM, c = 30 nM, nonspecific binding 
determined in the presence of 10 µM of famotidine; H3R: [
3H]Nα-methylhistamine, specific activity 
85.3 Ci/mmol, Kd = 8.6 nM, c = 3 nM, nonspecific binding determined in the presence of 10 µM of 
thioperamide; H4R: [
3H]histamine, specific activity 25 Ci/mmol, Kd = 16 nM, c = 10 nM, nonspecific 
binding determined in the presence of 10 µM of histamine. Filtration through 0.3% 
polyethyleneimine-pretreated glass microfiber filters (Whatman GF/B, Maidstone, UK) using a 
Brandel 96 sample harvester (Brandel, Gaithersburg, MD) separated unbound from membrane 
associated radioligand. After three washing steps with binding buffer, filter pieces for each well were 
punched and transferred into untapped 96-well sample plates 1450-401 (Perkin Elmer, Rodgau, 
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Germany). Each well was supplemented with 200 µL of scintillation cocktail (Rotiscint Eco plus, Roth, 
Karlsruhe, Germany) and incubated in the dark. Radioactivity was measured with a Micro Beta2 1450 
scintillation counter (Perkin Elmer, Rodgau, Germany). Protein concentration was determined by the 
method of Lowry using bovine serum albumin as standard.69 Data analysis of the resulting 
competition curves was accomplished by non-linear regression analysis using the algorithms in 
PRISM GraphPad Software (GraphPad Prism 5.0 software, San Diego, CA). Ki values were derived 
from the corresponding EC50 data utilizing the equation of Cheng and Prusoff.
39 
-  
 
3.5.3.2 Steady-State [γ-33P]GTPase activity assay 
GTPase activity assays were performed as previously described.32-34,55  
H1R assays: Sf9 insect cell membranes coexpressing the hH1R and RGS4 were employed. 
 
3.5.3.3 [35S]GTPγS binding assay70,71  
[35S]GTPγS binding assays were performed as previously described for the H2R,
35,36 H3R
37,38 and 
H4R.
33,49 Histamine dihydrochloride was purchased from Alfa Aesar (Karlsruhe, Germany). 
thioperamide was from R&D Systems (Wiesbaden, Germany), guanosine diphosphate (GDP) was 
from Sigma-Aldrich (Munich, Germany), unlabeled GTPγS was from Roche (Mannheim, Germany). 
[35S]GTPγS was from PerkinElmer Life Sciences (Boston, MA) or Hartmann Analytic GmbH 
(Braunschweig, Germany). GF/C filters were from Whatman (Maidstone, UK). H2R assays: Sf9 insect 
cell membranes expressing the hH2R‐GsαS fusion protein were employed, H3R assays: Sf9 insect cell 
membranes coexpressing the hH3R, mammalian Gαi2 and Gβ1γ2 were employed, H4R assays: Sf9 
insect cell membranes coexpressing the hH4R or the mH4R, mammalian Gαi2 and Gβ1γ2 were 
employed. The respective membranes were thawed and sedimented by 10 min centrifugation at 4 °C 
and 13000 g. Membranes were resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 
mM Tris/HCl, pH 7.4). Each assay tube contained Sf9 membranes expressing the respective HxR 
subtype (10-20 μG-Protein/tube), 1 μM GDP, 0.05% (w/v) bovine serum albumin, 0.2 nM [35S]GTPγS 
and the investigated ligands (dissolved in millipore water or in a mixture (v/v) of 80% millipore water 
and 20% DMSO) at various concentrations in binding buffer (total volume 100 μL). All H4R assays 
additionally contained 100 mM NaCl. For the determination of Kb values (antagonist mode of the 
[35S]GTPγS binding assay) histamine was added to the reaction mixtures (final concentrations: hH3/4R: 
100 nM, hH2R: 1 µM, mH4R: 10 µM). Incubation was conducted for 90 min at 25 °C and shaking at 
250 rpm. Bound [35S]GTPγS was separated from free [35S]GTPγS by filtration through GF/C filters, 
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followed by three washing steps with 2 mL of binding buffer (4 °C) using a Brandel Harvester. Filter-
bound radioactivity was determined after an equilibration phase of at least 12 h by liquid scintillation 
counting. The experimental conditions chosen ensured that not more than 10% of the total amount 
of [35S]GTPγS added was bound to the filters. Nonspecific binding was determined in the presence of 
10 μM unlabeled GTPγS. IC50 values were converted to Kb values using the Cheng-Prussoff equation.
39 
EC50 and Kb values from the functional GTPγS assays were analyzed by nonlinear regression and best 
fit to sigmoidal concentration-response curves (GraphPad Prism 5.0 software, San Diego, CA). 
 
3.5.3.4 Radioligand binding assay using HEK‐293 cells expressing the mH4R
51,72 
With some modifications, the radioligand binding assay was performed as described previously.51,72 
HEK293-SF-mH4R-His6 cells were seeded into 175-cm
2 culture flasks until they reached 80-100% 
confluency. After trypsinization, the cells were detached with Leibovitz’s L-15 medium without 
phenol red (Invitrogen, Karlsruhe, Germany) including 1% FCS and centrifuged for 10 min at 300 g. 
The supernatant was discarded and the cells were re-suspended in the aforementioned medium. 
After counting the cells in a hemocytometer, the cell density was adjusted to 2-3·106 cells/mL. As 
radioactive tracer [3H]UR-PI294 was used, which was synthesized in our laboratory (Kd = 75 nM).
5 For 
competition binding experiments, cells (160 μL of the cell suspension) were incubated with 
increasing concentrations of the unlabelled ligands in presence of 50 nM [3H]UR‐PI294 in a 96‐well 
plate (Greiner, Germany) (total volume 200 μL). Samples were shaken at 100 rpm for 90 min under 
light protection prior to harvesting. Cell‐bound radioactivity was transferred to a glass fibre filter 
GF/C (Skatron) pre‐treated with polyethyleneimine (0.3% (v/v) by a Combi Cell Harvester 11025. The 
filter was washed with PBS (4 °C) for approx. 10 s. Filter‐bound radioactivity was determined after an 
equilibration phase of at least 12 h by liquid scintillation counting. 
3.5.3.5 Radioligand binding studies on hM1R or hM2R expressing CHO-K9 cells 
CHO-K9 cells stably transfected with the human muscarinic receptors Mx (x = 1 or 2) were purchased 
from Missouri S&T cDNA Resource Centre and were cultured in HAM’s F12 medium supplemented 
with FCS (10%) and geneticin (750 µg/mL). The muscarinic receptor (MR) competitive antagonist 
[3H]-N-methylscopolamine ([3H]-NMS) (as = 80 Ci/mmol, purchased from Hartman Analytic GmbH, 
Germany) was used as radioligand. Prior to competition binding experiments the Kd values of 
[3H]-NMS were determined in saturation binding experiments at the distinct receptor subtypes. CHO 
cells were seeded in tissue-culture treated white 96-well plates with clear bottom (Corning 
Incorporated Life Sciences, Tewksbury, MA; Corning cat. no. 3610) one or two days prior to the 
experiment. Depending on the level of receptor expression the confluence of the cells was 10-20% 
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(high receptor density), 40-60% (medium receptor density) or 100% (low receptor content) on the 
day of the experiment (totally bound radioligand should not exceed 1,500 dpm per well). The culture 
medium was removed by suction, the cells were washed with phosphate buffered saline (PBS) 
(200 µL) and covered with Leibovitz’s L15 culture medium (Gibco, Life Technologies GmbH, 
Darmstadt, Germany) supplemented with 1% BSA (in the following referred to as L15 medium) 
(150 µL). For total binding L15 medium (18.8 μL) and L15 medium (18.8 μL) containing the 
radioligand (10-fold concentrated) was added. For non-specific binding and displacement of 
[3H]-NMS L15 medium (18.8 μL) containing the competitor (10-fold concentrated) and L15 medium 
(18.8 μL) containing the radioligand (10-fold concentrated) was added. The plates were shaken 
during incubation at ambient temperature (21-23 °C). After 3 h of incubation the medium was 
removed, the cells were washed twice with ice-cold PBS (200 μL; washing period ≤ 2 min) and lysis 
solution (urea (8 M), acetic acid (3 M) and Triton-X-100 (1%) in water) (25 µL) was added. The plates 
were shaken for 20 min, scintillation liquid (Optiphase Supermix, PerkinElmer, Überlingen, Germany) 
(200 µL) was added and the plates were sealed with a transparent sealing tape (permanent seal for 
microplates, PerkinElmer, prod. no. 1450-461). The plates were held up side down several times in 
order to achieve a complete mixing of scintillator and lysis solution. The samples were kept in 
darkness for at least 1 h prior to the measurement of radioactivity with a MicroBeta2 plate counter 
for 24 and 96 well plates (PerkinElmer) using a tritium dpm program linked with quench correction 
data determined in the same type of 96 well plate. The radioligand concentration was 0.2 nM 
throughout. Non-specific binding was determined in the presence of atropine (500-fold excess) and 
amounted to < 10% of total binding. Data analysis of the resulting competition curves was 
accomplished by non-linear regression analysis using the algorithms in PRISM GraphPad Software 
(GraphPad Prism 5.0 software, San Diego, CA). Ki values were derived from the corresponding EC50 
data utilizing the equation of Cheng and Prusoff.39 
3.5.3.6 Data analysis and pharmacological parameters 
All data are presented as mean of n independent experiments ± SEM. Dpm (decays per minute) 
values of total and nonspecific binding were processed with GraphPad Prism® 5 (GraphPad Software, 
San Diego (CA), USA). Specific binding was calculated by subtraction of nonspecific binding from the 
respective values for total binding. Agonist potencies were given as EC50 values (molar concentration 
of the agonist causing 50% of the maximal response). Maximal responses (intrinsic activities) were 
expressed as a values. The a value of histamine was set to 1.00, a values of other compounds were 
referred to this value. IC50 values were converted to Ki and Kb values using the Cheng‐Prusoff 
equation.39 pKi values were analyzed by nonlinear regression and best fit to one‐site (monophasic) 
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competition isotherms. pEC50 and pKb values from the functional [
35S]GTPγS and [33P]GTPase assays 
were analyzed by nonlinear regression and best fit to sigmoidal concentration‐response curves.  
 References 107 
3.6 References 
1. Igel, P.; Dove, S.; Buschauer, A. Histamine H4 receptor agonists. Bioorg. Med. Chem. Lett. 2010, 20, 7191-
7199. 
2. Schreeb, A.; Łażewska, D.; Dove, S.; Buschauer, A.; Kieć-Kononowicz, K.; Stark, H. Histamine H4 Receptor 
Ligands. In Histamine H4 Receptor: A Novel Drug Target in Immunoregulation and Inflammation, Stark, 
H., Ed. Versita: London, 2013; pp 21-62. 
3. Savall, B. M.; Edwards, J. P.; Venable, J. D.; Buzard, D. J.; Thurmond, R.; Hack, M.; McGovern, P. 
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands. Bioorg. Med. 
Chem. Lett. 2010, 20, 3367-3371. 
4. Geyer, R.; Kaske, M.; Baumeister, P.; Buschauer, A. Synthesis and Functional Characterization of 
Imbutamine Analogs as Histamine H3 and H4 Receptor Ligands. Arch. Pharm. (Weinheim). 2014, 347, 77-
88. 
5. Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A. Tritium-Labeled N
1
-[3-(1H-imidazol-4-
yl)propyl]-N
2
-propionylguanidine ([
3
H]UR-PI294), a High-Affinity Histamine H3 and H4 Receptor 
Radioligand. ChemMedChem 2009, 4, 225-231. 
6. Keller, M.; Bernhardt, G.; Buschauer, A. [
3
H]UR-MK136: A Highly Potent and Selective Radioligand for 
Neuropeptide Y Y1 Receptors. ChemMedChem 2011, 6, 1566-1571. 
7. Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Guanidine-
acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N
G
-
propionylargininamide ([
3
H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor 
antagonist. J. Med. Chem. 2008, 51, 8168-8172. 
8. Pluym, N.; Baumeister, P.; Keller, M.; Bernhardt, G.; Buschauer, A. [
3
H]UR-PLN196: a selective 
nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y2 receptor. 
ChemMedChem 2013, 8, 587-593. 
9. Savall, B. M.; Fontimayor, J. R.; Edwards, J. P. Selective phenol alkylation for an improved synthesis of 2-
arylbenzimidazole H4 receptor ligands. Tetrahedron Lett. 2009, 50, 2490-2492. 
10. 
Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. Acylguanidines as Bioisosteres of Guanidines: N
G
-Acylated 
Imidazolylpropylguanidines, a New Class of Histamine H2 Receptor Agonists. J. Med. Chem. 2008, 51, 
7193-7204. 
11. Feichtinger, K.; Zapf, C.; Sings, H. L.; Goodman, M. Diprotected Triflylguanidines: A New Class of 
Guanidinylation Reagents. J. Org. Chem. 1998, 63, 3804-3805. 
12. Kraus, A.; Ghorai, P.; Birnkammer, T.; Schnell, D.; Elz, S.; Seifert, R.; Dove, S.; Bernhardt, G.; Buschauer, 
A. N
G
-Acylated Aminothiazolylpropylguanidines as Potent and Selective Histamine H2 Receptor Agonists. 
ChemMedChem 2009, 4, 232-240. 
13. Iwanowicz, E. J.; Poss, M. A.; Lin, J. Preparation of N,N'-bis-tert-Butoxycarbonylthiourea Synth. Commun. 
1993, 23, 1443-1445. 
14. Poss, M. A.; Iwanowicz, E.; Reid, J. A.; Lin, J.; Gu, Z. A mild and efficient method for the preparation of 
guanidines. Tetrahedron Lett. 1992, 33, 5933-5936. 
15. Gausepohl, H.; Pieles, U.; Frank, R. W. In Schiff base analog formation during in situ activation by HBTU 
and TBTU, 1992; ESCOM: 1992; pp 523-524. 
16. DeMong, D. E.; Williams, R. M. The asymmetric synthesis of (2S,3R)-capreomycidine. Tetrahedron Lett. 
2001, 42, 3529-3532. 
17. Kim, K. S.; Qian, L. Improved method for the preparation of guanidines. Tetrahedron Lett. 1993, 34, 
7677-7680. 
18. Ghorai, P. Arpromidine-related acylguanidines: synthesis and structure activity relationships of a new 
class of guanidine-type histamine H2 receptor agonists with reduced basicity. University of Regensburg, 
Regensburg, Doctoral thesis, 2006. 
108 Chapter 3 
19. Kraus, A. Highly Potent, Selective Acylguanidine-Type Histamine H2 Receptor Agonists: Synthesis and 
Structure-Activity Relationships. University of Regensburg, Regensburg, Doctoral thesis, 2007. 
20. Elz, S.; Schunack, W. An alternative synthesis of homohistamine and structurally related (imidazol-4-
yl)alkylamines. Z. Naturforsch., B: Chem. Sci. 1987, 42, 238-242. 
21. Bredereck, H.; Theilig, G. Untersuchungen in der Oxazolreihe und Umwandlungen von Oxazolen in 
Imidazole mittels Formamids (Formamid-Reaktionen, I. Mitteil.). Chem. Ber. 1953, 86, 96-109. 
22. Mach, U. R.; Hackling, A. E.; Perachon, S.; Ferry, S.; Wermuth, C. G.; Schwartz, J. C.; Sokoloff, P.; Stark, H. 
Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as 
potent and selective dopamine D3 receptor ligands. ChemBioChem 2004, 5, 508-518. 
23. Habermehl, G. G.; Ecsy, W. The condensation of histamine with carbonyl compounds. Heterocycles 1976, 
5, 127-134. 
24. Igel, P. Synthesis and structure-activity relationships of N
G
-acylated arylalkylguanidines and related 
compounds as histamine receptor ligands: Searching for selective H4R agonists. University of 
Regensburg, Regensburg, Doctoral thesis, 2008. 
25. Finkelstein, H. Darstellung organischer Jodide aus den entsprechenden Bromiden und Chloriden. Ber. 
Dtsch. Chem. Ges. 1910, 43, 1528-1532. 
26. Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Miles, P. D.; Parsons, M. E.; Prain, H. D.; White, G. R. 
Cyanoguanidine-thiourea eqalence in the development of the histamine H2-receptor antagonist, 
cimetidine. J. Med. Chem. 1977, 20, 901-906. 
27. Keller, M.; Erdmann, D.; Pop, N.; Pluym, N.; Teng, S.; Bernhardt, G.; Buschauer, A. Red-fluorescent 
argininamide-type NPY Y1 receptor antagonists as pharmacological tools. Bioorg. Med. Chem. 2011, 19, 
2859-2878. 
28. Xu, C.-P.; Xiao, Z.-H.; Zhuo, B.-Q.; Wang, Y.-H.; Huang, P.-Q. Efficient and chemoselective alkylation of 
amines/amino acids using alcohols as alkylating reagents under mild conditions. Chem. Commun. 2010, 
46, 7834-7836. 
29. Bodensteiner, J.; Baumeister, P.; Geyer, R.; Buschauer, A.; Reiser, O. Synthesis and pharmacological 
characterization of new tetrahydrofuran based compounds as conformationally constrained histamine 
receptor ligands. Org. Biomol. Chem. 2013, 11, 4040-4055. 
30. Yellin, T. O.; Buck, S. H.; Gilman, D. J.; Jones, D. F.; Wardleworth, J. M. ICI 125,211: A new gastric 
antisecretory agent acting on histamine H2-receptors. Life Sci. 1979, 25, 2001-2009. 
31. Ghorai, P.; Kraus, A.; Birnkammer, T.; Geyer, R.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. 
Chiral N
G
-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant 
stereoselectivity. Bioorg. Med. Chem. Lett. 2010, 20, 3173-3176. 
32. Kelley, M. T.; Bürckstümmer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A.; Seifert, R. Distinct 
Interaction of Human and Guinea Pig Histamine H2-Receptor with Guanidine-Type Agonists. Mol. 
Pharmacol. 2001, 60, 1210-1225. 
33. Schneider, E. H.; Schnell, D.; Papa, D.; Seifert, R. High Constitutive Activity and a G-Protein-Independent 
High-Affinity State of the Human Histamine H4-Receptor. Biochemistry 2009, 48, 1424-1438. 
34. Seifert, R.; Wenzel-Seifert, K.; Bürckstümmer, T.; Pertz, H. H.; Schunack, W.; Dove, S.; Buschauer, A.; Elz, 
S. Multiple Differences in Agonist and Antagonist Pharmacology between Human and Guinea Pig 
Histamine H1-Receptor. J. Pharmacol. Exp. Ther. 2003, 305, 1104-1115. 
35. Houston, C.; Wenzel-Seifert, K.; Bürckstümmer, T.; Seifert, R. The human histamine H2-receptor couples 
more eficiently to Sf9 insect cell Gs-proteins than to insect cell Gq-proteins: limitations of Sf9 cells for the 
analysis of receptor/Gq-protein coupling. J. Neurochem. 2002, 80, 678-696. 
36. Wenzel-Seifert, K.; Kelley, M. T.; Buschauer, A.; Seifert, R. Similar Apparent Constitutive Activity of 
Human Histamine H2-Receptor Fused to Long and Short Splice Variants of Gsa. J. Pharmacol. Exp. Ther. 
2001, 299, 1013-1020. 
37. Rouleau, A.; Ligneau, X.; Tardivel-Lacombe, J.; Morisset, S.; Gbahou, F.; Schwartz, J. C.; Arrang, J. M. 
Histamine H3-receptor-mediated [
35
S]GTP S binding: evidence for constitutive activity of the 
recombinant and native rat and human H3 receptors. Br. J. Pharmacol. 2002, 135, 383-392. 
 References 109 
38. Schnell, D.; Burleigh, K.; Trick, J.; Seifert, R. No Evidence for Functional Selectivity of Proxyfan at the 
Human Histamine H3 Receptor Coupled to Defined Gi/Go Protein Heterotrimers. J. Pharmacol. Exp. Ther. 
2010, 332, 996-1005. 
39. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of 
inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 
22, 3099-3108. 
40. Xie, S.-X.; Ghorai, P.; Ye, Q.-Z.; Buschauer, A.; Seifert, R. Probing Ligand-Specific Histamine H1- and H2-
Receptor Conformations with N
G
-Acylated Imidazolylpropylguanidines. J. Pharmacol. Exp. Ther. 2006, 
317, 139-146. 
41. Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond, R. L.; Leurs, R. Evaluation of histamine H1-, 
H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as 
the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321. 
42. Hagelüken, A.; Grünbaum, L.; Klinker, J. F.; Nürnberg, B.; Harhammer, R.; Schultz, G.; Leschke, C.; 
Schunack, W.; Seifert, R. Histamine receptor-dependent and/or -independent activation of guanine 
nucleotide-bindinG-Proteins by histamine and 2-substituted histamine derivatives in human leukemia 
(HL-60) and human erythroleukemia (HEL) cells. Biochem. Pharmacol. 1995, 49, 901-914. 
43. Klinker, J. F.; Seifert, R. Rezeptor-unabhängige Aktivierung von G-Proteinen. Pharm. Unserer Zeit 1995, 
24, 250-263. 
44. Seifert, R.; Hageluken, A.; Hoer, A.; Hoer, D.; Grunbaum, L.; Offermanns, S.; Schwaner, I.; Zingel, V.; 
Schunack, W.; Schultz, G. The H1 receptor agonist 2-(3-chlorophenyl)histamine activates Gi proteins in 
HL-60 cells through a mechanism that is independent of known histamine receptor subtypes. Mol. 
Pharmacol. 1994, 45, 578-586. 
45. Mousli, M.; Bueb, J.-L.; Bronner, C.; Rouot, B.; Landry, Y. G-Protein activation: a receptor-independent 
mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol. Sci. 
1990, 11, 358-362. 
46. Wifling, D.; Löffel, K.; Nordemann, U.; Strasser, A.; Bernhardt, G.; Dove, S.; Seifert, R.; Buschauer, A. 
Molecular determinants for the high constitutive activity of the human histamine H4 receptor: 
Functional studies on orthologs and mutants. Br. J. Pharmacol. 2014, in press, doi: 10.1111/bph.12801. 
47. Lim, H. D.; de Graaf, C.; Jiang, W.; Sadek, P.; McGovern, P. M.; Istyastono, E. P.; Bakker, R. A.; de Esch, I. 
J.; Thurmond, R. L.; Leurs, R. Molecular determinants of ligand binding to H4R species variants. Mol. 
Pharmacol. 2010, 77, 734-743. 
48. Schnell, D.; Brunskole, I.; Ladova, K.; Schneider, E.; Igel, P.; Dove, S.; Buschauer, A.; Seifert, R. Expression 
and functional properties of canine, rat, and murine histamine H4 receptors in Sf9 insect cells. Naunyn-
Schmiedeberg's Arch. Pharmacol. 2011, 383, 457-470. 
49. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase 
Reporter Gene Assay on Human, Murine and Rat Histamine H4 Receptor Orthologs: Correlations and 
Discrepancies between Distal and Proximal Readouts. PLoS ONE 2013, 8, e73961. 
50. Liu, C.; Ma, X.-J.; Jiang, X.; Wilson, S. J.; Hofstra, C. L.; Blevitt, J.; Pyati, J.; Li, X.; Chai, W.; Carruthers, N.; 
Lovenberg, T. W. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) 
Expressed in Bone Marrow. Mol. Pharmacol. 2001, 59, 420-426. 
51. Nordemann, U. Radioligand binding and reporter gene assays for histamine H3 and H4 receptor species 
orthologs. University of Regensburg, Regensburg, Doctoral thesis, 2013. 
52. Igel, P.; Geyer, R.; Strasser, A.; Dove, S.; Seifert, R.; Buschauer, A. Synthesis and Structure−Activity 
Relationships of Cyanoguanidine-Type and Structurally Related Histamine H4 Receptor Agonists. J. Med. 
Chem. 2009, 52, 6297-6313. 
53. Spasov, A. A.; Yozhitsa, I. N.; Bugaeva, L. I.; Anisimova, V. A. Benzimidazole derivatives: Spectrum of 
pharmacological activity and toxicological properties (a review). Pharm Chem J 1999, 33, 232-243. 
54. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: a review. Bioorg. Med. Chem. 2012, 
20, 6208-6236. 
55. Ghorai, P.; Kraus, A.; Keller, M.; Goette, C.; Igel, P.; Schneider, E.; Schnell, D.; Bernhardt, G.; Dove, S.; 
Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. Acylguanidines as Bioisosteres of Guanidines: N
G
-Acylated 
110 Chapter 3 
Imidazolylpropylguanidines, a New Class of Histamine H2 Receptor Agonists. J. Med. Chem. 2008, 51, 
7193-7204. 
56. Eleftheriou, S.; Gatos, D.; Panagopoulos, A.; Stathopoulos, S.; Barlos, K. Attachment of histidine, 
histamine and urocanic acid to resins of the trityl-type. Tetrahedron Lett. 1999, 40, 2825-2828. 
57. Charlton, P. T.; Maliphant, G. M.; Oxley, P.; Peak, D. A. Antituberculous compounds. VII. Some further N-
substituted amidines and analogs. J. Chem. Soc. 1951, 485-492. 
58. Lee, B. H.; Miller, M. J. Natural ferric ionophores: total synthesis of schizokinen, schizokinen A, and 
arthrobactin. J. Org. Chem. 1983, 48, 24-31. 
59. Roy, S.; Eastman, A.; Gribble, G. W. Synthesis of bisindolylmaleimides related to GF109203x and their 
efficient conversion to the bioactive indolocarbazoles. Org. Biomol. Chem. 2006, 4, 3228-3234. 
60. Dodd, D. S.; Kozikowski, A. P. Conversion of Alcohols to Protected Guanidines Using the Mitsunobu 
Protocol. Tetrahedron Lett. 1994, 35, 977-980. 
61. Pluym, N.; Brennauer, A.; Keller, M.; Ziemek, R.; Pop, N.; Bernhardt, G.; Buschauer, A. Application of the 
Guanidine–Acylguanidine Bioisosteric Approach to Argininamide-Type NPY Y2 Receptor Antagonists. 
ChemMedChem 2011, 6, 1727-1738. 
62. Eriks, J. C.; Van der Goot, H.; Timmerman, H.; Koper, J. G. Preparation of (un)substituted 4(5)-(ω-
aminoalkyl)imidazoles for the treatment of heart failures or allergic conditions. WO8910360A1, 1989. 
63. Elz, S.; Schunack, W. An alternative synthesis of homohistamine and structurally related (imidazol-4-
yl)alkylamines. Z. Naturforsch. B 1987, 42, 238-242. 
64. Badorc, A.; Boldron, C.; Delesque, N.; Fossey, V.; Lassalle, G.; Yvon, X. Derivatives of N-[(1H-pyrazol-1-
yl)aryl]-1H-indole-3-carboxamide and N-[(1H-pyrazol-1-yl)aryl]-1H-indazole-3-carboxamide, their 
preparation and their use as P2Y12 antagonists. WO2012146318A1, 2012. 
65. Wolin, R.; Connolly, M.; Afonso, A.; Hey, J. A.; She, H.; Rivelli, M. A.; Willams, S. M.; West Jr, R. E. Novel 
H3 receptor antagonists. Sulfonamide homologs of histamine. Bioorg. Med. Chem. Lett. 1998, 8, 2157-
2162. 
66. Bouix-Peter, C.; Carlavan, I.; Soulet, C.; Parnet, V.; Voegel, J. Preparation of amino acid azetidine amide 
derivatives, as selective melanocortin receptor MC4R antagonists for pharmaceutical use. 
WO2010052256A1, 2010. 
67. Ankersen, M.; Crider, M.; Liu, S.; Ho, B.; Andersen, H. S.; Stidsen, C. Discovery of a Novel Non-Peptide 
Somatostatin Agonist with SST4 Selectivity. J. Am. Chem. Soc. 1998, 120, 1368-1373. 
68. Pop, N.; Igel, P.; Brennauer, A.; Cabrele, C.; Bernhardt, G. N.; Seifert, R.; Buschauer, A. Functional 
reconstitution of human neuropeptide Y (NPY) Y2 and Y4 receptors in Sf9 insect cells. J. Recept. Signal 
Transduct. 2011, 31, 271-285. 
69. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol 
reagent. J. Biol. Chem. 1951, 193, 265-275. 
70. Asano, T.; Pedersen, S. E.; Scott, C. W.; Ross, E. Reconstitution of catecholamine-stimulated binding of 
guanosine 5'-O-(3-thiotriphosphate) to the stimulatory GTP-bindinG-Protein of adenylate cyclase. 
Biochemistry 1984, 23, 5460-5467. 
71. Hilf, G.; Gierschik, P.; Jakobs, K. H. Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-
O-(3-thiotriphosphate) to guanine-nucleotide-bindinG-Proteins in cardiac membranes. Eur. J. Biochem. 
1989, 186, 725-731. 
72. Mosandl, J. Radiochemical and luminescence-based binding and functional assays for human histamine 
receptors using genetically engineered cells. University of Regensburg, Regensburg, Doctoral thesis, 
2009. 
 
 
  
 
Chapter 4 
4 Synthesis and Pharmacological 
Characterization of VUF 8430 Derivatives 
as Histamine H4 Receptor Ligands 
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4.1 Introduction 
The early pharmacological and 
physiological characterization of 
the H4R was based on the 
investigation of compounds 
previously known as ligands of the 
other histamine receptor subtypes. 
For example, the H3R/H4R agonists 
imetit1 and VUF 8328,2 the H3R 
antagonist/H4R agonist cloben-
probit3 and the H3R antagonist/H4R 
inverse agonist thioperamide4 show 
comparable affinities to both 
receptors.5 NG-alkylated and 
acylated imidazolyl-propylguani-
dines were originally developed as 
H2R agonists.
6-12 However, the 
parent compound, imidazolyl-
propylguanidine (SK&F-91486),13 
NG-alkylated analogs such as 
impromidine6 and NG-acylated 
analogs such as UR-AK24, UR-
AK5112 and UR-PG8014 were found 
to possess H3R and H4R affinity, too. 
Modification of the NG-acyl groups 
in UR-AK24 resulted in potent 
nearly full H4R agonists such as UR-
PI287, UR-PI288, UR-PI294 and UR-
PI295 with pEC50 values of 7.8 to 8.6 and 25- to 300-fold selectivity over the hH2R.
15 The major 
drawback of imidazole-containing hH4R agonists is the lack of selectivity over the other histamine 
receptor subtypes, in particular the hH3R. In addition, imidazole derivatives are potential inhibitors of 
cytochrome P450 enzymes.16,17 Replacement of the imidazole ring by various heterocycles as 
potential bioisosteres revealed only weak activity of most of the synthesized hetarylalkylamines at 
the H3R and the H4R.
18 Interestingly, VUF 8430, combining a guanidine via an ethylene spacer with an 
isothiourea group, was also initially designed as an H2R agonist related to dimaprit,
19 but proved to 
 
Figure 4.1 Histamine receptor ligands with agonistic activities at the 
hH4R. 
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be a potent hH4R agonist with ~30-fold selectivity over the hH3R (full agonism) and negligible affinity 
for hH1R and hH2R (partial agonism).
20,21  
Aiming at H4R agonists with increased selectivity over the other HxR subtypes, the present study was 
focused on the combination of crucial structural features of VUF 8430 and NG-acylated 
imidazolylpropylguanidines, i. e. guanidine and acylguanidine groups, as shown in Figure 4.2. In a first 
approach either a guanidine and an NG-acylated guanidine moiety or two acylguanidines were 
connected by an ethylene or a trimethylene spacer. The residues ‘R’ were selected with respect to 
comparison of the structure-activity relationship with those of the previously published 
imidazolylpropylguanidines,12,14,15 containing small residues such as ethoxycarbonyl or butyryl 
residues as well as more bulky moieties such as aromatic rings. Moreover, structural analogs bearing 
an isothiourea instead of a guanidine group were synthesized. 
 
Figure 4.2 Replacement of the imidazole-ring by guanidine and N
G
-acylated guanidine groups. 
4.2 Chemistry 
The preparation of 4.12-4.39 was performed according to Scheme 4.1, starting with the synthesis of 
the required guanidinylating reagents 4.3-4.11. The N-Boc protected S-methyisothiourea 4.2 and the 
di-protected analog 4.3 were synthesized as described previously.22-25 Acylation of 4.2 with the 
pertinent acids under standard conditions for amide coupling using TBTU yielded 4.4-4.11 in very 
good yields.26  
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Scheme 4.1 Synthesis of the acylguanidines 4.12-4.39 and the dimeric isothiourea 4.40. Reagents and 
conditions: (a) Thiourea, MeI, MeOH, rt, 1 h, 98%; (b) Boc2O, NEt3, rt, 20 h, 74%; (c) Boc2O, NEt3, rt, 22 h, 56%; 
(d) respective acid, TBTU, DIPEA, rt, O/N, 55-89%; (e) 1) ethanediamine or propanediamine, 4.4-4.11, 4.3, 
HgCl2, NEt3, CH2Cl2, rt, 24-48 h, 2) 5% TFA in CH2Cl2, rt, 4-8 h, 4-26%; (f) 1,3-dibromopropane, thiourea, EtOH, 
microwave 125 °C, 15 min, 65%. 
Ethandiamine or propanediamine were treated with the isothiourea derivatives 4.2 and 4.4-4.11, in 
the presence of HgCl2. Hereby, the metal ion acts as a desulfurizing agent via complex formation.
27,28 
After acidic cleavage of the protecting groups, purification by preparative HPLC afforded 4.12-4.39 in 
low to moderate yields. According to this combinatorial approach, the synthesis of 30 compounds via 
14 reactions became feasible. The preparation of the 4.40 was performed from 1,3-dibrom-propane 
and thiourea under microwave irradiation (cf. Scheme 4.1). Synthesis of 4.43 started from 
guanidinylating reagents 3.25 and 3-amino-propanol to obtain intermediate 4.41 in excellent yield.29 
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Conversion of the terminal hydroxyl-group to the bromide by refluxing with concentrated HBr 
yielded 4.42, which was subsequently allowed to react with thiourea under microwave irradiation to 
give 4.43 (cf. Scheme 4.2).20 
 
Scheme 4.2 Synthesis of the VUF 8430 analog 4.43. Reagents and conditions: (a) 3-Aminopropan-1-ol, NEt3, 
CH2Cl2 ml, rt, 40 min, 95%; (b) 47% HBr(aq.), 100 °C, 30 h; (c) thiourea, EtOH, microwave 125 °C, 15 min, 10% 
over two steps. 
4.3 Pharmacological Results and Discussion 
The synthesized compounds 4.12-4.40 and 4.43 were investigated at the hH3R and hH4R in 
radioligand binding assays using membrane preparations of Sf9 insect cells coexpressing the hH3R + 
Gαi2 + Gβ1γ2 or hH4R + Gαi2 + Gβ1γ2, respectively. Additionally, selected compounds were tested for 
hH2R affinity at the hH2R−Gsαs fusion protein. For comparison, VUF 8430 was included as a reference 
compound. The data are summarized in Table 4.1. 
VUF 8430 revealed a Ki value of 17.7 nM and a 33-fold selectivity over the hH3R, which were in good 
agreement with the pharmacological data reported for cell homogenates of SK-N-MC expressing the 
hH4R (Ki = 31.6 nM, 30-fold selectivity over the hH3R).
20 The extension of the ethylene linker by one 
methylene group (4.43) resulted in a decrease in affinity (Ki = 104 nM), whereas the selectivity ratio 
was retained. The results for 4.43 were inconsistent with reported data (Ki ~8000 nM)
20 for unknown 
reasons. The introduction of two guanidines (4.12), led to a 200-fold decrease in affinity at the hH4R 
compared to VUF 8430. Interestingly, the decrease in affinity was less pronounced in case of the 
homolog 4.13 (Ki = 442, Ki(ref)
20 = ~400 nM). The dimeric isothiourea 4.40 revealed a switch in receptor 
subtype preference with a lower Ki value at the hH3R (Ki = 1010 nM) compared to the hH4R (Ki = 
4200 nM). 
The bioisosteric exchange of an isothiourea by an acylguanidine group resulted in the derivatives 
4.14-4.18. In comparison to VUF8430, all of these compounds had lower affinities at the hH4R (Ki = 
550-1860 nM) and reduced selectivities towards the hH3R (2- to 5-fold). Analogs separating the 
guanidine and NG-acylated guanidines by a three-membered carbon spacer have higher affinity for 
the hH4R (compare 4.19-4.23) than their lower homologs, but were still inferior to VUF 8430. 
 
116 Chapter 4 
Table 4.1 Binding data of compounds 4.12-4.40 and 4.43 at the histamine receptor subtypes H2, H3 and H4
[a]
 
Compound 
hH2R hH3R hH4R Selectivity 
H4 : H3 Ki / nM n Ki / nM n Ki / nM n 
Histamine n.d. 20.1 ± 3.1 4 13.1 ± 1.1 4 1.5 : 1 
VUF 8430 >20000 2 587 ± 75 2 17.7 ± 1.4 4 33 : 1 
4.12 >20000 2 10100 ± 3760 3 3650 ± 290 2 2.8 : 1 
4.13 >20000 2 2310 ± 340 3 442 ± 79 3 5.2 : 1 
4.14 >10000 2 7000 ± 170 2 1400 ± 340 3 5 : 1 
4.15 n.a.
[b]
 2 2520 ± 630 2 1040 ± 9 2 1.8 : 1 
4.16 n.d. 6010 ± 1360 2 1820 ± 250 2 3.3 : 1 
4.17 n.a.
[b]
 2 3260 ± 480 2 1860 ± 170 2 1.8 : 1 
4.18 n.d. 1110 ± 160 3 550 ± 33 2 2 : 1 
4.19 n.d. 6240 ± 840 2 104 ± 41 2 60 : 1 
4.20 n.d. 12200 ± 1040 2 500 ± 40 2 24 : 1 
4.21 n.d. 4410 ± 580 2 98.3 ± 5.8 3 45 : 1 
4.22 n.d. 11300 ± 2300 2 350 ± 46 3 32 : 1 
4.23 n.d. 2360 ± 430 3 227 ± 35 3 10 : 1 
4.24 n.d. 2470 ± 1390 2 4670 ± 570 2 1 : 1.9 
4.25 n.d. 4620 ± 510 2 2870 ± 36 2 1.6 : 1 
4.26 n.d. 9410 ± 1100 2 7030 ± 250 2 1.3 : 1 
4.27 >10000 2 9300 ± 1650 2 9260 ± 2450 2 1 : 1 
4.28 n.d. > 20000 2 > 30000 2 - 
4.29 n.d. 19300 ± 25 2 8360 ± 370 2 2.3 : 1 
4.30 n.d. > 20000 2 > 20000 2 - 
4.31 n.d. 8170 ± 1790 2 6150 ± 2580 2 1.3 : 1 
4.32 n.d. 11100 ± 1800 2 2770 ± 30 2 4 : 1 
4.33 n.d. 8510 ± 2390 2 2890 ± 1280 3 3 : 1 
4.34 n.d. 45100 ± 4350 2 1580 ± 400 2 29 : 1 
4.35 n.d. 34300 ± 2420 2 6190 ± 1100 2 5.5 : 1 
4.36 n.d. 4030 ± 330 3 1380 ± 250 3 2.9 : 1 
4.37 n.d. 8090 ± 140 2 9270 ± 1790 2 1 : 1.2 
4.38 n.d. 7050 ± 660 2 3850 ± 1000 2 1.8 : 1 
4.39 n.d. n.a.
[b]
  n.a
[b]
  - 
4.40 > 20000 2 1010 ± 420 3 4200 ± 590 3 1 : 4.2 
4.43 n.d. 2670 ± 570 2 104 ± 0.2 2 26 : 1 
[a] Determined on membrane preparations of Sf9 insect cells expressing hH2R‐GsαS fusion protein, hH3R + Gαi2 
+ Gβ1γ2 or the hH4R + Gαi2 + Gβ1γ2; radioligands: for hH2R: [
3
H]UR-DE257, c = 20 nM), for hH3R: 
[
3
H]N -methylhistamine (c = 3 nM), for hH4R: [
3
H]Histamine (c = 10 nM); [b] no binding up to a concentration 
of 100 µM; n gives the number of independent experiments performed in triplicate; n.d. = not determined. 
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Highest affinities were obtained for the propionylguanidine 4.19 (Ki = 104 nM) and its isobutyryl 
analog 4.21 (Ki = 98 nM). Compared to VUF 8430, both compounds showed slightly higher 
selectivities for the hH4R over the hH3R (60-fold for 4.19 and 45-fold for 4.21, respectively). Among 
the acylguanidines 4.14-4.26 the H4R affinity and selectivity was strongly dependent on the structure 
of the NG-acyl substituent (cf. R in Scheme 4.1). Only small aliphatic residues were tolerated to retain 
submicromolar Ki values at the hH4R, which is in accordance to previously published data.
15,30 
Compounds bearing a phenyl group in the acyl moiety (4.24-4.26) showed only affinities in the 
micromolar range and were devoid of receptor subtype selectivity. For the dimeric acylguanidines 
4.27-4.39, the Ki values at the hH4R were also in the micromolar range and the selectivity towards the 
hH3R was reduced, regardless whether an ethylene or a trimethylene linker was incorporated. 
Noteworthy is compound 4.34 with a trimethylene spacer which had moderate affinity (Ki = 
1580 nM) but retained selectivity towards the hH3R. At the hH2R all investigated compounds of this 
series revealed Ki values higher than 10000 nM, which was in the same range as for VUF 8430. 
4.4 Summary and Outlook 
The bioisosteric replacment of the isothiourea group or both the guanidine and the isothiourea 
group in VUF 8430 by various NG-acylguanidine moieties (4.14-4.39) resulted in compounds with 
reduced hH4R affinities compared to the reference substance. Among these VUF 8430 analogs, 
highest affinity resided in compounds 4.19 and 4.21 with Ki values of around 100 nM at the hH4R and 
slightly higher selectivity over the H3R (60-fold for 4.19 and 45-fold for 4.21, respectively). 
Compounds comprising two chemically different basic moieties revealed higher hH4R binding than 
homodimeric analogs, i. e. compounds with two guanidine (4.12 and 4.13, respectively), two 
isothiourea (4.43) or two acylguanidine (4.27-4.39) groups. In the series acylguanidines 4.14-4.39 
only small aliphatic residues ‘R’ were tolerated to achieve submicromolar Ki values at the hH4R, and 
compounds with a linker length of three methylene groups were superior to the lower homologs.  
Suggestions for future structural modifications are shown in Figure 4.3. It is rather likely that the 
isothiourea group is accepted by the H4R as a bioisosteric mimic of the imidazole ring in histamine. 
Therefore, the combination of the acylguanidine with an isothiourea moiety should be taken into 
consideration. The influence of further extended linkers on H4R affinity should also be explored. 
Moreover, rigidization has been proven successful to improve the selectivity of H4R ligands.
31-34 This 
approach might be applied to non-imidazoles, e. g. by introduction of a ring or a multiple bond in the 
linker or by the incorporation of one of the basic centers in a heterocycle.  
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Figure 4.3 Suggestions of future structural variations H4R ligands derived from VUF 8430. 
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4.5 Experimental Section 
4.5.1 Chemistry 
4.5.1.1 General conditions  
See section 3.4.1.1 
Except for 4.23, 4.24, 4.26-4.29 and 4.38-4.44 the HPLC column was a Eurospher-100 (250 x 4 mm, 5 
µm) (Knauer, Berlin, Germany, t0 = 3.32 min) at a flow rate of 0.8 ml/min. For 4.23, 4.24, 4.26-4.29 
and 4.38-4.44 the column was a Luna C18(2) (150 × 4.6 mm, 3 μm) (Phenomenex, Aschaffenburg, 
Germany, t0 = 2.88 min). UV detection was done at 200 nm. VUF 8430 was synthesized by Dr. Roland 
Geyer in our research group by analogy with a previously published synthesis.20 
4.5.1.2 Preparation of the isothiourea derivatives 4.2 and 4.3 
General procedure for the synthesis of the guanidinylating reagents 4.2 and 4.3 
S-Methylthiouronium iodide (4.1)22 
Thiourea (12.9 g, 169 mmol, 1 eq) and MeI (10.6 g, 169 mmol, 1 eq) in MeOH (130 ml) were refluxed 
for 1 h. After evaporation of the solvent under reduced pressure the crude product was triturated 
with Et2O, filtered and washed twice with Et2O to yield the desired product as white solid (36.2 g, 
98%). The crude product was used in the next step without further purification. mp 111 °C (lit.35 
113.5-115 °C). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 2.56 (s, 3H), 8.86 (bs, s, 4H). 
13C-NMR (75 MHz, 
DMSO-d6): δ (ppm) 13.58, 171.10. MS (LC-MS, ESI): m/z 91.1 [M+H
+]. C2H6N2S (90.15). 
 
N-tert-Butoxycarbonyl-S-methylisothiourea (4.2)22 
To a solution of 4.1 (15.0 g, 68.8 mmol, 1 eq) and NEt3 (6.95 g, 68.8 mmol, 1 eq) in CH2Cl2 (107 ml) 
was added Boc2O (15.0 g, 68.8 mmol, 1 eq) in CH2Cl2 (27 ml) and the reaction was stirred for 20 h at 
room temperature. Subsequently, the mixture was washed with water, the organic layer dried over 
anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by flash‐
chromatography (eluent hexanes (A), EtOAc (B); gradient: 0 to 60 min: A/B 100/0 – 0/100 v/v, SF 65-
400 g) affording a white solid (9.63 g, 74%). mp 82 °C (lit.36 77 °C). Rf = 0.29 (hexane/EtOAc 5:1). 
1H-
NMR (300 MHz, CDCl3): δ (ppm) 1.49 (s, 9H), 2.43 (s, 3H), 7.52 (bs, 2H). MS (LC-MS, ESI): m/z 191.0 
[M+H+]. C7H14N2O2S (190.26). 
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N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (4.3)35,37 
To a solution of 4.1 (10.0 g, 45.9 mmol, 1 eq) and NEt3 (11.6 g, 115 mmol, 2.5 eq) in CH2Cl2 (80 ml) 
was added Boc2O (25 g, 115 mmol, 2.5 eq) in CH2Cl2 (80 ml). The mixture was stirred for 22 h at room 
temperature and subsequently washed with water and brine. The organic layer was dried over 
anhydrous MgSO4 and concentrated in vacuo. The crude product was purified by flash‐
chromatography (eluent hexanes (A), EtOAc (B); gradient: 0 to 60 min: A/B 100/0 – 3/1 v/v, SF 65-400 
g) affording a white solid (7.41 g, 56%). mp 122 °C (lit.37 122 – 123 °C). Rf = 0.52 (hexane/EtOAc 5:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.50 (s, 9H), 1.52 (s, 9H), 2.39 (s, 3H), 11.60 (s, 1H). MS (LC-MS, 
ESI): m/z 291.0 [M+H+]. C12H22N2O4S (290.38). 
 
4.5.1.3 Preparation of NG-acylated isothiourea derivatives 4.4-4.11 
General procedure for the synthesis of the isothiourea derivatives 4.4-4.11 
The pertinent acid (1 eq) was dissolved in CH2Cl2 (15-30 ml), DIPEA (3 eq) and TBTU (1.2 eq) were 
added and the reaction mixture was stirred at room temperature under argon atmosphere for 
20 min. The acylated isothiourea derivative (1 eq), dissolved in CH2Cl2 (5-15 ml) was added slowly, 
and stirring was continued overnight. The mixture was poured into ice cold water (20 ml), acidified 
with 0.1 M HCl (pH 4) and extracted two times with CH2Cl2 (20-40 ml). The combined organic phase 
was dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by 
flash‐chromatography. 
 
N-tert-Butoxycarbonyl-N’-ethoxycarbonyl-S-methylisothiourea (4.4)38 
The title compound was prepared from propionic acid (390 mg, 5.26 mmol, 1 eq), DIPEA (2.08 g, 
15.78 mmol, 3 eq), TBTU (2.03 g, 6.31 mmol, 1.2 eq) and 4.2 (1.00 g, 5.26 mmol, 1 eq). The crude 
product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) affording a pale 
yellow solid (1.15 g, 89%). mp 114 °C. Rf = 0.46 (hexane/EtOAc 5:1). 
1H-NMR (300 MHz, DMSO-d6): 
δ (ppm) 1.00 (t, J = 7.4, 3H), 1.42 (s, 9H), 2.28 (s, 3H), 2.36 (q, J = 7.4, 2H), 11.21 (bs, 1H). 13C-NMR 
(75 MHz, CDCl3): δ (ppm) 8.81, 14.46, 27.97 (3C), 31.15, 81.67 (br), 161.36, 171.02 (br), 172.00 (br). 
MS (LC-MS, ESI): m/z 247.0 [M+H+]. C10H18N2O3S (246.33). 
 
N-tert-Butoxycarbonyl-N’-(butyryl)-S-methylisothiourea (4.5) 
The title compound was prepared from butyric acid (278 mg, 3.15 mmol, 1 eq), DIPEA (2.08 g, 
15.78 mmol, 3 eq), TBTU (1.22 g, 3.78 mmol, 1.2 eq) and 4.2 (600 mg, 3.15 mmol, 1 eq). The crude 
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product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) affording a white 
solid (689 mg, 84%). mp 82 °C. Rf = 0.45 (hexane/EtOAc 5:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 0.97 
(t, J = 7.4, 3H), 1.51 (s, 9H), 1.63-1.77 (m, 2H), 2.39 (s, 3H), 2.42 (d, J = 7.3, 2H), 12.44 (bs, 1H). 
13C-NMR (75 MHz, CDCl3): δ (ppm) 13.62, 14.45, 18.25, 27.97 (3C), 39.77, 81.54, 160.77, 170.98, 
172.07. MS (LC-MS, ESI): m/z 261.13 [M+H+]. C11H20N2O3S (260.35). 
 
N-tert-Butoxycarbonyl-N’-(isobutyryl)-S-methylisothiourea (4.6) 
The title compound was prepared from isobutyric acid (277.8 mg, 3.15 mmol, 1 eq), DIPEA (2.08 g, 
15.78 mmol, 3 eq), TBTU (1.22 g, 3.78 mmol, 1.2 eq) and 4.2 (600 mg, 3.15 mmol, 1 eq). The crude 
product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) affording a white 
solid (706 mg, 86%). mp 86 °C. Rf = 0.52 (hexanes/EtOAc 5:1). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.15 
(d, J = 7.0, 1H), 1.45 (s, 9H), 2.33 (s, 3H), 2.47-2.63 (m, 1H), 12.47 (bs, 1H). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 14.48, 18.96 (2C), 27.94 (3C), 36.71, 81.62, 160.75 (br), 171.29, 175.28 (br). MS (LC-MS, ESI): 
m/z 261.13 [M+H+]. C11H20N2O3S (260.35). 
 
N-tert-Butoxycarbonyl-N’-(cyclopropylcarbonyl)-S-methylisothiourea (4.7) 
The title compound was prepared from cyclopropanecarboxylic acid (272 mg, 3.15 mmol, 1 eq), 
DIPEA (2.08 g, 15.78 mmol, 3 eq), TBTU (1.22 g, 3.78 mmol, 1.2 eq) and 4.2 (600 mg, 3.15 mmol, 
1 eq). The crude product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) 
affording a white solid (644 mg, 79%). mp 59 °C. Rf = 0.60 (hexane/EtOAc 5:1). 
1H-NMR (300 MHz, 
CDCl3): δ (ppm) 0.87-0.98 (m, 2H), 1.05-1.14 (m, 2H), 1.50 (s, 9H), 1.71 (s, 1H), 2.37 (s, 3H), 12.48 (bs, 
1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 10.00, 10.30, 14.49, 20.27, 28.06 (3C), 81.42, 161.00, 171.12, 
172.45. MS (LC-MS, ESI): m/z 259.11 [M+H+]. C11H18N2O3S (258.34). 
 
N-tert-Butoxycarbonyl-N’-(cyclopentylcarbonyl)-S-methylisothiourea (4.8) 
The title compound was prepared from cyclopentanecarboxylic acid (721 mg, 6.31 mmol, 1 eq), 
DIPEA (2.45 g, 18.94 mmol, 3 eq), TBTU (2.43 g, 7.58 mmol, 1.2 eq) and 4.2 (1.20 g, 6.31 mmol, 1 eq). 
The crude product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) 
affording a white solid (1.61 g, 89%). mp 81 °C. Rf = 0.46 (hexane/EtOAc 5:1). 
1H-NMR (300 MHz, 
CDCl3): δ (ppm) 1.53 (s, 9H), 1.56-2.00 (m, 8H), 2.39 (s, 3H), 2.76 (p, J = 8.0, 1H), 12.49 (s, 1H). 
13C-NMR (75 MHz, CDCl3): δ (ppm) 14.48, 25.88 (2C), 27.97 (3C), 29.96 (2C), 46.73, 81.28, 160.78, 
171.15, 175.36. MS (LC-MS, ESI): m/z 287.2 [M+H+]. C13H22N2O3S (286.39). 
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N-tert-Butoxycarbonyl-N’-[2-(phenylsulfanyl)acetyl]-S-methylisothiourea (4.9) 
The title compound was prepared from 3-(phenylsulfanyl)propanoic acid (562 mg, 3.08 mmol, 1 eq), 
DIPEA (1.20 g, 9.25 mmol, 3 eq), TBTU (1.19 g, 3.70 mmol, 1.2 eq) and 4.2 (586 mg, 3.08 mmol, 1 eq). 
The crude product was purified by flash‐chromatography (eluent hexanes (A), EtOAc (B); gradient: 0 
to 30 min: A/B 100/0 – 10/1 v/v, SF 15-24 g) affording a white solid (600 mg, 55 %). mp 66 °C. Rf = 
0.50 (hexane/EtOAc 10:1). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.50 (s, 9H), 2.38 (s, 3H), 2.64-2.87 (m, 
2H), 3.23 (t, J = 7.2, 2H), 7.17-7.24 (m, 1H), 7.29 (t, J = 7.4, 2H), 7.37 (d, J = 7.5, 2H), 12.14 (s, 1H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 14.48, 25.88 (2C), 27.97 (3C), 29.96 (2C), 46.73, 81.28, 160.78, 171.15, 
175.36. MS (LC-MS, ESI): m/z 354.9 [M+H+]. C16H22N2O3S2 (354.49). 
 
N-tert-Butoxycarbonyl-N’-(3-phenylpropanoyl)-S-methylisothiourea (4.10)38 
The title compound was prepared from 3-phenylpropanoic acid (948 mg, 6.31 mmol, 1 eq), DIPEA 
(2.45 g, 18.94 mmol, 3 eq), TBTU (2.43 g, 7.58 mmol, 1.2 eq) and 4.2 (1.20 g, 6.31 mmol, 1 eq). The 
crude product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) affording a 
white solid (1.58 mg, 78%). mp 103 °C. Rf = 0.52 (100% CH2Cl2). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 
1.51 (s, 9H), 2.39 (s, 3H), 2.70-2.87 (m, 2H), 2.96-3.04 (m, 2H), 7.17-7.24 (m, 3H), 7.26-7.32 (m, 2H), 
12.48 (s, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 14.52, 28.11 (3C), 30.39, 39.01, 81.28, 126.48, 
128.32 (2C), 128.59 (2C), 139.90, 160.95, 170.51, 171.15. MS (LC-MS, ESI): m/z 323.0 [M+H+]. 
C16H22N2O3S (322.42). 
 
N-tert-Butoxycarbonyl-N’-(3,3-diphenylpropanoyl)-S-methylisothiourea (4.11) 
The title compound was prepared from 3,3-diphenylpropanoic acid (1.43 mg, 6.31 mmol, 1 eq), 
DIPEA (2.45 g, 18.94 mmol, 3 eq), TBTU (2.43 g, 7.58 mmol, 1.2 eq) and 4.2 (1.20 g, 6.31 mmol, 1 eq). 
The crude product was purified by flash‐chromatography (eluent CH2Cl2, isocratic, SF 15-24 g) 
affording a white solid (1.85 mg, 74%). mp 123 °C. Rf = 0.67 (100% CH2Cl2). 
1H-NMR (300 MHz, CDCl3): 
δ (ppm) 1.47 (s, 9H), 2.36 (s, 3H), 3.08-3.33 (m, 2H), 4.56-4.73 (m, 1H), 7.14-7.32 (m, 10H), 11.94 (s, 
1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 14.69, 28.03 (3C), 43.93, 46.70, 126.44, 126.83, 127.74 (2C), 
127.84 (2C), 128.61 (2C), 128.79 (2C), 142.98, 144.18, 160.94, 170.86, 184.34. MS (LC-MS, ESI): m/z 
399.1 [M+H+]. C22H26N2O3S (398.52). 
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4.5.1.4 Preparation of the guanidine derivatives 4.12-4.39 
General procedure for the synthesis of the guanidine derivatives 4.12-4.39 
The diamine (1 eq), one of the guanidinylating reagents 4.4-4.11 (1 eq), the guanidinylating reagent 
4.3 (1 eq) and HgCl2 (4 eq) were dissolved in anhydrous CH2Cl2 (4-10 ml). NEt3 (4 eq) was added and 
the mixture was stirred at ambient temperature for 24 to 48 h. Subsequently, the precipitate was 
filtered over Celite and dried in vacuo. The residue was dissolved in CH2Cl2. TFA (50% final 
concentration) was added and the reaction mixture was stirred until the protection groups were 
removed (3–8 h, TLC control). After evaporation of the solvent in vacuo, the crude product was 
purified by preparative RP-HPLC. MeCN was removed under reduced pressure. After lyophilisation 
4.12-4.39 (bis(hydrotrifluoroacetate)) were obtained as white fluffy hydroscopic solids. 
 
1,1'-(Ethane-1,2-diyl)diguanidine bis(hydrotrifluoroacetate) (4.12), N-[N-(2-guanidinoethyl)-
carbamimidoyl]propionamide bis(hydrotrifluoroacetate) (4.14) and N,N'-[ethane-1,2-diylbis-
(azanediyl)]bis(iminomethylene)dipropionamide bis(hydrotrifluoroacetate) (4.27) 
The three title compounds were prepared in a one-pot reaction from ethane-1,2-diamine (41 mg, 
0.681 mmol, 1 eq), 4.3 (198 mg, 0.681 mmol, 1 eq), 4.4 (168 mg, 0.681 mmol, 1 eq), HgCl2 (740 mg, 
2.72 mmol, 4 eq) and NEt3 (276 mg, 2.72 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% 
aq. TFA 5/95−25/75) afforded 4.12 bis(hydrotrifluoroacetate) as white fluffy solid (27.9 mg, 22%, tR = 
6.0 min), 4.14 bis(hydrotrifluoroacetate) as white fluffy solid (26.8 mg, 18%, tR = 11.3 min) and 4.27 
bis(hydrotrifluoroacetate) as white fluffy solid (42.9 mg, 26%, tR = 21.4 min). 
4.12: 
Rf = 0.10 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 231, 191 nm. RP-HPLC (200 nm): 
97.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 3.7 min, k = 0.6). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 3.17-3.28 (m, 4H), 7.30 (bs, 6H), 7.66 (bs, 2H). 
13C-NMR 
(75 MHz, DMSO-d6 + TFA): δ (ppm) 40.03 (2C), 115.28 (q, J = 287.9, TFA), 157.02 (2C), 158.57 (q, J = 
38.2, TFA). MS (LC-MS, ESI): m/z 145.12 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C4H13N6
+: 
145.1196, found: 145.1194. 
4.14: 
Rf = 0.14 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 230, 204, 191 nm. RP-HPLC (200 
nm): 99.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 9.3 min, k = 
3.0). 1H-NMR (300 MHz, DMSO-d6 + TFA): δ (ppm) 1.04 (t, J = 7.4, 2H), 2.44 (q, J = 7.4, 1H), 3.24-3.48 
(m, 4H), 7.32 (bs, 2H), 7.72 (t, J = 5.7, 1H), 8.85 (bs, 2H), 9.35 (bs, 1H), 11.03 (bs, TFA), 11.96 (s, 1H). 
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13C-NMR (75 MHz, DMSO-d6 + TFA): δ (ppm) 8.25, 29.69, 39.04 (superimposed by solvent), 40.20, 
115.44 (q, J = 288.3, TFA), 153.60, 157.10, 158.72 (q, J = 37.6, TFA), 176.25. MS (LC-MS, ESI): m/z 
201.15 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C7H17N6O
+: 201.1458, found: 201.1460. 
4.27: 
Rf = 0.22 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 230, 204, 190 nm. RP-HPLC (200 
nm): 98.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 15.0 min, k 
= 5.5). 1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 1.04 (t, J = 7.4, 6H), 2.44 (q, J = 7.4, 4H), 3.39-
3.55 (m, 4H), 8.81 (bs, 4H), 9.32 (bs, 2H), 11.03 (bs, TFA), 11.85 (bs, 2H). 13C-NMR (75 MHz, DMSO-d6 
+ TFA): δ (ppm) 8.26 (2C), 29.74 (2C), 40.30 (2C), 115.34 (q, J = 288.6, TFA), 157.99 (2C), 158.75 (q, J = 
38.2, TFA), 176.14 (2C). MS (LC-MS, ESI): m/z 257.17 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C10H21N6O2
+: 257.1721, found: 257.1721. 
 
N-[N-(2-Guanidinoethyl)carbamimidoyl]butyramide bis(hydrotrifluoroacetate) (4.15) and N,N'-
[ethane-1,2-diylbis(azanediyl)]bis(iminomethylene)dibutyramide bis(hydrotrifluoroacetate) (4.28) 
The title compounds were prepared in a one-pot reaction from ethane-1,2-diamine (50 mg, 0.827 
mmol, 1 eq), 4.3 (240 mg, 0.827 mmol, 1 eq), 4.5 (215 mg, 0.827 mmol, 1 eq), HgCl2 (898 mg, 3.31 
mmol, 4 eq) and NEt3 (335 mg, 3.31 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−37 min: MeCN/0.1% aq. TFA 5/95−40/60) affording 4.15 bis(hydrotrifluoroacetate) as 
white fluffy solid (43.3 mg, 24%, tR = 16.1 min) and 4.28 bis(hydrotrifluoroacetate) as white fluffy 
solid (67.5 mg, 32%, tR = 23.4 min). Note: Compound 4.12 (see above) was not isolated from this 
reaction mixture. 
4.15: 
Rf = 0.11 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 200, 191 nm. RP-HPLC (200 nm): 
98.2% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 11.8 min, k = 
4.1). 1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 0.89 (t, J = 7.4, 3H), 1.58 (h, J = 7.3, 2H), 2.40 (t, J = 
7.2, 2H), 3.27-3.48 (m, 4H), 7.31 (bs, 2H), 7.72 (t, J = 5.7, 1H), 8.88 (bs, 2H), 9.37 (bs, 1H), 11.97 (s, 
1H), 13.78 (bs, TFA). 13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 13.27, 17.49, 38.07, 39.25 
(superimposed by solvent), 40.21, 115.52 (d, J = 293.6, TFA), 153.60, 157.14, 158.76 (q, J = 37.6, TFA), 
175.44. MS (LC-MS, ESI): m/z 215.16 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C8H19N6O
+: 
215.1615, found: 215.1614. 
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4.28: 
Rf = 0.24 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 206, 200, 191 nm. RP-HPLC 
(200 nm): 99.7% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 
20.4 min, k = 7.8). 1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 0.90 (t, J = 7.4, 6H), 1.58 (h, J = 7.3, 
4H), 2.40 (t, J = 7.2, 4H), 3.45-3.52 (m, 4H), 8.84 (bs, 4H), 9.36 (s, 2H), 11.89 (s, 2H), 12.40 (bs, TFA). 
13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 13.25 (2C), 17.46 (2C), 38.04 (2C), 54.93 (2C), 115.31 (q, 
J = 289.0, TFA). 153.55 (2C), 158.68 (q, J = 38.0, TFA), 175.26 (2C). MS (LC-MS, ESI): m/z 285.20 
[M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C10H21N6O2
+: 285.2034, found: 285.2038. 
 
N-[N-(2-Guanidinoethyl)carbamimidoyl]-2-methylpropanamide bis(hydrotrifluoroacetate) (4.16) 
and N,N'-[ethane-1,2-diylbis(azanediyl)]bis(iminomethylene)bis(2-methylpropanamide) bis(hydro-
trifluoroacetate) (4.29) 
The title compounds were prepared in a one-pot reaction from ethane-1,2-diamine (41 mg, 
0.681 mmol, 1 eq), 4.3 (198 mg, 0.681 mmol, 1 eq), 4.6 (168 mg, 0.681 mmol, 1 eq), HgCl2 (740 mg, 
2.72 mmol, 4 eq) and NEt3 (276 mg, 2.72 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−35 min: MeCN/0.1% aq. TFA 5/95−40/60) afforded 4.16 bis(hydrotrifluoroacetate) as 
white fluffy solid (18.0 mg, 12%, tR = 15.8 min) and 4.29 bis(hydrotrifluoroacetate) as white fluffy 
solid (90.4 mg, 52%, tR = 24.6 min). Note: Compound 4.12 (see above) was not isolated from this 
reaction mixture. 
4.16: 
Rf = 0.15 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 193 nm. RP-HPLC (200 nm): 97.3% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 11.4 min, k = 3.9). 
1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 1.10 (d, J = 6.8, 2H), 2.60-2.70 (m, 1H), 3.25-3.49 (m, 
4H), 7.32 (bs, 2H), 7.74 (t, J = 5.7, 1H), 8.91 (bs, 2H), 9.39 (s, 1H), 9.80 (bs, TFA), 11.92 (s, 1H). 
13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 18.47, 35.28, 39.15 (superimposed by solvent), 40.19, 
115.64 (d, J = 288.5, TFA), 153.76, 157.06, 158.68 (q, J = 37.3, TFA), 179.21. MS (LC-MS, ESI): m/z 
215.16 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C8H19N6O
+: 215.1615, found: 215.1617. 
4.29: 
Rf = 0.20 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 192 nm. RP-HPLC (200 nm): 99.3% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 17.7 min, k = 6.6). 
1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 1.10 (d, J = 6.8, 12H), 2.59-2.70 (m, 2H), 3.42-3.56 (m, 
4H), 8.89 (bs, 4H), 9.40 (s, 2H), 9.81 (bs, TFA), 11.86 (s, 2H). 13C-NMR (101 MHz, DMSO-d6 + TFA): 
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δ (ppm) 18.46 (4C), 35.28 (2C), 40.20 (2C), 115.38 (q, J = 289.6, TFA). 153.76 (2C), 158.69 (q, J = 37.6, 
TFA), 179.07 (2C). MS (LC-MS, ESI): m/z 285.20 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C10H21N6O2
+: 285.2034, found: 285.2038. 
 
N-[N-(2-Guanidinoethyl)carbamimidoyl]cyclopropanecarboxamide bis(hydrotrifluoroacetate) (4.17) 
and N,N'-[ethane-1,2-diylbis(azanediyl))]bis(iminomethylene)dicyclopropanecarboxamide bis-
(hydrotrifluoroacetate) (4.30) 
The title compounds were prepared in a one-pot synthesis from ethane-1,2-diamine (53 mg, 
0.884 mmol, 1 eq), 4.3 (257 mg, 0.884 mmol, 1 eq), 4.7 (228 mg, 0.884 mmol, 1 eq), HgCl2 (960 mg, 
3.54 mmol, 4 eq) and NEt3 (358 mg, 3.54 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−37 min: MeCN/0.1% aq. TFA 5/95−40/60) affording 4.17 bis(hydrotrifluoroacetate) as 
white fluffy solid (46.7 mg, 24%, tR = 16.1 min) and 4.30 bis(hydrotrifluoroacetate) as white fluffy 
solid (62.5 mg, 28%, tR = 16.1 min). Note: Compound 4.12 (see above) was not isolated from this 
reaction mixture. 
4.17: 
Rf = 0.12 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 229, 204, 190 nm. RP-HPLC 
(200 nm): 98.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 
10.1 min, k = 3.3). 1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 0.86-1.11 (m, 4H), 1.77-1.91 (m, 1H), 
3.24-3.48 (m, 4H), 7.29 (bs, 2H), 7.69 (t, J = 5.6, 1H), 9.42 (s, 1H), 9.54 (bs, TFA), 12.42 (s, 1H). 13C-
NMR (101 MHz, DMSO-d6): δ (ppm) 9.41 (2C), 14.53, 39.10 (superimposed by solvent), 40.07, 153.02, 
156.75, 175.72. MS (LC-MS, ESI): m/z 213.15 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C8H17N6O
+: 213.1458, found: 213.1459. 
4.30: 
Rf = 0.25 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 229, 202, 191 nm. RP-HPLC 
(200 nm): 99.7% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 90/10, tR = 17.1 
min, k = 6.3). 1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 0.89-0.96 (m, 4H), 0.99-1.05 (m, 4H), 1.78-
1.90 (m, 2H), 3.40-3.54 (m, 4H), 8.84 (bs, 4H), 9.37 (s, 2H), 12.25 (s, 2H), 12.37 (bs, TFA). 13C-NMR 
(151 MHz, DMSO-d6 + TFA): δ (ppm) 9.67 (4c), 14.87 (2C), 40.06 (2C), 115.27 (q, J = 288.7, TFA), 
153.28 (2C), 158.63 (q, J = 38.1, TFA), 175.86 (2C). MS (LC-MS, ESI): m/z 281.17 [M+H+]. HRMS (ESI-
MS): m/z [M+H+] calcd. for C12H21N6O2
+: 281.1721, found: 281.1721. 
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N-[N-(2-Guanidinoethyl)carbamimidoyl]cyclopentanecarboxamide bis(hydrotrifluoroacetate) (4.18) 
and N,N'-[ethane-1,2-diylbis(azanediyl)]bis(iminomethylene)dicyclopentanecarboxamide bis-
(hydrotrifluoroacetate) (4.31) 
The title compounds were prepared in a one-pot synthesis from ethane-1,2-diamine (41 mg, 
0.681 mmol, 1 eq), 4.3 (198 mg, 0.681 mmol, 1 eq), 4.8 (195 mg, 0.681 mmol, 1 eq), HgCl2 (740 mg, 
2.72 mmol, 4 eq) and NEt3 (276 mg, 2.72 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−35 min: MeCN/0.1% aq. TFA 5/95−45/55) afforded 4.18 bis(hydrotrifluoroacetate) as 
white fluffy solid (31.7 mg, 20%, tR = 21.2 min) and 4.31 bis(hydrotrifluoroacetate) as white fluffy 
solid (19.6 mg, 10%, tR = 30.1 min). Note: Compound 4.12 (see above) was not isolated from this 
reaction mixture. 
4.18: 
Rf = 0.16 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 219, 204, 191 nm. RP-HPLC 
(200 nm): 97.1% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−70/30, 31-40 min: 90/10, tR = 
16.5 min, k = 6.1). 1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 1.52-1.64 (m, 4H), 1.66-1.75 (m, 2H), 
1.81-1.90 (m, 2H), 2.85 (p, J = 7.8, 1H), 3.32 (q, J = 6.1, 2H), 3.42 (q, J = 6.1, 2H), 7.28 (bs, 4H), 7.67 (t, 
J = 5.9, 1H), 8.81 (bs, 2H), 9.31 (s, 1H), 11.78 (s, 1H), 12.89 (bs, TFA). 13C-NMR (151 MHz, DMSO-d6 + 
TFA): δ (ppm) 25.62 (2C), 29.47 (2C), 40.06, 40.23, 45.31, 115.29 (q, J = 288.9, TFA), 153.65, 157.05, 
158.61 (q, J = 38.0, TFA), 178.38. MS (LC-MS, ESI): m/z 241.18 [M+H+]. HRMS (ESI-MS): m/z [M+H+] 
calcd. for C10H21N6O
+: 241.1771, found: 241.1774. 
4.31: 
Rf = 0.30 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 220, 200, 191 nm. RP-HPLC 
(200 nm): 98.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 10/90−70/30, 31-40 min: 90/10, tR = 
27.4 min, k = 10.8). 1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 1.52-1.66 (m, 8H), 1.67-1.76 (m, 
4H), 1.82-1.91 (m, 4H), 2.85 (p, J = 7.8, 2H), 3.45-3.53 (m, 4H), 8.81 (bs, 4H), 9.31 (s, 2H), 11.74 (s, 
2H), 12.02 (bs, TFA). 13C-NMR (151 MHz, DMSO-d6 + TFA): δ (ppm) 25.61 (4C), 29.47 (4C), 40.06 (2C), 
45.28 (2C), 115.22 (q, J = 288.6, TFA), 153.65 (2C), 158.56 (q, J = 38.2, TFA), 178.26 (2C). MS (LC-MS, 
ESI): m/z 337.23 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C16H29N6O2
+: 337.2347, found: 
337.2343. 
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1,1'-(Propane-1,3-diyl)diguanidine bis(hydrotrifluoroacetate) (4.13), N-[N-(3-
guanidinopropyl)carbamimidoyl]propionamide bis(hydrotrifluoroacetate) (4.19) and N,N'-
[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)dipropionamide bis(hydrotrifluoroacetate) 
(4.32) 
The title compounds were prepared in a one-pot synthesis from propane-1,3-diamine (60 mg, 
0.813 mmol, 1 eq), 4.3 (237 mg, 0.813 mmol, 1 eq), 4.4 (200 mg, 0.813 mmol, 1 eq), HgCl2 (885 mg, 
3.26 mmol, 4 eq) and NEt3 (330 mg, 3.26 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% 
aq. TFA 10/90−25/75) afforded 4.13 bis(hydrotrifluoroacetate) as white fluffy solid (22.0 mg, 14%, 
tR = 5.4 min), 4.19 bis(hydrotrifluoroacetate) as white fluffy solid (18.3 mg, 10%, tR = 12.8 min) and 
4.32 bis(hydrotrifluoroacetate) as white fluffy solid (36.5 mg, 18%, tR = 26.1 min).  
4.13: 
Rf = 0.05 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 200, 191 nm. RP-HPLC (200 nm): 
96.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 3.9 min, k = 0.7). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.69 (p, J = 7.1, 2H), 3.12 (dd, J = 6.7, 4H), 7.23 (bs, 4H), 7.82 
(t, J = 5.3, 2H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 27.74, 38.08 (2C), 156.84 (2C). MS (LC-MS, ESI): 
m/z 159.1 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C5H15N6
+: 159.1353, found: 159.1347. 
4.19: 
Rf = 0.18 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 207, 192 nm. RP-HPLC (200 nm): 
99.0% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 7.5 min, k = 2.2). 
1H-NMR (300 MHz, MeOH-d4): δ (ppm) 1.14 (t, J = 7.4, 3H), 1.88-1.99 (m, 2H), 2.50 (q, J = 7.4, 2H), 
3.21-3.44 (m, 4H). 13C-NMR (101 MHz, DMSO-d6): δ (ppm) 1.04 (t, J = 7.4, 3H), 1.74 (p, J = 6.9, 2H), 
2.43 (q, J = 7.4, 2H), 3.14 (q, J = 6.5, 2H), 3.29 (q, J = 6.5, 2H), 7.35 (bs, 4H), 7.97 (t, J = 5.3, 1H), 8.94 
(bs, 2H), 9.56 (s, 1H), 12.20 (s, 1H). MS (LC-MS, EI): m/z 214.15 [M+•]. HRMS (ESI-MS): m/z [M+H+] 
calcd. for C10H21N6O
+: 215.1615, found: 215.1617. 
4.32: 
Rf = 0.22 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 209, 194 nm. RP-HPLC (200 nm): 
99.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−30/70, 31-40 min: 90/10, tR = 16.7 min, k = 
6.2). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 1.05 (t, J = 7.4, 6H), 1.72-1.88 (m, 2H), 2.44 (q, J = 7.4, 
4H), 3.23-3.41 (m, 4H), 8.85 (bs, 4H), 9.46 (s, 2H), 12.00 (s, 2H). 13C-NMR (101 MHz, DMSO-d6): 
δ (ppm) 8.18 (2C), 26.36, 29.50 (2C), 38.45 (2C), 153.12 (2C), 175.96 (2C). MS (LC-MS, ESI): m/z 271.1 
[M+H+]. HRMS (EI-MS): m/z [M+H+] calcd. for C16H29N6O2
+: 271.1877, found: 271.1877. 
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N-[N-(3-Guanidinopropyl)carbamimidoyl]butyramide bis(hydrotrifluoroacetate) (4.20) and N,N'-
[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)dibutyramide bis(hydrotrifluoroacetate) (4.33) 
The title compounds were prepared in a one-pot synthesis from propane-1,3-diamine (71 mg, 
0.960 mmol, 1 eq), 4.3 (279 mg, 0.960 mmol, 1 eq), 4.5 (250 mg, 0.960 mmol, 1 eq), HgCl2 (1.04 g, 
3.84 mmol, 4 eq) and NEt3 (388 mg, 3.84 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−35 min: MeCN/0.1% aq. TFA 5/95−40/60) afforded 4.20 bis(hydrotrifluoroacetate) as 
white fluffy solid (74.8 mg, 34%, tR = 17.4 min) and 4.33 bis(hydrotrifluoroacetate) as white fluffy 
solid (55.3 mg, 22%, tR = 24.5 min). Note: Compound 4.13 (see above) was not isolated from this 
reaction mixture. 
4.20: 
Rf = 0.20 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 190 nm. RP-HPLC (200 nm): 98.8% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 10.5 min, k = 5.2). 
1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 0.90 (t, J = 7.4, 3H), 1.55-1.61 (m, 2H), 1.74 (p, J = 7.1, 
2H), 2.39 (t, J = 7.2, 2H), 3.14 (q, J = 6.6, 2H), 3.28 (q, J = 6.6, 2H), 7.19 (bs, 4H), 7.67 (t, J = 5.5, 1H), 
8.76 (bs, 2H), 9.29 (s, 1H), 11.29 (bs, TFA), 11.75 (s, 1H). 13C-NMR (151 MHz, DMSO-d6 + TFA): δ (ppm) 
13.29, 17.47, 27.26, 38.07, 38.27, 38.59, 115.24 (q, J = 288.6, TFA), 153.16, 156.88, 158.58 (q, J = 
38.2, TFA), 175.22. MS (LC-MS, ESI): m/z 229.18 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C9H21N6O
+: 229.1771, found: 229.1771. 
4.33: 
Rf = 0.30 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 193 nm. RP-HPLC (200 nm): 100% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 17.8 min, k = 9.5). 
1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 0.90 (t, J = 7.4, 6H), 1.58 (h, J = 7.3, 4H), 1.79 (p, J = 6.8, 
2H), 2.39 (t, J = 7.2, 4H), 3.31 (q, J = 6.6, 4H), 8.70 (s, 4H), 9.25 (s, 2H), 11.65 (s, 2H), 12.17 (bs, TFA). 
13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 13.30 (2C), 17.47 (2C), 26.52, 38.09 (2C), 38.60 (2C), 
115.17 (q, J = 288.3, TFA), 153.10 (2C), 175.14 (2C), 158.54 (q, J = 38.5, TFA). MS (LC-MS, ESI): m/z 
299.22 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C13H27N6O2
+: 299.2190, found: 299.2184. 
 
N-[N-(3-Guanidinopropyl)carbamimidoyl]-2-methylpropanamide bis(hydrotrifluoroacetate) (4.21) 
and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)bis(2-methylpropanamide) bis(hydro-
trifluoroacetate) (4.34) 
The title compounds were prepared from propane-1,3-diamine (71 mg, 0.960 mmol, 1 eq), 4.3 
(279 mg, 0.960 mmol, 1 eq), 4.6 (250 mg, 0.960 mmol, 1 eq), HgCl2 (1.04 g, 3.84 mmol, 4 eq) and NEt3 
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(388 mg, 3.84 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) followed by preparative 
RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% aq. TFA 5/95, 5−35 min: 
MeCN/0.1% aq. TFA 5/95−40/60) afforded 4.21 bis(hydrotrifluoroacetate) as white fluffy solid 
(26.8 mg, 22%, tR = 17.6 min) and 4.34 bis(hydrotrifluoroacetate) as white fluffy solid (110.2 mg, 44%, 
tR = 25.7 min). Note: Compound 4.13 (see above) was not isolated from this reaction mixture. 
4.21: 
Rf = 0.15 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 192 nm. RP-HPLC (200 nm): 95.2% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 10.2 min, k = 5.0). 
1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 1.10 (d, J = 6.8, 6H), 1.74 (p, J = 7.1, 2H), 2.63 (p, J = 6.8, 
1H), 3.14 (q, J = 6.6, 2H), 3.29 (q, J = 6.6, 2H), 7.11 (bs, 4H), 7.69 (t, J = 5.5, 1H), 8.79 (bs, 2H), 9.32 (s, 
1H), 11.70 (s, 1H), 11.84 (bs, TFA). 13C-NMR (151 MHz, DMSO-d6 + TFA): δ (ppm) 18.50, 27.21, 35.33, 
38.27, 38.63, 115.27 (q, J = 288.8, TFA), 153.39, 156.88, 158.59 (q, J = 38.1, TFA), 179.03. MS (LC-MS, 
ESI): m/z 229.18 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C9H21N6O
+: 229.1771, found: 
229.1774. 
4.34: 
Rf = 0.30 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 193 nm. RP-HPLC (200 nm): 100% 
(gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 14.3 min, k = 7.5). 
1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 1.10 (d, J = 6.9, 6H), 1.80 (p, J = 6.8, 2H), 2.63 (p, J = 6.7, 
2H), 3.32 (q, J = 6.6, 4H), 8.75 (bs, 4H), 9.31 (s, 2H), 11.63 (s, 2H), 12.74 (bs, TFA). 13C-NMR (151 MHz, 
DMSO-d6 + TFA): δ (ppm) 18.50 (4C), 26.43, 35.34 (2C), 38.65 (2C), 115.21 (q, J = 288.6, TFA). 153.34 
(2C), 158.57 (q, J = 38.3, TFA), 178.95 (2C). MS (LC-MS, ESI): m/z 299.22 [M+H+]. HRMS (ESI-MS): m/z 
[M+H+] calcd. for C13H27N6O2
+: 299.2190, found: 299.2194. 
N-[N-(3-Guanidinopropyl)carbamimidoyl]cyclopropanecarboxamide bis(hydrotrifluoroacetate) 
(4.22) and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)dicyclopropanecarboxamide 
bis(hydrotrifluoroacetate) (4.35) 
The title compounds were prepared in a one-pot synthesis from propane-1,3-diamine (64 mg, 
0.867 mmol, 1 eq), 4.3 (252 mg, 0.867 mmol, 1 eq), 4.7 (224 mg, 0.867 mmol, 1 eq), HgCl2 (941 mg, 
3.47 mmol, 4 eq) and NEt3 (351 mg, 3.47 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−5 min: MeCN/0.1% 
aq. TFA 5/95, 5−35 min: MeCN/0.1% aq. TFA 5/95−40/60) afforded 4.22 bis(hydrotrifluoroacetate) as 
white fluffy solid (15.4 mg, 8%, tR = 12.6 min) and 4.35 bis(hydrotrifluoroacetate) as white fluffy solid 
(40.6 mg, 18%, tR = 20.0 min). Note: Compound 4.13 (see above) was not isolated from this reaction 
mixture. 
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4.22: 
Rf = 0.11 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 205, 192 nm. RP-HPLC (200 nm): 
97.0% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−40/60, 31-40 min: 90/10, tR = 13.6 min, k = 
4.9). 1H-NMR (400 MHz, DMSO-d6 + TFA): δ (ppm) 0.89-1.07 (m, 4H), 1.74 (p, J = 7.0, 2H), 1.79-1.90 
(m, 1H), 3.14 (q, J = 6.6, 2H), 3.29 (q, J = 6.6, 2H), 7.15 (bs, 4H), 7.72 (t, J = 5.5, 2H), 8.83 (bs, 2H), 9.42 
(s, 1H), 9.75 (bs, TFA), 12.33 (s, 1H). 13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 8.30, 9.61, 14.79, 
27.18, 38.20, 38.53, 115.21 (q, J = 287.9, TFA), 152.94, 156.85, 158.60 (q, J = 37.3, TFA), 175.83. MS 
(LC-MS, ESI): m/z 227.16 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C9H17N6O
+: 227.1615, found: 
227.1616. 
4.35: 
Rf = 0.25 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 203, 193 nm. RP-HPLC (200 nm): 
95.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 13.0 min, k = 
6.7). 1H-NMR (600 MHz, DMSO-d6 + TFA): δ (ppm) 0.90-1.04 (m, 8H), 1.73-1.92 (m, 3H), 3.31 (q, J = 
6.5, 1H), 8.73 (s, 4H), 9.31 (s, 2H), 12.10 (s, 2H), 12.16 (bs, TFA). 13C-NMR (151 MHz, DMSO-d6 + TFA): 
δ (ppm) 9.63 (4C), 14.88 (2C), 26.44, 38.60 (2C), 115.19 (q, J = 288.5), 152.86 (2C), 158.55 (q, J = 
38.4), 175.77 (2C). MS (LC-MS, ESI): m/z 295.19 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for 
C13H21N6O2
+: 295.1877, found: 295.1880. 
 
N-[N-(3-Guanidinopropyl)carbamimidoyl]cyclopentanecarboxamide bis(hydrotrifluoroacetate) 
(4.23) and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)dicyclopentanecarboxamide 
bis(hydro-trifluoroacetate) (4.36) 
The title compounds were prepared from propane-1,3-diamine (60 mg, 0.812 mmol, 1 eq), 4.3 
(237-mg, 0.812 mmol, 1 eq), 4.8 (333 mg, 0.812 mmol, 1 eq), HgCl2 (882 mg, 3.25 mmol, 4 eq) and 
NEt3 (329 mg, 3.25 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) followed by preparative 
RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50) 
afforded 4.23 bis(hydrotrifluoroacetate) as white fluffy solid (31.7 mg, 16%, tR = 13.6 min) and 4.36 
bis(hydrotrifluoroacetate) as white fluffy solid (60.9 mg, 26%, tR = 28.8 min). Note: Compound 4.13 
(see above) was not isolated from this reaction mixture. 
4.23: 
Rf = 0.25 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 211, 204, 191 nm. RP-HPLC 
(200-nm): 97.1% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 
12.6 min, k = 6.5). 1H-NMR (300 MHz, MeOH-d4): δ (ppm) 1.41-1.86 (m, 10H), 2.78-3.01 (m, 2H), 3.17 
(q, J = 6.5, 2H), 3.43 (q, J = 6.7, 2H). 13C-NMR (75 MHz, DMSO-d6 + TFA): δ (ppm) 24.56 (2C), 26.18, 
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28.91 (2C), 38.21, 38.51, 45.86, 115.24 (q, J = 288.7, TFA), 153.94, 156.87, 158.60 (q, J = 37.3, TFA), 
178.21. MS (LC-MS, ESI): m/z 255.1 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C11H23N6O
+: 
255.1928, found: 255.1928. 
4.36: 
Rf = 0.35 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 212, 205, 191 nm. RP-HPLC 
(200-nm): 98.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50, 31-40 min: 90/10, tR = 
17.3-min, k = 5.1). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 1.46-1.96 (m, 18H), 2.75-2.97 (m, 2H), 3.32 
(q, J = 6.0, 4H), 8.85 (bs, 4H), 9.46 (s, 2H), 11.92 (s, 2H). 13C-NMR (101 MHz, DMSO-d6): δ (ppm) 25.59 
(4C), 26.31, 29.40 (4C), 38.53 (2C), 45.11 (2C), 153.24 (2C), 178.18 (2C). MS (LC-MS, ESI): m/z 351.2 
[M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C17H31N6O2
+: 351.2503, found: 351.2501. 
 
N-[N-(3-Guanidinopropyl)carbamimidoyl]-3-(phenylsulfanyl)propanamide bis(hydrotrifluoro-
acetate) (4.24) and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)bis[3-
(phenylsulfanyl)propanamide] bis(hydrotrifluoroacetate) (4.37) 
The title compounds were prepared from propane-1,3-diamine (46 mg, 0.620 mmol, 1 eq), 4.3 
(180 mg, 0.620 mmol, 1 eq), 4.9 (220 mg, 0.620 mmol, 1 eq), HgCl2 (673 mg, 2.48 mmol, 4 eq) and 
NEt3 (251 mg, 2.48 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) followed by preparative 
RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 20/80−50/50) 
afforded 4.24 bis(hydrotrifluoroacetate) as white fluffy solid (39.3 mg, 24%, tR = 14.0 min) and 4.37 
bis(hydrotrifluoroacetate) as white fluffy solid (26.6 mg, 12%, tR = 18.3 min). Note: Compound 4.13 
(see above) was not isolated from this reaction mixture. 
4.24: 
Rf = 0.20 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 276, 213, 191 nm. RP-HPLC 
(200 nm): 97.5% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 
16.3 min, k = 8.7). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.73 (p, J = 6.8, 2H), 2.77 (t, J = 6.8, 2H), 
3.13 (q, J = 6.6, 2H), 3.21 (t, J = 6.9, 2H), 3.28 (q, J = 6.2, 2H), 6.94-7.43 (m, 9H), 7.73 (t, J = 5.4, 1H), 
8.80 (bs, 2H), 9.32 (bs, 1H), 11.98 (bs, 1H). 13C-NMR (101 MHz, DMSO-d6 + TFA): δ (ppm) 25.48, 26.85, 
28.88, 36.18, 38.15, 126.20, 128.66 (2C), 129.19 (2C), 131.41, 156.79, 162.31, 176.75. MS (LC-MS, 
ESI): m/z 323.17 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C14H23N6OS
+: 323.1649, found: 
323.1651. 
4.37: 
Rf = 0.35 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 282, 215, 191 nm. RP-HPLC 
(200 nm): 98.7% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 
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23.1 min, k = 12.7). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.77 (p, J = 6.3, 2H), 2.77 (t, J = 6.9, 4H), 
3.21 (t, J = 6.9, 4H), 3.30 (q, J = 6.1, 4H), 7.14-7.42 (m, 10H), 8.83 (bs, 4H), 9.41 (s, 2H), 12.10 (s, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) 26.35, 26.88 (2C), 36.14 (2C), 38.47 (2C), 126.15 (2C), 128.59 
(4C), 129.18 (4C), 135.20 (2C), 152.86 (2C), 173.30 (2C). MS (LC-MS, ESI): m/z 487.19 [M+H+]. HRMS 
(ESI-MS): m/z [M+H+] calcd. for C23H32N6O2S2
+: 487.1944, found: 487.1948. 
 
N-[N-(3-Guanidinopropyl)carbamimidoyl]-3-phenylpropanamide bis(hydrotrifluoroacetate) (4.25) 
and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)bis(3-phenylpropanamide) 
bis(hydrotrifluoroacetate) (4.38) 
The title compounds were prepared from propane-1,3-diamine (60 mg, 0.812 mmol, 1 eq), 4.3 
(237 mg, 0.812 mmol, 1 eq), 4.10 (323 mg, 0.812 mmol, 1 eq), HgCl2 (882 mg, 3.25 mmol, 4 eq) and 
NEt3 (329 mg, 3.25 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) followed by preparative 
RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40) 
afforded 4.25 bis(hydrotrifluoroacetate) as white fluffy solid (33.4 mg, 16%, tR = 14.7 min) and 4.38 
bis(hydrotrifluoroacetate) as white fluffy solid (37.0 mg, 14%, tR = 18.7 min). Note: Compound 4.13 
(see above) was not isolated from this reaction mixture. 
4.25: 
Rf = 0.45 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 278, 205, 191 nm. RP-HPLC 
(200 nm): 99.9% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 
15.0 min, k = 7.9). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 1.73 (p, J = 7.0, 2H), 2.75 (t, J = 7.5, 2H), 
2.88 (t, J = 7.4, 2H), 3.13 (q, J = 6.6, 2H), 3.28 (q, J = 6.6, 2H), 6.93-7.60 (m, 9H), 7.83 (t, J = 5.5, 1H), 
8.90 (bs, 2H), 9.48 (s, 1H), 12.19 (s, 1H). 13C-NMR (101 MHz, DMSO-d6): δ (ppm) 27.12, 29.54, 37.65, 
38.15, 38.48, 126.21, 128.26 (2C), 128.41 (2C), 140.18, 153.09, 156.84, 174.49. MS (LC-MS, ESI): m/z 
291.2 [M+H+]. C14H22N6O (290.36). 
4.38: 
Rf = 0.60 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 285, 218, 193 nm. RP-HPLC 
(200 nm): 95.6% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−50/50, 31-40 min: 90/10, tR = 
23.3 min, k = 12.8). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 1.78 (p, J = 6.5, 2H), 2.75 (t, J = 7.5, 2H), 
2.88 (t, J = 7.4, 2H), 3.30 (q, J = 6.3, 2H), 7.11-7.38 (m, 10H), 8.85 (bs, 4H), 9.45 (s, 2H), 12.10 (s, 2H). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) 26.34, 29.52 (2C), 37.64 (2C), 38.45 (2C), 126.20 (2C), 128.25 
(4C), 128.40 (4C), 140.15 (2C), 153.01 (2C), 174.40 (2C). MS (LC-MS, ESI): m/z 423.1 [M+H+]. HRMS 
(ESI-MS): m/z [M+H+] calcd. for C23H31N6O2
+: 423.2503, found: 423.2506. 
 
134 Chapter 4 
N-[N-(3-Guanidinopropyl)carbamimidoyl]-3,3-diphenylpropanamide bis(hydrotrifluoroacetate) 
(4.26) and N,N'-[propane-1,3-diylbis(azanediyl)]bis(iminomethylene)bis(3,3-diphenylpropanamide) 
bis(hydro-trifluoroacetate) (4.39) 
The title compounds were prepared in a one-pot synthesis from propane-1,3-diamine (60 mg, 
0.812 mmol, 1 eq), 4.3 (237 mg, 0.812 mmol, 1 eq), 4.11 (323 mg, 0.812 mmol, 1 eq), HgCl2 (882 mg, 
3.25 mmol, 4 eq) and NEt3 (329 mg, 3.25 mmol, 4 eq). Deprotection in CH2Cl2 (5 ml) and TFA (5 ml) 
followed by preparative RP-HPLC (column: Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% 
aq. TFA 25/75−60/40) afforded 4.26 bis(hydrotrifluoroacetate) as white fluffy solid (62.6 mg, 26%, tR 
= 13.6 min) and 4.39 bis(hydrotrifluoroacetate) as white fluffy solid (26.0 mg, 8%, tR = 28.8 min). 
Note: Compound 4.13 (see above) was not isolated from this reaction mixture. 
4.26: 
Rf = 0.35 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 284, 221, 196 nm. RP-HPLC 
(200 nm): 98.3% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−60/40, 31-40 min: 90/10, tR = 
18.7 min, k = 10.1). 1H-NMR (300 MHz, DMSO-d6 + TFA): δ (ppm) 1.69-1.84 (m, 2H), 2.67-2.86 (m, 
2H), 3.20-3.36 (m, 4H), 4.52 (t, J = 7.9, 1H), 7.10-7.37 (m, 10H), 7.75 (bs, 4H), 8.79 (bs, 2H), 9.33 (b, 
1H), 12.11 (s, 1H), 12.37 (bs, TFA). 13C-NMR (75 MHz, DMSO-d6 + TFA): δ (ppm) 25.89, 36.28, 38.08, 
41.70, 45.93, 115.41 (d, J = 289.2, TFA), 126.55 (2C), 127.49 (4C), 128.62 (4C), 143.46 (2C), 158.33, 
158.53 (d, J = 37.5, TFA), 159.31, 173.24. MS (LC-MS, ESI): m/z 367.2 [M+H+]. C20H26N6O (366.46). 
4.39: 
Rf = 0.55 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 285, 226, 191 nm. RP-HPLC 
(200 nm): 99.8% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−60/50, 31-40 min: 90/10, tR = 
23.9 min, k = 13.1). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.63-1.90 (m, 2H), 3.15-3.39 (m, 8H), 4.36-
4.50 (m, 2H), 7.10-7.37 (m, 20H), 8.00 (bs, 4H), 9.45 (bs, 2H), 12.46 (s, 2H). 13C-NMR (75 MHz, 
DMSO-d6): δ (ppm) 28.11, 31.19 (2C), 37.96 (2C), 38.22 (2C), 46.61 (2C), 126.18 (4C), 127.37 (8C), 
128.27 (8C), 143.71 (4C), 159.69 (2C), 171.03 (2C). MS (LC-MS, ESI): m/z 575.4 [M+H+]. HRMS (EI-MS): 
m/z [M+H+] calcd. for C35H39N6O2: 575.3129, found: 575.3134. 
 
4.5.1.5 Preparation of the dicarbamimidothioate 4.40 
Propane-1,3-diyl dicarbamimidothioate (dihydrobromide) (4.40)39 
Thiourea (45 mg, 0.594 mmol, 2 eq) and 1,3-dibromopropane (60 mg, 0.297 mmol, 1 eq) in EtOH 
(2 ml) were heated under microwave irradiation at 125 °C for 15 min. While the reaction mixture was 
allowed to cool to room temperature 4.40 was precipitating as white crystals (37 mg, 65%). 
mp 186 °C (lit.39 204-205 °C). Rf = 0.55 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM HCl): λmax 222, 
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192 nm. RP-HPLC (200 nm): 98.2% (gradient: 0−30 min: MeCN/0.1% aq. TFA 5/95−43/57, 31-40 min: 
90/10, tR = 4.8 min, k = 0.7). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.95 (p, J = 6.8, 2H), 3.24 (t, J = 
7.3, 4H), 9.07 (s, 8H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 28.43 (3C), 169.33 (2C). MS (LC-MS, ESI): 
m/z 193.0 [M+H+]. HRMS (ESI-MS): m/z [M+H+] calcd. for C5H13N4S2
+: 193.0576, found: 193.0580. 
 
4.5.1.6 Preparation of VUF 8430 analog 4.43 
1-(3-Hydroxypropyl)-N-,N'-Bis(tert-butoxycarbonyl)guanidine (4.41)29 
Neat 3-Aminopropan-1-ol (1.92 g, 25.6 mmol, 1.1 eq) was added to a solution of N,N'-Di-boc-N"-
trifluoromethanesulfonylguanidine (3.25, 9.00 g, 23.0 mmol, 1 eq) and triethylamine (2.59 g, 
25.6 mmol, 1.1 eq) in CH2Cl2 (100 ml) and the mixture was stirred at room temperature for 40 min. 
The mixture was diluted with CH2Cl2 (100 ml), washed with saturated KHSO4(aq.), saturated 
NaHCO3(aq.)) and water, dried over anhydrous Na2SO4 and concentrated in vacuo. A white solid was 
obtained (6.91 g, 95%). mp 105 °C (lit.40 112-113 °C).. Rf = 0.20 (CH2Cl2/MeOH 50:1). 
1H-NMR 
(300 MHz, DMSO-d6): δ (ppm) 1.39 (s, 9H), 1.47 (s, 9H), 1.62 (p, J = 6.4, 2H), 3.35 (t, J = 6.6, 2H), 3.44 
(q, J = 5.9, 2H), 4.64 (t, J = 5.2, 1H), 8.41 (t, J = 5.4, 1H), 11.48 (s, 1H). 13C-NMR (75 MHz, DMSO-d6): 
δ (ppm) 27.50 (3C), 27.87 (3C), 31.31, 37.91, 58.38, 77.98, 82.70, 151.88, 155.11. MS (LC-MS, ESI): 
m/z 318.0 [M+H+]. C14H27N3O5 (317.38). 
 
3-Guanidinopropyl carbamimidothioate bis(hydrotrifluoroacetate) (4.43)41 
4.41 (203 mg, 0.630 mmol, 1 eq) in 47% HBr(aq.) (6 ml) was heated at 100 °C for 30 h. After 
evaporation of the solvent in vacuo, thiourea (48 mg, 0.630 mmol, 1 eq) in EtOH (2 ml) was added 
and the mixture was heated under microwave irradiation at 125 °C for 15 min. After evaporation of 
the solvent in vacuo, the crude product was purified by preparative RP-HPLC (column: Nucleodur 250 
× 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 3/97) afforded 4.43 bis(hydrotrifluoroacetate) as 
white fluffy solid (25.2 mg, 10%, tR = 6.0 min). Rf = 0.15 (CH2Cl2/MeOH/NH3 80/19/1). UV/VIS (20 mM 
HCl): λmax 218, 196 nm. RP-HPLC (200 nm): 98.2% (gradient: 0−30 min: MeCN/0.1% aq. TFA 
5/95−43/57, 31-40 min: 90/10, tR = 4.8 min, k = 0.7). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.80 (p, J 
= 7.1, 1H), 3.06-3.23 (m, 4H), 7.26 (bs, 4H), 7.87 (t, J = 5.4, 1H), 9.35 (bs, 2H), 9.08 (bs, 2H). 13C-NMR 
(75 MHz, DMSO-d6): δ (ppm) 27.04, 27.95, 39.25, 156.70, 169.51. MS (LC-MS, ESI): m/z 176.0 [M+H
+]. 
HRMS (ESI-MS): m/z [M+H+] calcd. for C5H14N5S
+: 176.0964, found: 176.0962. 
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4.5.2 Pharmacological Methods 
4.5.2.1 General 
See section 3.4.3.1 
4.5.2.2 Competition binding experiments on membrane preparations of Sf9 insect cells 
See section 3.4.3.2 
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Chapter 5 
5 [3H]UR-DE257: A Selective and Highly 
Potent Tritium-Labeled Squaramide-type 
Histamine H2 Receptor Antagonist   
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5.1 Introduction 
The H2 receptor (H2R) is known as the target 
of drugs such as cimetidine, ranitidine, 
famotidine or roxatidine (Figure 1.6), which 
have been used, e.g., for the treatment of 
gastric or duodenal ulcers.1,2 Apart from 
marketed drugs, numerous structurally 
related compounds,3,4 e.g. iodoaminopotentidine,5 BMY 25368,6 and tiotidine,7 are known as H2R 
antagonists. Histamine as well as several of the antagonists were radiolabeled as pharmacological 
tools (for review see8).9-11 Nevertheless, [3H]histamine, [3H]ranitidine,12 [3H]cimetidine13 and 
[3H]tiotidine14 are far from being ideal. The H2R affinities of the endogenous (non-selective) agonist 
and the antagonists cimetidine and ranitidine are low. [3H]Tiotidine,14,15 although used as a standard 
radioligand for a long period of time, is known for high unspecific binding. [125I]Iodoamino-
potentidine10 has the highest affinity of all reported H2R ligands and was used, for instance, for 
autoradiography of the H2R in heart and brain of the guinea pig. Compared to tritium-labeled 
compounds, iodinated radioligands have the advantage of higher specific activity.16 However, 
[125I]iodoaminopotentidine is not commercially available and can only be used within 4-6 weeks after 
preparation. Selective H2R radioligands are indispensable for histamine receptor research including 
studies on receptor subtypes other than the H2R. In previous work, aiming at the development of 
high-affinity labeled H2R antagonists, the piperidinomethylphenoxyalkyl portion of aminopotentidine 
and related substances was retained, the polar group (‘urea eqalent’), was optimized by exploring 
cyanoguanidine, nitroethenediamine, amide or squaric amide moieties, and a terminal amino group, 
connected via a linker of different length, was introduced.17 In this series highest affinity and 
selectivity was found for UR-DE257, determined in radioligand binding assays, using membrane 
preparations of Sf9 insect cells, expressing the respective hHxR subtype (hH1R: Ki: >10000 nM, hH2R: 
Ki: 28 nM (Kb: 38 nM, neutral antagonism in the GTPase assay), hH3R: Ki: 3800 nM, hH4R: Ki: >10000 
nM). The propionyl group allowed coupling with succinimidyl [2,3-3H]propionate, which is 
commercially available, under standard laboratory conditions.18-21 Herein, the radiosynthesis of 
[3H]UR-DE257 and its pharmacological characterization is shown. In addition, the applicability to 
autoradiographic binding studies cryosections of a rat or guinea-pig brain and guinea-pig heart were 
incubated with [3H]UR-DE257. 
 
Figure 5.1 Structure of [
3
H]UR-DE257. 
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5.2 Results and Discussion 
5.2.1 Radiosynthesis 
 
Scheme 5.1 Synthesis of [
3
H]UR-DE257. Reagents and conditions: UR-DE92, succinimidyl [2,3-
3
H]-propionate, 
CH3CN/DMSO (1:1), NEt3, rt, 18 h, 44.6%. 
The [2,3-3H]propionyl-substituted amide ([3H]UR-DE257, N-{6-[3,4-dioxo-2-({3-[3-(piperidin-1-
ylmethyl)phenoxy]propylamino})-cyclo-but-1-enylamino]hexyl}-(2,3-3H2)-propionamide), the ‘hot’ 
form of UR-DE257, was prepared by acylation of an excess of amine precursor UR-DE92 in the 
presence of triethylamine with commercially available tritiated succinimidyl propionate (Scheme 5.1, 
cf.18-21). After purification by HPLC, [3H]UR-DE257 was obtained in a radiochemical purity of >99% 
(Figure 5.2) with a specific activity (as) of 63.0 Ci/mmol. The identity of the radioligand was confirmed 
by HPLC analysis of labeled and unlabeled UR-DE257. Moreover, chemical stability in EtOH at -20 °C 
was proven over a period of at least 24 months (cf. Figure 5.3). 
 
Figure 5.2 Identity and purity control of [
3
H]UR-DE257. A: Reaction control after 20 h. B: Purity control after 
purification (radiochromatograms). C: UV ( = 280 nm) chromatogram of UR-DE257, c: 100 μM. 
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Figure 5.3 Example of a radiochromatogram of [
3
H]UR-DE257 after storage in ethanol at -20 °C for a period of 
24 months. 
5.2.2 Determination of binding constants of [3H]UR-DE257 
[3H]UR-DE257 was characterized by saturation and kinetic binding experiments on membrane 
preparations of Sf9 insect cells expressing the fusion proteins hH2R-GsαS, gpH2R-GsαS or rH2R-GsαS or on 
HEK293T CRE-Luc hH2R cells stably expressing the hH2R. [
3H]UR-DE257 was bound in a saturable 
manner (cf. Figure 5.4 for the hH2R; Figure 5.5 for the gpH2R, Figure 5.6 for the rH2R at Sf9 insect cell 
membranes and Figure 5.7 for the hH2R experiments on HEK cells). Up to a radioligand concentration 
of 200 nM, nonspecific binding, determined in the presence of famotidine (10 µM), was low, 
amounting to 5–20% of total binding. Specific binding versus [3H]UR-DE257 concentration was best 
fitted by nonlinear regression to a one-site binding model, nonspecific binding to a standard linear 
curve. The determined Kd values (27-55 nM, Table 5.1) were comparable with the Kb values from 
functional GTPase assays (Kb = 38 nM).
17 Moreover, the Ki values of [
3H]UR-DE257 determined in 
radioligand binding assays on different H2R species orthologs using membrane preparations and 
whole cells, respectively, were in the same range (Ki = 16-44 nM). The maximum number of binding 
sites (Bmax) ranged between 0.8 and 4.1 pmol/mg membrane protein in the Sf9 cell membranes and 
2.4 x 106 sites on HEK cells. In all cases, within the investigated concentration range, the Scatchard 
plots were linear, in agreement with the binding of [3H]UR-DE257 to a single binding site, following 
the law of mass action (Figure 5.4-5.7 C).  
 Results and Discussion 145 
  
 
Figure 5.4 A. Representative saturation binding curve 
(dpm). Total binding: ○; specific binding: ●; 
nonspecific binding: □. B. Saturation binding curve of 
[
3
H]UR-DE257 to the hH2R expressed in Sf9 
membranes. Specific binding: ●; nonspecific binding: 
□; Kd(sat) = 31 ± 5 nM. C. Scatchard plot for the binding 
of [
3
H]UR-DE257 to the hH2R expressed in Sf9 
membranes, best fitted by linear regression, 
Kd = -1/slope = 37 ± 3 nM; (mean values ± SEM, n = 3, 
performed in triplicate). 
 
Table 5.1 Saturation binding parameters of [
3
H]UR-DE257 on membranes of Sf9 cells expressing human, guinea 
pig and rat H2R  and at hH2R in HEK293T CRE-Luc hH2R cells.
[a]
 
 
Kd / nM
 
Kd (scatchard) / nM
 
Bmax / pmol/mG-Protein
 Specific binding    
sites / well 
hH2R
[b]
 31 ± 5 37 ± 3 0.78 ± 0.08 4.8 x 10
10
 
hH2R
[c]
 55 ± 8 52 ± 9 - 2.4 x 10
6[d]
 
gpH2R
[b]
 37 ± 13 39 ± 24 0.77 ± 0.03 3.0 x 10
10
 
rH2R
[b]
 29 ± 2 40 ± 12 4.07 ± 0.11 13.6 x 10
10
 
[a] Data are the mean of two independent experiments, each performed in triplicate. [b] Binding data determined 
on membranes of Sf9 insect cells expressing the respective xH2R-GsαS fusion protein (x = h, gp or r); radioligand: 
[
3
H]UR-DE257 (30 nM). [c] hH2R binding: HEK293T CRE-Luc hH2R cells; radioligand: [
3
H]UR-DE257 (30 nM). 
[d] Estimated Bmax (sites / cell). 
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Figure 5.5 A. Representative saturation binding curve 
(dpm). Total binding: ○; specific binding: ●; 
nonspecific binding: □. B. Saturation binding curve of 
[
3
H]UR-DE257 on membranes of Sf9 cells expressing 
the gpH2R. Specific binding: ●; nonspecific binding: □; 
Kd(sat) = 37 ± 13 nM. C. Scatchard plot for the binding 
of [
3
H]UR-DE257 to the gpH2R expressed in Sf9 
membranes, best fitted by linear regression, 
Kd = -1/slope = 39 ± 24 nM. (mean values ± SEM, n = 2, 
performed in triplicate). 
 
  
 
Figure 5.6 A. Representative saturation binding 
curve (dpm). Total binding: ○; specific binding: ●; 
nonspecific binding: □. B. Saturation binding curve 
of [
3
H]UR-DE257 on membranes of Sf9 cells 
expressing the rH2R. Specific binding: ●; nonspecific 
binding: □; Kd(sat) = 29 ± 2 nM. C. Scatchard plot for 
the binding of [
3
H]UR-DE257 to the rH2R expressed 
in Sf9 membranes, best fitted by linear regression, 
Kd = –1/slope = 40 ± 12 nM; (mean values ± SEM, 
n = 2, performed in triplicate). 
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Figure 5.7 A. Representative saturation binding curve 
(dpm). Total binding: ○; specific binding: ●; 
nonspecific binding: □. B. Saturation binding curve of 
[
3
H]UR-DE257 to the hH2R expressed HEK293T CRE-
Luc hH2R cells. Specific binding: ●; nonspecific 
binding: □; Kd(sat) = 55 ± 8 nM. C. Scatchard plot for the 
binding of [
3
H]UR-DE257 to the hH2R stably expressed 
in HEK293T CRE-Luc hH2R cells, best fitted by linear 
regression, Kd = –1/slope = 52 ± 9 nM. (mean values ± 
SEM, n = 3, performed in triplicate). 
 
The results of kinetic studies of [3H]UR-DE257 (c = 30 nM) at the hH2R on Sf9 cell membranes at 22 °C 
are presented in Figure 5.8. Similar data were obtained for gpH2R and rH2R (Sf9 cell membranes) and 
hH2R expressed in HEK293 cells (cf. Figures 5.10-5.12). Linearization of the association curves 
revealed straight lines with kob values ranging from 0.050 to 0.073 min
-1. Dissociation in the presence 
of famotidine (Figure 5.8 C) was slow and gave comparable results for all investigated H2R orthologs 
in Sf9 membranes and HEK293 cells. After 90 minutes the residual specific binding of the tritiated 
compound amounted to approximately 60-70%, suggesting (pseudo)irreversible binding (cf.21). 
Linearization of the dissociation kinetics revealed two straight lines with different slopes (Figure 5.8 B 
and Figures 5.10-5.12 B, inset). The equilibrium dissociation constant of [3H]UR-DE257, calculated 
from kinetics (Kd = koff/kon = 13-20 nM; Figure 5.8 and Figures 5.10-5.12, Table 5.2), was consistent 
with the Kd values derived from saturation binding experiments (Kd = 27-55 nM), proving that 
radioligand [3H]UR-DE257 follows the law of mass action,22 provided that the koff value of the fast 
dissociation was considered. 
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Figure 5.8 Association and dissociation kinetics of the radiolabeled H2R antagonist [
3
H]UR-DE257 on hH2R‐GsαS 
(Sf9 cell membranes). A. Radioligand (c = 30 nM) association as a function of time. Inset: Linearization 
ln[Beq/(Beq-B)] versus time of the association kinetic for the determination of kob and kon, slope = kob = 
0.050 min
–1
, kon = (kob - koff)/[L] = 8.6 x 10
–4
 min
–1
 x nM
–1
. B. Radioligand (c = 30 nM, pre-incubation for 60 min) 
dissociation as a function of time, monophasic exponential fit, t1/2 = 5.5 min, dissociation determined in the 
presence of a 100-fold excess of famotidine. Inset: Linearization ln(B/B0) versus time of the dissociation 
kinetics for the determination of koff = slope
-1
 = 0.020 min
–1
. (mean values ± SEM, n = 4) Inset: Representative 
dissociation curve (dpm) for linearization. C. Comparison of the radioligand (c = 30 nM, pre-incubation for 60 
min) dissociation as a function of time, monophasic exponential fit, determined in Sf9 insect cell membranes 
expressing the respective xH2R-GsαS subtype or in HEK293T CRE-Luc hH2R cells. 
The pseudo-irreversibility of binding is reminiscent of the pharmacological behavior reported for 
several classes of H2R antagonists, for instance, piperidinylmethylphenoxyalkyl substituted 
squaramides, thiadiazolamines or aminotriazoles.6,23-25 Piperidinylmethylphenoxyalkyl-substituted 
squaramides such as BMY 25368 (Figure 1.6) were described as insurmountable H2R antagonists, 
causing a concentration- dependent depression of the maximal response to the agonist and tight 
binding to the H2R in the guinea pig right atrium (Kb = 13 nM) compared to standard ligands such as 
famotidine.26 
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Such peculiar behavior at the 
guinea pig right atrium was 
also confirmed for UR-DE91 
(pA2 = 7.36 ± 0.14) and UR-
DE111 (pA2 = 7.22 ± 0.08).
17 
Both compounds caused a concentration-dependent decrease in the maximum response to 
histamine (at antagonist concentration of 1 µM: Emax (histamine): 54% (UR-DE91) and 77% (UR-
DE111), respectively).17 Recently, a Y2R selective radioligand with similar properties in kinetic and 
functional experiments was reported as an insurmountable pseudo-irreversible non-peptide 
neuropeptide Y antagonist.21 Possible explanations are a slow rate of dissociation from the 
receptor27, a slow rate of interconversion between inactive and active receptor conformations28,29 or 
stabilization of a ligand (antagonist) specific inactive receptor conformation.30 
Table 5.2 H2R binding and functional characteristics of [
3
H]UR‐DE257. 
Receptor koff / min
–1[a] 
kon / min
–1
 nM
–1[b]
 koff/kon / nM
[c] 
Kd / nM
[d] 
t1/2 / min
[e] 
hH2R (Sf9) 0.024 0.00086 20 31 5.5 
gpH2R (Sf9) 0.015 0.00033 44 37 16 
rH2R (Sf9) 0.019 0.0015 13 29 5.1 
hH2R (HEK293) 0.025 0.0016 16 55 5.9 
[a] Dissociation rate constant determined by linear regression. [b] Association rate constant determined by 
linear regression. [c] Kinetically determined dissociation constant. [d] Equilibrium dissociation constant 
determined by saturation binding experiments. [e] Dissociation half-life. 
 
  
Figure 5.10 Association and dissociation kinetics of the specific gpH2R binding of [
3
H]UR-DE257 in Sf9 
membranes. a) Radioligand (c = 30 nM) association as a function of time. Inset: Linearization ln[Beq/(Beq-B)] 
versus time of the association kinetic for the determination of kob and kon, slope = kob = 0.025 min
–1
, kon = (kob - 
koff)/[L] = 3.3 x 10
–4
 min
–1
 x nM
–1
. b) Radioligand (c = 30 nM, pre-incubation for 60 min) dissociation as a 
function of time, monophasic exponential fit, t1/2 = 16 min, dissociation performed with 100-fold excess of 
Famotidine. c) Linearization ln(B/B0) versus time of the dissociation kinetic for the determination of koff = 
slope
-1
 = 0.015 min
–1
. (mean values ± SEM, n = 4) Inset: Representative dissociation curve (dpm) for 
linearization. 
 
Figure 5.9 Structures of UR-DE91 and UR-DE111. 
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Figure 5.11 Association and dissociation kinetics of the specific rH2R binding of [
3
H]UR-DE257 in Sf9 
membranes. a) Radioligand (c = 30 nM) association as a function of time. Inset: Linearization ln[Beq/(Beq-B)] 
versus time of the association kinetic for the determination of kob and kon, slope = kob = 0.065 min
–1
, kon = (kob - 
koff)/[L] = 1,5 x 10
–3
 min
–1
 x nM
–1
. b) Radioligand (c = 30 nM, pre-incubation for 60 min) dissociation as a 
function of time, monophasic exponential fit, t1/2 = 5.1 min, dissociation performed with 100-fold excess of 
famotidine. c) Linearization ln(B/B0) versus time of the dissociation kinetic for the determination of koff = slope
–1
 
= 0.019 min
–1
. (mean values ± SEM, n = 2) Inset: Representative dissociation curve (dpm) for linearization. 
  
Figure 5.12 Association and dissociation kinetics of the specific H2R binding of [
3
H]UR-DE257 in HEK293T CRE-
Luc hH2R cells. a) Radioligand (c = 30 nM) association as a function of time. Inset: Linearization ln[Beq/(Beq-B)] 
versus time of the association kinetic for the determination of kob and kon, slope = kob = 0.073 min
–1
, kon = (kob - 
koff)/[L] = 0.0016 min
–1
 x nM
–1
. b) Radioligand (c = 30 nM, pre-incubation for 60 min) dissociation as a function 
of time, monophasic exponential fit, t1/2 = 5.9 min, dissociation performed with 100-fold excess of Famotidine. 
c) Linearization ln(B/B0) versus time of the dissociation kinetic for the determination of koff = slope
–1
 = 
0.025 min
–1
. (mean values ± SEM, n = 4)  
Regardless of the apparent incomplete dissociation (Figure 5.8 B and Figures 5.10-5.12 B) in 
competition binding studies, the radioligand [3H]UR-DE257 was completely displaceable and proved 
to be a very useful tool to determine the binding data of H2R agonists and antagonists as shown for 
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some reference compounds in Figures 5.13-5.16. The Kd value determined from binding kinetics was 
applied for the calculation of Ki values by means of the Cheng-Prusoff equation.
31 The hH2R binding 
affinity of the agonists histamine (Ki = 534 nM), amthamine (Ki = 244 nM), UR-Bit24
32 (Ki = 7.1 nM) 
and UR-AK48033 (Ki = 1.9 nM) and the antagonists famotidine (Ki = 136 nM), ranitidine (Ki = 1730 nM), 
BMY 25368 (Ki = 19 nM) and iodoaminopotentidine (Ki = 0.31 nm) performed on Sf9 insect cell 
membranes expressing the hH2R-GsαS fusion protein were consistent with reported data from 
functional and binding experiments, respectively.26,34 The Ki value of UR-DE257 (28 nM), determined 
by competition binding experiments with the labeled analog [3H]UR-DE257, corresponds very well to 
the Kd value of [
3H]UR-DE257 (31 nM). 
 
Figure 5.13 Displacement of [
3
H]UR-DE257 (c = 30 nM, Kd = 31 nM) by the histamine H2R ligands UR-AK480 ( , 
Ki = 1.9 ± 0.5 nM), UR-DE257 (○, Ki = 28 ± 2 nM), famotidine (●, Ki = 136 ± 17 nM), histamine (▲, Ki = 534 ± 52 
nM), UR-Bit24 (◊, Ki = 7.1 ± 1.2 nM), amthamine (▼, Ki = 244 ± 46 nM) and ranitidine (♦, Ki = 1730 ± 220 nM). 
The assay was performed on Sf9 insect cell membranes expressing the hH2R-GsαS fusion protein. The incubation 
period was 60 min. Data are mean values ± SEM (n = 2-3). 
Table 5.3 H2R binding to the human/guinea-pig and rat receptor subtype of H2R agonists and antagonists. 
Compound 
Ki / nM 
hH2R
[b] 
rH2R
[b] 
gpH2R
[b]
 hH2R
[c]
 
Histamine 534 ± 52 486 ± 106 150 ± 29 99700 ± 21500 
Amthamine 244 ± 46 - - 19900 ± 4940 
UR-AK480 1.9 ± 0.5 1.7 ± 0.5 0.15 ± 0.02 8.2 ± 3 
UR-Bit24 7.1 ± 1.2 54 ± 3 9.5 ± 2 107 ± 32 
Famotidine 136 ± 17 423 ± 33 107 ± 5 147 ± 43 
Ranitidine 1730 ± 220 - - - 
Iodoaminopotentine 0.31 ± 0.04 - - - 
BMY 25368 19 ± 1  - - - 
UR-DE257 28 ± 2 16 ± 1 43 ± 30 - 
[a] Length of the linker expressed as number of atoms connecting the ‘urea eqalent’ and the -amino function 
(structures cf. Scheme 3); [b] h/gp/rH2R binding: Sf9 insect cell membranes expressing the respective xH2R-GsαS 
subtype; [c] hH2R binding: HEK293T CRE-Luc hH2R cells. radioligand: [
3
H]UR-DE257. (30 nM); value represents 
the mean ± SEM of 2-3 independent experiments each performed in triplicate. 
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Figure 5.14 Displacement of the radioligand [
3
H]UR-DE257 (c = 30 nM, Kd = 37 nM) by histamine H2R ligands 
UR-Ak480
33
 ( , Ki = 0.15 ± 0.02 nM), UR-DE257 (○, Ki = 43 ± 30 nM), famotidine (●, Ki = 107 ± 5 nM), histamine 
(▲, Ki = 150 ± 29 nM), UR-Bit24
32
 (◊, Ki = 9.5 ± 2 nM) and dimaprit (■, Ki = 104 ± 20 nM). The assay was 
performed on membranes of Sf9 insect cells expressing the gpH2R-GsαS; incubation period: 60 min, data 
represent mean values ± SEM (n = 2). 
 
 
Figure 5.15 Displacement of the radioligand [
3
H]UR-DE257 (c = 30 nM, Kd = 29 nM) by histamine H2R ligands 
UR-AK480 ( , Ki = 1.7 ± 0.5 nM), UR-DE257 (○, Ki = 16 ± 1 nM), famotidine (●, Ki = 423 ± 33 nM), histamine (▲, 
Ki = 486 ± 106 nM), UR-Bit24 (◊, Ki = 54 ± 3 nM) and dimaprit (■, Ki = 600 nM). The assay was performed on 
membranes of Sf9 insect cells expressing the rH2R-GsαS with an incubation period of 60 min (mean values ± 
SEM, n = 1-2). 
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Figure 5.16 Displacement of the radioligand [
3
H]UR-DE257 (c = 30 nM, Kd = 55 nM) by histamine H2R ligands 
UR-AK480 ( , Ki = 8.2 ± 3 nM), famotidine (●, Ki = 147 ± 43 nM), histamine (▲, Ki = 100 ± 18 µM), UR-Bit24 (◊, Ki 
= 107 ± 32 nM), cimetidine (x, Ki = 428 ± 7 nM) and amthamine (▼, Ki = 20 ± 1 µM). The assay was performed 
on HEK293T CRE-Luc hH2R cells with an incubation period of 60 min (mean values ± SEM, n = 2-3). 
5.2.3 Autoradiography 
In the guinea-pig brain, with [125I]iodoaminopotentidine as radioligand, H2R binding sites were 
described in the cerebral cortex in layers I-III (I: molecular layer; II: external granular layer; III: layer of 
medium-sized pyramidal cells), in the thalamus, and in the hippocampus .10,34,35 To explore, if [3H]UR-
DE257 is also a useful radioligand for autoradiography, cryosections of guinea-pig and rat brain were 
incubated with [3H]UR-DE257. However, there were no significant differences between the 
autoradiographs representing specific and nonspecific binding (cf. Figure 5.17-5.20).  
To identify H2R binding sites in guinea-pig heart, adjacent transverse ventricular or atrium 
cryosections were incubated with [3H]UR-DE257. Unfortunately, as depicted in Figure 5.21 and 5.22 
there was no indication of specific binding.  
A        total B   non-specific C   H3R blocked D   H2R blocked E     H & E 
     
Figure 5.17 Binding of the tritiated H2R antagonist [
3
H]UR-DE257 (c = 30 nM) to adjacent coronal cerebrallar 
sections of rat brain (male Wistar rat, 3-4 month old). A. Total binding. B. Non-specific binding, determined 
with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. C. Binding of 
[
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-DE257 (c = 
30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
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A        total B   non-specific C   H3R blocked D   H2R blocked 
    
Figure 5.18 Binding of the tritiated H2R antagonist [
3
H]UR-DE257 (c = 30 nM) to adjacent coronal frontal lobe 
sections of rat brain (male Wistar rat, 3-4 month old). A. Total binding. B. Non-specific binding, determined 
with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. C. Binding of 
[
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-DE257 (c = 
30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
A        total B   non-specific C   H3R blocked D   H2R blocked E     H & E 
     
Figure 5.19 Binding of the tritiated H2R antagonist [
3
H]UR-DE257  (c = 30 nM) to adjacent coronal cerebral 
sections of guinea-pig brain (female guinea-pig, 2 month old). A. Total binding. B. Non-specific binding, 
determined with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. 
C. Binding of [
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-
DE257 (c = 30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
A        total B   non-specific C   H3R blocked D   H2R blocked E     H & E 
     
Figure 5.20 Binding of the tritiated H2R antagonist [
3
H]UR-DE257  (c = 30 nM) to adjacent coronal olfactory bulb 
sections of guine-pig brain (female guinea-pig, 2 month old). A. Total binding. B. Non-specific binding, 
determined with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. 
C. Binding of [
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-
DE257 (c = 30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
A        total B   non-specific C   H3R blocked D   H2R blocked E     H & E 
     
Figure 5.21 Binding of the tritiated H2R antagonist [
3
H]UR-DE257  (c = 30 nM) to adjacent transverse ventricular 
sections of guinea-pig heart (female guinea-pig, 2 month old). A. Total binding. B. Non-specific binding, 
determined with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. 
C. Binding of [
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-
DE257 (c = 30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
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A        total B   non-specific C   H3R blocked D   H2R blocked E     H & E 
    
 
Figure 5.22 Binding of the tritiated H2R antagonist [
3
H]UR-DE257  (c = 30 nM) to adjacent transverse atrium 
sections of guine-pig heart (female guinea-pig, 2 month old). A. Total binding. B. Non-specific binding, 
determined with famotidine (c = 6 µM) and histamine (c = 6 µM) for blocking all histamine receptor subtypes. 
C. Binding of [
3
H]UR-DE257 (c = 30 nM) with thioperamide (c = 6 µM) for blocking the H3R. D. Binding of [
3
H]UR-
DE257 (c = 30 nM) with famotidine (c = 6 µM) for blocking the H2R. E. H & E stained adjacent section. 
5.3 Summary 
There has been a shortage of high affinity radioligands for the investigation of the histamine H2 
receptor. Therefore, N-[6-(3,4-dioxo-2-{3-[3-(piperidin-1-ylmethyl)phenoxy]-propylamino}cyclobut-1-
enylamino)-hexyl]-(2,3-3H2)propionamide ([
3H]UR-DE257) as a tritium-labeled H2R antagonist 
(Kb: 38 nM, GTPase assay) was synthesized and characterized. Acylation of the amine precursor with 
succinimidyl [2,3-3H2]propionate gave the tritium-labeled radioligand with a high specific activity 
(63 Ci/mmol). This compound binds with high affinity (Kd, from saturation binding: 31 nM, kinetic 
studies: 20 nM) and selectivity for the hH2R over the other HR subtypes. Affinities and selectivities of 
the unlabeled form, UR-DE257, were determined in radioligand binding assays, using membrane 
preparations of Sf9 insect cells, expressing the respective hHxR subtype (Ki values: hH1R: >10000 nM, 
hH2R: 28 nM, hH3R: 3800 nM, hH4R: >10000 nM). The determined Kd value (20 nM) from kinetic 
experiments was in good agreement with the dissociation equilibrium constant (31 nM) from 
saturation analysis. [3H]UR-DE257 proved to be a useful tool to determine the H2R binding affinities 
of unlabeled compounds in competition binding experiments, as confirmed for a set of reference 
ligands. [3H]UR-DE257 is an attractive alternative to [3H]tiotidine,14,15 which showed a high degree of 
unspecific binding. Compared to [125I]iodoaminopotentidine,10 [3H]UR-DE257 has a longer half-life, 
which is of advantage with respect to performing both synthesis and pharmacological studies, and 
the compound is more convenient to handle with respect to safety precautions.  
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5.4 Experimental Section 
5.4.1 General conditions for radiosynthesis 
Chemicals and solvents were purchased from Merck KGaA (Darmstadt, Germany) and Sigma Aldrich 
GmbH (Munich, Germany) and were used without further purification unless otherwise stated. All 
solvents were of analytical grade, and DMSO was distilled prior to use and stored over 4 Å molecular 
sieves. Succinimidyl [2,3-3H]-propionate was purchased from Hartmann Analytic GmbH 
(Braunschweig, Germany) and provided in ethyl acetate (specific activity as = 2.96 TBq/mmol, 
80/mmol; av =185 MBq/mL, 5 mCi/mL). Scintillation cocktail Rotiscint Eco Plus was from Carl Roth 
(Karlsruhe, Germany). Analytical HPLC was performed on a system from Waters (Eschborn, 
Germany), equipped with a pump control module, a 510 HPLC pump, a 486 UV/VIS detector, and a 
Flo-One beta series A-500 radiodetector (Packard, Meriden, USA). The stationary phase was a Synergi 
Hydro-RP (250 x 4.6 mm, 4 µM) column equipped with a Luna C18 (4 x 3.0 mm) column guard 
(Phenomenex, Aschaffenburg, Germany). Linear gradients of CH3CN/TFA 0.05% (v/v) and H2O/TFA 
0.05% (v/v) were used as mobile phases at a flow rate of 0.8 mL/min. Absorbance was detected at 
280 nM, and radioactivity was measured with the radiodetector by liquid scintillation counting (liquid 
scintillator: Rotiscint Eco Plus, flow rate: 3.8 mL/min). 
5.4.2 Synthesis of N-[6-(3,4-Dioxo-2-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl-
amino}-cyclobut-1-enylamino)hexyl]-[2,3-3H2]propionamide ([
3H]UR-DE257):  
Succinimidyl [2,3-3H2]propionate (5.35 µg, 0.0313 µmol, 1 eq, 2.5 mCi) in 500 µL ethyl acetate were 
transferred in a 1.5 mL Eppendorf reaction vessel (screw top) and the solvent was removed in a 
vacuum concentrator (40 °C) over a period of 30 min. Compound 12 (553 µg, 1.25 µmol, 40 eq) in 
DMSO (69 µL) and NEt3 (253 µg, 2.50 µmol, 80 eq) in CH3CN (69 µL) were added. After addition of 
62 µL of CH3CN, the reaction mixture was vigorously blended (vortexer), briefly centrifuged and 
stirred with a magnetic microstirrer for 18 h at room temperature. The reaction was monitored by 
HPLC. Reaction mixture (0.5 µL) was added to 105 µL of unlabeled compound UR-DE92 solution 
(50 µM), the ‘cold’ version of [3H]UR-DE257, to allow for UV detection in addition to radiodetection; 
injection volume: 100 µL). For purification, the reaction mixture was diluted with 1060 µL of a 
mixture of CH3CN/H2O 20:80 (v/v) containing 0.05% TFA and the product was isolated (seven 
injections, 180 µL each) with analytical HPLC. In this instance, radiometric detection was not 
performed. Fractions containing the radioligand were collected at ~20 min (gradient: 0.05% TFA in 
CH3CN/0.05% TFA in H20: 0 min: 20:80 (v/v), 37 min: 30:70 (v/v), 38 min 90:10 (v/v), 48 min 90:10 
(v/v)). The solvent of the combined fractions was evaporated under reduced pressure, the product 
dissolved in 1000 μL ethanol and transferred to an Amersham glass vial.  
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Quantification: A four-point calibration was performed with the unlabeled ligand UR-DE257 (1.0, 2.5, 
5.0 and 7.5 μM, inj. vol.: 100 μL, gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min: 20:80 (v/v), 
15 min: 52.5:47.5 (v/v), 16 min: 90:10 (v/v), 21 min: 90:10 (v/v), tR ~ 14 min, see Figure 5.2). The 
solutions for injection were prepared in CH3CN/0.05% aq. TFA (20/80) less than 5 min prior to 
injection. All standard solutions were prepared from a 100 µM solution of UR-DE257 (in 
CH3CN/0.05% aq. TFA 20:80), which was freshly made from a 10 mM stock solution of UR-DE257 in 
CH3CN. Two aliquots (2.0 µL) of the ethanolic solution of the product were diluted with 100 µL of 
CH3CN/0.05% aq. TFA (20:80), and 100 µL were analyzed by HPLC. Whereas one sample was only 
used for quantification of the product by UV detection, the second sample was additionally 
monitored radiometrically to determine radiochemical purity. The molarity of the ethanolic solution 
of [3H]UR-DE257 was calculated from the mean of the peak areas, and the linear calibration curve 
was obtained from the peak areas of the standards. Yield: 7.01 µg (14.0 nmol, 44.6%). 
Determination of the specific activity: An aliquot (1.5 µL) of the ethanolic solution was diluted with 
448.5 mL of a mixture of CH3CN and H2O (20:80) in duplicate, and 50 µL of the 1:300 dilutions were 
counted three times in Rotiszint eco plus (3 mL) in a LS 6500 liquid scintillation counter (Beckmann 
Coulter, München, Germany). The total activity in 1000 µL stock solution amounted to 32.5 MBq 
(0.877 mCi), resulting in a calculated specific activity of 2.33 TBq/mmol (63.0 Ci/mmol). The activity 
of the stock solution was adjusted to 9.25 MBq/mL, (0.25 mCi/mL, c = 3.97 µM) by adding EtOH. 
HPLC analysis showed a radiochemical purity of >99%. The identity of the radioligand was confirmed 
by HPLC analysis of labeled and unlabeled UR-DE257 under the same conditions, resulting in identical 
retention times. [3H]UR-DE257 was stored at –20 °C. 
Control of chemical stability of [3H]UR-DE257 by HPLC: 2 µL of the adjusted stock solution of [3H]UR-
DE257 (activity concentration: 9.25 MBq/mL) in ethanol was diluted with 100 µL of CH3CN/0.1% aq. 
TFA (20:80) to a total volume of 102 µL. 100 µL of this solution were injected into the HPLC system 
and analyzed by means of radiometric- and UV-detection. (gradient: 0.05% TFA in CH3CN/0.05% TFA 
in H20: 0 min: 20:80 (v/v), 37 min: 30:70 (v/v), 38 min 90:10 (v/v), 48 min 90:10 (v/v)). 
5.4.3 Pharmacological methods 
5.4.3.1 Histamine radioligand binding assays on membrane preparations of Sf9 insect cells 
5.4.3.1.1 Competition binding experiments 
Competition binding experiments were performed on membrane preparations of Sf9 insect cells 
expressing the hH1R + RGS4, hH2R-GsαS, gpH2R-GsαS, rH2R-GsαS, hH3R + Gαi2 + β1γ2 or the hH4R + 
Gαi2 + β1γ2 as described in Section 3.5.1.3.  
158 Chapter 5 
5.4.3.1.2 Saturation binding experiments 
Saturation binding experiments were conducted with radioligand concentrations (final 
concentration) between 1 nM and 200 nM. There, unspecific binding was determined with 10 μM 
famotidine. The membrane-ligand mixtures were incubated for 60 min at RT und shaking at 300 rpm. 
Separation of bound and unbound radioligand was performed by filtration as described before. 
5.4.3.1.3 Kinetic experiments 
In kinetic experiments the membranes were prepared as described before. Association and 
dissociation kinetic experiments were started by addition of [3H]UR-DE257 (final concentration = 
30 nM). During incubation the plate was shaken (300 rpm) at 22 °C. The wells for total binding in 
association experiments additionally contained 10 μL H2O (millipore), the wells for unspecific binding 
10 μL of a 100 µM solution of famotidine (final concentration = 10 µM) in H2O (millipore). The 
respective radioligand or radioligand plus famotidine was added at different time points (0‐180 min) 
to the membrane containing wells. After the last addition of radioligand bound radioligand was 
separated from free radioligand. Thus the last time point (last addition of radioligand) represented 
the shortest incubation time (0 min), whereas the first time point represents the longest incubation 
time (180 min). In dissociation experiments all wells were preincubated with [3H]UR-DE257 (without 
10 µM famotidine for total binding, with 10 µM famotidine for unspecific binding, final 
concentration: 30 nM in each well) for 60 min, before starting dissociation by addition of famotidine 
(final concentration: 10 μm/well). Preincubation was started for each data set at different time 
points. Dissociation kinetics was measured over 120 min. After the last addition of radioligand bound 
radioligand was separated from free radioligand by filtration. Thus the last time point (last addition 
of famotidine) represented the shortest dissociation time, whereas the first time point represents 
the longest dissociation time.  
5.4.3.2 Radioligand binding assay at HEK293T CRE-Luc hH2R cells 
Leibovitz without phenol red (L15) from Life Technologies GmbH (Darmstadt, Germany), PP-96-well 
plates flat bottom from Greiner (Frickenhausen, Germany), GF/C filters from Skatron Instruments AS 
(Lier, Norway), fetal bovine serum (FBS) and G418 from Biochrom AG (Berlin, Germany), hygromycin 
B from MoBiTec GmbH (Göttingen, Germany) and Rotiszint eco plus from Carl Roth GmbH (Karslruhe, 
Germany). Separation of bound radioactivity from free radioactive tracer was done with a Brandel 
Harvester (CH-620), Robotic Cell Harvester, Gaithersburg, MD, US) and radioactivity could be 
measured by scintillation counting on a microplate counter (Microbeta 2450) from Perkin Elmer 
(Waltham, MA, US). HEK293T CRE-Luc hH2R cells were essentially cultured and used as described
40 
with minor modifications: Cells were cultured in DMEM with 10% FBS and selection antibiotics 
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(600 μg/mL of G418 and 250 μg/mL of hygromycin B) in a water saturated atmosphere containing 5% 
CO2 at 37 °C. Cells were seeded into 175 cm
2 culture flasks (Sarstedt, Nümbrecht, Germany) and 
grown to approximately 90% confluence. The radioligand assay was performed as described 
previously,40 with some modifications: On the day of the investigation the cells were detached with 
trypsin, suspended in L15 and centrifuged for 10 min at 300 g. The medium was discarded and the 
cells were resuspended in L15. After counting the cells, the cell density was adjusted to 
approximately 1-1.5 x 106 cells/mL. PP-96-well plates were either provided with 10 µL Leibovitz 
medium for the determination of total binding or 10 μL of famotidine (10 μM, final concentration) to 
determine the unspecific binding. 80 μL of the cell suspension were added per well. The samples 
were completed by adding 10 μL of radioligand. Samples were incubated for 60 minutes at 300 rpm. 
Competition binding experiments were performed in analogy to described methods with minor 
modifications. In brief: 160 μL of the suspended cells (2‐4 x106 cells/mL in L15) were used per well 
(96 well plate). The cells were incubated in the presence of 30 nM [3H]UR-DE257 (final concentration 
in L-15, Kd: 55 nM) with the ligand of interest at various concentrations (0.1 nM - 1 mM, final 
concentration) to measure total binding. Unspecific binding was the value determined at the highest 
concentration of the ligand of interest (1 μM-1 mM, final concentration) in the presence of 30 nM 
[3H]UR-DE257 (final concentration). This concentration was sufficient to prevent specific binding of 
the radioactive tracer. The well plate was shaken (RT, light protection) for 60 min at 300 rpm. 
Separation of bound and unbound radioligand was performed by filtration as described before. 
Saturation binding and kinetic experiments were performed in the same manner as mentioned for 
membrane preparations of Sf9 insect cells. 
5.4.4 Autoradiography 
The rat brain (female Wistar rat, 3-4 month, 250 g), the guinea-pig brain and the guinea-pig heart 
were taken from the animals (24-48 h prior to experiment), immediately frozen in Tissue-Tek with 
the help of a mixture of dry ice and 2-propanol, and stored at -18 °C. Cryosections (10 μm) were 
obtained at -18 °C (for brain tissues) or -16 °C (for the guinea-pig heart) with a 2800 Frigocut E 
freezing microtome (Reichert-Jung/Leica, Germany). Two adjacent sections were mounted on a 
microscopic slide (Superfrost Plus, 75 × 25 × 1 mm), put 1 min into a chamber of 100% humidity and 
then carefully covered with binding buffer (800 µL) or fixed for 20 s in an alcoholic formaldehyde 
fixative (40 mL of 37% formaldehyde, 360 mL of 95% ethanol and 0.2 g calcium acetate.41 The binding 
buffer was removed (after a period of less than 60 min under cooling) by putting the slides uprightly 
on a paper towel (~1 min). For total binding the sections were covered with binding buffer (about 600 
to 800 μL for one slide) containing [3H]UR-DE257 (30 nM). For non-specific binding the sections were 
covered with binding buffer containing [3H]UR-DE257 (30 nM) and either famotidine (6 µM) for 
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blocking the H2R, thioperamide (6 µM) for blocking the H3R or famotidine (6 µM) and histamine 
(6 µM) for blocking all histamine receptor subtypes. The sections were incubated at room 
temperature (22-25 °C) for a period of 30 min. After incubation the binding buffer was removed, the 
slides were immerged three times into binding buffer split to 3 vessels (4 °C, 10 s) and finally rinsed 
with distilled water (4 °C, 10 s). The slides were put uprightly on a paper towel for 1 min and then 
dried in horizontal position in a desiccator over P4O10 under reduced pressure. The slides were set in 
close contact with a tritium sensitive screen (PerkinElmer, 192 × 125 mm, Überlingen, Germany) 
using an X-ray film cassette and stored in a dark room for 14-17 d. The autoradiographic image was 
generated from the tritium screen using a phosphor imager (Cyclone Storage Phosphor System, 
Packard, Meriden, USA). The fixed sections were stained with haematoxylin and eosin: H & E: rinsing 
(H2Odemin), Mayer’s S11 haemalum solution (Merck) 1:3 diluted in water (11 min), rinsing (tap water), 
1% aq. acetic acid (3 × immersion), running tap water (10 min), rinsing (H2Odemin), eosin standard 
solution (2 min), running H2Odemin (5 min); 96% aq. EtOH (2 × 3 min), 100% EtOH (2 × 3 min), 100% 
xylene (3 min). Entellan (Merck) was used for covering. 
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6.1 Introduction 
JNJ7777120 (1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methyl-pipera-
zine) has been described as the first potent and selective antagonist 
at the H4 receptor in 2003.
1,2 It resulted from in-house high-
throughput screening (HTS) followed by optimization at Johnson & 
Johnson (J&J). JNJ7777120 binds to the human H4 receptor with 
high affinity (Ki = 4.1 nM), it is also considered to be equipotent at 
the mouse and rat receptors and has a high selectivity over the 
other three histamine receptor subtypes. The antagonist properties of this compound have been 
described against histamine in a forskolin-stimulated cAMP-mediated reporter gene assay with a 
resulting pA2 of 8.1 for the human H4R and comparable values for other H4R orthologs.
3,4 Regardless 
of unfavourable pharmacokinetic properties (short half-life), JNJ7777120 has been widely used to 
investigate the physiological role of the H4R in various animal modelsR.
5-18 Meanwhile, apart from 
off-target effects at higher concentrations, the ‘standard’ H4R antagonist JNJ7777120 was reported 
to produce H4R-mediated paradoxical effects, for example regarding arrestin recruitment and 
agonist-like properties, depending on the assay and the H4R species ortholog considered.
19-22 A 
detailed overview over the behavior of JNJ7777120 in different in vitro test systems is given by 
Seifert et al.19 In principle, differential activation or inhibition of signaling pathways including G-
protein- and -arrestin-mediated responses is compatible with the concept of functional selectivity 
or biased signaling,19 assuming unique ligand-specific receptor conformations with distinct signal 
transduction capabilities. In addition, discrepancies between pharmacological data may result from 
the substantially different constitutive activities of H4R species orthologs.
20 
In general, the investigation of the (patho)physiological role of the H4R and its validation as a drug 
target in translational animal models are compromised by distinct species-dependent discrepancies 
regarding potencies and receptor subtype selectivities of the pharmacological tools. Moreover, the 
pharmacological evaluation of murine cell systems is hampered by the lack of selective and suitable 
pharmacological tools like fluorescent- or radioligands. Radioligand binding studies at the H4R, using 
[3H]histamine,20-24 [3H]JNJ7777120,3,25 the iodinated H3R ligand [
125I]iodophenpropit25,26 and the 
recently developed high affinity hH3/4R radioligand [
3H]UR‐PI29427 have were published. 
[3H]Thioperamide28 was reported as a radioligand for the H3R, but radioligand binding studies for the 
H4R are not available. Yet, none of these radiotracers is universally applicable. [
3H]Histamine binding 
data were reported for the hH4R,
20-24 the cH4R,
4 the mH4R
21,22 and the rH4R.
21 However, the analysis of 
radioligand binding studies with [3H]histamine at the mH4R and the rH4R turned out to be difficult if 
not impossible, at least in the Sf9 cell system, due to too low specific binding of [3H]histamine at 
 
Figure 6.1 JNJ7777120. 
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these H4R species orthologs.
20,29 Further drawbacks of [3H]histamine are low specific activity 
(10-25 Ci/mmol) of the commercially available radioligand and lack of HR subtype selectivity. 
[125I]iodophenpropit, a radioligand with high affinity to the H3R (pKi = 8.2) showed also rather high 
affinity to the hH4R (pKi = 7.8) and was considered as a potential hH4R radioligand, but its use was 
limited due to a high level of nonspecific binding and a Bmax value varying from the expected one, 
determined with [3H]histamine.25 [3H]UR-PI294 was applied in binding studies on the hH4R and the 
mH4R, using Sf9 cell membranes and HEK293T cells.
27 However, the pharmacological evaluation of 
mH4R binding is hampered by lower affinity of UR-PI294 to the mH4R.
30 Furthermore, as [3H]UR-PI294 
and [3H]histamine are agonist at the hH4R, binding can influenced by G-protein coupling,
31,32 
preference for a receptor subpopulation33 (the high affinity state) or internalization. As an 
antagonist, [3H]JNJ7777120 should be superior to labeled agonists. Unfortunately, [3H]JNJ7777120 is 
not commercially available and a consumer commissioned synthesis is overpriced. Hence, we 
decided to synthesize [3H]JNJ7777120 in house and to evaluate the suitability of this radioligand at 
the hH4R and the mH4R using Sf9 cell membranes and HEK293T cells expressing the receptor of 
interest. 
6.2 Chemistry 
6.2.1 Optimization of the synthesis 
The key step in radiosynthesis is the introduction of a radiolabeled group. Due to the practicability 
and easier handling with respect to safety precautions this should be done in the last step of the 
synthesis. In search for a suitable commercially available precursor we found [3H]MeI as an 
appropriate methylation reagent.34 In order to be able to use [3H]MeI in the last step, we adapted the 
procedure of the published synthesis1 of JNJ7777120 accordingly (Scheme 6.1). Preparation of 
JNJ7777120 (6.4a) started from piperazine, which was converted to the mono-Boc-protected 
derivative (6.1) in the first step. Reaction of 6.2 with 5-chloroindol-2-carboxylic acid under amide 
coupling conditions using EDC/HOBT followed by acidic Boc-deprotection yielded the des-methylated 
JNJ7777120 derivative 6.3 as di-TFA salt. In the next step methylation reaction was explored under 
HPLC control (cf. Table 6.1).  
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Scheme 6.1 Synthesis of JNJ7777120 (6.4a), [
3
H]JNJ7777120 (6.4b) and 6.5. Reagents and conditions: (a) Boc2O, 
CH2Cl2, 0 °C, 2 h, 71%; (b) 5-chloroindole-2-carboxylic acid, EDC x HCl, HOBt x H2O, DIPEA, THF, 26 h, rt, 52%; 
(c) for 6.4a: MeI, K2CO3, acetone/toluene (20:1), 24 h, rt, 56%; for 6.4b: [
3
H]MeI, K2CO3, acetone/toluene (20:1), 
24 h, rt, 9.6%; for 6.5: MeI, K2CO3, acetone, 24 h, rt, 98%. 
The ratio of building block 6.3, K2CO3 and MeI was optimized to prevent the formation of the 
quaternary ammonium compound 6.5. A ratio of 1 eq MeI, 10 eq of 6.3 and 30 eq of K2CO3 in a 
mixture of MeCN and toluene gave exclusively 6.4a. Toluene was added because [3H]MeI was 
provided as a solution in toluene. To identify the tertiary amine and the quaternary ammonium 
compound in HPLC analysis, for comparison, the di-methylated product 6.5 was synthesized from 6.3 
with a large excess of MeI in acetone. 
Table 6.1 Test reactions
[a]
 for the methylation of compound 6.3. 
eq MeI eq 6.3 eq K2CO3 
Product ratio 
(6.3 : 6.4a : 6.5) 
N 
1 1 3 18 : 69 : 13 1 
1 5 15 80 : 18 : 2 1 
1 10 30 90 : 10 : 0 3 
[a] Reagents and conditions: 190 µL acetone, 10 µL toluene, rt, 24 h. 
6.2.2 Radiosynthesis of [3H]JNJ7777120 
The [3H]methylated indol 6.4b ([3H]JNJ7777120, [3H](5-chloro-1H-indol-2-yl)(4-methylpiperazin-1-yl)-
methanone), the ‘hot’ form of 6.4a, was prepared by methylation of an excess of amine precursor 
6.3 in the presence of K2CO3 with commercially available [
3H]MeI in a mixture of MeCN and toluene 
(Scheme 6.1). Purification by HPLC afforded the radioligand 6.4b in a radiochemical purity of >97% 
(Figure 6.2 A) with a specific activity (as) of 78.3 Ci/mmol. 
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Figure 6.2 Identity and purity control of [
3
H]JNJ7777120 (6.4b). A: Purity control (radiochromatogram) after 
isolation by HPLC. B: Reaction control after 22 h. C: UV (  = 220 nm) chromatogram of the reaction mixture 
spiked with 6.4a, c: 100 μM, column: Agilent Scalar C18 (4.6 x 250 mm, 5 µm), gradient: 0.05% TFA in 
CH3CN/0.05% TFA in H2O: 0 min 25:75 (v/v), 30 min 25:75 (v/v), 31 min 95:5 (v/v), 40 min 95:5 (v/v). The minor 
difference in retention times (tR) of both chromatograms results from the setup of the UV and the radioactivity 
detector in series. 
The identity of the radioligand was confirmed by comparing the HPLC retention times (tR) of labeled 
(6.4b) and unlabeled JNJ7777120 (6.4a, cf. Figure 6.2). To exclude that di-methylation of 6.3 had 
occurred during the radiosynthesis, HPLC analysis was performed. Labeled JNJ7777120 (6.4b), 
unlabeled JNJ7777120 (6.4a) and the di-methylated analog (6.5) were compared on a YMC Triart C18 
column, which is stable under basic conditions. Under these conditions the quaternary amine 6.5 is 
permanently charged and its retention time is very different from that of JNJ7777120 (cf. Figure 6.3). 
Lastly, chemical stability in EtOH/H2O 1:1 (v/v) at -20 °C was proven over a period of at least 12 
months (cf. Figure 6.4). 
 
Figure 6.3 Identity control of [
3
H]JNJ7777120 (6.4b). Red line: Radiochromatogram of 6.4b; black dashed line: 
UV (  = 220 nm) chromatogram of the 6.4a (c = 100 µM) and 6.5 (c = 100 µM), column: YMC Triart C18 (150 x 2 
mm, 5 µm). The minor difference in retention times (tR) of both chromatograms results from the setup of the 
UV and the radioactivity detector in series. gradient: 0.5% NH3 in CH3CN/0.5% NH3 in H2O: 0 min 50:50 (v/v), 30 
min 80:20 (v/v), 31 min 95:5 (v/v), 40 min 95:5 (v/v). 
168 Chapter 6 
 
Figure 6.4 Long-term stability of [
3
H]JNJ7777120. Example of a radiochromatogram of 6.4b after storage in 
EtOH/H2O (9:1 (v/v) at -20 °C for a period of 12 months, column: Agilent Scalar C18 (4.6 x 250 mm, 5 µm), 
gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min 25:75 (v/v), 30 min 25:75 (v/v), 31 min 95:5 (v/v), 40 
min 95:5 (v/v). 
6.3 Results and Discussion 
6.3.1 Histamine receptor subtype affinities 
The synthesized compounds 6.3 and 6.4a (JNJ7777120) were investigated at the hH3R and hH4R in 
radioligand binding assays using membrane preparations of Sf9 insect cells expressing the hH3R + 
Gαi2 + Gβ1γ2 or hH4R + Gαi2 + Gβ1γ2, respectively as reported before.
35 Surprisingly, the demethylated 
compound 6.3 showed higher affinity to the hH4R (Ki = 39.6 nM) and higher selectivity for the hH4R 
versus the hH3R (hH3R: Ki = 35700 nM, selectivity H4:H3: 900:1) than JNJ7777120 (6.4a). Even though 
it is not crucial for the further investigation of JNJ7777120 as a radioligand, it is noteworthy that 
methylation of the free piperazine nitrogen is not mandatory for potential H4R ligands. The affinities 
of JNJ7777120 (6.4a) to both receptors (hH3R: Ki = 13100 nM, hH4R: Ki = 39.6 nM) were in good 
agreement with reported data in a Sf9 membrane system.20 
Table 6.2 Binding data of 6.3 and 6.4a at the hH3R and hH4R.
[a]
 
Compound 
hH3R hH4R Selectivity 
H4:H3 Ki / nM n Ki / nM n 
Histamine 20.1 ± 3.1 4 13.1 ± 1.1 4 0.65 : 1 
6.3 35700 ± 5900 2 39.6 ± 1.4 2 900 : 1 
6.4a (JNJ7777120) 13100 ± 3500 2 65.3 ± 12.8 2 200 :1 
[a] Determined on membrane preparations of Sf9 insect cells expressing the hH3R + Gαi2 + Gβ1γ2 or hH4R + Gαi2 + 
Gβ1γ2; radioligands: for hH3R: [
3
H]N -methylhistamine (c =3 nM), for hH4R: [
3
H]Histamine (c =10 nM). n gives the 
number of independent experiments, each performed in triplicate. 
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6.3.2 Pharmacological characterization of [3H]JNJ7777120 (6.4b) on Sf9 cell 
membranes 
6.3.2.1 Saturation binding of [3H]JNJ7777120 at the hH4R 
Binding of [3H]JNJ7777120 (6.4b) was determined on membranes of Sf9 insect cell expressing the 
hH4R. Nonspecific binding was determined in the presence of an excess of histamine (100 µM), 
thioperamide (10 μM) or JNJ7777120 (6.4a, 10µM). Thereby, histamine or thioperamide revealed 
comparable results as competitor.  
 
Figure 6.5 Saturation binding of 6.4b to the hH4R expressed in Sf9 membranes. A. Competitor: Histamine (c = 
100 µM); specific binding: ●; nonspecific binding: □; Kd(sat) = 29.5 ± 4.0 nM; inset: Scatchard plot for the binding 
of 6.4b, Kd = –1/slope = 25.8 nM). B. Competitor: thioperamide (c = 100 µM); specific binding: ●; nonspecific 
binding: □; Kd(sat) = 25.1 ± 4.6 nM; inset: Scatchard plot for the binding of 6.4b, Kd = –1/slope = 22.6 nM). 
C. Competitor: JNJ7777120 (6.4a, c = 10 µM); specific binding: ○; nonspecific binding: Not shown, amounted to 
~50% (cf. appendix); Kd(sat)low = 8.7 ± 3.8 nM; Kd(sat)high = 36.8 ± 5.8 nM. Best fitted by nonlinear regression for 
specific binding and linear regression for nonspecific binding; mean values ± SEM, two independent 
experiments, each performed in triplicate. 
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In both cases, [3H]JNJ7777120 (6.4b) specifically bound to the hH4R (Figure 6.7 A+B) in a saturable 
manner with a Kd value of 29.5 nM for histamine and 25.1 nM for thioperamide, respectively, which 
were in good agreement with the potency determined in the steady-state GTPase assay (EC50 = 31.6 
nM)20 and the affinity determined with [3H]histamine (Ki = 65 nM). Within the investigated 
concentration range, nonspecific binding amounted to approximately 30-40% of total binding and 
the calculated Bmax values were 0.94 pmol per mg membrane for histamine and 0.90 pmol per mg 
membrane for thioperamide. The Scatchard plots of both experiments were linear, according to the 
binding of [3H]JNJ7777120 to a single binding site, following the law of mass action (Figure 6.7 A+B: 
Insets). 
Table 6.3 Saturation binding of [
3
H]JNJ7777120 (6.4b) at the hH4R in Sf9 cells membranes compared to 
[
3
H]histamine as a radioligand. 
Radioligand 
Nonspecific binding 
determined by co-
incubation with: 
Kd / nM
 
Kd (scatchard) / 
nM
 
Bmax / pmol x mg 
membrane
-1 
Nreceptor / 
well 
6.4b
[a]
 Histamine
[b]
 29.5 ± 4.0 25.8 0.94 15.3 x 10
9
 
6.4b
[a]
 Thioperamide
[b]
 25.1 ± 4.6 22.6 0.90 14.6 x 10
9
 
6.4b
[a]
 JNJ7777120
[c]
 
8.7 ± 3.8 n.d. 0.32
[d]
 5.2 x 10
9[d]
 
36.8 ± 5.8 n.d. 0.60
[d]
 9.7 x 10
9[d]
 
[
3
H]Histamine
[a]
 Histamine
[c]
 9.5 ± 1.2 n.d. 1.06 13.0 x 10
9
 
[a] Concentration range: 0.5-100 nM; [b] final concentration : 100 µM; [c] final concentration competitor: 
10 µM. [d] ∑ Bmax = 0.92 pmol/mg membrane; ∑ Nreceptor/well = 14.9 x 10
10
. 
By contrast, when JNJ7777120 (6.4a) was used as a competitor, 6.4b seemed to bind in a biphasic 
manner (Figure 6.7 C), resulting in a low Kd value of 8.7 nM with a Bmax of 0.32 pmol per mg 
membrane and a high Kd value of 36.8 nM with a Bmax of 1.52 pmol per mg membrane. This might be 
interpreted as a hint to conformational states with different accessibility for the antagonist 
JNJ7777120 compared to the endogenous agonist histamine or the inverse agonist thioperamide. 
The sum (0.92 pmol per mg membrane) of the Bmax values for the two putative binding sites 
determined in the presence of unlabeled JNJ7777120 (6.4a) was in good agreement with the Bmax 
values in the presence of histamine or thioperamide. However, displacement of the radioligand by its 
unlabeled version from a JNJ7777120-specific site different from the H4R cannot be ruled out.  
6.3.2.2 Kinetics at the hH4R 
The results of kinetic studies with [3H]JNJ7777120 (c = 20 nM) at the hH4R in Sf9 cell membranes at 
20 °C are presented in Figure 6.6. Association was almost complete after 20 minutes. Linearization of 
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the association curves revealed a straight line with a kob value of 0.062 min
-1. Dissociation, initiated 
by JNJ7777120 (6.4a) was almost complete after 10 min indicating that [3H]JNJ7777120 binds 
reversibly to the receptor (t1/2 = 4.8 min). The resulting dissociation rate constant (koff) was 0.171 
min-1. The determination of a Kd value from the ratio of the koff and kon values failed because the kon 
value was not calculable from kon = (kob - koff)/[L], indicating [
3H]JNJ7777120 did not follow the law of 
mass action as also assumed by the varying results from saturation binding. 
 
 
Figure 6.6 Association and dissociation kinetics of the specific H4R binding of 6.4b in Sf9 membranes. A: 
Radioligand (c = 20 nM) association as a function of time; inset: Linearization ln[Beq/(Beq-B)] versus time of the 
association kinetics for the determination of kob, slope = kob = 0.062 min
–1
. B: Radioligand (c = 20 nM, pre-
incubation for 60 min) dissociation as a function of time, monophasic exponential fit, t1/2 = 4.8 min, 
dissociation performed with 100 µM of JNJ7777120 (6.4a); inset: Linearization ln(B/B0) versus time of the 
dissociation kinetic for the determination of koff = slope
-1
 = 0.171 min
–1
. 
6.3.2.3 Competition binding at the hH4R 
Regardless of the inconsistent saturation binding and kinetic experiments, competition binding 
studies showed that [3H]JNJ7777120 (c = 20 nM) was completely displaceable and proved to be 
useful as a radioligand in competition binding studies with H4R agonists and antagonists as shown in 
Figure 6.7. Ki values were calculated by means of the Cheng-Prusoff equation.
36 Therein, the Kd value 
was set to 20 nM. Due to the varying Kd values in saturation binding experiments (cf. Table 6.3) a 
more precise value was not available. The hH4R binding affinity of histamine (Ki = 2.4 ± 0.4 nM), 
5-methylhistamine (Ki = 49.1 ± 8.1 nM), VUF 8430 (Ki = 39.8 ± 15.7 nM), 3.16 (Ki = 4.2 ± 1.2 nM) and 
UR-PI376 (Ki = 58.4 ± 22.2 nM) are consistent with Ki values from binding experiments with 
[3H]histamine and reported data (cf. Table 6.4). 
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Figure 6.7 Displacement of the radioligand 6.4b (c = 20 nM) by histamine H4R ligands histamine (□, Ki = 2.4 ± 
0.4 nM), 5-methylhistamine (20a, ▼, Ki = 49.1 ± 8.1 nM), VUF 8430 (○, Ki = 39.8 ± 15.7 nM), 3.16 (●, Ki = 4.2 ± 
1.2 nM), UR-PI376 (◊, Ki = 58.4 ± 22.2 nM) and JNJ7777120 (6.4a, ■, Ki = 39.1 ± 8.2 nM). Assaya were performed 
on Sf9 insect cell membranes expressing the hH4R + G i2 + 1 2 with an incubation period of 60 min (mean 
values ± SEM, n = 3). 
The Ki value of JNJ7777120 (6.4a, Ki = 39.1 ± 8.2 nM), determined by competition binding 
experiments with the labeled analog 6.4b, were in the same range as the Kd value of compound 6.4b 
(~20 nM, cf. Table 6.4). 
Table 6.4 Displacement of the radioligands [
3
H]JNJ7777120 (6.4b) and [
3
H]histamine by H4R standard ligands. 
Compound 
[
3
H]Histamine
[a]
 [
3
H]JNJ7777120
[b] 
Reference data
 
Ki / nM n Ki / nM n Ki / nM n 
Histamine 13.1 ± 1.1 4 2.4 ± 0.4 3 12.7 ± 1.5
[c]
 3 
5-Me-histamine 28.5 ± 4.4 3 49.1 ± 8.1 3 50.1 ± 10.3
[d]
 - 
VUF8430 17.7 ± 1.4 4 39.8 ± 15.7 3 31.6
[e]
 - 
UR-PI376 n.d. 58.4 ± 22.2 3 57.5 ± 11.8
[f]
 3 
JNJ7777120 65.3 ± 12.8 3 39.1 ± 8.2 3 16
[d]
 - 
3.16 11.2 ± 1.8 3 4.2 ± 1.2 3 0.21
[g]
 - 
[a] Radioligand: [
3
H]Histamine (c = 10 nM, Kd = 15.9 nM); [b] radioligand: 6.4b (c = 20 nM, Kd = 8.7 nM); [c] 
Geyer et al. 2014;
35
 [d] Lim et al. 2005;
25
 [e] Igel et al. 2010;
37
 [f] Igel et al. 2009;
38
 [f] Savall et al. 2010.
39
 
Assays were performed on Sf9 insect cell membranes expressing the hH4R with an incubation period of 60 min 
(mean values ± SEM). n gives the number of independent experiments, each performed in triplicate. 
6.3.2.4 Membranes of Sf9 cells expressing the mH4R 
As high affinity of JNJ7777120 to the mH4R was reported,
3 we performed binding experiments on 
membranes of Sf9 insect cells expressing the mH4R. Nonspecific binding was detected with ‘cold’ 
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JNJ7777120 at a concentration of 100 µM. As presented in Figure 6.8, no specific binding was 
detectable up to a concentration of 150 nM of [3H]JNJ7777120. Possible reasons are low affinity of 
JNJ7777120 to the mH4R in the Sf9 membrane system, high nonspecific binding to membranes, or 
the presence of a receptor conformation, which is not accessible for JNJ7777120. A similar 
phenomenon was observed for binding experiments with [3H]histamine at the mH4R using Sf9 
membranes, suggesting that it is exceedingly difficult to perform meaningful radioligand binding 
studies in this system.20 Competition binding experiments were performed in order to elucidate if 
[3H]JNJ7777120 is displaceable from the mH4R, although specific binding could not be determined. 
The concentration of [3H]JNJ7777120 was set to 20 nM, but neither agonists, nor antagonists 
displaced [3H]JNJ7777120 from mH4R expressing membranes (data not shown). 
 
Figure 6.8 Saturation binding of 6.4b to the mH4R expressed in Sf9 membranes. Competitor: JNJ7777120 (c = 
100 µM); total binding: ∆; specific binding: ○; nonspecific binding: □. 
6.3.3 Saturation binding at HEK293-SF-H4R-His6 cells 
Saturation binding experiments were performed on HEK cells stably expressing the hH4R (HEK293-SF-
hH4R-His6 cells) to explore the applicability of [
3H]JNJ7777120 in mammalian systems. In these 
studies binding was not saturable up to a concentration of 150 nM and the amount of nonspecific 
binding depended on the ligand used as a competitor (cf. Figure 6.9 A+B). In the presence of the 
‘cold’ analog 6.4a (c = 10 µM), nonspecific binding was approximately 50%, in the presence histamine 
(c = 100µM) nonspecific and total binding were in the same range. This suggests that [3H]JNJ7777120 
bound in a way or at a site, making the displacement by histamine impossible at the chosen 
concentration. For further exploration, control experiments were performed on parental HEK293-
CRE-Luc cells, not expressing the hH4R. As displayed in Figure 6.9 (C+D), the results were the same. 
Pseudospecific binding was found, when unlabeled JNJ7777120 was used as a competitor. This 
demonstrates that there is no specific binding of [3H]JNJ7777120 to the hH4R on HEK cells stably 
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expressing the hH4R. In conclusion, [
3H]JNJ7777120 was inappropriate for the pharmacological 
characterization of HEK293-SF-H4R-His6 cells. 
 
Figure 6.9 Saturation binding of 6.4b to the hH4R expressed in HEK cells. A: Cells: HEK293-SF-hH4R-His6; 
competitor: 6.4a (c = 10 µM); total binding: ∆; specific binding: ○; nonspecific binding: □. B: Cells: HEK293-SF-
hH4R-His6; competitor: Histamine (c = 100 µM); total binding: ∆; specific binding: ○; nonspecific binding: □. 
C: Cells: HEK293-CRE-Luc; competitor: 6.4a (c = 10 µM); total binding: ∆; specific binding: ○; nonspecific 
binding: □. D: Cells: HEK293-CRE-Luc; histamine (c = 100 µM); total binding: ∆; specific binding: ○; nonspecific 
binding: □. 
6.4 Summary and Conclusion 
The tritium-labeled version of the widely use potent H4R ligand JNJ7777120 was synthesized and 
pharmacologically characterized. The radioligand proved to be suitable for the investigation of the 
hH4R in Sf9 insect cell membranes. However, saturation binding revealed discrepancies, when 
different competitors were used. With histamine and the inverse agonist thioperamide as 
competitors, [3H]JNJ7777120 bound monophasic. In case that ‘cold’ JNJ7777120 was used, a biphasic 
curve with a low and a high Kd value could be fitted, suggesting the binding to different H4R 
subpopulations (conformations). The association of [3H]JNJ7777120 at the hH4R in Sf9 cell 
membranes was almost complete after 20 min, whereas dissociation after almost 10 min. 
Linearization of both curve indicated, that [3H]JNJ7777120 did not follow the law of mass action. 
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Above all, competition binding experiments were in good accordance to reported data. Even high 
affinity to the mH4R is reported,
3 saturation and competition binding did not work with Sf9 cell 
membranes expressing the mH4R. Similarly, the mH4R/Sf9 cell system also failed when [
3H]histamine 
was used as a radioligand, suggesting that Sf9 cells membranes were not appropriate for mH4R 
binding studies. Binding of [3H]JNJ7777120 at HEK-hH4R cells (HEK293-SF-hH4R-His6 cells) was not 
saturable and revealed ‘pseudospecific’ in binding experiments, just when the ‘cold’ analog 
JNJ7777120 was used as a competitor. Control experiments with HEK cells (HEK293-CRE-Luc) not 
expressing the hH4R proved hH4R-independent binding. 
In summary, although JNJ7777120 has been used for the study of the H4R in animal models, the 
investigation of the tritiated version, [3H]JNJ7777120, revealed that this compound is far from being 
an ideal standard ligand or an optimal pharmacological tool. Due to very high non-specific binding an 
expected advantage of [3H]JNJ7777120 as a H4R selective antagonist compared to [
3H]histamine, a 
non-selective HxR radiolabeled agonist could not be confirmed. On the whole, a ‘perfect’ radioligand 
for the H4R is not available so far. This holds, in particular, for the analysis of the murine H4R, due to 
substantially reduced or lack of mH4R affinity of several reference compounds compared to the hH4R, 
depending on the test system, for example, membrane preparations or mammalian cells. Thus, there 
is still a need for molecular tools such as high affinity fluorescent and radiolabeled H4R ligands for the 
study of various H4R species orthologs. 
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6.5 Experimental Section 
6.5.1 Chemistry 
6.5.1.1 General 
See section 3.5.1.1 
6.5.1.2 Preparation of the indol derivatives 6.4a and 6.5 
tert-Butyl piperazine-1-carboxylate (6.1)40 
A solution of 10.91 g (0.05 mol, 1eq) of di-tert-butyl dicarbonate in anhydrous CH2Cl2 (20 mL) was 
added dropwise within 30 min to a stirred solution of 8.61 g (0.10 mol, 2eq) of piperazine in 
anhydrous CH2Cl2 (100 mL) and stirred for 2 h. The precipitate was filtered off and washed with 
CH2Cl2 (3 × 50 mL). The solvent was removed under reduced pressure, the colorless oily residue was 
dissolved in 100 mL of water and stirred for 1 h. The insoluble bis(tert-butoxycarbonyl) derivative was 
removed by filtration and washed with water. The filtrate was saturated with K2CO3, extracted with 
diethyl ether (3 × 100 mL) and dried over anhydrous Na2SO4. Concentration in vacuo afforded the 
product as a white crystalline solid (6.40 g, 71%), mp 47 °C (lit.41 45-46 °C). Rf = 0.7 (CH2Cl2/MeOH 
25:1). 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.39 (s, 9H), 3.15-3.25 (m, 4H), 2.56-2.63 (m, 4H). 
13C-NMR (75 MHz, DMSO-d6): δ = 28.07 (3C), 45.44, 78.49, 153.95. MS (GC-MS, CI): m/z 187.2 [M+H
+]. 
C9H18N2O2 (186.25). 
 
tert-Butyl 4-(5-chloro-1H-indole-2-carbonyl)piperazine-1-carboxylate (6.2)42 
EDC × HCl (0.49 g, 2.56 mmol, 1 eq), HOBt × H2O (0.39 g, 2.56 mmol, 1 eq), 5-chloro-1H-indole-2-
carboxylic acid (0.50 g, 2.56 mmol, 1 eq) and DIPEA (0.48 g, 3.74 mmol, 1.46 eq) were dissolved in 
anhydrous THF (20 mL), cooled to 0 °C and stirred for 2 h. Subsequently, 6.1 (0.52 g, 2.77 mmol, 
1.08 eq) in anhydrous THF (5 mL) was added within 5 min. The reaction mixture was stirred for 26 h 
at room temperature. The solvent was evaporated and the residue was dissolved in CH2Cl2 (50 mL). 
The solution was washed with saturated NaHCO3(aq.) and brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash‐chromatography (eluent CH2Cl2 (A), 
MeOH (B); gradient: 0 to 30 min: A/B 100/0 - 90/10 v/v, SF15-12 g) and afforded a white powder 
(0.48 g, 52%). Rf = 0.15 (CH2Cl2/MeOH 10:1). 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 1.42 (s, 9H), 3.39-
3.50 (m, 4H), 3.73 (br, 4H), 6.79 (d, J = 1.6, 1H), 7.17 (dd, J = 8.7, 2.0, 1H), 7.43 (d, J = 8.7, 1H), 7.63 (d, 
J = 1.8, 1H), 11.80 (s, 1H). 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 28.03 (3C), 78.50, 78.94, 79.19 (2C), 
79.38, 103.75, 113.65, 120.33, 123.36, 124.24, 127.82, 131.18, 134.37, 153.78, 161.75. MS (LC-MS, 
ESI): m/z 364.0 [M+H+]. C18H22ClN3O3 (363.84). 
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(5-Chloro-1H-indol-2-yl)(piperazin-1-yl)methanone hydrotrifluoroacetate (6.3)42 
6.2 (0.38 g, 1.04 mmol) was dissolved in anhydrous CH2Cl2 (4.5 mL) and TFA (0.5 mL) was added 
dropwise. The mixture was stirred at room temperature for 4 h and the solvents were removed 
under reduced pressure. CH2Cl2 (3 x 10 mL) was added and evaporated to remove remaining TFA. The 
crude product was obtained as a beige-colored solid (0.43 g, 83%) and used without further 
purification. 50 mg of the crude product were purified with preparative HPLC (column: Nucleodur 
250 × 21 mm; gradient: 0−5 min: MeCN/0.1% aq. TFA 5/95, 5−35 min: MeCN/0.1% aq. TFA 
5/95−40/60) and removal of the solvent from the eluate by evaporation and lyophilisation afforded 
6.2 (hydrotrifluoroacetate) as a white fluffy solid (33 mg, 66%). Rf = 0.05 (CH2Cl2/MeOH 5:1). UV/VIS 
(20 mM HCl): λmax 293, 233, 213 nm. RP-HPLC (220 nm): 99.0% (gradient: 0−30 min: MeCN/0.1% aq. 
TFA 5/95−80/20, 31-40 min: 90/10, tR = 15.3 min, k = 8.1). 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 
3.23 (br, 4H), 3.94 (br, 4H), 6.89 (d, J = 1.6, 1H), 7.21 (dd, J = 1.7, 8.7, 1H), 7.45 (dd, J = 1.5, 8.7, 1H), 
7.67 (d, J = 1.9, 1H), 8.99 (s, 2H), 11.85 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 42.75, 104.26, 
113.82, 120.45, 123.65, 124.35, 127.81, 130.61, 134.57, 161.89. MS (LC-MS, ESI): m/z 264.0 [M+H+]. 
HRMS (EI-MS): m/z M+• calcd. for C13H14ClN3O: 263.0825, found: 263.0831. 
 
(5-Chloro-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone hydrotrifluoroacetate (JNJ7777120, 
6.4a)1,42 
To a mixture of 6.3 (50 mg, 0.132 mmol, 1eq) and powdered K2CO3 (54.9 mg, 0.397 mmol, 3 eq) in 
acetone (1 mL), MeI (18.8 mg, 0.132 mmol, 1 eq) in acetone (100 µL) was added. The resulting white 
suspension was stirred for 6 h, quenched with water (20 mL), extracted with EtOAc (3 x 25ml), dried 
over anhydrous Na2SO4 and dried in vacuo. The product was purified with preparative HPLC (column: 
Nucleodur 250 × 21 mm; gradient: 0−30 min: MeCN/0.1% aq. TFA 30/70−60/40, tR = 23.3 min) and 
removal of the solvent from the eluent by evaporation and lyophilisation afforded 6.4a 
(hydrotrifluoroacetate) as a white fluffy solid (29 mg, 56%). Rf = 0.05 (CH2Cl2/MeOH 5:1). UV/VIS (20 
mM HCl): λmax 294, 235, 219 nm. RP-HPLC (220 nm): 99.5% (gradient: 0−30 min: MeCN/0.1% aq. TFA 
5/95−80/20, 31-40 min: 90/10, tR = 15.9 min, k = 8.4). 
1H NMR (300 MHz, DMSO-d6, 6.4a x HCl): 
δ (ppm) 2.78 (d, J = 3.3, 3H), 3.01-3.22 (m, 2H), 3.37-3.69 (br, 4H, superimposed by water), 4.53 (br, 
2H), 6.89 (d, J = 1.6, 1H), 7.21 (dd, J = 2.1, 8.7, 1H), 7.46 (d, J = 8.7, 1H) 7.67 (d, J = 2.0, 1H), 11.49 (br, 
1H), 11.92 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 41.98 (2C), 52.02 (2C), 104.33, 113.81, 
120.44, 123.65, 124.32, 127.77, 130.46, 134.56, 161.75. MS (LC-MS, ESI): m/z 278.0 [M+H+]. HRMS 
(EI-MS): m/z M+• calcd. for C14H16ClN3O: 277.0982, found: 277.0980.  
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4-[(5-Chloro-1H-indol-2-yl)carbonyl]-1,1-dimethylpiperazinium trifluoroacetate (6.5) 
To a mixture of 6.3 (5.0 mg, 0.0132 mmol, 1eq) and powdered K2CO3 (24 mg, 0.174 mmol, 13 eq) in 
acetone (0.4 mL), MeI (681 mg, 4.798 mmol, 364 eq) was added. The resulting white suspension was 
stirred at rt for 16 h and the solvent was evaporated under reduced pressure affording a white 
powder (5.2 mg, 98%). Rf = 0.03 (CH2Cl2/MeOH 5:1). RP-HPLC (220 nm): 99.5% (gradient: 0−30 min: 
MeCN/0.1% aq. TFA 5/95−80/20, 31-40 min: 90/10, tR = 16.4 min, k = 8.7). 
1H NMR (300 MHz, DMSO-
d6): δ (ppm) 3,15 (s, 6H), 3.25 (br, 2H), 3.38-3.79 (br, 4H), 4.35 (br, 2H), 6.91 (d, J = 1.8, 1H) , 7.02 (dd, 
J = 1.6, 8.5, 1H), 7.38 (dd, J = 1.9, 8.2, 1H) 7.60 (d, J = 1.7, 1H), 11.57 (s, 1H). MS (LC-MS, ESI): m/z 
293.0 [M+H+]. 
 
Optimization of the methylation of compound 6.3 
To a mixture of 6.3 (hydrotrifluoroacetate) and powdered K2CO3 in a mixture of acetone (90 µL) and 
toluene (10 µL), MeI (0.177 mg, 1.25 µmol, 1 eq, 78 nl) in acetone (90 µL) was added. The resulting 
white suspension was stirred for 24 h, quenched with 0.1% TFA(aq.) and the reaction was controlled by 
analytical HPLC. The ratio of 6.3 and the reagents was varied as summarized in Table 6.5. 
Table 6.5 Testreactions for the methylation of compound 6.3 (x TFA). 
6.3 (x TFA) K2CO3 
Product ratio 
(6.3 : 6.4a : 6.5) 
N 
eq n
[a] 
/ µmol m
[b]
 / mg eq n / µmol m /mg   
1 1.25 0.47 3 3.75 5.2 18 : 69 : 13 1 
2 2.5 0.94 6 7.5 10.4 80 : 18 : 2 1 
10 12.5 4.7 30 37.5 51.8 90 : 10 : 0 3 
            [a] n = amount of substance; [b] m = weight; N gives the number of independent experiments. 
6.5.2 Preparation of [3H]JNJ7777120 (6.4b) 
General conditions for radiosynthesis  
Commercial reagents and solvents were purchased from Acros Organics (Geel, Belgium), Alfa Aesar 
(Karlsruhe, Germany), Sigma Aldrich GmbH (Munich, Germany), TCI Deutschland (Eschborn, 
Germany) or Merck KGaA (Darmstadt, Germany) and were used without further purification unless 
otherwise stated. All solvents were of analytical grade. [3H]Methyl iodide dissolved in toluene (as = 
2.96 TBq/mmol, 80 Ci/mmol; av = 18.5 GBq/ml, 0.5 Ci/ml) was from Hartmann Analytic 
(Braunschweig, Germany). Scintillation cocktail Rotiscint Eco Plus was from Carl Roth (Karlsruhe, 
Germany). Analytical HPLC was performed on a system from Waters (Eschborn, Germany), equipped 
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with a pump control module, a 510 HPLC pump, a 486 UV/VIS detector, and a Flo-One beta series A-
500 radiodetector (Packard, Meriden, USA). The stationary phase was a Agilent Scalar C18 column 
(250 × 4.6 mm, 5 μm) equipped with a Luna C18 (4 x 3.0 mm) column guard (Phenomenex, 
Aschaffenburg, Germany) or a YMC Triart C18 (150 x 2 mm, 5 µm) equipped with a Luna C18 (4 x 
3.0 mm) column guard (Phenomenex, Aschaffenburg, Germany). Linear gradients or isocratic 
mixtures of CH3CN/TFA 0.05% (v/v) and H2O/TFA 0.05% (v/v) were used as mobile phases at a flow 
rate of 0.8 mL/min. Absorbance was detected at 220 nm, and radioactivity was measured with the 
radiodetector by liquid scintillation counting (liquid scintillator: Rotiscint Eco Plus, flow rate: 
3.8 mL/min). 
 
(5-Chloro-1H-indol-2-yl)[4-(methyl-t3)piperazin-1-yl]methanone hydrotrifluoroacetate (6.4b, 
[3H]JNJ7777120)  
Compound 6.3 hydrotrifluoroacetate (0.307 mg, 0.625 µmol, 10 eq) and powdered K2CO3 (0.259 mg, 
1.875 µmol, 30 eq) dissolved in acetone (190 µL) were added to a solution of [3H]MeI (8.875 µg, 
0.0625 mmol, 1 eq, 5 mCi) in toluene (10 µL), and stirred for 22 h at room temperature. The reaction 
was monitored by HPLC. The reaction mixture (1 µL) was added to a solution of unlabeled compound 
6.4a (99 µL, c = 100 µM), the ‘cold’ version of 6.4b, to allow UV detection in addition to 
radiodetection; injection volume: 95 µL. The solvent was removed under reduced pressure, and the 
residue was redissolved in 600 µL of a mixture of CH3CN/H2O 25:75 (v/v) containing 0.05% TFA. For 
isolation of 6.4b, aliquots (12 x 60µl) were injected into an HPLC instrument. Fractions containing the 
radioligand were collected at ~17 min (gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min 25:75 
(v/v), 30 min 25:75 (v/v), 31 min 95:5 (v/v), 40 min 95:5 (v/v), 41 min 25:75 (v/v), 50 min 25:75 (v/v). 
The solvent of the combined fractions was evaporated, and the residue was dissolved in 150 µL of a 
mixture of CH3CN/H2O 25:75 (v/v) containing 0.05% TFA. The supernatant were purified by HPLC to 
achieve high purity. The solvent of the combined fractions was evaporated and the residue was 
redissolved in 650 µL of EtOH/H2O 9:1 (v/v), and transferred into a 5 mL Amersham glass vial.  
Quantification: A five-point calibration was performed with the unlabeled ligand 6.4b (0.5, 1.0, 2.0, 
3.0 and 5.0 μM, inj. vol.: 100 μL, (gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min 25:75 (v/v), 
30 min 25:75 (v/v), 31 min 95:5 (v/v), 40 min 95:5 (v/v), 41 min 25:75 (v/v), 50 min 25:75 (v/v), tR ~17 
min. The solutions for injection were prepared in 0.05% TFA in CH3CN/0.05% TFA 25:75 (v/v) less 
than 5 min prior to injection. All standard solutions were prepared from a 100 µM solution of 6.4a (in 
CH3CN/0.05% TFA 25:75 (v/v)), which was freshly made from a 10 mM stock solution of 6.4a in EtOH. 
Two aliquots (10.5 µL) of the ethanolic solution of the product were diluted with 94.5 µL of 
CH3CN/0.05% TFA 25:75 (v/v), and 100 µL were analyzed by HPLC. Whereas one sample was only 
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used for quantification of the product by UV detection, the second sample was additionally 
monitored radiometrically to determine radiochemical purity (cf. Figure 6.2). The minor difference in 
retention times (tR) of both chromatograms results from the setup of the UV and the radiodetector in 
series. The molarity of the ethanolic solution of 6.4b was calculated from the mean of the peak areas, 
and the linear calibration curve was obtained from the peak areas of the standards. Yield: 1.70 µg 
(5.98 nmol, 9.6%). 
Determination of the specific activity: An aliquot (5 µL, in duplicate) of the ethanolic solution was 
diluted with 445 mL of a mixture of CH3CN and H2O 25:75 (v/v) in duplicate, and 50 µL of 1:300 
dilutions were counted three times in Rotiszint eco plus (3 mL) in a LS 6500 liquid scintillation counter 
(Beckmann Coulter, München, Germany). The total activity in the stock solution amounted to 
17.3 MBq (0.468 mCi), corresponding to a calculated specific activity of 2.90 TBq/mmol 
(78.3 Ci/mmol). The activity of the stock solution was adjusted to 9.25 MBq/ml, (0.25 mCi/ml, c = 
2.99 µM) by adding EtOH/H2O 1:1 (v/v). HPLC analysis showed a radiochemical purity of >97%. The 
identity of the radioligand was confirmed by HPLC analysis of labeled 6.4b and unlabeled 6.4a under 
the same conditions, resulting in identical retention times. The radioligand 6.4b was stored at –20 °C. 
Control of chemical stability of [3H]JNJ7777120 by HPLC: 1 μL of the adjusted stock solution of 
[3H]JNJ7777120 (av: 9.25 MBq/ml) in EtOH/H2O 1:1 (v/v) was diluted with 109 μL of CH3CN/0.05% TFA 
25:75 (v/v) to a total volume of 110 μL. 100 μL of this solution were injected into the HPLC system 
and analyzed by radiometric detection. Gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min 25:75 
(v/v), 30 min 25:75 (v/v), 31 min 95:5 (v/v), 40 min 95:5 (v/v). 
6.5.3 Radioligand binding assay for the hHxR 
See Chapter 5.4.3 
6.5.4 Saturation binding assay for the mH4R 
Saturation binding experiments using HEK293-SF-mH4R-His6 cells were performed by Dr. Uwe 
Nordemann in our research group as described previously.30 
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7 Subtype-selective Nonpeptide 
Radioligands for the NPY Y2 Receptor  
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7.1 Introduction 
The (S)-configured arginine-
amide BIIE 0246, the first 
potent and selective Y2R 
receptor (Y2R) antagonist, 
has been widely used as a 
pharmacological tool for 
the investigation of the 
physiological role of the 
Y2R.
1 Aiming at potent and 
subtype selective tracers 
for the Y2R, a series of 
derivatives of BIIE 0246 was 
synthesized.3 Application of 
the guanidine-acylguani-
dine bioisosteric approach 
resulted in the first tritiated 
Y2R selective non-peptide 
radioligand, [3H]UR-PLN196.2 More detailed binding and functional studies of UR-PLN196 revealed 
insurmountable antagonism versus pNPY and pseudo-irreversible binding at the Y2R. Here the 
synthesis and characterization of [3H]UR-PLN208, a structurally related radiotracer is reported and 
binding as well as functional data are compared with those of [3H]UR-PLN196 and the unlabeled 
analogs.  
7.2 Results and Discussion 
7.2.1 Synthesis of [3H]UR-PLN208 
[3H]UR-PLN208 was synthesized, as the ‘cold’ analog showed improved binding affinity compared to 
the previously prepared radioligand [3H]UR-PLN196 (Ki = 5.2 nM vs. 16 nM) in a flow cytometric 
binding assay, using CHO cells stably expressing the human Y2 receptor (hY2R)
4 and fluorescence-
labeled pNPY (Cy5-pNPY or Dy-635- pNPY).5 Antagonistic activity (Kb = 8.2 nM) was proven in a 
spectrofluorimetric Ca2+ assay (Fura-2 assay)6 with CHO cells stably expressing the hY2R compared to 
UR-PLN196.2 Moreover, high selectivity for the hY2R over the other hYxR-subtypes was observed for 
UR-PLN208 (Ki values: hY1R: >3500 nM; hY4R: >6500 nM; hY5R: >5000 nM).
7  
 
Figure 7.1 Structure and pharmacological profile of BIIE 0246
1
 and the 
argininamide-type radioligands [
3
H]UR-PLN196
2
 and [
3
H]UR-PLN208. 
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Scheme 7.1 Synthesis of [
3
H]UR-PLN208. Reagents and conditions: a) UR-PLN205, succinimidyl [2,3-
3
H]-
propionate, NEt3, MeCN, rt, 16 h; b) TFA, rt, 2 h, 7.9%. 
[3H]UR-PLN208 was obtained by direct acylation of UR-PLN205, the mono-Boc protected analog of 
BIIE 0246, with commercially available succinimidyl [2,3-3H2]propionate in the presence of 
triethylamine followed by in situ deprotection with TFA (Scheme 7.1). After purification by HPLC, the 
radioligand was obtained with a high specific activity (as) of 75 Ci/mmol in radiochemical purity of 
>99% (cf. Figure 7.2), similar to [3H]UR-PLN196 (81 Ci/mmol; radiochemical purity >99%). The identity 
of the radioligand was confirmed by HPLC analysis of labeled and unlabeled UR-PLN208. 
Furthermore, chemical stability in ethanol at -20 °C was proven over a period of at least 12 months 
(cf. Figure 7.3). 
 
Figure 7.2 Identity and purity control of [
3
H]UR-PLN208. A: Purity control after isolation by HPLC 
(radiochromatogram). B: Reaction control after 18 h. C: UV (  = 220 nm) chromatogram of the reaction control 
spiked with ‘cold’ UR-PLN208, c = 100 μM; gradient: CH3CN/0.1% TFA in H20: 0 min: 25:75 (v/v), 30 min: 90:10 
(v/v), 40 min 90:10 (v/v). 
 
188 Chapter 7 
 
Figure 7.3 Long-term stability of [
3
H]UR-PLN208. Example of a radiochromatogram (red solid line) after storage 
in ethanol (+ 50 µM TFA) at -20 °C for a period of 12 months. The identity of [
3
H]UR-PLN208 was confirmed by 
spiking with larger amounts of the ‘cold’ form of UR-PLN208 (c = 100 µM), which allowed UV detection (black 
dashed line). The minor difference in retention times (tR) of both chromatograms results from the setup of the 
UV and the radiodetector in series. gradient: CH3CN/0.1% TFA in H20: 0 min: 25:75 (v/v), 30 min: 90:10 (v/v), 40 
min 90:10 (v/v). 
7.2.2 Pharmacological characterization of [3H]UR-PLN208 and ‘cold’ analogs at CHO-
hY2R cells 
7.2.2.1 Determination of binding constants of [3H]UR-PLN208 
The radioligand [3H]UR-PLN208 was characterized by saturation binding experiments within a 
concentration range of 0.5 to 150 nM using CHO-hY2R cells as shown in Figure 7.4. For these 
experiments special surface-modified plates (BD Primaria 96-well plates; Becton Dickinson GmbH, 
Germany) were used to reduce the adsorption of the radioligand to the plastic as reported 
previously.7 Nonspecific binding was determined in the presence of BIIE 0246 (30-fold concentrated), 
a structurally related antagonist, or pNPY (100-fold concentrated), a peptidic agonist. Nonspecific 
binding in the presence of pNPY was more than twice as high (~60%) as in the presence of BIIE 0246 
(~25%). This may be interpreted a hint to different binding modes of peptidic (endogenous) Y2R 
ligands and non-peptidic BIIE 0246-type antagonists, binding of the radioligand, at least in part, to a 
site distinct from the peptide agonist binding site. Most probably, the Y2R binding sites of BIIE 0246-
like antagonists and NPY overlap only partially,8 as also reported for other GPCRs.9 It is also 
conceivable that cellular uptake of the radioligand is involved, e. g. via transporters, which could be 
occupied by BIIE 0246, resulting in reduced [3H]UR-PLN208 uptake and unspecific binding, 
respectively.10 Hence, the maximum number of binding sites (Bmax) amounted to approximately 
387,000 and 108,000 per cell in the presence of BIIE 0246 pNPY, respectively. Regardless of that, 
[3H]UR-PLN208 bound in a saturable manner in both experiments with similar Kd values up to a 
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concentration of 40 nM, (Kd(pNPY) = 23.5 ± 2.3 nM, Kd(BIIE 0246) = 19.2 ± 2.3 nM; Kd(∑) 21.3 ± 1.8 nM; Figure 
7.4 C, D). A more complex binding behavior became obvious when concentrations higher than 40 nM 
of [3H]UR-PLN208 were taken into account. Between 50 and 150 nM, specific binding of [3H]UR-
PLN208 increased again and was saturable, fitted by nonlinear regression with a Kd value of 
approximately 100 nM (Figure 7.4 A, B). For elucidation of a real second binding site, higher 
concentrations of [3H]UR-PLN208 would be required to achieve saturation. Unfortunately, the 
radioligand was not available in sufficiently large amount.  
 
Figure 7.4 Saturation binding of [
3
H]UR-PLN208 at CHO-hY2R cells. A: Biphasic curve (c([
3
H]UR-PLN208) = 0-150 
nM); Nonspecific binding determined by co-incubation with: pNPY (100-fold concentration of [
3
H]UR-PLN208); 
specific binding: ●; nonspecific binding: not shown cf. appendix; Kd(sat)low = 23.5 ± 2.3 nM; Kd(sat)high = 66.2 ± 6.9 
nM. B: Biphasic curve (c([
3
H]UR-PLN208) = 0-150 nM); Nonspecific binding determined by co-incubation with: 
BIIE 0246 (30-fold concentration of [
3
H]UR-PLN208); specific binding: ●; nonspecific binding: not shown cf. 
appendix; Kd(sat)low = 19.2 ± 2.3 nM; Kd(sat)high = 107.7 ± 29.3 nM. C: Monophasic curve (c([
3
H]UR-PLN208) = 0-40 
nM); Nonspecific binding determined by co-incubation with: pNPY (100-fold concentration of [
3
H]UR-PLN208); 
specific binding: ●; nonspecific binding: □; Kd(sat) = 23.5 ± 2.3 nM. D: Monophasic curve (c([
3
H]UR-PLN208) = 0-
40 nM); Nonspecific binding determined by co-incubation with: BIIE 0246 (30-fold concentration of [
3
H]UR-
PLN208); specific binding: ●; nonspecific binding: □; Kd(sat) = 19.2 ± 2.3 nM. n = 2; best fitted by nonlinear 
regression for specific binding and linear regression for nonspecific binding; mean values ± SEM, performed in 
triplicate. 
In short, binding was saturable up to a concentration of 40 nM, but there were differences in the 
portion of specific binding compared to nonspecific binding depending on the chosen competitor. 
The results suggest the existence of a second binding site, which is sensitive to BIIE 0246-related 
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compounds, but this could not be proven due to limited amounts of available radioligand. In 
contrast, [3H]UR-PLN196 did not show such discrepancies in saturation experiments up to a 
concentration of 150 nM. Yet, as the Kd value of [
3H]UR-PLN196 (67 nM)2 for the so-called high-
affinity binding site was higher than that of [3H]UR-PLN208, presumably, a second binding site might 
not have been detected within the investigated concentration range (up to 200 nM). 
Table 7.1 Saturation binding parameters of [
3
H]UR-PLN208 at CHO-hY2R cells. 
Competitor Kd / nM
 
Estimated Bmax (sites / cell).
 
BIIE 0246
[a]
 
19.2 ± 2.3 (high)
[b]
 387,400 
107.7 ± 29.3 (low)
[b]
 1,107,500 
pNPY
[c]
 
23.5 ± 2.3 (high)
[b]
 107,500 
66.2 ± 6.9 (low)
[b]
 271,000 
Mean value
[d]
 21.3 ± 1.8
[e]
 - 
[a] 30-fold concentration of [
3
H]UR-PLN208; [b] n = 2; [c] 30-fold concentration of [
3
H]UR-
PLN208; [d] mean value of 4 independent experiments (high affintiy binding site), twice 
performed with BIIE 0246 as competitor, twice with pNPY; [e] n = 4. 
7.2.2.2 Association and dissociation kinetics of [3H]UR-PLN208  
In spite of differences regarding saturation binding, the analysis of the association kinetics for the 
specific Y2R binding of [
3H]UR-PLN196 and [3H]UR-PLN208 at CHO-hY2R cells revealed comparable 
results. In both cases, association was almost complete after 30 minutes (cf. Figure 7.5 A). In 
dissociation experiments the residual specific binding of the tritiated compounds amounted to 
approximately 25% for [3H]UR-PLN196 and 60% for [3H]UR-PLN208 after preincubation of the CHO-
hY2R cells with the respective radioligand for 60 min (cf. Figure 7.5 B). Dissociation was induced by 
removing the free radioligand by suction and addition of a 100-fold excess of BIIE 0246 to prevent 
reassociation. For both radioligands the results suggest in part irreversible binding to a specific 
binding site. Further possible explanations for such a behavior are a slow rate of dissociation from 
the receptor,11 a slow rate of interconversion between inactive and active receptor 
conformations,12,13 or stabilization of an inactive ligand (antagonist)-specific receptor conformation.14 
To elucidate if the residual binding of [3H]UR-PLN208 is time-dependent, the dissociation experiment 
was repeated with different periods of preincubation 30 and 90 min. However, the amount of 
residual binding remained unchanged (data not shown). A preincubation period shorter than 30 min 
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is inappropriate due to incomplete association as shown before. Therefore, a time-dependency of 
the incomplete dissociation could not be detected in the evaluable time range. 
 
Figure 7.5 Association and dissociation kinetics of [
3
H]UR-PLN196 and [
3
H]UR-PLN208 at CHO-hY2R cells. A: 
Radioligand association kinetics ([
3
H]UR-PLN196 (c = 75 nM, ●, blue curve); [
3
H]UR-PLN208 (c = 30 nM, ■, green 
curve)). B: Radioligand dissociation kinetics ([
3
H]UR-PLN196 (c = 75 nM, ●, blue curve); [
3
H]UR-PLN208 (c = 30 
nM, ■, green curve), preincubation for 60 min)), monophasic exponential fit, dissociation performed in the 
presence of a 100-fold excess of BIIE 0246. 
7.2.2.3 Competition binding experiments 
Contrary to the incomplete dissociation in kinetic studies, the radioligands [3H]UR-PLN196 and 
[3H]UR-PLN208 were completely displaceable in competition binding studies. Interestingly, 
tremendous discrepancies became obvious when competitors of different chemical nature were 
used. In case of nonpeptide Y2R antagonists (BIIE 0246,
1 SF-1115 and CMY948416) (for structures see 
Chapter 1) the displacement was monophasic (cf. Table 7.2 A). The peptidic agonist pNPY displaced 
[3H]UR-PLN196 in a biphasic manner, indicative of a high (Ki = 2.0 nM) and a low affinity binding site 
(Ki = 1300 nM, cf. Table 7.2 B).
2 By contrast, displacement of [3H]UR-PLN208 with pNPY revealed only 
a low affinity binding site (Ki = 2100 nM), suggesting either pseudo-irreversible binding or 
stabilization of a ligand specific Y2R conformation. When the competition binding experiment was 
performed in an inverse manner, that is to say by displacing Dy-635-pNPY with ‘cold’ UR-PLN196 in a 
flow cytometric assay, the Ki value of UR-PLN196 was comparable with the Kd value of [
3H]UR-
PLN196.2 
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Figure 7.6 A. Displacement of [
3
H]UR-PLN208 by hY2R antagonists at CHO-hY2R cells. B. Competition binding 
experiments of different radio- and fluorescent ligands. Data represent the mean ± SEM (n=2–5, see also Table 
7.2).  
Such differences became also obvious when [3H]UR-PLN208 was displaced with the peptidic ligands 
pPYY, hPP, pNPY13-36 and pNPY22-36. The hY2R affinity was at least 70-fold lower than data obtained 
from the displacement of [3H]pNPY or Dy-635-pNPY. This indicates that the apparent discrepancies at 
the hY2R are characteristic for peptidic agonists, when BIIE 0246-type radioligands are used. In 
competition binding experiments with peptidic agonists such as pNPY, an incubation time of at least 
90 min is recommended, due to slow association of pNPY to the receptor.17 To clarify if the 
displacement curve as shown in Figure 7.6 B (○, pNPY vs [3H]UR-PLN208) is time-dependent, the 
incubation time was set to 60 or 120 min, respectively. The received Ki values and the shape of the 
curves revealed no differences in the displacement of pNPY by [3H]UR-PLN208 between 60 and 120 
min (cf. Figure 7.7). 
 
   
 
Incubation time 
/ min 
hY2R 
 Ki (pNPY) /nM 
 30 1630 
 60 1410 
 120 1750 
   
Figure 7.7 Displacement of [
3
H]UR-PLN208 by pNPY at CHO-hY2R cells after different periods of incubation. hY2R 
radioligand binding assay on CHO cells, stably expressing the hY2R; radioligand: [
3
H]UR-PLN208 (20 nM); 
incubation time: 30 min (●, orange curve, Ki = 1630 nM); 60 min (■, red curve, Ki = 1410 nM); 120 min (▲, brown 
curve, Ki = 1750 nM). 
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Table 7.2 Ki values of hY2R ligands, determined with [
3
H]UR-PLN196, [
3
H]UR-PLN208, Dy-635-pNPY or [
3
H]pNPY, 
and functional data at CHO-hY2R cells; A: Nonpeptidic antagonists, B: Peptidic agonists. 
Compound 
hY2R binding: Ki / nM, determined with 
hY2R 
antagonism: 
[
3
H]UR- 
PLN196
[a]
 
[
3
H]UR- 
PLN208
[b]
 
Cy5- 
pNPY
[c]
 
[
3
H]pNPY
[d]
 
Kb
[e]
 or (IC50)
[f]
 
 / nM 
A 
PLN196 47 ± 7 80 ± 13 9.9 ± 1
[g]
 n.d. 16 ± 8
[g]
 
PLN208 33 ± 7 39 ± 1 5.2 ± 2
[g]
 n.d. 8.2 ± 0
[g]
 
BIIE 0246 17 ± 3 21 ± 5 2.6 ± 1.2
[h]
 24.2
[l]
 6.0 ± 0
[h]
 
SF11
[f]
 2800 ± 710 840 ± 110 1300 ± 350
[i]
 n.d. (190 ± 10)
[j]
 
CMY 9484 8.3 ± 0.5 200 ± 64 n.d. n.d. (19)
[i]
 
B 
pNPY: Ki    high 2.0 ± 1.1 - 0.8 ± 0.2
[k]
 0.4 ± 0.1
[k]
 
n.d. 
  low 1300 ± 700 2100 ± 170 - - 
pNPY13-36 n.d. 3600 ± 87 1.7 ± 0.4
[k]
 1.7 ± 0.4
[k]
 n.d. 
pNPY22-36 n.d. 9800 ± 2200 110 ± 37
[j]
 n.d. n.d. 
hPP n.d. 5000 ± 1700 n.d. 68 ± 1
[l]
 n.d. 
pPYY n.d. n.a.
[m]
 0.4 ± 1
[k]
 0.06 ± 0.01
[k]
 n.d. 
[a] hY2R radioligand binding assay with CHO cells, stably expressing the hY2R; radioligand: [
3
H]UR-PLN196 (75 
nM); [b] hY2R radioligand binding assay on CHO cells, stably expressing the hY2R; radioligand: [
3
H]UR-PLN208 (20 
nM); [c] hY2R flow cytometric competition binding assay on CHO cells, stably expressing the hY2R; fluorescent 
ligand: Cy5-pNPY (5 nM); [d] hY2R radioligand binding assay with CHO cells, stably expressing the hY2R; 
radioligand: [
3
H]pNPY (1 nM);
 
[e] inhibition of pNPY (70 nM)-induced [Ca
2+
]i mobilization in hY2R-expressing CHO 
cells; [f] data from a Y2R cAMP biosensor assay; [g] Pluym et al. 2013;
2
 [h] Pluym et al. 2011;
3
 [i] Pluym, N. 2011;
7
 
[j]Kaske, M. 2012;
18
 [k]Ziemek et al. 2006;
4
 [l] Ziemek, R. 2006;
19
 [m] up to a concentration of 10 µM. incubation 
time: 30-90 min, mean values ± SEM, n = 2-5, n.d. means not determined. 
7.2.2.4 Calcium assay on hY2R-expressing CHO cells 
Y2R antagonism of UR-PLN196 and UR-PLN208 was investigated in a Fura-2 based Ca
2+ assay on hY2R-
expressing CHO cells, revealing Kb values of 16 nM for UR-PLN196 and 8.2 nM for UR-PLN208, 
respectively. Moreover, concentration-response curves (CRCs) of NPY were constructed in the 
absence and presence of different concentrations of the antagonist UR-PLN196.2 Simultaneous 
addition of pNPY and UR-PLN196 suggested competitive antagonism. By contrast, pretreatment with 
UR-PLN196 for 20 min caused a decrease in the maximal agonist response in a concentration-
dependent manner, indicating insurmountable antagonism against pNPY by analogy with previous 
reports on BIIE 0246.20,4 In addition to concentration-dependency of insurmountable antagonism, 
time-dependency was investigated. The concentrations of pNPY and the antagonists UR-PLN196 or 
UR-PLN208 were kept constant and the time interval between addition of the antagonist and pNPY 
was varied as shown in Figure 7.8. The depression of the maximal response to pNPY (c = 300 nM) by 
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UR-PLN196 proved to be both concentration- and time dependent: At a concentration of 30 nM of 
UR-PLN196 the maximum response of pNPY was reduced to 60% after 20 minutes, at a concentration 
of 75 nM the effect of pNPY amounted to 40% after the same time. Pretreatment with 30 nM of UR-
PLN208 for 10 minutes completely inhibited the Ca2+ response of pNPY (c = 300 nM). These results 
were in good accordance to the incomplete dissociation rates for both radioligands from the 
receptor in dissociation experiments. Apart from classical irreversible binding, the aforementioned 
stabilization of an inactive ligand (antagonist)-specific receptor conformation14, which is not 
accessible for pNPY any longer, could explain this phenomenon.  
Irreversibly binding antagonists could be useful tools for the determination of spare receptors. 
Lipophilic antagonists capable of stabilizing the receptor in an inactive state, have been taken for co-
crystallization of different GPCRs.21-23 Therefore, the (pseudo)irreversibly binding BIIE-type ligands 
might be useful for the crystallization of the NPY Y2R. 
 
Figure 7.8 Time course of the pNPY (c = 300 nM)-induced Ca
2+
 signal in the presence of BIIE 0246-type 
antagonists. Fura-2 assay on CHO-hY2R cells performed after pretreatment of the cells with UR-PLN196 (A: ▲: c 
= 30 nM; ■: c = 75 nM) or UR-PLN208 (B: ○: c = 30 nM) for different periods of time; mean values ± SEM, n = 
2-3. 
7.2.3 Pharmacological characterization of [3H]UR-PLN208 and non-labeled analogs 
on the hY2R at Sf9 insect cell membranes 
7.2.3.1 hY2R antagonist activity of BIIE 0246 and related compounds in thesteady-state [γ-
33P]GTPase assay 
The steady-state [γ-33P]GTPase activity assay using the baculovirus/Sf9 cell system has been 
established as a reliable functional readout for the analysis of hY2R ligands.
24 It is characterized by a 
high signal-to-noise ratio and the proximal readout avoids bias from downstream signaling.25 
Therefore, the GTPase assay is well suited to complement the data from the Fura-2 assay, to 
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compare Kb values from different readouts and to examine, whether insurmountable antagonism of 
BIIE 0246-related compounds is detectable in the GTPase assay too. As displayed in Table 7.3, the Kb 
values for BIIE 0246 (Kb(GTPase) = 11.9 ± 1.7), UR-PLN74 (Kb(GTPase) = 4.2 ± 0.1, structure is shown in 
Figure 7.11), UR-PLN196 (Kb(GTPase) = 4.3 ± 1.6) and UR-PLN208 (Kb(GTPase) = 8.3 ± 0.5) determined in the 
GTPase assay, were in good accordance to the Kb values determined in the Fura-2 assay.
2,3 Also for 
SF11, a Y2R antagonist with a different scaffold, the determined Kb value of 59.0 ± 34.5 was in the 
same range as published data.15 
Table 7.3 hY2R antagonism of selected ligands the GTPase assay compared to reported data from functional 
and binding assays. 
Compound 
hY2R 
Kb(GTPase) / nM
[a]
 n Kb(Ca-assay) or (IC50) / nM
[b]
 Ki / nM
[c]
 
BIIE 0246 11.9 ± 1.7 2 5.6 ± 0.4
[d]
 2.6 ± 1.2
[d]
 
UR-PLN74 4.2 ± 0.1 2 1.8 ± 0.2
[e]
 3.2 ± 0.3
[e]
 
UR-PLN196 4.3 ± 1.6 4 16 ± 8
[e]
 9.9 ± 1.0
[e]
 
UR-PLN208 8.3 ± 0.5 4 8.2 ± 0.4
[e]
 5.2 ± 1.8
[e]
 
SF11
[f]
 59.0 ± 34.5 2 (190 ± 10)
[f]
 1.6 ± 0.9
 [f]
 
[a] Steady-state GTPase assay on membranes of Sf9 cells expressing the hY2R + G i2 + G 1 2, mean values ± SEM, 
performed in duplicate, Kb values were calculated according to the Cheng-Prusoff equation;
26
 [b] inhibition of 
pNPY (70 nM)-induced [Ca
2+
]i mobilization in hY2R-expressing CHO cells; mean values ± SEM; [c] Ki values were 
determined in a flow cytometric binding assay from the displacement of Cy5-pNPY (Kd=5.2 nM, c=5 nM) at CHO-
hY2R cells; [d] Pluym et al. 2011;
3
 [e] Pluym et al. 2013;
2
 [f] Brothers et al. 2010;
15
 IC50 obtained from an 
antagonist concentration-response curve in a Y2R cAMP biosensor assay, Ki obtained from displacement of 
125
I-PYY from Y2R-expressing cells. 
 
To investigate if the maximum response of pNPY is reduced by BIIE 0246-type antagonists in the 
GTPase assay, the typical experimental procedure was modified. Instead of inducing the maximum 
response of the system by the addition of pNPY at first, followed by addition of the antagonists, the 
receptor ligands were added in inverse order. Different concentrations of UR-PLN196 or UR-PLN208 
were incubated with the Y2R containing cell membranes in the absence of pNPY for different periods 
of time (0, 15, 30 min) followed by addition of pNPY (c = 100 nM). The minimum and maximum 
values were compared among the concentration response curves as well as the Kb values determined 
at different time points. Neither UR-PLN196 nor UR-PLN208 showed significant changes in maximal 
responses or Kb values (cf. Figure 7.9 and Table 7.4), which would be expected in case of 
insurmountable antagonism. It is difficult to provide a satisfactory explanation for the discrepancy 
between the results from GTPase and Ca2+ assay. These  two artificial test systems are different, 
using insect cell membranes and mammalian cells, respectively, distinct functional readouts (GTPase 
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activity vs. Ca2+-signal) and a different experimental setup. It is worth mentioning that the addition of 
BIIE 0246-related compounds without the addition of pNPY did not reduce the constitutive activity of 
the hY2R in the GTPase assay, indicating that these compounds do not act as inverse agonists but as 
neutral antagonists. 
 
Figure 7.9 Concentration-response curves of the hY2R ligands UR-PLN196 and UR-PLN208. Determined vs. 100 
nM pNPY in a steady-state GTPase assay with membranes expressing the hY2R + G i2 + G 1 2 after 
pretreatment of the membranes with UR-PLN196 (A. ○: 0 min, ∆: 15 min; □: 30 min) or UR-PLN208 (B. ○: 0 min, 
∆: 15 min; □: 30 min) for different periods of time ; mean values ± SEM, n = 2-4. 
Table 7.4 hY2R antagonism of UR-PLN196 and UR-PLN208 in the GTPase assay determined after different 
periods of preincubation manner.
[a]
 
Compound 
Preincubation with antagonist: 
0 min 15 min 30 min 
Kb / nM] Kb / nM] Kb / nM] 
UR-PLN196 4.4 ± 2.5 3.8 ± 0.2 4.8 ± 0.6 
UR-PLN208 2.4 ± 0.5 3.8 ± 0.8 3.6 ± 1.1 
[a] Data are mean values ± SEM from 2 independent experiments performed in duplicate. 
 
7.2.3.2 Saturation binding of [3H]UR-PLN208 using hY2R-insect cell membrane preparations 
The functional data for the BIIE 0246-type antagonists gained from the steady-state GTPase assay on 
membranes of Sf9 insect cells expressing the hY2R were in good agreement with the Kb values 
determined in the calcium assay on  hY2R expressing CHO cells. In order to explore if membranes of 
Sf9 insect cells are suitable for binding studies on the hY2R using radioligands such as UR-PLN208, a 
saturation binding experiment was performed. For these experiments BD Primaria 96-well plates 
A B 
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(Becton Dickinson GmbH, Germany) were used to reduce the adsorption of the radioligand to the 
plastic as reported previously.7  
 
Figure 7.10 Saturation binding of [
3
H]UR-PLN208 at Sf9-hY2R cells membrane preparations. Total binding: ●; 
nonspecific binding: □; n = 2. 
As shown in Figure 7.10, no specific binding was detected within the investigated concentration 
range of 0.5-150 nM. It is rather likely that membrane preparations are not suitable for lipophilic 
ligands like UR-PLN208, due to nonspecific binding to membrane lipids or the formation of micelles 
which include the lipophilic compounds. Similar findings in membrane systems have been reported 
for [3H]iodophenpropit27, [3H]tiotidine28 and [3H]JNJ7777120 (cf. Chapter 6). Moreover, the work-up 
via filtration over GF/C cellulose filters could lead to such high nonspecific binding, although the 
filters were pretreated with PEI (polyethylenimine) to prevent the binding of the positively charged 
radioligand to the filters. Optimization of the work-up procedure or the addition of a detergent like 
Triton X might be beneficial, but such attempts were not taken into account due to the limited 
available amounts of the radioligand [3H]UR-PLN208. 
7.2.4 Stability of argininamide-type NPY Y2R antagonists 
As recently reported, Nω-acylated argininamides have to be considered critically with respect to 
chemical stability, depending on the structure of the acyl substituent.29-32 Therefore, a selection of 
compounds with different substituents at the guanidine group (UR-PLN26, UR-PLN74 and UR-
PLN208, for structures cf. Figure 7.11) were investigated with regard to decomposition giving BIIE 
0246 under assay-like conditions (aqueous buffer, pH 7.4, 20 °C, time scale 90 min to 48 h, cf. Figure 
7.11). As such compounds are of potential value as ligands for Y2R crystallization experiments, 
stability was also investigated over a longer time period (24 and 48 h, respectively) than required for 
pharmacological in vitro studies (incubation time: 90 min).7 In the latter the release of BIIE 0246 
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under assay conditions has to be taken into account, because the high potency of cleavage product 
BIIE 0246 (Ki = 2.6 nM) might feign or mask the activity of the decomposing Y2R antagonist. Cleavage 
of aminoalkanoylguanidines was already observed for NG-acylated argininamide-type Y1R 
antagonists.29,32  
 
 
 
 
 
Time 
Peak ratio (UV detection) / % 
UR-PLN26 : 
BIIE 0246 
UR-PLN74 : 
BIIE 0246 
UR-PLN208 : 
BIIE 0246 
 
0 min 97 : 3 100 : 0 97 : 3 
90 min  83 : 17 100 : 0 96 : 4 
24 h  11 : 89 100 : 0  79 : 21 
48 h      0 : 100 100 : 0  61 : 39 
    
Figure 7.11 HPLC analysis of the chemical stability of N
G
-substituted Y2R antagonists. BIIE 0246 is formed by 
decomposition of the ligands. Incubation: 0 min, 90 min, 24 h and 48 h in buffer, c = 50 µM, pH 7.4, 20 °C 
(A. UR-PLN26; B. UR-PLN74; C. UR-PLN208; cf. Appendix for the complete chromatograms; D. Ratios calculated 
from the peak ratio (UV detection) of the respective antagonist and BIIE 0246 after different periods of time. 
 
A 
B 
D 
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In case of the Y2R antagonists the deacylation proved to be rapid in case of UR-PLN26 (90 min: almost 
20% decomposition, 24 h: 90%), probably favored by an intramolecular nucleophilic attack at the 
carbonyl group. In case of the propionylated radioligand UR-PLN208, only traces of the parent 
compound BIIE 0246 were detected after 90 min (4%), but the amount of BIIE 0246 was increasing 
from 24 h (~20%) to 48 h (~40%). The exchange of the acylguanidine moiety by carbamoylated 
analogs led to high stability, as shown for UR-PLN74 in Figure 7.11 B. Recently, considerably 
improved stability of carbamoylguanidines compared to acylguanidines has been demonstrated for 
radiolabeled and fluorescent Y1R antagonists.
30,31 Thus, the carbamoylguanidine structural motif 
should be preferred for future design of BIIE 0246-type ligands. 
7.3 Summary and Outlook 
The guanidine-acylguanidine bioisosteric approach was applied to the preparation of the tritiated 
Y2R-selective radioligands [
3H]UR-PLN1962 and [3H]UR-PLN208. The difference between peptidic 
agonists and nonpeptide antagonists regarding displacement of both radioligands suggests a slow 
interconversion between inactive and active receptor conformations,12,13 a slow rate of dissociation 
from the receptor,11 stabilization of an inactive ligand-specific receptor conformation,14 or binding to 
a site distinct from the peptide agonist binding site. The presented data also indicate that the Y2R 
binding sites of BIIE 0246-derived antagonists and NPY are different or overlap only partially. 
Recently, a Y5R-selective radioligand with similar behavior in kinetic and functional studies was 
reported as an insurmountable pseudo-irreversible nonpeptide antagonist.33 Regardless of 
insurmountable antagonism and pseudo-irreversible binding, both radioligands are valuable 
pharmacological tools for the detection of Y2R binding sites, investigations on ligand binding modes 
and the characterization of nonpeptide Y2 receptor antagonists. The steady-state GTPase assay 
revealed Kb values consistent with reported data from the Ca
2+ (Fura-2) assay, but did not show 
insurmountable antagonism of the BIIE 0246-related compounds. The pharmacological 
characterization of [3H]UR-PLN208 at the hY2R using membrane preparations of Sf9 insect cells failed 
due to high degree of nonspecific binding, presumably resulting from the physicochemical properties 
of this ligand. High stability under physiological conditions over severals days is crucial for 
crystallization experiments and was shown for carbamoylguanidines such as UR-PLN74. Therefore, 
future design of argininamide-type Y2R antagonists should be focused on carbamoylguanidines 
instead of less stable acylguanidines. With [3H]UR-PLN187 and [3H]propionyl-NPY, two additional 
radioligands were synthesized in our working group. In comparison, these ligands can hopefully give 
new insights in the mechanism of both, agonist and antagonist binding at the hY2R. Future direction 
in search for new radioligands should focus on antagonists structurally distinct from BIIE 0246-type 
ligands to compare the binding behavior of antagonists with different scaffolds.  
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Figure 7.12 Structure of [
3
H]PLN187. 
 
7.4 Experimental Section 
7.4.1 General 
Chemicals and solvents were purchased from Merck KGaA (Darmstadt, Germany) and Sigma Aldrich 
GmbH (Munich, Germany) and were used without further purification unless otherwise stated. BIIE 
0246, UR-PLN26, UR-PLN74, UR-PLN205 and ‘cold’ UR-PLN208 were synthesized by Dr. Nikola Pluym 
in our research group as part of his doctoral project.7 Porcine NPY (pNPY) was kindly provided by 
Prof. Dr. C. Cabrele (Paris-Lodron-University, Salzburg, Austria). SF-11 was purchased from Tocris 
Bioscience (Bristol, United Kingdom). CMY 9484 was synthesized by Kilian Kuhn in our research group 
by analogy with a previously published synthesis.16 Succinimidyl [2,3-3H2]-propionate was purchased 
from Hartmann Analytic GmbH (Braunschweig, Germany) and provided as solution in ethyl acetate 
(specific activity as = 2.96 TBq/mmol, 80 Ci/mmol; av =185 MBq/mL, 5 mCi/mL). Scintillation cocktail 
Rotiscint Eco Plus was from Carl Roth (Karlsruhe, Germany). Radioanalytical HPLC was performed on 
a system from Waters (Eschborn, Germany), equipped with a pump control module, a 510 HPLC 
pump, a 486 UV/VIS detector, and a Flo-One beta series A-500 radiodetector (Packard, Meriden, 
USA). The stationary phase was a Synergi Hydro-RP (250 x 4.6 mm, 4 µm) column equipped with a 
Luna C18 (4 x 3.0 mm) column guard (Phenomenex, Aschaffenburg, Germany). Linear gradients of 
CH3CN/TFA 0.05% and H2O/TFA 0.05% were used as mobile phases at a flow rate of 0.8 mL/min. 
Absorbance was detected at 220 nm, and radioactivity was measured with the radiodetector by 
liquid scintillation counting (liquid scintillator: Rotiscint Eco Plus, flow rate: 3.8 mL/min). Chemical 
stability investigations of UR-PLN26, UR-PLN74 and UR-PLN208 were performed on a HPLC system 
from Merck, composed of an L‐5000 controller, a 655A‐12 pump, a 655A‐40 auto sampler and an L‐
4250 UV‐VIS detector. The column was a Eurospher-100 (250 x 4 mm, 5 µm) (Knauer, Berlin, 
Germany) at a flow rate of 0.8 mL/min. UV-detection was done at 220 nm. Mixtures of 0.05% TFA in 
acetonitrile and 0.05% aq. TFA were used as mobile phase. Helium degassing prior to HPLC analysis 
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was necessary. Compound purities were calculated as percentage peak area of the analyzed 
compound by UV detection at 220 nm.  
7.4.2 Synthesis of (2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N -
{2-[1-({2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-
1-yl]ethyl})cyclopentyl]acetyl}-N -([2,3-3H2]propanoyl)argininamide ([
3H]UR-
PLN208) 
Succinimidyl [2,3-3H2]propionate (5.35 µg, 31.25 nmol, 1 eq, 2.5 mCi) in 800 µL ethyl acetate was 
transferred into a 1.5 mL Eppendorf reaction vessel (screw top) and the solvent was removed in a 
vacuum concentrator (40 °C) over a period of 30 min. UR-PLN205 (1.245 mg, 1.250 µmol, 40 eq) in 
MeCN (125 µL) and NEt3 (253.0 µg, 2.50 µmol, 80 eq) in CH3CN (5 µL) were added, the components 
were mixed (vortex), briefly centrifuged and stirred with a magnetic microstirrer for 16 h at room 
temperature. Subsequently, 25 µL TFA were added and stirred for further 2 h. The reaction was 
monitored by HPLC. Reaction mixture (0.5 µL) was added to 105 µL of unlabeled UR-PLN208 solution 
(100 µM, CH3CN/H2O 20:80 (v/v)), the ‘cold’ version of [
3H]UR-PLN208, to allow UV detection in 
addition to radiodetection; injection volume: 100 µL). For purification, the reaction mixture was 
diluted with 400 µL H2O containing 0.05% TFA and the product was isolated (3 injections, 175 µL 
each) by analytical HPLC. In this instance, radiometric detection was not performed. Fractions 
containing the radioligand were collected at ~21 min (gradient: 0.05% TFA in CH3CN/0.05% TFA in 
H20: 0 min: 20:80 (v/v), 30 min: 95:5 (v/v), 40 min 95:5 (v/v), 41 min 20:80 (v/v), 50 min 20:80 (v/v)). 
The solvent of the combined fractions was evaporated, and the residue was dissolved in 190 µL of 
CH3CN/H2O 20:80 (v/v) containing 0.05% TFA. The supernatant was purified by HPLC to achieve high 
purity. The solvent of the combined fractions was evaporated under reduced pressure, the product 
dissolved in 200 µL EtOH containing 100 µM TFA and transferred to an Amersham glass vial.  
Quantification: A five-point calibration was performed with the unlabeled ligand UR-PLN208 (2.5, 
5.0, 7.5, 10 μM and 15 µM, inj. vol.: 100 μL, gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min: 
50:50 (v/v), 20 min: 80:20 (v/v), 21 min: 95:5 (v/v), 25 min: 95:5 (v/v), 26 min: 50:50 (v/v), 30 min: 
50:50 (v/v). tR ~ 21 min). The solutions for injection were prepared in CH3CN/0.05% aq. TFA (20/80) 
less than 5 min prior to injection. All standard solutions were prepared from a 100 µM solution of 
UR-PLN208 (in CH3CN/0.05% aq. TFA 20:80) which was freshly made from a 10 mM stock solution of 
UR-PLN208 in DMSO. Two aliquots (2.0 µL) of the ethanolic solution of the product were diluted with 
100 µL of CH3CN/0.05% aq. TFA (20:80), and 100 µL were analyzed by HPLC. Whereas one sample 
was only used for quantification of the product by UV detection, the second sample was additionally 
monitored radiometrically to determine radiochemical purity. The molarity of the ethanolic solution 
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of [3H]UR-PLN208 was calculated from the mean of the peak areas, and the linear calibration curve 
was obtained from the peak areas of the standards. Yield: 2.35 µg (2.46 nmol, 7.9%).  
Determination of the specific activity: An aliquot (1.5 µL) of the ethanolic solution was diluted with 
448.5 µL of a mixture of CH3CN/H2O 20:80 (v/v)  in duplicate, and 50 µL of the 1:90 dilutions were 
counted three times in Rotiszint eco plus (3 mL) in a LS 6500 liquid scintillation counter (Beckmann 
Coulter, München, Germany). The total activity in 200 µL stock solution amounted to 6.823 MBq 
(0.1844 mCi), resulting in a calculated specific activity of 2.772 TBq/mmol (74.92 Ci/mmol). The 
activity of the stock solution was adjusted to 9.25 MBq/mL, (0.25 mCi/mL, c = 3.337 µM) by adding 
EtOH. HPLC analysis showed a radiochemical purity of >98%. The identity of the radioligand was 
confirmed by HPLC analysis of labeled and unlabeled UR-PLN208 under the same conditions, 
resulting in identical retention times. The radioligand was stored at –20 °C. 
Control of chemical stability of [3H]UR-PLN208 by HPLC: 2 μL of the adjusted stock solution of 
[3H]UR-PLN208 (av: 9.25 MBq/mL) in ethanol containing TFA (100 μM) was diluted with 108 μL of 
CH3CN/0.1% aq. TFA (20:80) containing 102 µM of ‘cold’ UR-PLN208 to a total volume of 110 μL. 100 
μL of this solution were injected into the HPLC system and analyzed by radiometric and UV detection. 
Gradient: CH3CN/0.1% TFA in H20: 0 min: 25:75 (v/v), 30 min: 90:10 (v/v), 40 min 90:10 (v/v).  
7.4.3 Investigation of the chemical stability 
The stability of the Y2R antagonists UR-PLN26, UR-PLN74 and UR-PLN208 regarding the formation of 
BIIE 0246 was investigated at neutral pH in binding buffer. Incubation was started by addition of 
50 μL of a 1 mM solution of the compounds in DMSO/H2O 1:1, which was freshly prepared from a 
10 mM stock solution in DMSO, to 950 μL of buffer to give a final concentration of 50 μM. After 1.5 h, 
24 h and 48 h a 150 μL aliquot was taken and diluted with 150 µL of a mixture of acetonitrile, H2O 
and 1 % aq. TFA (60:90:1). 150 μL of the resulting solution were analyzed by HPLC on a RP-column 
(Eurospher-100 C18, 250 × 4 mm, 5 μm, Knauer, Berlin, Germany). Gradient: CH3CN/0.1% TFA in H2O: 
0 min: 20:80 (v/v), 30 min: 95:5 (v/v), 40 min: 95:5. The flow rate was set to 0.8 mL/min, the column 
temperature to 30 °C and the detection wavelength to 220 nm. The quantity of decomposition 
product BIIE 0246 was estimated from the peak integrals of the incubation sample and a reference 
chromatogram of the analyzed compound. The blank HPLC run was performed under identical 
conditions without any Y2R antagonist. For the reference HPLC runs (0 min equal to purity control of 
the stock solutions) of UR-PLN26, UR-PLN74, UR-PLN208 and BIIE 0246, 25 µM solutions in 300 µL of 
CH3CN/0.1% TFA in H2O 20:80 (v/v) was prepared from the respective 1 mM solution in DMSO/H2O 
1:1 (v/v). 
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7.4.4 Pharmacological methods 
7.4.4.1 Cell culture 
CHO-hY2-K9-qi5-K9-mtAEQ-A7 (abbreviated: CHO-hY2R) cells were cultured as described elsewhere.
4 
7.4.4.2 Spectrofluorimetric Ca2+ assay (Fura-2 assay) 
Y2R antagonistic activities (Kb values) were determined by spectrofluorimetric measurement of the 
inhibition of pNPY-induced (70 nM) mobilization of intracellular [Ca2+]i in CHO-hY2R cells by analogy 
with the general procedure described previously,6 using a LS50 B spectrofluorimeter from Perkin 
Elmer (Überlingen, Germany). 
7.4.4.3 Radioligand binding assay 
General. The buffer for the Y2R binding studies of [
3H]UR-PLN208 was prepared by the addition of 1% 
BSA to Leibovitz medium without phenol red (L15) from Life Technologies GmbH (Darmstadt, 
Germany). Bacitracin (100 μg/mL) was added for binding studies with pNPY. PBS (phosphate buffered 
saline) buffer without additives was used to wash the cells previous to and after radioligand binding. 
The lysis solution for the radioligand binding assays consisted of urea (8 M), acetic acid (3 M), and 
Triton-X-100 (1%) in H2O. Stock solutions of all compounds were prepared in DMSO (10 mM) and 
stored at –20 °C.  
Protocol. The radioligand binding assay was essentially performed as described.4 The radioligand was 
diluted 1:10 with unlabeled ligand due to economic reasons. Cells were seeded in BD Primaria 96-
well plates (Becton Dickinson GmbH, Germany) 3-4 days prior to the experiment. On the day of the 
experiment, confluency of the cells was at least 90%. The culture medium was removed by suction, 
the cells were washed once with PBS buffer (200 μL), and covered with Leibovitz medium. Leibovitz 
medium (10 μL) and Leibovitz medium (10 μL) containing [3H]UR-PLN208 (10-fold concentrated) was 
added for total binding. For non-specific binding and displacement of UR-PLN208 Leibovitz medium 
(10 μL) containing the respective competitor 10-fold concentrated and Leibovitz medium (10 μL) with 
[3H]UR-PLN208 (10-fold concentrated) were added. During incubation at room temperature the 
plates were shaken at 300 rpm. After incubation (saturation experiments and competition with 
nonpeptidic Y2R antagonists: 30 min; competition with peptidic agonists: 2 h) the binding buffer was 
removed, the cells were washed twice with PBS buffer (200 μL, 4 °C), covered with lysis solution 
(25 μL) and the plates were gently shaken for at least 30 min. The lysates were transferred into 96-
well sample plates 1450-401 (Perkin Elmer, Rodgau, Germany) and washed once with lysis solution 
(25 μL). Each well was supplemented with 200 µL of scintillation cocktail (Rotiscint Eco plus, Roth, 
Karlsruhe, Germany) and incubated in the dark. Radioactivity was measured with a Micro Beta2 1450 
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scintillation counter (Perkin Elmer, Rodgau, Germany). In case of determining the dissociation 
kinetics, the cells were incubated with Leibovitz medium (100 μL) containing the respective 
competitor (BIIE 0246: 30-fold-, pNPY: 100-fold higher concentrated than the radioligand). After 
incubation with [3H]UR-PLN208 (20 nM) and subsequent washing (200 μL, 4 °C, twice). After different 
periods of time, the cells were washed twice with PBS buffer (200 μL, 4 °C) followed by the addition 
of lysis solution. For association kinetics, cells were incubated with [3H]UR-PLN208 (20 nM) in 
Leibovitz medium (100 μL). The supernatant was sucked off after different periods of time and the 
adherent cells were washed twice with cold PBS buffer (200 μL, 4 °C) before lysis solution was added. 
Non-specific binding was determined with BIIE 0246 (30-fold higher concentrated than the 
radioligand) in kinetic studies. Assays were performed in triplicate. 
7.4.4.4 Steady‐state GTPase activity assay 
GTPase activity assays were performed as previously described.24 hY2R assays: Sf9 insect cell 
membranes coexpressing the hY2R, mammalian G i2 and Gβ1 2 were employed. The membranes 
were thawed, sedimented by centrifugation at 4 °C and 13,000 g for 10 min. Membranes were 
resuspended in 10 mM Tris/HCl, pH 7.4. Each assay tube contained the hY2R expressing Sf9 
membranes, (10 µG-Protein/tube), 2 mM MgCl2, 200 μM EDTA, 200 μM ATP, 200 nM GTP, 200 μM 
adenylyl imidophosphate, 2.4 mM creatine phosphate, 2 μg creatine kinase and 0.4% (w/v) bovine 
serum albumin in 100 mM Tris/HCl, pH 7.4 and the investigated ligands at various concentrations. 
For the determination of pKb values (antagonist mode of the GTPase activity assay), pNPY was added 
to the reaction mixtures (final concentrations: 100 nM). The reaction mixtures (80 μL) were 
incubated for 2 min at 25 °C. After the addition of 20 μL of [33P]GTP (0.1 μCi/tube), the reaction 
mixtures were incubated for 20 min at 25 °C. Reactions were terminated by the addition of 900 μL 
slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. The charcoal‐quenched 
reaction mixtures were centrifuged for 7 min at room temperature at 13,000 g. 600 μL of the 
supernatant were removed and 33Pi was determined by liquid scintillation counting. Spontaneous 
[33P]GTP degradation was determined in tubes containing all components described above, plus a 
high concentration of unlabeled GTP (1 mM), which, due to competition with [33P]GTP, prevents 
[33P]GTP hydrolysis by enzymatic activities present in Sf9 membranes. Spontaneous [33P]GTP 
degradation was <1% of the total amount of radioactivity added. The experimental conditions chosen 
ensured that not more than 10% of the total amount of [33P]GTP added was converted to 33Pi. 
7.4.4.5 Saturation binding of [3H]UR-PLN208 at the hY2R on membrane preparations of Sf9 
insect cells 
For membrane preparation see 7.4.4.4 
 Experimental Section 205 
The radioligand was diluted 1:10 with unlabeled ligand due to economic reasons. Saturation binding 
experiments were conducted with radioligand concentrations (final conc.) between 1 nM and 150 
nM. There, unspecific binding was determined with 30-fold excess of BIIE 0246. The membrane-
ligand mixtures were incubated for 60 min at RT and shaking at 300 rpm. Separation of bound and 
unbound radioligand was performed by filtration as described before (cf. Chapter 5). 
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G-protein coupled receptors (GPCRs) are the most important class of biological targets for the 
currently available pharmacotherapeutics and hold great potential for the development of future 
drugs as well. Histamine and neuropeptide Y (NPY) receptors may be considered representative 
examples of aminergic and peptidergic GPCRs, respectively. 
The histamine H4 receptor (H4R), the latest addition to the histamine receptor family, has been 
suggested as a potential therapeutic target for the modulation of various inflammatory and 
immunological disorders. However, the (patho)physiological role of the H4R is far from being fully 
understood, and its elucidation is hampered by substantial species-dependent differences of 
available ligands regarding potency, receptor selectivity and even the quality of action. Therefore, 
additional potent and receptor subtype selective H4R ligands, antagonists as well as agonists, are 
required as molecular tools. 
In search for agonists for the human (h) and murine (m) H4R, a series of 2-arylbenzimidazoles was 
synthesized, inspired by the structure of a recently published H4R agonist (N-[2-(1H-imidazol-4-
yl)ethyl]-3-[4-(5-fluoro-4-methyl-1H-benzo[d]imidazol-2-yl)-3-methylphenoxy]propan-1-amine), 
bearing a histamine moiety. The compounds were pharmacologically characterized in vitro in 
radioligand and [35S]GTP S binding assays using membrane preparations of Sf9 insect cells expressing 
the human and murine HxR subtypes and in radioligand binding studies on HEK293 cells stably 
expressing the mH4R. The substitution pattern at the benzimidazole moiety proved to be important 
with regard to selectivity for the H4R over the other hHxR subtypes. Extension of the carbon chain 
between the imidazole and the amino group by two methylene groups (imbutamine derivative) was 
tolerated, revealing higher affinities and potencies, in part in the subnanomolar range (Ki = 0.58 nM, 
EC50 = 1.2 nM). By incorporation of the higher homolog impentamine, agonism switched to 
antagonism at the hH4R and antagonism to agonism at the hH3R. In addition to the introduction of a 
5-methyl substituent at the imidazole ring, rigidization to a spinaceamine derivative was most 
effective regarding H4R selectivity. Structural changes aiming at replacing the imidazole moiety, e. g. 
by guanidines, amides and aromatic residues, resulted in a decrease in affinity at the hH4R. Affinities 
and activities at the mH4R were lower compared to the data for the hH4R. Nevertheless, the 5-
methylimbutamine derivative, surprisingly, revealed an EC50 value of 7.0 nM at the mH4R with almost 
full agonist activity. Moreover, high affinity at the hH2R, the hH3R, the hH4R and the mH4R depending 
on the substitution pattern make the 2-arylbenzimidazole building block an extremely versatile 
scaffold to tune subtype, functional and ortholog selectivity in the histamine receptor field. 
It is not astonishing that ligands incorporating an imidazole moiety as the endogenous ligand 
histamine, showed low selectivity for a unique histamine receptor subtype. Aiming at H4R agonists 
with increased selectivity for the H4R over the other HxR subtypes, the combination of the imidazole-
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free molecule VUF 8430 (S-(2-guanidinylethyl)isothiourea, Ki (hH4R) = 17.7 nM)) with the putatively 
bioisosteric acylguanidine moiety of the NG-acylated imidazolylalkylguanidines was applied. This 
approach resulted in compounds with reduced hH4R affinities compared to the reference substance. 
Highest hH4R affinity (Ki value ca. 100 nM) and slightly higher selectivity over the H3R than VUF 8430 
were found for small alkanoyl residues (propanoyl/isobutyryl) at the guanidine group in combination 
with a 3-membered linker. 
Due to a shortage of high affinity radioligands for the investigation of the histamine H2 receptor, the 
squaramide [3H]UR-DE257 (N-{6-[3,4-dioxo-2-({3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino})-
cyclo-but-1-enylamino]hexyl}-(2,3-3H2)-propionamide) was synthesized and pharmacologically 
characterized. The Kd‐value (20 nM) determined from kinetic experiments was in good agreement 
with the dissociation equilibrium constant (31 nM) from saturation analysis. [3H]UR-DE257 proved to 
be a useful tool to determine the H2R binding affinities of unlabeled ligands in competition binding 
experiments. Future detailed analyses on the binding kinetics and quality of action (insurmountable 
H2R antagonism) must show, if [
3H]UR-DE257 is an appropriate molecular tool to study functional 
selectivity at H2R and receptor dynamics. 
The tritium-labeled version of the widely used potent H4R antagonist JNJ7777120 ((5-chloro-1H-
indol-2-yl)(4-methylpiperazine-1-yl)methanone) was synthesized and pharmacologically 
characterized. The radioligand proved to be suitable for the investigation of the hH4R in Sf9 insect cell 
membranes. Although JNJ7777120 has been used for the study of the H4R in animal models, the 
investigation of the tritiated version, [3H]JNJ7777120, revealed that this compound is far from being 
an ideal standard ligand or, not to mention, an optimal pharmacological tool. Due to very high non-
specific binding, an advantage  of [3H]JNJ7777120 as a radiolabeled selective H4R antagonist 
compared to the non-selective HxR agonist [
3H]histamine was not confirmed. Nevertheless, the 
results of competition binding experiments were in good accordance to reported data. The 
exceptionally high affinity of JNJ7777120 for the murine H4R, reported in literature, could not be 
confirmed in saturation and competition binding studies on Sf9 cell membranes. Binding of 
[3H]JNJ7777120 at HEK-hH4R cell membranes was insaturable and was predominantly hH4R-
independent. 
To better understand the biological role of the NPY Y2 receptor (Y2R) subtype, pharmacological tools 
such as radioligands are required. The guanidine-acylguanidine bioisosteric approach was applied to 
the preparation of the tritiated argininamide-type Y2R-selective radioligand [
3H]UR-PLN208, 
structurally related to the previously published [3H]UR-PLN196 from our laboratory. Pharmacological 
investigation revealed differences between peptidic agonists and nonpeptide antagonists regarding 
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displacement of the radioligand, compatible with the concept of insurmountable antagonism and 
pseudo-irreversible binding, and discrepancies depending on the assays used. Whereas time-
dependent depression of the NPY-induced Ca2+-response was demonstrated in the fura-2 assay on 
hY2R expressing CHO cells, insurmountable antagonism was not detectable in the steady-state 
GTPase assay on Sf9 cell membranes, but the Kb values from both assays were consistent. The data 
suggest different or partially overlapping binding sites of BIIE 0246-like antagonists and NPY, 
supporting the idea of ligand-specific receptor conformations. Yet, [3H]UR-PLN208 is a valuable 
pharmacological tool for the detection of Y2R binding sites, investigations on ligand binding modes 
and the characterization of nonpeptide Y2R antagonists. 
Taken together, several of the synthesized 2-arylbenzimidazoles harbor the potential of molecular 
tools and will hopefully contribute to a better understanding of the structure-activity- and structure-
selectivity relationships of H4R ligands on human and murine receptor orthologs. The synthesized and 
pharmacologically characterized tritium-labeled radioligands [3H]UR-DE257, [3H]JNJ7777120 and 
[3H]UR-PLN208 for GPCRs are proven pharmacological tools for the detection of the respective 
receptor in vitro and for investigations on the antagonistic binding mode, respectively, as well as for 
the identification and characterization of new ligands at the respective target. 
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9.1 Synthesis and Application of the First Radioligand Targeting the Allosteric 
Binding Pocket of Chemokine Receptor CXCR3 
 
As part of a cooperation with the working group of Dr. Nuska Tschammer at the FAU Erlangen-
Nürnberg a radioligand called RAMX3 was synthesized and purified for further pharmacological 
investigation. These results are published in: 
Bernat, V.; Heinrich, M. R.; Baumeister, P.; Buschauer, A.; Tschammer, N. Synthesis and application of 
the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3. 
ChemMedChem 2012, 7, 1481-1489. doi: 10.1002/cmdc.201200184. 
Contribution of Paul Baumeister: Synthesis, analytical and radiochemical characterization of the 
radiolabeled form of RAMX3 as outlined in the following. 
9.1.1 Abstract 
Strategies for the identification of allosteric modulators of chemokine receptors largely rely on 
various cell-based functional assays. Radioligand binding assays are typically not available for 
allosteric binding sites. We synthesized, purified, and applied the first tritium-labeled allosteric 
modulator of the human chemokine receptor CXCR3 (RAMX3, [3H]N-{1-[3-(4-ethoxyphenyl)-4-oxo-
3,4-dihydropyrido[2,3-d]pyrimidin-2-yl]ethyl}-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[(1-methylpip-
eridin-4-yl)methyl]acet-amide). RAMX3 is chemically derived from 8-azaquinazolinone-type allosteric 
modulators and binds to the CXCR3 receptor with a Kd value of 1.08 nM (specific activity: 80.4 
Ci/mmol). Radioligand displacement assays showed potent negative cooperativity between RAMX3 
and chemokine CXCL11, providing a basis for the use of RAMX3 to investigate other potential 
allosteric modulators. Additionally, the synthesis and characterization of a number of other full and 
truncated 8-azaquinazoline analogs were used to validate the binding properties of RAMX3. We 
demonstrate that RAMX3 can be efficiently used to facilitate the discovery and characterization of 
small molecules as allosteric modulators of the CXCR3 receptor. 
9.1.2 General conditions for radiosynthesis:  
Commercial reagents and solvents were purchased from Acros Organics (Geel, Belgium), Alfa Aesar 
(Karlsruhe, Germany), or Merck KGaA (Darmstadt, Germany) and were used without further 
purification unless otherwise stated. All solvents were of analytical grade, and DMSO was distilled 
prior to use and stored over 4 Å molecular sieves. [3H]Methyl iodide dissolved in toluene (as = 
3.15 TBq/mmol, 85 Ci/mmol; av = 37 GBq/mL, 1 Ci/mL) was from Hartmann Analytic (Braunschweig, 
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Germany). Compound 9.1 and ‘cold’ RAMX3 was synthesized in the laboratory of Dr. Nuska 
Tschammer by Viachaslau Bernat (FAU Erlangen-Nürnberng, Germany). Scintillation cocktail Rotiscint 
Eco Plus was from Carl Roth (Karlsruhe, Germany). Analytical HPLC was performed on a system from 
Waters (Eschborn, Germany), equipped with a pump control module, a 510 HPLC pump, a 486 
UV/VIS detector, and a Flo-One beta series A-500 radiodetector (Packard, Meriden, USA). The 
stationary phase was a Synergi Hydro-RP (250 x 4.6 mm, 4 µm) column equipped with a Luna C18 (4 x 
3.0 mm) column guard (Phenomenex, Aschaffenburg, Germany). Linear gradients of CH3CN/TFA 
0.05% (v/v) and H2O/TFA 0.05% (v/v) were used as mobile phases at a flow rate of 0.8 mL/min. 
Absorbance was detected at 220 nm, and radioactivity was measured with the radiodetector by 
liquid scintillation counting (liquid scintillator: Rotiscint Eco Plus, flow rate: 3.8 mL/min). 
9.1.3 Radiosynthesis of [3H]N-{1-[3-(4-Ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-
d]pyrimidin-2-yl]ethyl}-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[(1-
methylpiperidin-4-yl)methyl]acetamide (RAMX3) 
 
Scheme 9.1 Synthesis of radioligand RAMX3. Reagents and conditions: a) [
3
H]MeI, DIPEA, CH2Cl2, 20 h, RT, 
20.7%. 
Compound 9.1 (402.7 mg, 0.6588 mmol, 11.2 eq), dissolved in CH2Cl2 (50 µL), and DIPEA (123.9 mg, 
0.9588 mmol, 16.3 eq) in CH2Cl2 (50 µL) were added to a solution of [3H]methyl iodide (8.875 mg, 
0.0588 mmol, 1 eq, 5 mCi) in toluene (5 µL), and the reaction mixture was diluted with CH2Cl2 (100 µL) 
and stirred for 20 h at room temperature. The reaction was monitored by HPLC. Reaction mixture 
(1 µL) was added to 104 µL of ‘cold’ RAMX3 solution (100 µM) to allow for UV detection in addition 
to radiodetection; injection volume: 100 µL, see Figure 9.1). The solvent was removed under reduced 
pressure, and the residue was redissolved in 1000 µL of a mixture of CH3CN/H2O 95:5 (v/v) containing 
0.05% TFA.  
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Figure 9.1 Identity and purity control of RAMX3 by HPLC. A. Reaction control after 20 h; B. Purity control after 
first purification; C. Final purity control; D. UV (  = 220 nm) chromatogram of unlabeled RAMX at 100 µM. 
Conditions: injection volume: 100 µL, gradient: 0.05% TFA in CH3CN (v/v)/0.05% TFA in H2O (v/v): 0 min 5:95, 
10 min 45:55, 34 min 35:65, 36 min 95:5, 41 min 95:5, 43 min 5:95, 50 min 5:95, flow: 0.8 mL/min, tR~25 min. 
Minor differences in retention times (tR) result from the setup of the UV and the radiodetector in series. The 
identity of RAMX3 was confirmed by spiking with ‘cold’ RAMX3. 
For isolation of RAMX3, aliquots (1 x 100 µL, 5 x 180 µL) were injected into an HPLC instrument. 
Fractions containing the radioligand were collected at ~24 min (gradient: 0.05% TFA in CH3CN/0.05% 
TFA in H2O: 0 min 5:95 (v/v), 10 min 45:55 (v/v), 34 min 35:65 (v/v), 36 min 95:5 (v/v), 41 min 95:5 
(v/v), 43 min 5:95 (v/v), 50 min 5:95 (v/v)). The solvent of the combined fractions was evaporated, 
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and the residue was dissolved in 540 mL of a mixture of CH3CN/H2O 5:95 (v/v) containing 0.05% TFA. 
Aliquots (3 x 180 µL) of the supernatant were purified by HPLC to achieve high purity. The solvent of 
the combined fractions was evaporated and the residue was re-dissolved in freshly distilled DMSO 
(720 µL) and transferred into a 5 mL Amersham glass vial.  
 
Figure 9.2 Purity control of RAMX3 by HPLC after storage at room temperature for five months. A. 
Radiochromatogram of RAMX3. B. UV detection (λ = 220 nm) of RAMX3 spiked with unlabeled RAMX3, c: 
100 μM. Conditions: injection volume: 100 μL, gradient: 0.05% TFA in MeCN (v/v) / 0.05% TFA in H2O (v/v): 0 
min: 5/95, 10 min: 45/55, 34 min: 35/65, 36 min: 95/5, 41 min: 95/5, 43 min: 5/95, 50 min: 5/95, flow: 0.8 
mL/min, tR ~25 min. The minor difference in retention times (tR) results from the setup of the UV and the 
radiodetector in series. The identity of RAMX3 was confirmed by spiking with ’cold’ RAMX3. 
The concentration of the radioligand in the stock solution was determined from a five point 
calibration curve for unlabeled ligand RAMX3 (1.0, 2.5, 5.0, 7.5, and 10 µM; inj. vol.: 100 µL; HPLC: 
=220 nm, gradient: 0.05% TFA in CH3CN/0.05% TFA in H2O: 0 min 5:95 (v/v), 10 min 75:25 (v/v), 
20 min 85:15 (v/v), 21 min 95:5 (v/v), 25 min 95:5 (v/v), 26 min 5:95 (v/v), 30 min 5:95 (v/v), 
tR~14 min) from the peak area of 100 µL of a mixture of stock solution (10.5 µL) diluted with 94.5 µL 
CH3CN/H2O 5:95 (v/v) containing 0.05% TFA (16.86 µM, 12.14 nmol, yield: 20.7 %). All standard 
solutions were prepared separately from a 100 µM solution of unlabeled RAMX3 in a mixture of 
CH3CN/H2O 5:95 (v/v) containing 0.05% TFA, which was freshly prepared from a 10 mM solution of 
unlabeled RAMX3 in CH3CN. To determine the total radioactivity of RAMX3, stock solution (5 µL) was 
diluted with 445 µL of a mixture of CH3CN/H2O 5:95 (v/v) containing 0.05% TFA, and 50 µL of this 
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solution was measured three times in scintillation cocktail Rotiscint Eco Plus (3 mL) in a LS 6500 liquid 
scintillation counter (Beckmann Coulter, München, Germany). The total activity in 720 µL stock 
solution amounted to 36.1 MBq (0.976 mCi), resulting in a calculated specific activity of 
2.98 TBq/mmol (80.4 Ci/mmol). The activity of the stock solution was adjusted to 37 MBq/mL; 
(1 mCi/mL, c=12.40 µM) by adding a mixture of DMSO/EtOH 98:2 (v/v) containing 100 µM TFA. HPLC 
analysis showed a radiochemical purity of >99.9 %. The identity of the radioligand was confirmed by 
HPLC analysis of labeled and unlabeled RAMX3 under the same conditions, resulting in identical 
retention times. Moreover, chemical stability in DMSO/EtOH 98:2 (v/v) containing 100 µM TFA at 
room temperature was proven over a period of at least 5 months (see Figure 9.2). 
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9.2 Nonspecific binding of [3H]JNJ7777120 at the hH4R in Sf9 cell membranes 
(cf. Chapter 6) 
 
Figure 9.3 Nonspecific binding of [
3
H]JNJ7777120 at the hH4R in Sf9 insect cell membranes. A. Nonspecific 
binding: □; competitor: JNJ7777120 (6.4a) (c = 10µM); specific binding is shown in Figure 6.5. 
9.3 Nonspecific binding of [3H]UR-PLN208 at CHO-hY2R cells (cf. Chapter 7) 
  
Figure 9.4 Nonspecific binding of [
3
H]UR-PLN208 at CHO-hY2R cells. A. Nonspecific binding: □; competitor: pNPY 
(100 fold concentration of [
3
H]UR-PLN208); specific binding is shown in Figure 7.4. B. Nonspecific binding: □; 
competitor: BIIE 0246 (30 fold concentration of [
3
H]UR-PLN208); specific binding is shown in Figure 7.4. 
  
A B 
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9.4 NMR-Spectra of selected compounds 
 
 
Figure 9.5 
1
H- & 
13
C-Spectra of 3.16. 
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Figure 9.6 
1
H- & 
13
C-Spectra of 4.19. 
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Figure 9.7 
1
H- & 
13
C-Spectra of JNJ7777120 (6.4a). 
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9.5 HPLC Purity Data 
No Gradient  / nm tR k Purity / % 
3.11 30/70-60/40 220 22.5 10.1 99.4 
3.16 20/80-50/50 220 11.2 3.0 99.9 
3.17 20/80−50/50 220 6.9 1.5 99.6 
3.18 20/80−50/50 220 10.9 2.9 99.6 
3.19 20/80−50/50 220 6.5 1.3 99.8 
3.20 10/90−80/20 220 6.5 1.3 99.8 
3.22 20/80−50/50 220 12.3 3.4 99.2 
3.23 30/70−60/40 220 7.6 1.6 100 
3.26 20/80−50/50 220 16.9 6.3 98.7 
3.30 5/95-80/20 220 15.7 8.3 97.8 
3.31 30/70−60/40 220 9.0 2.2 99.4 
3.32 30/70−60/40 220 12.7 3.5 100 
3.33 20/80−80/20 220 13.3 4.7 100 
3.34 40/60−90/10 220 16.6 6.1 100 
3.35 40/60−90/10 220 17.5 6.5 99.9 
3.36 40/60−90/10 220 15.7 5.7 99.6 
3.37 5/95-80/20 220 20.2 11.0 98.3 
3.42 5/95-50/50 220 2.5 0.5 99.3 
3.49 3/97 (isocratic) 220 8.7 2.1 99.6 
3.50 3/97 (isocratic) 220 5.0 0.8 98.3 
3.61 5/95−80/20 220 26.0 10.1 97.0 
3.62 5/95-80/20 220 13.3 6.9 98.8 
3.63 5/95-80/20 220 13.1 6.8 99.3 
3.64 10/90−80/20 220 14.9 5.4 99.4 
3.65 10/90−80/20 220 11.3 3.8 100 
3.66 10/90−80/20 220 15.2 5.5 100 
3.67 10/90−80/20 220 14.4 5.2 98.6 
3.68 5/95-80/20 220 13.0 6.7 96.4 
3.69 10/90−70/30 220 14.4 5.2 99.3 
3.70 10/90−70/30 220 14.0 5.0 99.3 
3.71 10/90−80/20 220 14.4 5.2 99.9 
3.72 10/90−80/20 220 17.1 6.3 99.0 
3.77 10/90−80/20 220 15.4 5.6 99.9 
3.78 10/90−80/20 220 16.1 5.9 99.9 
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No Gradient  / nm tR k Purity / % 
4.12 5/95−30/70 200 3.7 0.6 97.3 
4.13 5/95−30/70 200 3.9 0.7 96.8 
4.14 5/95−30/70 200 9.3 3.0 99.8 
4.15 5/95−43/57 200 11.8 4.1 98.2 
4.16 5/95−43/57 200 11.4 3.9 97.3 
4.17 5/95−43/57 200 10.1 3.3 98.3 
4.18 10/90−70/30 200 16.5 6.1 97.1 
4.19 5/95−30/70 200 7.5 2.2 99.0 
4.20 5/95−50/50 200 10.5 5.2 98.8 
4.21 5/95−50/50 200 10.2 5.0 95.2 
4.22 5/95−40/60 200 13.6 4.9 97.0 
4.23 5/95−50/50 200 12.6 6.5 97.1 
4.24 5/95−50/50 200 16.3 8.7 97.5 
4.25 5/95−50/50 200 15.0 7.9 99.9 
4.26 5/95−60/40 200 18.7 10.1 98.3 
4.27 5/95−30/70 200 15.0 5.5 98.9 
4.28 5/95−43/57 200 20.4 7.8 99.7 
4.29 5/95−43/57 200 17.7 6.6 99.3 
4.30 5/95−43/57 200 17.1 6.3 99.7 
4.31 10/90−70/30 200 27.4 10.8 98.9 
4.32 5/95−30/70 200 16.7 6.2 99.3 
4.33 5/95−50/50 200 17.8 9.5 100 
4.34 5/95−50/50 200 14.3 7.5 100 
4.35 5/95−50/50 200 13.0 6.7 95.8 
4.36 20/80−50/50 200 17.3 5.1 98.8 
4.37 5/95−50/50 200 23.1 12.7 98.7 
4.38 5/95−50/50 200 23.3 12.8 95.6 
4.39 5/95−60/50 200 23.9 13.1 99.8 
4.40 5/95−43/57 200 4.8 0.7 98.2 
4.43 5/95−43/57 200 4.8 0.7 98.2 
6.3 5/95-80/20 220 15.3 8.1 99.0 
6.4a 5/95-80/20 220 15.9 8.4 99.5 
Regular column: Eurospher-100 (250 x 4 mm, 5 µm) (Knauer, Berlin, Germany, t0 = 3.32 min); flow rate: 0.8 
mL/min; column for 3.30, 3.37, 3.42, 3.62, 3.63, 3.68, 4.23, 4.24, 4.26-4.29, 4.38-4.44, 6.3 and 6.4a: Luna 
C18(2) (150 × 4.6 mm, 3 μm) (Phenomenex, Aschaffenburg, Germany, t0 = 2.88 min); solvent mixture: 0.05% 
TFA in MeCN and 0.05% aq. TFA; gradient: 0-30 min: see table, 31-40 min: 95/5; compound purities were 
calculated as percentage peak area of the analyzed compound by UV detection at 200/220 nm. The capacity 
(retention) factors were calculated according to k = (tR-t0)/t0. 
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9.6 Abbreviations 
α    intrinsic activity or selectivity factor 
A    agonist 
abs     absolute 
AC    adenylyl cyclase 
aq    aqueous 
as    specific activity 
atm    atmosphere 
ATP     adenosine triphosphate 
av    activity concentration 
Boc     tert-butoxycarbonyl 
Boc2O    di-tert-butyl dicarbonate 
Bq    becquerel 
bs    broad singulet 
c    concentration 
calcd.    calculated 
cAMP     cyclic 3’, 5’-adenosine monophosphate 
cat.     catalytical amounts 
CH2Cl2    dichloromethane 
CHCl3    chloroform 
CH3CN    acetonitrile 
Ci    curie 
CI    chemical ionization 
CNS     central nervous system 
COSY     correlated spectroscopy 
cpm    counts per minute 
Cquat     quaternary carbon atom 
Cs2CO3    caesium carbonate 
d    day or doublet 
DAG     diacylglycerol 
dd    doublet of doublets 
DIPEA    diisopropylethylamine 
DMF    dimethylformamide 
DMSO    dimethylsulfoxide 
EC50  molar concentration of the agonist causing 50 % of the maximal 
response 
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EDC x HCl   N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
eq    equivalents 
EI    electron ionization 
Emax     maximal response relative to the endogenous ligand (1.00) 
ESI    electrospray ionization 
Et2O    diethylether 
EtOAc    ethyl acetate 
EtOH    ethanol 
FBS     fetal bovine serum 
G    giga or G-Protein  
GC    gas chromatography 
GDP     guanosine diphosphate 
GF/C    glass microfibre, grade c (fine) 
GPCR     G-Protein coupled receptor 
GTP     guanosine triphosphate 
GTPγS    guanosine 5'-thiotriphosphate 
h    hour(s) or human 
HCl    hydrochloric acid 
HEK    human embryonic kidney 
HOBt x H2O   1-Hydroxybenzotriazole hydrate 
HPLC    high-performance liquid chromatography 
HR     histamine receptor 
hH1R     human histamine H1 receptor 
hH2R     human histamine H2 receptor 
hH2R-GsαS    fusion protein between the hH2R and short splice variant of Gsα 
hH3R     human histamine H3 receptor 
hH4R     human histamine H4 receptor 
HMBC     heteronulcear multiple bond correlation 
HMQC    heteronuclear multiple quantum correlation 
H1R, H2R, H3R, H4R   histamine receptor subtypes 
HRMS     high resolution mass spectroscopy 
HSQC    heteronuclear single quantum correlation 
hY2R    human Y2 receptor 
Hz    hertz 
IC50  functional assay: antagonist (inverse agonist) concentration 
suppressing 50 % of an agonist induced effect 
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radioligand binding assay: ligand concentration inhibiting the binding 
of a radioligand by 50 % 
IP3     inositol-1,4,5-trisphosphate 
IR    infrared 
J    coupling constant 
k     capacity factor 
Kb     dissociation constant (functional assay)  
KBr    potassium bromide 
K2CO3    potassium carbonate 
Kd     dissociation constant (saturation binding) 
KHSO4    potassium bisulfate 
Ki     dissociation constant (competition binding) 
kob     observed rate constant 
koff     dissociation rate constant 
kon     association rate constant 
L    liter 
LC    liquid chromatography 
m     multiplet or milli or mouse 
M    mega or mol/L 
MAPK     mitogen-activated protein kinase 
mAU    milli absorbance units 
MeCN    acetonitrile 
mH4R    mouse histamine H4 receptor 
MeI    methyl iodide 
MeOD    deuterated methanol 
MeOH    methanol 
MgSO4    magnesium sulfate 
min    minute(s) 
µ    micro 
mp    melting point 
MS    mass spectrometry 
n    nano or amount of substance 
NaHCO3   sodium bicarbonate 
NaI    sodium iodide 
NaOH    sodium hydroxide 
Na2SO4    sodium sulfate 
Na2S2O5    sodium metabisulfite 
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NEt3    triethylamine 
NG     guanidino-nitrogen 
NHS    N-hydroxysuccinimide 
nm    nanometer 
NMR    nuclear magnetic resonance 
NOESY     nuclear overhauser enhancement spectroscopy 
NP    normal phase 
NPY    neuropeptide Y 
p    quintet  
PBS    phoshpate buffered saline 
PE     petroleum ether 
pEC50  negative decadic logarithm of the molar concentration of the agonist 
causing 50 % of the maximal response 
PEI    polyethyleneimine 
Ph     phenyl 
Pi     inorganic phosphate 
PIP2     phosphatidylinositol-4,5-bisphosphate 
PKA     protein kinase A 
PKC     protein kinase C 
PLA2    phospholipase A2 
PLCβ     phospholipase Cβ 
Phthal     phthalimide 
ppm    parts per million 
q    quartet 
R     inactive state of a GPCR 
R*     active state of a GPCR 
ref    reference 
Rf    retardation factor 
RGS     regulator of G-protein signaling 
RP    reversed phase 
rpm     revolutions per minute 
rt    room temperature 
s    singlet 
sat.    saturated 
SEM     standard error of the mean 
SF    SuperFlash 
Sf9     Spodoptera frugiperda insect cell line 
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SK-N-MC cells  human neuroblastoma cell line established from the supraorbital 
metastasis of a neuroblastoma of a 14-year old girl in 1971 
t    triplet 
T    tera 
t0     dead time 
TBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate  
TFA    trifluoroacetic acid 
THF    tetrahydrofuran 
TLC    thin layer chromatography 
TM     transmembrane 
TMS    trimethylsilyl 
tR    retention time 
Tris     tris(hydroxymethyl)aminomethane 
Trt    trityl, triphenylmethyl 
UV    ultraviolett 
Vis    visible 
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